WO2009024819A1 - Cannabinoid receptor ligands - Google Patents

Cannabinoid receptor ligands Download PDF

Info

Publication number
WO2009024819A1
WO2009024819A1 PCT/GB2008/050713 GB2008050713W WO2009024819A1 WO 2009024819 A1 WO2009024819 A1 WO 2009024819A1 GB 2008050713 W GB2008050713 W GB 2008050713W WO 2009024819 A1 WO2009024819 A1 WO 2009024819A1
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydro
pyran
carbazole
alkyl
methyl
Prior art date
Application number
PCT/GB2008/050713
Other languages
French (fr)
Inventor
Sara Beha
William Brown
Shawn Johnstone
Ziping Liu
Daniel PAGÈ
Miroslaw Tomaszewski
Zhong-Yong Wei
Shi Yi Yue
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to BRPI0815493-7A2A priority Critical patent/BRPI0815493A2/en
Priority to EP08788684A priority patent/EP2190838A1/en
Priority to CA2696697A priority patent/CA2696697A1/en
Priority to MX2010001574A priority patent/MX2010001574A/en
Priority to AU2008290325A priority patent/AU2008290325A1/en
Priority to US12/673,617 priority patent/US20110160180A1/en
Priority to JP2010520636A priority patent/JP2010536737A/en
Priority to CN200880112253A priority patent/CN101827838A/en
Publication of WO2009024819A1 publication Critical patent/WO2009024819A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof.
  • the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.
  • cannabinoid receptor e.g., CBi receptor, CB 2 receptor
  • CBi receptors e.g., CBi receptor, CB 2 receptor
  • agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CBi and/or CB 2 receptors.
  • CBi receptors are located predominately in the central nervous system
  • CB 2 receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system.
  • CBi receptor agonists such as ⁇ 9 -tetrahydrocannabinol ( ⁇ 9 -THC) and anadamide
  • CNS side-effects e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc.
  • CBi receptors located in CNS There are lines of evidence, however, suggesting that CBi agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile.
  • the present invention provides CBi receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.
  • C m _ n or "C m _ n group” refers to any group having m to n carbon atoms.
  • alkyl refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms.
  • alkyls include, but are not limited to, Ci_6alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3 -methyl- 1 -butyl, 2- methy 1-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3 -methyl- 1-pentyl, 4-methyl- 1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3, 3 -dimethyl- 1 -butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl, and
  • alkylene used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
  • alkylidene used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together and the two radicals are located on the same carbon atom.
  • alkenyl refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.
  • the double bond of an alkenyl can be unconjugated or conjugated to another unsaturated group.
  • Suitable alkenyl groups include, but are not limited to C 2 - 6 alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)- pentenyl.
  • An alkenyl can be unsubstituted or substituted with one or two suitable substituents.
  • cycloalkyl refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.
  • cycloalkyls include, but are not limited to, C3_7cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes.
  • a cycloalkyl can be unsubstituted or substituted by one or two suitable substituents.
  • the cycloalkyl is a monocyclic ring or bicyclic ring.
  • cycloalkenyl refers to a monovalent ring- containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.
  • aryl refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms.
  • heterocycle refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms there between. Heterocycle may have aromatic character or may not have aromatic character.
  • heterocyclyl refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.
  • Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro- pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3- dihydropyr
  • heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3- triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4- thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.
  • heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1 ,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, p
  • heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings.
  • bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.
  • heteroaryl refers to a heterocyclyl having aromatic character (e.g., 4n + 2 delocalized electrons.)
  • heterorocylcoalkyl refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation.
  • heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl.
  • a heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents.
  • the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and form 1 to 3 heteroatoms, referred to herein as C 3 . 6 heterocycloalkyl.
  • the term "six-membered” refers to a group having a ring that contains six ring atoms.
  • the term “five-membered” refers to a group having a ring that contains five ring atoms.
  • a five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
  • Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.
  • a six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
  • Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
  • alkoxy refers to radicals of the general formula -O-R, wherein R is selected from a hydrocarbon radical.
  • exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.
  • Halogen includes fluorine, chlorine, bromine and iodine.
  • RT room temperature
  • an embodiment of the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, a diastereomer, an enantiomer, or a mixture thereof:
  • R 5 is selected from -H, Ci- 6 alkyl, and C 3 - 6 cycloalkyl;
  • R 6 is independently selected from -H, -CN, -NO 2 , Ci- ⁇ alkoxy, halogen, Ci ⁇ alkyl, -OH, -NH 2 , -NHC(O)R 12 and -C(O)NR 12 R 13 ;
  • R 12 and R 13 are independently selected from -H, Ci-6alkyl, Ci_6alkoxy, C 3- 6 heterocycloalkyl, C 3 _ 6 Cycloalkyl-Ci_ 4 alkyl, and C 3 _ 6 cycloalkyl wherein said Ci_ 6 alkyl, Ci- ⁇ alkoxy, Cs- ⁇ heterocycloalkyl, C 3 _ 6 Cycloalkyl-Ci_ 4 alkyl and C 3 _ 6 cycloalkyl used in defining R 12 and R 13 are optionally substituted with one or more halogens or -OH; R 14 and R 15 are independently selected from -H, Ci-6alkyl, C ⁇ -ioaryl, C ⁇ -ioaryl-Ci-
  • R is independently Ci_ 6 alkyl.
  • R 2 is selected from Ci- 6 alkyl, C 2 -sheterocycloalkyl and C 3 _ 6 cycloalkyl wherein said Ci- 6 alkyl, C 2 -sheterocycloalkyl and C 3 _ 6 cycloalkyl used in defining R 2 is optionally substituted with one or more groups selected from -OR, R, NO 2 , -CO 2 H, -CO 2 -R, -SO 2 - R, halogen, -OH, -NH 2 , -NHR, -CN, -C(O)-NH 2 , and -C(O)-NHR; R 3 and R 4 are independently selected from -H, C 3 - 6 Cycloalkyl, C 3 .
  • R 5 is selected from -H, Ci_ 6 alkyl, and C 3 _ 6 cycloalkyl;
  • R 12 and R 13 are independently selected from -H, Ci- 6 alkyl, Ci_ 6 alkoxy, C 3 . ⁇ heterocycloalkyl, C 3 _ 6 Cycloalkyl-Ci_ 4 alkyl, and C 3 _ 6 cycloalkyl wherein said Ci_ 6 alkyl, Ci- ⁇ alkoxy, Q- ⁇ heterocycloalkyl, C3-6Cycloalkyl-Ci -4 alkyl, and C3_6cycloalkyl used in defining R 12 and R 13 is optionally substituted with one or more haolgens; and
  • R is independently Ci- ⁇ alkyl.
  • benzyl 4- aminobenzyl, 4-nitrobenzyl, 4-methylsulfonyl-benzyl, 4-methylthio-benzyl, 4- acetylamino-benzyl, 4-methoxy-benzyl, 4-ethoxy -benzyl, 2,6-difluorobenzyl, (6-chloro- l,3-benzodioxol-5-yl)methyl, (5 -ethoxycarbonyl)-fur-2-yl- methyl, (2-methyl-l,3-thiazol- 4-yl)-methyl, (5-methyl-isoxazol-4-yl)-methyl, pyridin-2-ylmethyl, cyclobutylmethyl, and cyclopropylmethyl.
  • R 2 is selected from methyl, ethyl, isopropyl, propyl, 2- methy-propyl, 1 -butyl, tert-butyl, 1-pentyl, l-acetyl-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro-2H-pyranyl, tetrahydro-thiopyran-4-yl, 2-pyrimidinyl, 1- iminoethyl, 2-pyridinyl, 3,4,5,6-tetrahydropyrdin-2-yl, 3,4-dihydro-2H-pyrrol-5-yl, 2- pyridinyl- methyl, 3-pyridinylmethyl, 4-pyridinylmethyl, l-methyl-4-pipe
  • Y is
  • R 5 is selected from -H, Ci- 6 alkyl, and C 3 - 6 cycloalkyl; R 3 and R 4 are independently selected from -H, C3-6cycloalkyl, C3-
  • Q is Ci-6alkylene or Ci_6alkylidene, optionally substituted with one or more -CH 2 OH;
  • R is Ci_ 6 alkyl.
  • Y is
  • R 5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl;
  • R 3 and R 4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl
  • R is C 1-6 alkyl.
  • R 5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl;
  • R 3 and R 4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, meth
  • Q is selected from Ci-6alkylene, hydroxymethyl-Ci_6alkylene, and Ci_6alkylidene;
  • R 2 is tetrahydropyranyl.
  • Y is ,
  • R 5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl;
  • R 3 and R 4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl and cyclohexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, and cyclohexyl used in defining R 3 and R 4 are optionally substituted with one or more fluoro;
  • R is tetrahydropyranyl; n is selected from 1,2 and 3; and p, q are independently selected from 0, 1, 2 and 3.
  • Y is
  • Y is ;
  • R 2 is selected from C 3 _ 6 cycloalkyl, tetrahydropyranyl and Ci_ 6 alkyl; and n is 1,2 or 3; and m is 1.
  • Y is
  • R > 5 is selected from -H, Ci_ 6 alkyl, and C 3 _ 6 cycloalkyl;
  • Q is Ci-6alkylene or Ci_6alkylidene
  • R is Ci- ⁇ alkyl
  • R 14 and R 15 are independently selected from -H, Ci- ⁇ alkyl, C ⁇ -ioaryl, C ⁇ -ioaryl-Ci. 4 alkyl, C 3 _6heterocyclyl, C3-6heterocyclyl-Ci -4 alkyl, C 2 _6alkenyl, C3_6cycloalkyl, C 3 .
  • R 5 is methyl
  • Y is
  • R 3 and R 4 are independently selected from -H, Ci- ⁇ alkyl, Ci_ 6 cycloalkyl, C 3 . 6 heterocycloalkyl, wherein said C h alky 1, Ci- 3 cycloalkyl, and Q- ⁇ heterocycloalkyl are optionally substituted with one or more groups selected from -OR, R, NO 2 , -CO 2 H, -CO 2 - R, -SO 2 -R, halogen, -OH, -NH 2 , -NHR, -C(O)-NH 2 , -CN, -C(O)-NR 2 and -C(O)- NHR; and
  • R is C 1-6 alkyl.
  • Y i .s ; and R 3 and R 4 are independently selected from -H, methyl, and ethyl wherein said methyl and ethyl are optionally substituted with -OH or halogen.
  • R 2 is tetrahydropyranyl. In a further embodiment, R 2 is 4-tetrahydropyranyl. In another embodiment, a compound of the invention may be selected from:
  • Methyl methyl[2-(methyl ⁇ [9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazol-6-yl]carbonyl ⁇ amino)ethyl]carbamate; N- ⁇ 2-[(Cyclopropylcarbonyl)(methyl)amino]ethyl ⁇ -N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
  • the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture.
  • the present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I.
  • the optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.
  • certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes.
  • the present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the Formula I. It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the Formula I. Within the scope of the invention are also salts of the compounds of the Formula
  • salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion.
  • a sufficiently basic compound for example an alkyl amine
  • a suitable acid for example, HCl or acetic acid
  • a corresponding alkali metal such as sodium, potassium, or lithium
  • an alkaline earth metal such as a calcium
  • a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.
  • a suitably acidic proton such as a carboxylic acid or a phenol
  • an alkali metal or alkaline earth metal hydroxide or alkoxide such as the ethoxide or methoxide
  • a suitably basic organic amine such as choline or meglumine
  • the compound of Formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or />-toluenesulphonate.
  • an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or />-toluenesulphonate.
  • the compounds of the invention exhibit selective activity as agonist of the CBi receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc.
  • This list should however not be interpreted as exhaustive.
  • compounds of the present invention are useful in other disease states in which dysfunction of CBi receptors is present or implicated.
  • the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, obesity, gastrointestinal disorders and cardiovascular disorders. Even furthermore, the compounds of the invention may be useful in enhancing smoking cessation.
  • Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.
  • Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography
  • Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, obesity, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
  • stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema
  • Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care.
  • Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
  • any of the compounds according to the Formula I above for the manufacture of a medicament for the treatment of any of the conditions discussed above.
  • a further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such treatment.
  • the invention provides a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • the present invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • therapy also includes
  • prophylaxis unless there are specific indications to the contrary.
  • therapeutic and “therapeutically” should be contrued accordingly.
  • therapy within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.
  • the compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.
  • the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, transdermally, intracerebroventricularly and by injection into the joints.
  • the route of administration may be oral, intravenous or intramuscular.
  • inert, pharmaceutically acceptable carriers can be either solid and liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture in then poured into convenient sized moulds and allowed to cool and solidify.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.
  • Liquid form compositions include solutions, suspensions, and emulsions.
  • sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.
  • a therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.
  • any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.
  • a further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such therapy.
  • composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.
  • composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.
  • present invention provides a method of preparing the compounds of the present invention.
  • the invention provides a process for preparing a compound of Formula I comprising: reacting a compound of Formula II with Y-H,
  • Y, R 1 and R 2 are defined above;
  • Z is a halogen or -OH.
  • the step of reacting a compound of formula II with a compound of Y-H is carried out in the presence of a coupling reagent, such as HATU, and an amine base, such as DIPEA.
  • a coupling reagent such as HATU
  • an amine base such as DIPEA
  • the invention provides a process for preparing a compound of Formula I
  • X 1 is selected from halogen and OH; and R 2 , R 1 and Y are defined above.
  • the step of reacting a compound of formula III with a compound of R ! -X ! is carried out in the presence of a base, such as sodium hydride, sodium borohydride, aluminum hydride, sodium aluminum hydride, alkaline metal hydride, alkaline earth metal hydride or equivalence thereof.
  • a base such as sodium hydride, sodium borohydride, aluminum hydride, sodium aluminum hydride, alkaline metal hydride, alkaline earth metal hydride or equivalence thereof.
  • BioSignal (I1CB2) membranes are thawed at 37 0 C, passed 3 times through a 25-gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCb, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates.
  • the IC50 of the compounds of the invention at hCBi and I1CB2 are evaluated from 10-point dose-response curves done with 3 H-CP55,940 at 20000 to 25000 dpm per well (0.17-0.21 nM) in a final volume of 300 ⁇ l.
  • the total and non-specific binding are determined in the absence and presence of 0.2 ⁇ M of HU210 respectively.
  • the plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl 2 , 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 0 C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 ⁇ l/well of MS-20 scintillation liquid.
  • TopCount Packard
  • Human CBi receptor from Receptor Biology (hCBi) or human CB 2 receptor membranes (BioSignal) are thawed at 37 0 C, passed 3 times through a 25-gauge blunt- end needle and diluted in the GTP ⁇ S binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl 2 , pH 7.4, 0.1% BSA).
  • the EC 50 and E max of the compounds of the invention are evaluated from 10-point dose-response curves done in 300 ⁇ l with the appropriate amount of membrane protein and 100000-130000 dpm of GTPg 35 S per well (0.11 -0.14 nM).
  • the basal and maximal stimulated binding is determined in absence and presence of 1 ⁇ M (hCB 2 ) or 10 ⁇ M (hCBi) Win 55,212-2 respectively.
  • the membranes are pre-incubated for 5 minutes with 56.25 ⁇ M (hCB2) or 112.5 ⁇ M (hCBi) GDP prior to distribution in plates (15 ⁇ M (hCB 2 ) or 30 ⁇ M (hCBi) GDP final).
  • the plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl 2 , 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 0 C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 ⁇ l/well of MS-20 scintillation liquid.
  • wash buffer 50 mM Tris, 5 mM MgCl 2 , 50 mM NaCl, pH 7.0.
  • Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist.
  • the dissociation constant (Ki) for a particular compound of the invention towards a particular receptor is determined using the following equation:
  • Ki IC 50 /(l+[rad]/Kd), Wherein IC50 is the concentration of the compound of the invention at which 50% displacement has been observed; [rad] is a standard or reference radioactive ligand concentration at that moment; and
  • Kd is the dissociation constant of the radioactive ligand towards the particular receptor.
  • Step A N- [2-(Cyclopropylamino)-2-oxoethyl] -iV,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
  • HATU 145 mg, 0.38 mmol
  • V-cyclopropyl-N ⁇ methylglycinamide 50 mg, 0.38 mmol
  • HATU 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid
  • DIPEA 89 ⁇ L, 0.48 mmol
  • Step G 3-(Tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid
  • Step I 9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid
  • N-(2-(Cyclopropylamino)-2-oxoethyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (490 mg, 1.16 mmol) was separated by preparative chiral HPLC using a Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou, 35% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, at rt in two runs (245 mg loadings).
  • Step A iV-ethyl-iV- [2-(ethylamino)-2-oxoethyl] -9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
  • Step A iV-Ethyl-iV-[2-(isopropylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
  • Step A N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)piperidine-4-carboxamide
  • Boc-Isonipecotic acid 500 mg, 2.18 mmol
  • cyclopropylamine (0.180 mL, 2.61 mmol)
  • HATU 995 mg, 2.61 mmol
  • the solvent was evaporated.
  • the residue was dissolved in EtOAc and washed with 5% KHSO 4 , saturated aqueous NaHCO 3 , brine and dried over anhydrous Na2SO 4 .
  • the solvent was evaporated.
  • the residue was dissolved in 20 mL of IM HCl/AcOH and stirred at rt for 3h. The solvent was evaporated.
  • Step A N-Cyclopropyl-2-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole- ⁇ -carbony ⁇ azetidin-S-y ⁇ acetamide
  • Step B 2-Azetidin-3-yl-iV-cyclopropylacetamide hydrochloride
  • HATU (789 mg, 2.07 mmol) was added to a stirring DMF (25 mL) solution of 9-methyl- 3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxylic acid (500 mg, 1.60 mmol), N,N'-dimethylethylenediamine (0.849 mL, 7.98 mmol) and N,N- diisopropylethylamine (0.417 mL, 2.39 mmol) and was stirred at 23 °C for Ih. The solvent was evaporated.
  • Example 12 N-(2-(3-Cyclopropyl-l-methylthioureido)ethyl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
  • N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide trifluoroacetic acid salt 100 mg, 0.20 mmol was dissolved in dichloromethane (10 mL) containing N,N-diisopropylethylamine (0.053 mL, 0.30 mmol) at 0 0 C. Cyclopropyl isothiocyanate (0.024 mL, 0.26 mmol) was added dropwise and the solution was stirred at rt for Ih.
  • the solution was washed with saturated aqueous NaHCC ⁇ , brine and dried over anhydrous Na2SC>4.
  • the product was purified by reversed-phase HPLC using 30-50% CH 3 CN/H 2 O and lyophilized (80 mg, 82 %).
  • the solution was washed with saturated aqueous NaHCC ⁇ , brine and dried over anhydrous Na2SC>4.
  • the product was purified by reversed-phase HPLC using 40-60% CH 3 CN/H 2 O and lyophilized (50 mg, 87 %).
  • N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide trifluoroacetic acid salt 100 mg, 0.20 mmol was dissolved in DCM (10 mL) containing N,N-diisopropylethylamine (0.088 mL, 0.50 mmol). Cyclopropanecarbonyl chloride (0.022 mL, 0.24 mmol) was added dropwise and the solution was stirred at 23 0 C for Ih.
  • the solution was washed with saturated aqueous NaHCC ⁇ , brine and dried over anhydrous Na2SU4.
  • the product was purified by reversed-phase HPLC using 30-50% CH 3 CN/H 2 O and lyophilized (90 mg, 99 %).
  • Step A N-Cyclopropyl-l- ⁇ [9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazol- ⁇ -yljcarbonylJazetidine-S-carboxamide
  • Step B 3-[(Cyclopropylamino)carbonyl]azetidinium chloride
  • Example 19 Step A: N-Ethyl-N- ⁇ 2-[(l-isocyanocyclopropyl)amino]-2-oxoethyl ⁇ -9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
  • Step C Methyl 7V-ethyl-7V- ⁇ [9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazol-6-yl] carbonyl ⁇ glycinate
  • Step B 3-cyclohexyl-2,3,4,9-tetrahydro-LH-carbazole-6-carboxylic acid
  • Step C 3-cyclohexyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH- carbazole
  • DIPEA (0.65 g, 0.89 mL, 5.0 mmol) was added to a solution of 3-cyclohexyl-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid (0.83 g, 2.5 mmol) and 4-methylpiperidine (0.50 g, 0.60 mL, 5.0 mmol) in DMF (15 mL). Stirring for 20 min, ⁇ ATU (1.43 g, 3.75 mmol) was added at 0 0 C. The mixture was stirred overnight at room temperature, quenched with water (100 mL) and extracted with EtOAc (3x50 mL).
  • Step A 3-cyclohexyl-N- [2-(cyclopropylamino)-2-oxoethyl] -N-methyl-9-
  • Step B 3-cyclohexyl-iV-[2-(cyclopropylamino)-2-oxoethyl]-iV-methyl-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
  • reaction mixture was stirred for 2 hr at r.t, and followed by addition of (S)-tetrahydrofuran-3 -amine (35.0 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated.
  • the product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water N-ethyl-9-methyl-N-(2-oxo-2-((S)- tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (8.0 mg, 8.5 %).
  • reaction mixture was stirred for 2 hr at r.t, and followed by addition of (R)-tetrahydrofuran-3 -amine (35.0 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated.
  • the product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water N-ethyl-9-methyl-N-(2-oxo-2-((R)- tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (9.0 mg, 9.6 %).
  • reaction mixture was stirred for 2 hr at r.t, and followed by addition of oxetan-3-amine, HCl (44.0 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated.
  • the product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water and purified by high pH HPLC (20 -40) again to provide the title compound N-ethyl-9-methyl-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (34.0 mg, 37.3 %).
  • the product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-ethyl-N-(4-hydroxybutyl)- 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (52.0 mg, 62.7 %) as a white solid.
  • the product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-(2- (cyclopropylamino)-2-oxoethyl)-N-ethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (26.0 mg, 20.42 %) as white solid.
  • the product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-((S)- 1 -(2-fluoroethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (18.0 mg, 13.5 %) as white solid.
  • the product was purified by preparative reverse- phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-((S)-l-(cyclopropylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (75 mg, 57 %) as white solid.
  • Step A N-(4-(Cyclopropylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
  • Step B 4-(cyclopropylamino)-4-oxobutan-l-aminium chloride
  • the product was purified by preparative reverse- phase HPLC using an acetonitrile gradient 20 to 50 % in water after three times to provide the title compound N-ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (22.86 %) as white solid (54 mg).
  • HATU (71.8 mg, 0.19 mmol) and ethylamine hydrochloride (15.39 mg, 0.19 mmol) were added slowly at 0 0 C to a solution of (2R)-2-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)propanoic acid (37.6 mg, 0.09 mmol) and N,N-diisopropylethylamine (0.049 mL, 0.28 mmol) in DMF (0.749 mL). Reaction mixture was stirred at room temperature for an O/N.
  • Step A N-ethyl-N-(2-hydroxypropyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
  • N-ethyl-N-(2-hydroxypropyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (21.4 mg, 16 %) was purified by Prep-HPLC reverse-phase using a low pH 40-60% ACN/water system.
  • Step B N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
  • N-ethyl-N-(2-hydroxyethyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (179 mg, 56.2 %) was purified by Prep-HPLC reverse-phase using a low pH 50-70% ACN/water system.
  • Step C N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
  • reaction mixture was stirred for 2 hr at r.t, and followed by addition of 3-aminopropanenitrile (41.9 mg, 0.60 mmol) and HATU (125 mg, 0.33 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated.
  • the product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water to provide N-(2-(2- cyanoethylamino)-2-oxoethyl)-N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (66.0 mg, 41.8 %).
  • Step A (3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)piperidine-3-carboxamide
  • HATU 141 mg, 0.37 mmol
  • cyclopropylamine 0.026 mL, 0.37 mmol
  • the solvent was evaporated.
  • the residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4.
  • the product was purified by reversed-phase HPLC using 50-70%B and lyophilized.
  • Step B (3S)-Ethyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidine-3-carboxylate
  • the molecular structure is shown in the following diagram.
  • Chiral analytical HPLC ChiraPak AD column, 15% MeOH:iPrOH / hexanes, lmL/min, 30 min run, 25°C. Products needed to be repurif ⁇ ed by reversed-phase HPLC as their NMR showed the presence of impurities.
  • Reversed-phase purification Gilson system equipped with Luna C-18 column, 250 X 21.2 mm, 15u. Mobile phase: 30- 50%B; A: H 2 O with 0.05% TFA v/v; B: CH 3 CN; 30mL/min, 25 min run, rt.
  • Step A (3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (Isomers 1 and 2).
  • Step C (3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole- ⁇ -carbony ⁇ pyrrolidine-S-carboxamide
  • Step B (RJ-N-Cyclopropylpyrrolidine-S-carboxamide hydrochloride
  • Step C (3R)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole- ⁇ -carbony ⁇ pyrrolidine-S-carboxamide
  • Step A N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide
  • Methyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)pyrrolidine-3-carboxylate (100 mg, 0.24 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.471 mL, 0.47 mmol) (IM) at 23 0 C for Ih. The solvent was evaporated.
  • the product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H 2 O with 0.05% TFA v/v; B: CH 3 CN; 30mL/min, 25 min run, rt.
  • Step B Methyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)pyrrolidine-3-carboxylate
  • Step B (R)-N-Cyclopropyl-2-(pyrrolidin-3-yl)acetamide hydrochloride
  • Step A N-((3S)-l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide
  • Step B tert-Butyl (3S)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole- ⁇ -carbony ⁇ pyrrolidin-S-ylcarbamate
  • Step A (3S)-N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (Isomers 1 and 2).
  • Step B (S)-N-(2-Fluoroethyl)pyrrolidine-3-carboxamide hydrochloride
  • Step C (3S)-N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole- ⁇ -carbony ⁇ pyrrolidine-S-carboxamide
  • Step A (3S)-N-(Cyclopropylmethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- l ⁇ -tetrahydro-lH-carbazole-o-carbony ⁇ pyrrolidine-S-carboxamide
  • Step B (S)-N-(Cyclopropylmethyl)pyrrolidine-3-carboxamide hydrochloride
  • Step A N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-4-yl)cyclopropanecarboxamide
  • Step B tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-4-ylcarbamate
  • Step A N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-yl)cyclopropanecarboxamide
  • Step B tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-ylcarbamate
  • Step A (R)-(3S)-N-(2,2-Difluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- l ⁇ -tetrahydro-lH-carbazole-o-carbony ⁇ pyrrolidine-S-carboxamide.
  • Step B (S)-N-(2,2-Difluoroethyl)pyrrolidine-3-carboxamide hydrochloride
  • Step C (R)-Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate and (S)-Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxylate
  • Step D (R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid.
  • Step A (R)-(3S)-N-Ethyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole- ⁇ -carbony ⁇ pyrrolidine-S-carboxamide.
  • Step B (S)-N-E thylpyrrolidine-3-carboxamide hydrochloride
  • Step B (3-Aminopiperidin-1 -yl)(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-1 H-carbazol-6-yl)methanone
  • N,N-diisopropylethylamine (0.050 mL, 0.28 mmol) at 23 0 C for Ih.
  • the solvent was evaporated.
  • the product was directly purified by reversed-phase HPLC and lyophilized.
  • Reversed-phase purification Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: 30-50%B; A: H 2 O with 0.05% TFA v/v; B: CH 3 CN;
  • the product was dissolved in DMF (5.00 mL) containing N,N-diisopropylethylamine (0.102 mL, 0.59 mmol) and ethanolamine (0.017 mL, 0.28 mmol) along with HATU (107 mg, 0.28 mmol) were added. The solution was stirred at 23 0 C for Ih. The solvent was evaporated. The product was directly purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u.
  • Step B Methyl 4-(tert-butoxycarbonyl(methyl)amino)butanoate
  • Step D (R)-Methyl 4-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamido)butanoate (Isomer 1).
  • Step B (R)- tert-Butyl (3S)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)piperidin-3-ylcarbamate.
  • Example 75 (R)-N,9-Dimethyl-N-(4-oxo-4-((S)-tetrahydrofuran-3-ylamino)butyl)-3- (tetrahydro-lH-pyran ⁇ -y ⁇ -l ⁇ P-tetrahydro-lH-carbazole- ⁇ -carboxamide.
  • Step B (R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)butanoic acid (Isomer 1)
  • Step A (R)-N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3- (tetrahydro-lH-pyran ⁇ -yl ⁇ jS ⁇ P-tetrahydro-lH-carbazole-o-carboxamide
  • Step B Methyl S-Ctetrahydro- ⁇ H-pyran ⁇ -yl ⁇ S ⁇ -tetrahydro-lH-carbazole- ⁇ - carboxylate
  • Step C (R)-Methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylate and (S)-Methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate
  • Step D (R)- Methyl 9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylate.
  • the mixture is diluted in IN NaOH (50 mL) and extracted 3 times with EtOAc (3X50 mL). The combined organic phases are dried over sodium sulfate, the mixture is filtered, and the solvent is evaporated.
  • aqueous phase is extracted 3 times with EtOAc (3X75mL), and organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated.
  • Step A 9-[(Dimethylamino)carbonyl]-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid
  • Step B N6-Ethyl-N6-(2-(ethylamino)-2-oxoethyl)-N9,N9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-3,4-dihydro-lH-carbazole-6,9(2H)-dicarboxamide
  • the aqueous phase is extracted 3 times with EtOAc (3X75mL).
  • the organic phases are combined and dried over sodium sulfate.
  • the mixture is filtered, and the solvent is evaporated.
  • N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide (0.996 g, 2.42 mmol) is mixed in THF (40.0 mL) and cooled to 0 0 C. Solid KHMDS (2.414 g, 12.10 mmol) is added, and the mixture is stirred at 0 0 C for 30 minutes. Ethyl 2-iodoacetate (1.431 mL, 12.10 mmol) is added, and the mixture is stirred for 30 minutes.
  • the mixture is diluted with a saturated solution of ammonium chloride (75mL), and then extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated.
  • the mixture is washed with EtOAc (5OmL), and the organic phase is extracted 3 times with IN NaOH (3X50 mL).
  • the aqueous phases are combined, and 6N HCl is added until the pH is acidic, as indicated by pH paper.
  • the aqueous phase is extracted 3 times with EtOAc (3X50mL).
  • the organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated.
  • the mixture is stirred at room temperature for 1 hour and then diluted with IN HCl (75mL).
  • the aqueous phase is extracted 3 times with EtOAc (3X75mL).
  • the organic phases are combined and dried over sodium sulfate.
  • the mixture is filtered, and the solvent is evaporated.
  • Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)- 3,4-dihydro-lH-carbazol-9(2H)-yl)acetate (105 mg, 0.21 mmol) is mixed in THF (10.0 mL) and cooled to 0 0 C. Methylmagnesium bromide (0.482 mL, 0.68 mmol) is added, and the mixture is stirred for 45 minutes. The mixture is diluted with a saturated solution of ammonium chloride (75mL) and then extracted 3 times with EtOAc (3X75mL).
  • Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)- 3,4-dihydro-lH-carbazol-9(2H)-yl)acetate (105 mg, 0.21 mmol) is mixed in THF (10.0 mL) and cooled to 0 0 C. LAH (0.264 mL, 0.53 mmol) is added, and the mixture is stirred at 0 0 C for 20 minutes. The mixture is diluted with a saturated solution of ammonium chloride (75mL) and extracted 3 times with EtOAc (3X75mL).
  • the mixture is filtered, and the solvent is evaporated.
  • the aqueous phase is extracted 3 times with EtOAc (3X75mL).
  • the organic phases are combined and dried over sodium sulfate.
  • the mixture is filtered, and the solvent is evaporated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Description

CANNABINOID RECEPTOR LIGANDS
BACKGROUND OF THE INVENTION
1. Field of the invention
The invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.
2. Discussion of Relevant Technology
Pain management has been studied for many years. It is known that cannabinoid receptor (e.g., CBi receptor, CB2 receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CBi and/or CB2 receptors. Generally, CBi receptors are located predominately in the central nervous system, whereas CB2 receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system.
While CBi receptor agonists, such as Δ9-tetrahydrocannabinol (Δ9-THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side-effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc. These undesired side effects are known to be mediated by the CBi receptors located in CNS. There are lines of evidence, however, suggesting that CBi agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile.
Therefore, there is a need for new CBi receptor ligands such as agonists that may be useful in managing pain or treating other related symptoms or diseases with reduced or minimal undesirable CNS side-effects. DESCRIPTION OF THE EMBODIMENTS
The present invention provides CBi receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.
The term "Cm_n" or "Cm_n group" refers to any group having m to n carbon atoms. The term "alkyl" refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms. Illustrative examples of alkyls include, but are not limited to, Ci_6alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3 -methyl- 1 -butyl, 2- methy 1-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3 -methyl- 1-pentyl, 4-methyl- 1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3, 3 -dimethyl- 1 -butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longer alkyl groups, such as heptyl, and octyl. An alkyl can be unsubstituted or substituted with one or two suitable substituents.
The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
The term "alkylidene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together and the two radicals are located on the same carbon atom.
The term "alkenyl" refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms. The double bond of an alkenyl can be unconjugated or conjugated to another unsaturated group. Suitable alkenyl groups include, but are not limited to C2-6alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)- pentenyl. An alkenyl can be unsubstituted or substituted with one or two suitable substituents.
The term "cycloalkyl" refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms. Examples of cycloalkyls include, but are not limited to, C3_7cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl can be unsubstituted or substituted by one or two suitable substituents. Preferably, the cycloalkyl is a monocyclic ring or bicyclic ring.
The term "cycloalkenyl" refers to a monovalent ring- containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.
The term "aryl" refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms. The term "heterocycle" refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms there between. Heterocycle may have aromatic character or may not have aromatic character.
The term "heterocyclyl" refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom. Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro- pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3- dihydropyranyl, tetrahydropyranyl, 1 ,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-lH-azepinyl, homopiperazinyl, 1,3- dioxepanyl, 4,7-dihydro-l,3-dioxepinyl, and hexamethylene oxidyl.
In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3- triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4- thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl. Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1 ,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.
In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.
The term "heteroaryl" refers to a heterocyclyl having aromatic character (e.g., 4n + 2 delocalized electrons.) The term "heterocylcoalkyl" refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and form 1 to 3 heteroatoms, referred to herein as C3. 6heterocycloalkyl. The term "six-membered" refers to a group having a ring that contains six ring atoms. The term "five-membered" refers to a group having a ring that contains five ring atoms.
A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.
A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
The term "alkoxy" refers to radicals of the general formula -O-R, wherein R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.
Halogen includes fluorine, chlorine, bromine and iodine.
"RT" or "rt" means room temperature.
In one aspect, an embodiment of the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, a diastereomer, an enantiomer, or a mixture thereof:
Figure imgf000006_0001
wherein Y is selected from
Figure imgf000007_0001
Figure imgf000007_0002
R is selected from -H, Ci-βalkyl, C2-6alkenyl, C3_6cycloalkyl, C3_6cycloalkyl-Ci_ 4alkyl, -C(=O)-NR14R15, -SC=O)2-NR14R15, -S(=O)2-Ci_6alkyl, -S(=0)2-C6-ioaryl, - S(=O)2-C2-5lieteroaryl, -C(=O)-C1-6alkyl, -C(=O)-O-C1-6alkyl, C6-ioaryl-Ci_4alkyl and C2- 5heteroaryl-Ci-4alkyl, wherein said Ci^alkyl, C2-6alkenyl, -S(=O)2-Ci_6alkyl, -S(=O)2-C6- loaryl, -S(=O)2-C2_5lieteroaryl, -C(=0)-Ci_6alkyl, C6-ioaryl-Ci-4alkyl and C2_5lieteroaryl- Ci_4alkyl used in defining R are optionally substituted with one or more groups selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(=0> NH2, -C(O)-NR2 and -C(O)-NHR;
R2 is selected from Cs-όheterocycloalkyl, C3-6heterocycloalkyl-Ci-4alkyl, C3_6cycloalkyl, C3-6Cycloalkyl-Ci-4alkyl, Ci-βalkyl, C2-6alkenyl, Cβ-ioaryl, Co-ioaryl-Ci- 4alkyl, C2-6heteroaryl, C2-6heteroaryl-Ci-4alkyl, -C(=O)-Ci_6alkyl, -C(=O)-C3-6cycloalkyl and -C(=NH)-Ci_6alkyl, wherein said C3_6heterocycloalkyl, C3_6heterocycloalkyl-Ci_ 4alkyl, C3-6cycloalkyl, C3-6cycloalkyl-Ci_4alkyl, Ci-βalkyl, C2-6alkenyl, Cβ-ioaryl, Cδ-ioaryl- Ci_4alkyl, C2-6heteroaryl, C2-6heteroaryl-Ci-4alkyl, -C(=O)-Ci_6alkyl, -C(O)-C3- όCycloalkyl and -C(=NH)-Ci_6alkyl used in defining R2 are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -CN, -C(O)-NH2 and -C(O)-NHR; R3 and R4 are independently selected from -H, C3-6cycloalkyl,
C^δheterocycloalkyl, C2_sheteroaryl, Cβ-ioaryl, Ci-βalkyl, Ci_6alkoxy, amino, Ci- galkylamino, diCi_6alkylamino, -C(O)-C1-6alkyl, -C(O)-0-C1-6alkyl, -C(O)-C3- ecycloalkyl, -C(O)-NR14R15 and -S(=O)2-NR14R15, wherein said C3-6cycloalkyl, C^δheterocycloalkyl, C2_sheteroaryl, Cβ-ioaryl, Ci-βalkyl, Ci_6alkoxy, Ci_6alkylamino, diCi_6alkylamino, -C(O)-C1-6alkyl, -C(O)-0-C1-6alkyl, and -C(=O)-C3-6cycloalkyl used in defining R3 and R4 are optionally substituted with one or more groups selected from - OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -Q=O)-NH2, -CN, -C(=O)-NR2 and -C(O)-NHR;
R5 is selected from -H, Ci-6alkyl, and C3-6cycloalkyl;
R6 is independently selected from -H, -CN, -NO2, Ci-βalkoxy, halogen, Ci^alkyl, -OH, -NH2, -NHC(O)R12 and -C(O)NR12R13;
R12 and R13 are independently selected from -H, Ci-6alkyl, Ci_6alkoxy, C3- 6heterocycloalkyl, C3_6Cycloalkyl-Ci_4alkyl, and C3_6cycloalkyl wherein said Ci_6alkyl, Ci- βalkoxy, Cs-όheterocycloalkyl, C3_6Cycloalkyl-Ci_4alkyl and C3_6cycloalkyl used in defining R12 and R13 are optionally substituted with one or more halogens or -OH; R14 and R15 are independently selected from -H, Ci-6alkyl, Cό-ioaryl, Cό-ioaryl-Ci-
4alkyl, C2_sheterocyclyl, C2-5heterocyclyl-Ci-4alkyl, C2_6alkenyl, C3_6cycloalkyl, and C3- 6cycloalkyl-Ci_4alkyl, N,N-di(Ci_4alkyl)amido-Ci_6alkyl, hydroxy-Ci_6alkyl and Ci- 6alkoxy-Ci_6alkyl that are optionally substituted with one or groups selected from halogen, -OH, -CN, -NH2 and methoxy; Q is independently selected from Ci^alkylene, Ci^alkylidene and
Figure imgf000008_0001
, wherein said Ci_6alkylene and Ci_6alkylidene are optionally substituted with on or more groups selected from -OR, -R, hydroxy-Ci_6alkyl, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)- NR2 and -C(O)-NHR; X is selected from -OH, halogen or -OR; n is independently selected from 1 , 2 and 3 ; p, q and m are independently selected from O, 1, 2 and 3; and
R is independently Ci_6alkyl.
In another embodiment, R1 is selected from Ci-6alkyl, C3_6cycloalkyl, C3- 6cycloalkyl-Ci_4alkyl, and -S(=O)2-Ci_6alkyl;
R2 is selected from Ci-6alkyl, C2-sheterocycloalkyl and C3_6cycloalkyl wherein said Ci-6alkyl, C2-sheterocycloalkyl and C3_6cycloalkyl used in defining R2 is optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2- R, halogen, -OH, -NH2, -NHR, -CN, -C(O)-NH2, and -C(O)-NHR; R3 and R4 are independently selected from -H, C3-6Cycloalkyl, C3. 6heterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and Ci^alkyl, wherein said C3-6cycloalkyl, Q-δheterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and Ci_6alkyl used in defining R is optionally substituted with one or more groups selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(=O)-NH2, -C(=O)-NR2, and -C(O)-NHR;
R5 is selected from -H, Ci_6alkyl, and C3_6cycloalkyl;
R6 is selected from C1-6alkyl, -OH, -NH2, -NHC(=O)R12 and -C(=O)NR12R13;
R12 and R13 are independently selected from -H, Ci-6alkyl, Ci_6alkoxy, C3. όheterocycloalkyl, C3_6Cycloalkyl-Ci_4alkyl, and C3_6cycloalkyl wherein said Ci_6alkyl, Ci- βalkoxy, Q-όheterocycloalkyl, C3-6Cycloalkyl-Ci-4alkyl, and C3_6cycloalkyl used in defining R12 and R13 is optionally substituted with one or more haolgens; and
R is independently Ci-βalkyl.
In another embodiment, R1 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1- butyl, 2-butyl, t-butyl, allyl, -S(O)2-CH3, -S(=O)2-CH2CH3, 2-methoxyethyl, tetrahydropyran-4-yl-methyl, 1-propylsulfonyl, 2-propylsulfonyl, cyclopropylsulfonyl, phenyl, phenylsulfonyl, 2-(methoxycarbonyl)-phenylsulfonyl; 2-(hydroxycarbonyl)- phenylsulfonyl, 1 -methyl- lH-imidazol-4-yl-sulfonyl, lH-imidazol-1-yl-sulfonyl, (5- methylisoxazol-4-yl)sulfonyl, morpholin-4-ylcarbonyl, 4-amino-phenyl, -CH2-C(O)- N(CH3)2, -C(O)-N(CH3)2, -S(=O)2-N(CH3)2, -S(=O)2-NHCH2CH3, -C(O)-
CH2CH2CH3, -CH2-C(O)-OCH3, -CH2-C(O)-OCH2CH3, -CH2-CO2H, benzyl, 4- aminobenzyl, 4-nitrobenzyl, 4-methylsulfonyl-benzyl, 4-methylthio-benzyl, 4- acetylamino-benzyl, 4-methoxy-benzyl, 4-ethoxy -benzyl, 2,6-difluorobenzyl, (6-chloro- l,3-benzodioxol-5-yl)methyl, (5 -ethoxycarbonyl)-fur-2-yl- methyl, (2-methyl-l,3-thiazol- 4-yl)-methyl, (5-methyl-isoxazol-4-yl)-methyl, pyridin-2-ylmethyl, cyclobutylmethyl, and cyclopropylmethyl.
In a further embodiment, R2 is selected from methyl, ethyl, isopropyl, propyl, 2- methy-propyl, 1 -butyl, tert-butyl, 1-pentyl, l-acetyl-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro-2H-pyranyl, tetrahydro-thiopyran-4-yl, 2-pyrimidinyl, 1- iminoethyl, 2-pyridinyl, 3,4,5,6-tetrahydropyrdin-2-yl, 3,4-dihydro-2H-pyrrol-5-yl, 2- pyridinyl- methyl, 3-pyridinylmethyl, 4-pyridinylmethyl, l-methyl-4-piperidinyl, 4- piperidinyl, (6-methyl-pyridin-2-yl)methyl, (2-ethyl-4-methyl- lH-imidazol-5-yl)methyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-3-ylmethyl, 1 -ethyl- IH- pyrazol-4-yl, l,3-dimethyl-lH-pyrazol-5-yl, (3-methylpyridin-4-yl)methyl, l,3-oxazol-2- ylmethyl, l,3-oxazol-5-ylmethyl, 2-(tetrahydro-2H-pyran-4-yl)ethyl, tetrahydro-2H- pyran-4-ylmethyl, 2-phenylethyl, 2-methoxybenzyl, 3,3,3-trifluoropropyl, 2,2- difluoroethyl, 2-hydroxycyclopentyl, (l-ethyl-3 -methyl- lH-pyrazol-5-yl)methyl, 2,1,3- benzoxadiazol-5-ylmethyl, 3-thienylmethyl, 2-trifluoromethyl-benzyl, 3-methylbutyl, cyclohex-3 -en- 1 -ylmethyl, 2-fluoro-6-methoxybenzyl, 2-phenyl-propyl, 2-ethyl-butyl, cyclobutylcarbonyl, 2,2-difluoropropanoyl, cyclopentylcarbonyl, tetrahydro-2H-pyran-4- ylcarbonyl, cyclopropylcarbonyl, propylcarbonyl, N-ethylaminocarbonyl, N- isopropylaminocarbonyl, cyclopropylsulfonyl, and ethylsulfonyl.
In another embodiment, Y is
Figure imgf000010_0001
R5 is selected from -H, Ci-6alkyl, and C3-6cycloalkyl; R3 and R4 are independently selected from -H, C3-6cycloalkyl, C3-
6heterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and Ci^alkyl, wherein said Ci-βalkyl, Cs-δheterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and C3- όCycloalkyl used in defining R3 and R4 are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, - C(O)-NH2, -CN, and -C(=0)-NHR;
Q is Ci-6alkylene or Ci_6alkylidene, optionally substituted with one or more -CH2OH; and
R is Ci_6alkyl.
In another embodiment, Y is
Figure imgf000010_0002
R5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl; R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl used in defining R3 and R4 are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen; -OH, -NH2, -NHR, -C(O)-NH2, -CN and -C(O)-NHR; Q is Ci_6alkylene or Ci_6alkylidene, optionally substituted with one or more
-CH2OH; and
R is C1-6alkyl.
In an even further embodiment, Y is
Figure imgf000011_0001
R5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl;
R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl used in defining R3 and R4 are optionally substituted with one or more groups selected from fluoro, -CN, -OH, and methoxy; R1 is selected from methyl, ethyl, -S(O)2-CH3, -S(O)2-CH2CH3, and 2- propylsulfonyl;
Q is selected from Ci-6alkylene, hydroxymethyl-Ci_6alkylene, and Ci_6alkylidene; and
R2 is tetrahydropyranyl. In another embodiment, Y is
Figure imgf000012_0001
,
R5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl;
R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl and cyclohexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, and cyclohexyl used in defining R3 and R4 are optionally substituted with one or more fluoro;
R1 is selected from methyl, ethyl, -S(=O)2-CH3, -S(=O)2-CH2CH3, and 2- propylsulfonyl;
Q . i.s
Figure imgf000012_0003
R is tetrahydropyranyl; n is selected from 1,2 and 3; and p, q are independently selected from 0, 1, 2 and 3.
In a further embodiment, Y is
Figure imgf000012_0002
R6 ' iiss sseelleecctteedd from C1-6alkyl, -OH, -NH2, -NHC(=O)R12 and -C(=O)NR12R13 wherein R12 and R13 are independently selected from -H, Ci_6alkyl, and C3_6Cycloalkyl wherein said Ci_6alkyl and C3_6cycloalkyl used in defining R12 and R13 is optionally substituted with one or more halogens; and n is 1, 2, or 3; and m is 1. In an even further embodiment, Y is
Figure imgf000013_0001
;
R6 is selected from methyl, -OH, -NH2, -NHC(=O)R12 and -C(=O)NR12R13 wherein R12 and R13 are independently selected from -H, Ci_6alkyl, and C3_6cycloalkyl wherein said Ci_6alkyl and C3_6cycloalkyl used in defining R12 and R13 is optionally substituted with one or more halogens;
R1 is selected from methyl, ethyl, -S(=O)2-CH3, -SC=O)2-CH2CH3, and 2- propylsulfonyl;
R2 is selected from C3_6cycloalkyl, tetrahydropyranyl and Ci_6alkyl; and n is 1,2 or 3; and m is 1.
In another embodiment, Y is
Figure imgf000013_0002
R > 5 is selected from -H, Ci_6alkyl, and C3_6cycloalkyl;
R and R , 4 are independently selected from -H, Ci_6alkyl, -C(=0)-Ci_6alkyl, -C(=O)-C3-6cycloalkyl, -C(=O)-NR14R15 and -S(O)-NR14R15; wherein said C1-6alkyl, -C(=O)-Ci_6alkyl and -C(=O)-C3-6cycloalkyl used in defining R3 and R4 is optionally substituted with one or more group selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(O)-NH2, -C(O)-NR2 and -C(O)-NHR;
Q is Ci-6alkylene or Ci_6alkylidene;
R is Ci-βalkyl; and
R14 and R15 are independently selected from -H, Ci-βalkyl, Cβ-ioaryl, Cδ-ioaryl-Ci. 4alkyl, C3_6heterocyclyl, C3-6heterocyclyl-Ci-4alkyl, C2_6alkenyl, C3_6cycloalkyl, C3. 6Cycloalkyl-Ci-4alkyl, N,N-di(Ci-4alkyl)amido-Ci-6alkyl, hydroxy-Ci_6alkyl and Ci- 6alkoxy-Ci_6alkyl that are optionally substituted with one or more groups selected from halogen, -OH, -CN, -NH2 and methoxy. In another embodiment, Y is
Figure imgf000014_0001
R5 is methyl; and
R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, cyclohexyl, - C(=O)-cyclopropyl, -CO2CH3, and -S(=O)2-NH-cyclopropyl.
In another embodiment, Y is
Figure imgf000014_0002
R3 and R4 are independently selected from -H, Ci-βalkyl, Ci_6cycloalkyl, C3. 6heterocycloalkyl, wherein said Chalky 1, Ci-3cycloalkyl, and Q-δheterocycloalkyl are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2- R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)-NR2 and -C(O)- NHR; and
R is C1-6alkyl.
In a further embodiment, Y i .s
Figure imgf000014_0003
; and R3 and R4 are independently selected from -H, methyl, and ethyl wherein said methyl and ethyl are optionally substituted with -OH or halogen.
In another embodiment, R2 is tetrahydropyranyl. In a further embodiment, R2 is 4-tetrahydropyranyl. In another embodiment, a compound of the invention may be selected from:
N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(+)-N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; (-)-N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-N-[2-(ethylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-[2-(isopropylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidine-4-carboxamide;
N-Ethyl-N-{2-[(2-fluoroethyl)amino]-2-oxoethyl}-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-[2-(Cyclopropylamino)-2-oxoethyl]-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Cyclopropyl-2-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^azetidin-S-y^acetamide;
N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide; N-(2-(3-Cyclopropyl-l-methylureido)ethyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(3 -Cyclopropyl- 1 -methylthioureido)ethyl)-N,9-dimethyl-3 -(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-{2-[(2-Fluoroethyl)amino]-2-oxoethyl}-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-[2-(methylamino)-2-oxoethyl]-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
Methyl, methyl[2-(methyl{[9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazol-6-yl]carbonyl}amino)ethyl]carbamate; N-{2-[(Cyclopropylcarbonyl)(methyl)amino]ethyl}-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Cyclopropyl- 1 - { [9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazol-β-yljcarbonyljpiperidine-S-carboxamide;
N-Cyclopropyl- 1 - { [9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazol-β-yljcarbonyljazetidine-S-carboxamide; N-Ethyl-N-{2-[(l-isocyanocyclopropyl)amino]-2-oxoethyl}-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(3-(cyclopropylamino)-3-oxopropyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Cyclopropylamino)-4-oxobutyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Cyclopropylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Methylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Ethylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
3-cyclohexyl-9-methyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH- carbazole;
3-cyclohexyl-9-ethyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3 ,4,9-tetrahydro- IH- carbazole;
3-cyclohexyl-6-[(4-methylpiperidin-l-yl)carbonyl]-9-(methylsulfonyl)-2,3,4,9- tetrahydro- lH-carbazole;
3-cyclohexyl-9-(ethylsulfonyl)-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro- lH-carbazole; 3-cyclohexyl-N-[2-(cyclopropylamino)-2-oxoethyl]-N-methyl-9-(methylsulfonyl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
3-cyclohexyl-N-[2-(cyclopropylamino)-2-oxoethyl]-9-(isopropylsulfonyl)-N-methyl-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-(2-oxo-2-(tetrahydro-2H-pyran-4-ylamino)ethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-9-methyl-N-(2-oxo-2-((S)-tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-(2-oxo-2-((R)-tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-9-methyl-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-N-(4-hydroxybutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(Cyanomethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-((S)- 1 -(2-Fluoroethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3 -(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; N-((S)- 1 -(Cyclopropylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-(4-(Cyclopropylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-(l-(Cyclopropylcarbamoyl)cyclopropyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-Fluoroethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide;
N-Ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-((R)- 1 -(2-fluoroethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3 -(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-((R)- 1 -(ethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-N-(2-hydroxypropyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(2-(2-Cyanoethylamino)-2-oxoethyl)-N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(3 S)-N-Cyclopropyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^piperidine-S-carboxamide; (3 S)-N-cyclopropyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^piperidine-S-carboxamide;
N,9-Dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-ethyl-N-(2-hydroxyethyl)-9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3R)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
N-(2-Fluoroethyl)- 1 -(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^pyrrolidine-S-carboxamide; N-Ethyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)pyrrolidine-3-carboxamide;
N-Cyclopropyl-2-((3R)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidin-S-y^acetamide;
N-((3 S)- 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide; (3S)-N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3S)-N-(Cyclopropylmethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-β-carbony^pyrrolidine-S-carboxamide; N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-4-yl)cyclopropanecarboxamide;
N-( 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-3-yl)cyclopropanecarboxamide;
(3S)-N-(2,2-Difluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3 S)-N-Ethyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
N-( 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-3-yl)propionamide; N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-3-yl)isobutyramide;
2-Cyclopropyl-N-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^piperidin-S-y^acetamide;
N-(4-(2-Hydroxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-((3 S)- 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-3-yl)cyclopropanecarboxamide;
N,9-Dimethyl-N-(4-oxo-4-((S)-tetrahydrofuran-3-ylamino)butyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N,9-Dimethyl-N-(4-(oxetan-3-ylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(3-Hydroxypropylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; (9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((R)-3 -hydroxypyrrolidin- 1 -yl)methanone;
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((S)-3-hydroxypyrrolidin- 1 -yl)methanone; (9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazol-6- yl)((R)-3 -hydroxypiperidin- 1 -yl)methanone;
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6-yl)(4- hydroxypiperidin- 1 -yl)methanone;
N6-Ethyl-N6-(2-(ethylamino)-2-oxoethyl)-N9,N9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-3,4-dihydro- lH-carbazole-6,9(2H)-dicarboxamide;
N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)-
3,4-dihydro-lH-carbazol-9(2H)-yl)acetate; 2-(6-(Ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3 -(tetrahydro-2H-pyran-4-yl)-3 ,A- dihydro- lH-carbazol-9(2H)-yl)acetic acid;
9-(2-(diethylamino)-2-oxoethyl)-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-(methylamino)-2-oxoethyl)-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-hydroxy-2-methylpropyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-hydroxyethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; 2-(N-Ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid;
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-methoxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-9-(ethylsulfonyl)-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-[2-(cyclopropylamino)-2-oxoethyl]-9-(cyclopropylmethyl)-N-ethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; 9-(Cyclopropylmethyl)-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
9-Cyclobutyl-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-Cyclobutyl-N-ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4- yl)-2 ,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxamide;
9-Cyclobutyl-N-ethyl-N-(2-(isopropylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-Ethyl-N-methyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; 9-Ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-N-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(2,2-difluoroethylamino)-4-oxobutyl)-9-ethyl-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
9-Ethyl-N-methyl-N-(4-oxo-4-(2,2,2-trifluoroethylamino)butyl)-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-Ethyl-N-(4-(2-hydroxyethylamino)-4-oxobutyl)-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(4-(Ethylamino)-4-oxobutyl)-9-(2-fluoroethyl)-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-9-(ethylsulfonyl)-N-(2-(3-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-ethyl-9-(ethylsulfonyl)-N-(2-(3-fluoropropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-9-(ethylsulfonyl)-N-(2-(2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; 2-(N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid;
N-(2-(cyclopropylamino)-2-oxoethyl)-9-(ethylsulfonyl)-N-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(2R)- 1 -(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole- 6-carbonyl)-N-(2-fluoroethyl)pyrrolidine-2-carboxamide;
N-(2-(2,2-difluoroethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-ethyl-N-(2-((R)-2-hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-ethyl-N-(2-((S)-2-hydroxypropylamino)-2-oxoethyl)-9-methyl-3 -(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-N-(2-(2-methoxyethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-((R)-l-(cyclopropylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(R)-N-((S)-l-Hydroxy-5-(oxetan-3-ylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-((S)-5-(2,2-Difluoroethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; (R)-N-((S)-5-(2-Fluoroethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-(4-(Cyanomethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(R)-N-((S)-l-Hydroxy-5-(methylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; (R)-N-((S)-l-Hydroxy-5-(isopropylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-((S)-5-(Ethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; (R)-N-(4-(Methoxyamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(R)-N-(4-(2,2-Dimethylhydrazinyl)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-(4-(2-Methoxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2 ,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxamide;
(R)-N-(4-(lH-Pyrrol-l-ylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-Ethyl-N-(4-(2-hydroxyethylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; (R)-N-(4-(2-Hydroxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; and pharmaceutically acceptable salts thereof.
It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.
It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the Formula I. It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the Formula I. Within the scope of the invention are also salts of the compounds of the Formula
I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.
In one embodiment, the compound of Formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or />-toluenesulphonate. We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists of CBi receptors. More particularly, the compounds of the invention exhibit selective activity as agonist of the CBi receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction of CBi receptors is present or implicated. Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, obesity, gastrointestinal disorders and cardiovascular disorders. Even furthermore, the compounds of the invention may be useful in enhancing smoking cessation.
Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.
Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography
(PET).
Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, obesity, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
Also within the scope of the invention is the use of any of the compounds according to the Formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above. A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such treatment. Thus, the invention provides a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
In a further aspect, the present invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy. In the context of the present specification, the term "therapy" also includes
"prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be contrued accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.
The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.
In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, transdermally, intracerebroventricularly and by injection into the joints.
In one embodiment of the invention, the route of administration may be oral, intravenous or intramuscular.
The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient. For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture in then poured into convenient sized moulds and allowed to cool and solidify.
Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.
Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.
A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.
Within the scope of the invention is the use of any compound of Formula I as defined above for the manufacture of a medicament.
Also within the scope of the invention is the use of any compound of Formula I for the manufacture of a medicament for the therapy of pain.
Additionally provided is the use of any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain. A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such therapy.
Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.
Further, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above. In a further aspect, the present invention provides a method of preparing the compounds of the present invention.
In one embodiment, the invention provides a process for preparing a compound of Formula I comprising: reacting a compound of Formula II with Y-H,
Figure imgf000029_0001
comprising reacting a compound of Formula II with Y-H,
Figure imgf000029_0002
wherein
Y, R1 and R2 are defined above; and
Z is a halogen or -OH.
Optionally, the step of reacting a compound of formula II with a compound of Y-H is carried out in the presence of a coupling reagent, such as HATU, and an amine base, such as DIPEA.
In another embodiment, the invention provides a process for preparing a compound of Formula I
Figure imgf000030_0001
comprising reacting a compound of formula III with R 1 -X vl ,
Figure imgf000030_0002
wherein,
X1 is selected from halogen and OH; and R2, R1 and Y are defined above.
Optionally, the step of reacting a compound of formula III with a compound of R!-X! is carried out in the presence of a base, such as sodium hydride, sodium borohydride, aluminum hydride, sodium aluminum hydride, alkaline metal hydride, alkaline earth metal hydride or equivalence thereof.
Biological Evaluation hCBi^ and hCB2 receptor binding Human CBi receptor from Receptor Biology (hCBi) or human CB2 receptor from
BioSignal (I1CB2) membranes are thawed at 37 0C, passed 3 times through a 25-gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCb, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC50 of the compounds of the invention at hCBi and I1CB2 are evaluated from 10-point dose-response curves done with 3H-CP55,940 at 20000 to 25000 dpm per well (0.17-0.21 nM) in a final volume of 300 μl. The total and non-specific binding are determined in the absence and presence of 0.2 μM of HU210 respectively. The plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl2, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 0C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid.
!1CB1 and hCB2 GTPΎS binding
Human CBi receptor from Receptor Biology (hCBi) or human CB2 receptor membranes (BioSignal) are thawed at 37 0C, passed 3 times through a 25-gauge blunt- end needle and diluted in the GTPγS binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl2, pH 7.4, 0.1% BSA). The EC50 and Emax of the compounds of the invention are evaluated from 10-point dose-response curves done in 300μl with the appropriate amount of membrane protein and 100000-130000 dpm of GTPg35S per well (0.11 -0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 μM (hCB2) or 10 μM (hCBi) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 μM (hCB2) or 112.5 μM (hCBi) GDP prior to distribution in plates (15 μM (hCB2) or 30 μM (hCBi) GDP final). The plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl2, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 0C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist.
Based on the above assays, the dissociation constant (Ki) for a particular compound of the invention towards a particular receptor is determined using the following equation:
Ki = IC50/(l+[rad]/Kd), Wherein IC50 is the concentration of the compound of the invention at which 50% displacement has been observed; [rad] is a standard or reference radioactive ligand concentration at that moment; and
Kd is the dissociation constant of the radioactive ligand towards the particular receptor. Using the above-mentioned assays, the compounds of the invention are found to be active towards human CBi receptors.
In addition, certain compounds of the invention are tested using one or more assays shown above and the test results are summarized in Table 1 below.
Table 1. Certain Biological Activities of Certain Compounds of the Invention
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
EXAMPLES Example 1 iV-[2-(Cyclopropylamino)-2-oxoethyl]-iV,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000052_0001
Step A. N- [2-(Cyclopropylamino)-2-oxoethyl] -iV,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000052_0002
HATU (145 mg, 0.38 mmol) and V-cyclopropyl-N^methylglycinamide (50 mg, 0.38 mmol) were added to a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid (100 mg, 0.32 mmol) and DIPEA (89 μL, 0.48 mmol) in DMF (15 mL). The reaction mixture was stirred for 2 hrs. and the solvent was concentrated. The product was purified by preparative reverse-phase ΗPLC using an acetonitrile gradient 10 to 80% in water to provide the TFA salt of the title compound as white solid (47 mg, 27 %). 1U NMR (400 MHz, CDCl3) δ 0.48 - 0.65 (m, 2 H), 0.80 (q, J=6.64 Hz, 2 H), 1.34 - 1.67 (m, 5 H), 1.75 (t, J=10.35 Hz, 2 H), 2.07 - 2.25 (m, 1 H), 2.30 - 2.53 (m, 1 H), 2.58 - 2.97 (m, 4 H), 3.14 (s, 3 H), 3.42 (t, J=I 1.72 Hz, 2 H), 3.64 (s, 3 H), 3.93 - 4.24 (m, 4 H), 7.16 - 7.35 (m, 2 H), 7.62 (s, 1 H); MS (ESI) (M+H)+ 424.2.
Step B. 4-[4-(Benzyloxy)phenyl]tetrahydro-2H-pyran-4-ol
Figure imgf000052_0003
A solution of l-(benzyloxy)-4-bromobenzene (12.6 g, 48.1 mmol) in THF (50 mL) was slowly added to a mixture of magnesium (1.06 g, 43.7 mmol) and THF (10 mL) at room temperature. Iodine (50 mg, 0.2 mmol) was added. The reaction mixture was heated to 700C until the magnesium disappearance (4hrs.). The reaction mixture was cooled to ambient temperature and tetrahydro-4H-pyran-4-one (4.38 g, 43.7 mmol) was slowly added. The solution was stirred overnight and quenched with cold 0.5M HCl (200 mL). The product was extracted with EtOAc and purified by normal-phase MPLC using EtOAc 30 to 90% gradient in hexane to provide the title compound as white solid (6.87 g, 50 %). 1H NMR (400 MHz, CDCl3) δ 1.64 - 1.75 (m, 2 H), 2.07 - 2.21 (m, 2 H), 3.81 - 3.98 (m, 4 H), 5.03 - 5.10 (m, 2 H), 6.94 - 7.01 (m, 3 H), 7.29 - 7.47 (m, 6 H).
Step C. 4-[4-(Benzyloxy)phenyl]-3,6-dihydro-2H-pyran
Figure imgf000053_0001
A solution of 4-[4-(benzyloxy)phenyl]tetrahydro-2H-pyran-4-ol (6.80 g, 23.9 mmol) in toluene (100 mL) under molecular sieves (5 g) was heated to reflux (1230C) for 18 hrs.
The solvent was concentrated and the product was purified by normal-phase MPLC using
EtOAc 30 to 90% gradient in hexane to provide the title compound as white solid (4.55 g,
71 %). 1U NMR (400 MHz, CDCl3) δ 2.44 - 2.54 (m, 2 H), 3.92 (t, J=5.47 Hz, 2 H), 4.31
(q, J=2.99 Hz, 2 H), 5.07 (s, 2 H), 5.99 - 6.06 (m, 1 H), 6.90 - 6.99 (m, 3 H), 7.29 - 7.36 (m, 3 H), 7.36 - 7.46 (m, 3 H).
Step D. 4-(Tetrahydro-2H-pyran-4-yl)phenol
Figure imgf000053_0002
A solution of 4-[4-(benzyloxy)phenyl]-3,6-dihydro-2H-pyran (4.50 g, 16.8 mmol) in EtOH (150 mL) was teated with Pd/C 10% in a Parr hydrogenation apparatus under a 50 PSI hydrogen atmosphere for 3 days. The mixture was filtered on a celite pad and the solvent was concentrated to provide the title compound as grey solid (2.72 g, 90 %). 1H NMR (400 MHz, CDCl3) δ 1.61 - 1.87 (m, 4 H), 2.59 - 2.78 (m, 1 H), 3.54 (td, J=I 1.13, 3.52 Hz, 2 H), 4.00 - 4.16 (m, 2 H), 6.79 (d, J=8.59 Hz, 2 H), 7.09 (d, J=8.59 Hz, 2 H).
Step E. 4-(Tetrahydro-2H-pyran-4-yl)cyclohexanol
Figure imgf000054_0001
A mixture of 4-(tetrahydro-2H-pyran-4-yl)phenol (2.60 g, 14.5 mmol), Pd/C 10% (0.77 g, 0.72 mmol), sodium formate (14.8 g, 0.21 mol) and water (50 mL) was heated to 1050C for 18 hrs. The reaction mixture was filtered and the filtrate was extracted with ethyl acetate. The residue was thoroughly washed with ethyl acetate. The ethyl acetate extracts were combined and concentrated to provide the title compound as white solid (2.47 g, 92 %). 1H NMR (400 MHz, CDCl3) δ 0.88 - 1.13 (m, 2 H), 1.13 - 1.44 (m, 5 H), 1.44 - 1.67 (m, 3 H), 1.66 - 1.87 (m, 2 H), 1.91 - 2.11 (m, 2 H), 3.23 - 3.45 (m, 2 H), 3.47 - 3.61 (m, 1 H), 3.87 - 4.08 (m, 2 H).
Step F. 4-(Tetrahydro-2H-pyran-4-yl)cyclohexanone
Figure imgf000054_0002
Concentrated H2SO4 (3 mL) was slowly added to a solution of CrO 3 (3.0 g, 30 mmol) in water (9 mL) at 00C. The resulting solution was added drop wise to a solution of 4- (tetrahydro-2H-pyran-4-yl)cyclohexanol (2.41 g, 13.0 mmol) in acetone (70 mL) at 00C. The reaction mixture was stirred for 1 hr. at 00C and ethyl ether (300 mL) was added. The solution was washed with brine, water and dried over anhydrous MgSO4. The solvent was concentrated to provide the title compound as white solid (2.02 g, 85 %). 1H NMR (400 MHz, CDCl3) δ 1.31 - 1.51 (m, 5 H), 1.51 - 1.59 (m, 1 H), 1.59 - 1.70 (m, J=9.96, 9.96 Hz, 2 H), 2.00 - 2.18 (m, 2 H), 2.23 - 2.49 (m, 4 H), 3.38 (t, J=I 1.33 Hz, 2 H), 3.93 - 4.07 (m, 2 H).
Step G. 3-(Tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid
Figure imgf000055_0001
A mixture of 4-hydrazinobenzoic acid (0.83 g, 5.48 mmol) and 4-(tetrahydro-2H-pyran- 4-yl)cyclohexanone (1.00 g, 5.48 mmol) in dioxane (35 mL) and concentrated HCl (8 mL) was heated to 1000C for 3 hrs. The reaction mixture was concentrated to dryness and recovered in NaOH 2M (50 mL). The solution was cooled in an ice bath and slowly acidified to pΗ 4 using concentrated HCl. The precipitate was collected and dried to provide the title compound as brown solid (1.21 g, 74 %). MS (ESI) (M+Η)+ 300.1.
Step H. Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate
Figure imgf000055_0002
Sodium hydride (1.5 g, 36.7 mmol) was added to a solution of 3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (1.10 g, 3.67 mmol) in DMF (150 mL) under nitrogen atmosphere. The reaction mixture was stirred for 1.5 hr. and methyl iodide (2.4 mL, 36.7 mmol) was added. The mixture was stirred for 1.5 hr., cooled to 00C and quenched with NH4Cl saturated solution. The mixture was concentrated to dryness and recovered in water. The product was extracted with EtOAc and purified by normal- phase MPLC using EtOAc 20 to 70% gradient in heptane to provide the title compound as white solid (0.60 g, 50 %). 1H NMR (400 MHz, CDCl3) δ 1.38 - 1.68 (m, 5 H), 1.76 (d, J=I 1.72 Hz, 2 H), 2.07 - 2.22 (m, 1 H), 2.43 (dd, J=15.23, 8.59 Hz, 1 H), 2.61 - 2.98 (m, 3 H), 3.42 (t, J=I 1.72 Hz, 2 H), 3.64 (s, 3 H), 3.93 (s, 3 H), 4.04 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.24 (d, J=8.59 Hz, 1 H), 7.86 (dd, J=8.59, 1.56 Hz, 1 H), 8.23 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+ 328.1.
Step I. 9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid
Figure imgf000056_0001
A mixture of methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate (0.57 g, 1.74 mmol), MeOH (30 mL) and NaOH 2M (40 mL) was heated to 850C for 4 hrs. The solution was concentrated to 40 mL, cooled to 00C and acidified to pΗ 4 using concentrated HCl. The precipitate was collected and dried to provide the title compounds as white solid (0.48 g, 88 %). 1Η NMR (400 MHz, CD3SOCD3) δ 1.20 - 1.40 (m, 2 H), 1.41 - 1.61 (m, 3 H), 1.63 - 1.78 (m, 2 H), 1.98 - 2.15 (m, 1 H), 2.34 (dd, J=14.84, 7.81 Hz, 1 H), 2.55 - 2.73 (m, 1 H), 2.73 - 2.90 (m, 2 H), 3.19 - 3.36 (m, 2 H), 3.62 (s, 3 H), 3.80 - 3.96 (m, 2 H), 7.39 (d, J=8.59 Hz, 1 H), 7.67 (dd, J=8.59, 1.56 Hz, 1 H), 8.04 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)+ 314.1.
Example 2 & 3
(R)-iV-[2-(Cyclopropylamino)-2-oxoethyl]-iV,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide and (S)-N- [2- (Cyclopropylamino)-2-oxoethyl]-iV,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
N-(2-(Cyclopropylamino)-2-oxoethyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (490 mg, 1.16 mmol) was separated by preparative chiral HPLC using a Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou, 35% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, at rt in two runs (245 mg loadings).
(R)-N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 1, 206 mg):
Figure imgf000057_0001
1H NMR (400 MHz, CHLOROFORM-D) δ 0.53 - 0.58 (m, 2 H), 0.77 - 0.84 (m, 2 H), 1.44 - 1.50 (m, 2 H), 1.52 - 1.58 (m, 2 H), 1.58 - 1.63 (m, 2 H), 1.70 - 1.80 (m, 2 H), 2.12 - 2.19 (m, 1 H), 2.36 - 2.46 (m, 1 H), 2.65 - 2.72 (m, 1 H), 2.72 - 2.78 (m, 1 H), 2.79 - 2.91 (m, 2 H), 3.15 (s, 3 H), 3.38 - 3.46 (m, 2 H), 3.64 (s, 3 H), 4.05 (dd, J=I 1.33, 3.12 Hz, 2 H), 4.09 (s, 1 H), 6.96 (s, 1 H), 7.25 (s, 2 H), 7.62 (s, 1 H); Rf = 4.11; MS (ESI) (M+H) = 424.2; [α]D = +53.6° (1.007, CDCl3); Anal. CaIc. For C25H33N3O3 + 0.5 EtOH C: 69.93 H: 8.12 N: 9.41 found: C: 69.46 H: 8.09 N: 9.85. (S)-N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 2, 220 mg):
Figure imgf000057_0002
1H NMR (400 MHz, CHLOROFORM-D) δ 0.53 - 0.58 (m, 2 H), 0.77 - 0.84 (m, 2 H), 1.44 - 1.50 (m, 2 H), 1.52 - 1.58 (m, 2 H), 1.58 - 1.63 (m, 2 H), 1.70 - 1.80 (m, 2 H), 2.12 - 2.19 (m, 1 H), 2.36 - 2.46 (m, 1 H), 2.65 - 2.72 (m, 1 H), 2.72 - 2.78 (m, 1 H), 2.79 - 2.91 (m, 2 H), 3.15 (s, 3 H), 3.38 - 3.46 (m, 2 H), 3.64 (s, 3 H), 4.05 (dd, J=I 1.33, 3.12 Hz, 2 H), 4.09 (s, 1 H), 6.96 (s, 1 H), 7.25 (s, 2 H), 7.62 (s, 1 H); Rf = 5.54; MS (ESI) (M+H) = 424.2; [α]D = -51.2° (0.997, CDCl3); Anal. CaIc. For C25H33N3O3 + 0.7 EtOH C: 69.57 H: 8.23 N: 9.22 found: C: 68.85 H: 7.47 N: 9.52.
Chiral analytical HPLC: ChiraPak AD column, 30% EtOH/hexanes, lmL/min, 30 min ran, 25°C
Example 4 iV-Ethyl-iV-[2-(ethylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000058_0001
Step A. iV-ethyl-iV- [2-(ethylamino)-2-oxoethyl] -9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000058_0002
Following the procedure of example 1 step A and using V^-diethylglycinamide (50 mg, 0.38 mmol) provided the title compound as white solid (83 mg, 48 %). IH NMR 1H NMR (400 MHz, CDCl3) δ 1.19 (q, J=7.29 Hz, 6 H), 1.38 - 1.67 (m, 5 H), 1.69 - 1.82 (m, 2 H), 2.09 - 2.21 (m, 1 H), 2.33 - 2.48 (m, j=14.26, 7.62 Hz, 1 H), 2.62 - 2.77 (m, 1 H), 2.77 - 2.92 (m, 2 H), 3.27 - 3.38 (m, 2 H), 3.38 - 3.47 (m, 2 H), 3.51 (q, J=6.12 Hz, 2 H), 3.64 (s, 3 H), 4.05 (dd, J=11.33, 3.12 Hz, 2 H), 4.09 - 4.19 (m, 2 H), 7.17 - 7.31 (m, 2 H), 7.58 (s, 1 H); MS (ESI) (M+H)+ 426.2.
Example 5 iV-Ethyl-iV-[2-(isopropylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000059_0001
Step A. iV-Ethyl-iV-[2-(isopropylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000059_0002
Following the procedure of example 1 step A and using N^ethyl-N1- isopropylglycinamide (50 mg, 0.38 mmol) provided the title compound as white solid (75 mg, 42 %). 1H NMR (400 MHz, CDCl3) δ 1.09 - 1.27 (m, 8 H), 1.38 - 1.67 (m, 5 H), 1.74 (t, J=I 1.33 Hz, 3 H), 2.08 - 2.21 (m, 1 H), 2.41 (dd, J=15.23, 8.59 Hz, 1 H), 2.61 - 2.75 (m, 1 H), 2.77 - 2.90 (m, 2 H), 3.35 - 3.47 (m, 2 H), 3.51 (q, J=7.03 Hz, 2 H), 3.64 (s, 3 H), 3.95 - 4.18 (m, 5 H), 7.18 - 7.25 (m, 2 H), 7.56 (s, 1 H); MS (ESI) (M+H)+ 440.2.
Example 6:
N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidine-4-carboxamide
Figure imgf000060_0001
Step A: N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)piperidine-4-carboxamide
Figure imgf000060_0002
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (150 mg, 0.48 mmol), HATU (218 mg, 0.57 mmol) and N-cyclopropylpiperidine-4- carboxamide, HCl (147 mg, 0.72 mmol) were stirred in DMF (10 mL) containing N,N- diisopropylethylamine (0.250 mL, 1.44 mmol) at 23 0C for Ih. The solvent was evaporated and the residue was dissolved in EtOAc. The organic phase was washed with saturated aqueous sodium bicarbonate, brine and dried over anhydrous sodium sulfate. The product was purified by reversed-phase HPLC using a 40-60% CH3CN/H2O gradient. The fractions were evaporated, dissolved in EtOAc and washed with saturated i aqueous sodium bicarbonate solution, brine and evaporated (130 mg, 56 %). H NMR
(400 MHz, CHLOROFORM-D) δ 0.45 - 0.51 (m, 2 H), 0.76 - 0.82 (m, 2 H), 1.42 - 1.51 (m, 2 H), 1.52 - 1.60 (m, 3 H), 1.69 - 1.84 (m, 6 H), 2.11 - 2.19 (m, 1 H), 2.23 - 2.33 (m, 1 H), 2.36 - 2.45 (m, 1 H), 2.65 - 2.76 (m, 2 H), 2.78 - 2.86 (m, 2 H), 2.87 - 2.97 (m, 2 H), 3.42 (t, J=I 1.72 Hz, 3 H), 3.63 (s, 3 H), 4.05 (dd, J=I 1.13, 3.71 Hz, 2 H), 5.65 (s, 1 H), 7.18 - 7.24 (m, 2 H), 7.55 (s, 1 H); MS (ESI) (M + H)+ = 464.2.
Step B: N-Cyclopropylpiperidine^-carboxamide hydrochloride
Figure imgf000061_0001
Boc-Isonipecotic acid (500 mg, 2.18 mmol), cyclopropylamine (0.180 mL, 2.61 mmol) and HATU (995 mg, 2.61 mmol) were stirred in 10 mL of DMF containing DIPEA (0.570 mL, 3.27 mmol) at 23°C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The residue was dissolved in 20 mL of IM HCl/AcOH and stirred at rt for 3h. The solvent was evaporated. The product was precipitated in ether, filtered and dried (450 mg, 99 %). 1H NMR (400 MHz, METHANOL-D4) δ 0.41 - 0.49 (m, 2 H), 0.67 - 0.75 (m, 2 H), 1.79 - 1.89 (m, 2 H), 1.86 - 1.94 (m, 2 H), 2.37 - 2.48 (m, 1 H), 2.59 - 2.67 (m, 1 H), 2.92 - 3.04 (m, 2 H), 3.35 - 3.45 (m, 2 H).
Example 7:
N-Ethyl-N-{2-[(2-fluoroethyl)amino]-2-oxoethyl}-9-methyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000061_0002
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (150 mg, 0.48 mmol), HATU (236 mg, 0.62 mmol) and N2-ethyl-N1-(2- fluoroethyl)glycinamide HCl (177 mg, 0.96 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.210 mL, 1.20 mmol) at 23 0C for Ih. The solvent was evaporated and the residue was dissolved in EtOAc. The organic phase was washed with saturated aqueous sodium bicarbonate, brine and dried over anhydrous sodium sulfate. The product was purified by silica gel flash chromatography using EtOAc as eluent (105 mg, 50 %). 1H NMR (400 MHz, CHLOROFORM-D) δ 1.20 (t, J=6.84 Hz, 3 H), 1.43 - 1.51 (m, 2 H), 1.51 - 1.59 (m, 2 H), 1.75 (t, J=9.57 Hz, 2 H), 2.12 - 2.18 (m, 1 H), 2.21 - 2.30 (m, 1 H), 2.37 - 2.45 (m, 1 H), 2.65 - 2.76 (m, 2 H), 2.79 - 2.90 (m, 2 H), 3.42 (t, J=I 1.13 Hz, 2 H), 3.51 (q, J=5.86 Hz, 2 H), 3.59 (q, J=5.21 Hz, 1 H), 3.63 - 3.69 (m, 4 H), 4.04 (d, J=10.55 Hz, 2 H), 4.16 (s, 2 H), 4.46 (t, J=4.88 Hz, 1 H), 4.58 (t, J=4.88 Hz, 1 H), 7.22 - 7.26 (m, 2 H,) 7.59 (s, 1 H); MS (ESI) (M + H)+ = 444.2.
Example 8:
N-[2-(Cyclopropylamino)-2-oxoethyl]-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000062_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (150 mg, 0.48 mmol), HATU (236 mg, 0.62 mmol) and V-cyclopropyl-N2- ethylglycinamide HCl (171 mg, 0.96 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.210 mL, 1.20 mmol) at 23 0C for Ih. The solvent was evaporated and the residue was dissolved in EtOAc. The organic phase was washed with saturated aqueous sodium bicarbonate, brine and dried over anhydrous sodium sulfate. The product was purified by silica gel flash chromatography using EtOAc as eluent (109 mg, 52 %). 1U NMR (400 MHz, CHLOROFORM-D) δ 0.52 - 0.58 (m, 2 H), 0.77 - 0.84 (m, 2 H), 1.19 (t, J=7.03 Hz, 3 H), 1.43 - 1.51 (m, 2 H), 1.51 - 1.59 (m, 3 H), 1.70 - 1.79 (m, 2 H), 2.12 - 2.19 (m, 1 H), 2.21 - 2.29 (m, 1 H), 2.37 - 2.46 (m, 1 H), 2.67 - 2.78 (m, 2 H), 2.79 - 2.89 (m, 2 H), 3.38 - 3.46 (m, 2 H), 3.49 (q, J=7.03 Hz, 2 H), 3.64 (s, 3 H), 4.05 (dd, J=I 1.72, 3.12 Hz, 2 H,) 4.09 (s, 2 H), 7.23 - 7.28 (m, 2 H), 7.56 (s, 1 H); MS (ESI) (M + H) = 483.3. Example 9:
N-Cyclopropyl-2-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)azetidin-3-yl)acetamide
Figure imgf000063_0001
Step A: N-Cyclopropyl-2-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-ό-carbony^azetidin-S-y^acetamide
Figure imgf000063_0002
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (125 mg, 0.40 mmol), HATU (182 mg, 0.48 mmol) and 2-(azetidin-3-yl)-N- cyclopropylacetamide HCl (91 mg, 0.48 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.174 mL, 1.00 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCC>3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50% CH3CN/H2O. The fractions were evaporated and extracted with CH2CI2 (3X). The organic phase was washed with brine and dried over anhydrous Na2SO4 (35 mg, 20 %). H NMR (400 MHz, CHLOROFORM-D) δ 0.44 -
0.52 (m, 2 H), 0.71 - 0.78 (m, 2 H), 1.42 - 1.50 (m, 2 H), 1.51 - 1.55 (m, 1 H), 1.56 - 1.61 (m, 2 H), 1.71 - 1.78 (m, 2 H), 2.11 - 2.18 (m, 1 H), 2.35 - 2.44 (m, 1 H), 2.48 (d, J=7.81 Hz, 2 H), 2.62 - 2.73 (m, 2 H), 2.78 (s, 1 H), 2.81 - 2.90 (m, 2 H), 3.00 - 3.10 (m, 1 H), 3.42 (t, J=I 1.72 Hz, 2 H), 3.62 (s, 3 H), 3.85 (s, 1 H), 4.04 (dd, ./=10.94, 2.73 Hz, 2 H), 4.30 - 4.38 (m, 1 H), 4.53 - 4.60 (m, 1 H), 6.02 (s, 1 H), 7.20 (d, J=8.59 Hz, 1 H), 7.45 (d, J=8.59 Hz, 1 H), 7.79 (s, 1 H); MS (ESI) (M+H)+ = 450.2.
Step B: 2-Azetidin-3-yl-iV-cyclopropylacetamide hydrochloride
Figure imgf000064_0001
2-(l-(fert-Butoxycarbonyl)azetidin-3-yl)acetic acid (125 mg, 0.58 mmol), cyclopropylamine (0.060 mL, 0.87 mmol) and HATU (265 mg, 0.70 mmol) were stirred in DMF (5 mL) containing DIPEA (0.203 mL, 1.16 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% aqueous KHSO4, saturated aqueous sodium bicarbonate, brine and dried over anhydrous sodium sulfate. The solvent was evaporated. The product was then stirred in IM HCl/AcOH (5 mL) at 23 0C for 2h. The solvent was evaporated. The product was crashed in ether and the ether layer was decanted. The final product was dried under vacuum (100 mg, 90 %).
1H NMR (400 MHz, METHANOL-D4) δ 0.40 - 0.52 (m, 2 H), 0.62 - 0.74 (m, 2 H), 1.35 (dd, J=6.64, 4.30 Hz, 1 H), 2.51 (d, J=7.42 Hz, 2 H), 3.14 - 3.23 (m, 1 H), 3.81 - 3.96 (m, 2 H), 4.10 (U=9.96 Hz, 2 H).
Example 10:
N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000065_0001
HATU (789 mg, 2.07 mmol) was added to a stirring DMF (25 mL) solution of 9-methyl- 3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxylic acid (500 mg, 1.60 mmol), N,N'-dimethylethylenediamine (0.849 mL, 7.98 mmol) and N,N- diisopropylethylamine (0.417 mL, 2.39 mmol) and was stirred at 23 °C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 30-50% CH3CN/H2O and lyophilized (320 mg, 40 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.38 - 1.48 (m, 2 H), 1.53 - 1.61 (m, 3 H), 1.77 (t, J=14.26 Hz, 2 H), 2.13 - 2.20 (m, 1 H), 2.35 - 2.43 (m, 1 H), 2.64 - 2.73 (m, 1 H), 2.75 (s, 3 H), 2.81 - 2.85 (m, 1 H), 2.85 - 2.90 (m, 1 H), 3.11 (s, 3 H), 3.29 - 3.33 (m, 2 H), 3.37 - 3.47 (m, 2 H), 3.63 (s, 3 H), 3.82 (t, J=5.66 Hz, 2 H), 3.95 - 3.97 (m, 1 H), 3.98 - 4.00 (m, 1 H), 7.22 - 7.27 (m, 1 H), 7.32 - 7.36 (m, 1 H), 7.61 (s, 1 H); MS (ESI) (M+H)+ = 384.2.
Example 11:
N-(2-(3-Cyclopropyl-l-methylureido)ethyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000065_0002
To a solution of triphosgene (59.6 mg, 0.20 mmol) in dichloromethane (2 mL) at 0 0C under N2 was added a solution of cyclopropylamine (0.042 mL, 0.60 mmol) and N,N- diisopropylethylamine (0.175 mL, 1.00 mmol) in dichloromethane (5 mL) dropwise. The solution was stirred at 0 0C for 15 min. A solution of N,9-dimethyl-N-(2- (methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamide trifluoroacetic acid salt (lOOmg, 0.20 mmol) in dichloromethane (5 mL) was added dropwise. After stirring at rt for 30 min, the reaction mixture was washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 30-50% CH3CN/H2O and lyophilized (59 mg, 62 %). H NMR (400 MHz, METHANOL-D4) δ 0.26 - 0.48 (m, 2 H), 0.58 (d, 2 H), 1.37 - 1.49 (m, 2 H), 1.52 - 1.61 (m, 3 H), 1.77 (t, J=I 1.52 Hz, 2 H), 2.12 - 2.20 (m, I H), 2.34 - 2.42 (m, 1 H), 2.47 - 2.57 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.83 (s, 1 H), 2.88 (m, 3 H), 3.05 - 3.12 (m, 3 H), 3.35 (s, 1 H), 3.38 - 3.46 (m, 2 H), 3.57 - 3.61 (m, 2 H), 3.62 (s, 3 H), 3.66 - 3.72 (m, 1 H), 3.97 (dd, J=10.94, 2.73 Hz, 2 H), 7.10 - 7.16 (m, 1 H), 7.30 (d, J=7.81 Hz, 1 H), 7.44 - 7.48 (m, 1 H); MS (ESI) (M+H)+ = 467.3.
Example 12: N-(2-(3-Cyclopropyl-l-methylthioureido)ethyl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000066_0001
N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide trifluoroacetic acid salt (100 mg, 0.20 mmol) was dissolved in dichloromethane (10 mL) containing N,N-diisopropylethylamine (0.053 mL, 0.30 mmol) at 0 0C. Cyclopropyl isothiocyanate (0.024 mL, 0.26 mmol) was added dropwise and the solution was stirred at rt for Ih. The solution was washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 30-50% CH3CN/H2O and lyophilized (80 mg, 82 %). H NMR (400 MHz, METHANOL-D4) (rotomers) δ 0.42 (s, 0.6 H), 0.57 (s, 1.4 H), 0.63 (s, 0.6 H), 0.71 (s, 1.4 H), 1.38 - 1.48 (m, 2 H), 1.56 (s, 3 H), 1.71 - 1.82 (m, 2 H), 2.16 (s, 1 H), 2.39 (s, 1 H), 2.67 (s, 2 H), 2.85 (d, J=16.41 Hz, 2 H), 2.96 (s, 0.6 H), 3.07 - 3.18 (m, 5.4 H), 3.41 (t, J=10.55 Hz, 2 H), 3.61 (s, 3 H), 3.69 (s, 0.6 H), 3.75 (s, 1.4 H), 3.97 (d, J=10.94 Hz, 2.7 H), 4.17 (s, 1.3 H), 7.09 (s, 0.4 H), 7.19 (s, 0.6 H), 7.29 (d, J=6.64 Hz, 1 H), 7.45 (s, 0.4 H), 7.57 (s, 0.6 H); MS (ESI) (M+H)+) = 483.3.
Example 13:
N-{2-[(2-Fluoroethyl)amino]-2-oxoethyl}-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000067_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (150 mg, 0.48 mmol), HATU (218 mg, 0.57 mmol) and 2-(2-fluoroethylamino)-N- methyl-2-oxoethanaminium chloride (98 mg, 0.57 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.208 mL, 1.20 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 40-60% CH3CN/H2O and lyophilized (150 mg, 73 %).
1H NMR (400 MHz, METHANOL-D4) δ 1.34 - 1.47 (m, 2 H), 1.54 (s, 3 H), 1.75 (t, J=13.28 Hz, 2 H), 2.14 (s, 1 H), 2.36 (s, 1 H), 2.63 - 2.72 (m, 1 H), 2.77 - 2.86 (m, 2 H), 3.09 (s, 3 H), 3.36 - 3.45 (m, 2 H), 3.48 (s, 1 H), 3.54 (s, 1 H), 3.61 (s, 3 H), 3.97 (dd, J=I 1.33, 3.91 Hz, 2 H), 4.02 (s, 1 H), 4.20 (s, 1 H), 4.39 (s, 1 H), 4.51 (s, 1 H), 7.20 (s, 1 H), 7.30 (d, J=8.20 Hz, 1 H), 7.54 (d, J=30.08 Hz, 1 H); MS (ESI) (M+H)+ = 430.2.
Example 14:
N-Ethyl-9-methyl-N-[2-(methylamino)-2-oxoethyl]-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000068_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (150 mg, 0.48 mmol), N-ethyl-2-(methylamino)-2-oxoethanaminium chloride (88 mg, 0.57 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (218 mg, 0.57 mmol) were stirred in DMF (10 mL) containing N,N- diisopropylethylamine (0.208 mL, 1.20 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCθ3, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 40-60% CH3CN/H2O and lyophilized (141 mg, 72 %). 1U NMR (400 MHz, METHANOL-D4) δ 1.15 (s, 3 H), 1.35 - 1.46 (m, 2 H), 1.50 - 1.59 (m, 3 H), 1.75 (t, J=13.67 Hz, 2 H), 2.14 (d, J=4.69 Hz, 1 H), 2.31 - 2.41 (m, 1 H), 2.62 - 2.70 (m, 1 H), 2.75 (s, 3 H), 2.77 - 2.88 (m, 2 H), 3.36 - 3.45 (m, 2 H), 3.45 - 3.57 (m, 2 H), 3.61 (s, 3 H), 3.97 (dd, J=10.94, 3.52 Hz, 2 H), 4.10 (s, 2 H), 7.19 (s, 1 H), 7.30 (d, J=7.81 Hz, 1 H), 7.54 (s, 1 H); MS (ESI) (M+H)+ = 412.3.
Example 15:
Methyl, methyl[2-(methyl{[9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazol-6-yl]carbonyl}amino)ethyl] carbamate
Figure imgf000068_0002
N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide, trifluoroacetic acid salt (65 mg, 0.13 mmol) was dissolved in DCM (5 mL) containing N,N-diisopropylethylamine (0.057 mL, 0.33 mmol). Methyl chloroformate (0.012 mL, 0.16 mmol) was added dropwise and the solution was stirred at 23 0C for Ih. The solution was washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 40-60% CH3CN/H2O and lyophilized (50 mg, 87 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.36 - 1.49 (m, 2 H), 1.53 - 1.62 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 2.13 - 2.21 (m, 1 H), 2.34 - 2.43 (m, 1 H), 2.49 (s, 1 H), 2.62 - 2.74 (m, 1 H), 2.80 - 2.90 (m, 2 H), 2.95 - 3.02 (m, 2 H), 3.03 - 3.13 (m, 3 H), 3.33 (s, 2 H), 3.37 - 3.46 (m, 2 H), 3.50 - 3.61 (m, 2 H), 3.62 (s, 3 H), 3.66 - 3.78 (m, 3 H), 3.98 (dd, J=I 0.94, 3.52 Hz, 2 H), 7.10 (s, 1 H), 7.31 (dd, J=8.40, 2.15 Hz, 1 H), 7.38 - 7.46 (m, 1 H);
Example 16:
N-{2-[(Cyclopropylcarbonyl)(methyl)amino]ethyl}-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000069_0001
N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide trifluoroacetic acid salt (100 mg, 0.20 mmol) was dissolved in DCM (10 mL) containing N,N-diisopropylethylamine (0.088 mL, 0.50 mmol). Cyclopropanecarbonyl chloride (0.022 mL, 0.24 mmol) was added dropwise and the solution was stirred at 23 0C for Ih. The solution was washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 30-50% CH3CN/H2O and lyophilized (90 mg, 99 %). 1H NMR (400 MHz, METHANOL-D4) (rotomers) δ 0.13 (s, 0.25 H), 0.48 (s, 0.25 H), 0.77 (s, 1.75 H), 0.89 (s, 1.75 H,) 1.38 - 1.49 (m, 2 H), 1.52 - 1.61 (m, 3 H), 1.78 (t, J=I 1.91 Hz, 2 H), 1.89 (s, 0.25 H), 2.09 (s, 0.25 H), 2.13 - 2.21 (m, 1 H), 2.32 - 2.44 (m, 1 H), 2.62 - 2.75 (m, 2 H), 2.80 - 2.89 (m, 2 H), 3.04 (s, 2 H), 3.07 - 3.17 (m, 2 H), 3.37 - 3.47 (m, 2.25 H), 3.58 (s, 0.5 H), 3.63 (s, 3.5 H), 3.72 - 3.81 (m, 2 H), 3.85 - 3.91 (m, 0.25 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.06 - 7.17 (m, 1 H), 7.26 - 7.36 (m, 1 H), 7.38 - 7.52 (m, 1 H); MS (ESI) (M+H)+ = 452.2.
Example 17:
N-Cyclopropyl-l-IIP-methyl-S-Ctetrahydro-lH-pyran-^y^-l^^^-tetrahydro-lH- carbazol-6-yl]carbonyl}piperidine-3-carboxamide
Figure imgf000070_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (100 mg, 0.32 mmol), HATU (146 mg, 0.38 mmol) and 3- (cyclopropylcarbamoyl)piperidinium 2,2,2-trifluoroacetate (108 mg, 0.38 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 40-60% CH3CN/H2O and lyophilized (45 mg, 30 %). 1H NMR (400 MHz, METHANOL-D4) δ 0.45 (s, 2 H), 0.68 (s, 2 H), 1.36 - 1.50 (m, 3 H), 1.51 - 1.62 (m, 4 H), 1.77 (t, J=12.50 Hz, 3 H), 1.88 - 1.96 (m, 1 H), 2.11 - 2.22 (m, 1 H), 2.32 - 2.44 (m, 2 H), 2.63 - 2.74 (m, 2 H), 2.78 - 2.90 (m, 2 H), 3.12 (s, 2 H), 3.37 - 3.50 (m, 2 H), 3.63 (s, 3 H), 3.80 (s, 1 H), 3.98 (dd, J=I 1.33, 3.12 Hz, 2 H), 4.46 (s, 1 H), 7.12 (dd, J=8.20, 1.56 Hz, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (d, J=0.78 Hz, 1 H). MS (ESI) (M+H)+ = 464.2.
Example 18:
Step A: N-Cyclopropyl-l-{ [9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazol-ό-yljcarbonylJazetidine-S-carboxamide
Figure imgf000071_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (125 mg, 0.40 mmol), HATU (182 mg, 0.48 mmol) and 3- (cyclopropylcarbamoyl)azetidinium chloride (85 mg, 0.48 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.174 mL, 1.00 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCC^, brine and dried over anhydrous Na2SC>4. The product was purified by reversed-phase HPLC using 30-50% CH3CN/H2O and lyophilized (55 mg, 32 %). 1H NMR (400 MHz, DMSO-D6) δ 0.34 - 0.41 (m, 2 H), 0.57 - 0.63 (m, 2 H), 1.27 - 1.38 (m, 2 H), 1.46 - 1.58 (m, 3 H), 1.71 (d, J=I 3.28 Hz, 2 H), 2.04 - 2.13 (m, 1 H), 2.33 (m, 1 H), 2.59 - 2.70 (m, 2 H), 2.76 - 2.88 (m, 2 H), 3.25 - 3.35 (m, 3 H), 3.61 (s, 3 H), 3.89 (dd, J=10.94, 3.12 Hz, 2 H), 4.01 (s, 1 H), 4.09 (s, 1 H), 4.29 (s, 1 H), 4.40 (s, 1 H), 7.36 (d, J=I.17 Hz, 1 H), 7.36 (s, 1 H), 7.67 (s, 1 H), 8.07 (d, J=3.91 Hz, 1 H). MS (ESI) (M+H)+ = 436.2.
Step B: 3-[(Cyclopropylamino)carbonyl]azetidinium chloride
Figure imgf000071_0002
l-Boc-azetidine-S-carboxylic acid (125 mg, 0.62 mmol), O-(7-azabenzotriazol-l-yl)- N,N,N',N'-tetramethyluronium hexafluorophosphate (283 mg, 0.75 mmol) and cyclopropylamine (0.052 mL, 0.75 mmol) were stirred in DMF (8 mL) containing N,N- diisopropylethylamine (0.162 mL, 0.93 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCC^, 5% KHSO4, brine and dried over anhydrous Na2SC>4. The solvent was evaporated. The residue was dissolved in IM Hydrogen chloride (3.11 mL, 3.11 mmol) in AcOH and stirred at 23 0C for 2h. The solvent was evaporated. The residue was rinsed twice with ether and dried under vacuum (109 mg, 99 %). ^H NMR (400 MHz, METHANOL-D4) δ 0.43 - 0.51 (m, 2 H), 0.67 - 0.78 (m, 2 H), 2.64 - 2.72 (m, 1 H), 3.47 - 3.59 (m, 1 H), 4.15 (d, J=7.81 Hz, 4 H).
Example 19: Step A: N-Ethyl-N-{2-[(l-isocyanocyclopropyl)amino]-2-oxoethyl}-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000072_0001
Methyl 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetate (130 mg, 0.32 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.630 mL, 0.63 mmol) (lM/water) at 50 0C for 2h. The solvent was evaporated. The residue was dissolved in DMF (5.00 mL) containing N,N- diisopropylethylamine (0.137 mL, 0.79 mmol) and 1 -amino- 1 -eye lopropancarbonitirle HCl (44.8 mg, 0.38 mmol) along with HATU (144 mg, 0.38 mmol) were added. The solution was stirred at rt for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3 solution, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 50-70% CH3CN/H2O and lyophilized (80 mg, 55 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.07 - 1.30 (m, 5 H), 1.39 - 1.51 (m, 5 H), 1.56 (s, 3 H), 1.77 (t, J=I 1.52 Hz, 2 H), 2.15 (m, 1 H), 2.38 (m, 1 H), 2.62 - 2.74 (m, 1 H), 2.78 - 2.90 (m, 2 H), 3.36 - 3.46 (m, 3 H), 3.49 - 3.59 (m, 1 H), 3.62 (s, 2 H), 3.97 (dd, J=10.94, 3.52 Hz, 3 H), 4.08 (s, IH), 7.17 (s, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.43 - 7.58 (m, 1 H); MS (ESI) (M+H)+ = 463.3. Step B: N-Ethyl-2-methoxy-2-oxoethanaminium chloride
Figure imgf000073_0001
2-(tert-Butoxycarbonyl(ethyl)amino)acetic acid (500 mg, 2.46 mmol) was dissolved in MeOH (10 mL) at 00C. (Trimethylsilyl)diazomethane (3.69 mL, 7.38 mmol) was added dropwise to the stirring solution until a light yellow color persisted. The solution was then stirred at rt for 20 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The product was then stirred in IM HCl/AcOH (12.30 mL, 12.30 mmol) at rt for 2h. The solvent was evaporated. The residue was washed with ether and the ether was decanted. The product was dried under vacuum
(307 mg, 81 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.30 (t, J=7.23 Hz, 3 H), 3.10 (q, J=7.16 Hz, 2 H), 3.82 (s, 3 H), 3.96 (s, 2 H).
Step C: Methyl 7V-ethyl-7V-{[9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazol-6-yl] carbonyl} glycinate
Figure imgf000073_0002
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-ό-carboxylic acid (100 mg, 0.32 mmol), HATU (146 mg, 0.38 mmol) and N-ethyl-2-methoxy-2- oxoethanaminium chloride (58.8 mg, 0.38 mmol) were stirred in DMF (8 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3 solution, brine and dried over anhydrous Na2SO4. The product was purified by flash chromatography using a gradient form 50% EtO Ac/heptane to 100% EtOAc (130 mg, 99 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.10 - 1.17 (m, 2 H), 1.20 (d, J=5.47 Hz, 2 H), 1.38 - 1.49 (m, 1 H), 1.53 - 1.62 (m, 3 H), 1.77 (t/=13.67 Hz, 2 H), 2.14 - 2.20 (m, 1 H), 2.34 - 2.44 (m, 1 H), 2.64 - 2.75 (m, 1 H), 2.79 - 2.91 (m, 2 H), 3.37 - 3.47 (m, 3 H), 3.58 (s, 1 H), 3.63 (s, 3 H), 3.66 - 3.71 (m, 1 H), 3.76 (s, 2 H), 3.98 (dd, J=I 1.33, 3.52 Hz, 2 H), 4.22 (s, 2 H), 7.16 (d, J=8.98 Hz, 1 H), 7.33 (d, J=8.20 Hz, 1 H), 7.49 (s, 1 H); MS (ESI) (M+H)+ = 413.28.
Example 20:
N-Ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000074_0001
To a solution of 2-(ethylamino)ethanol (133 mg, 1.49 mmol), 9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (156 mg, 0.50 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (128 mg, 67 %). IH NMR (400 MHz, METHANOL-D4) δ 1.11 (m, 2 H), 1.25 (m, 1 H), 1.35 - 1.46 (m, 2 H), 1.49 - 1.59 (m, 3 H), 1.74 (m, 2 H), 2.09 - 2.18 (m, 1 H), 2.31 - 2.40 (m, 1 H), 2.65 (m, 1 H), 2.77 - 2.86 (m, 2 H), 3.36 - 3.47 (m, 4 H), 3.53 - 3.65 (m, 6 H), 3.72 - 3.84 (m, 1 H), 3.96 (m, 2 H), 7.12 (d, J=8.20 Hz, 1 H), 7.30 (d, J=8.20 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ 385.25.
Example 21: N-(3-(cyclopropylamino)-3-oxopropyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000075_0001
To a solution of 3-(cyclopropylamino)-N-methyl-3-oxopropan-l-aminium chloride (178 mg, 1.00 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (156 mg, 0.50 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (8 mg, 3.4 %). IH NMR (400 MHz, METHANOL-D4) δ 0.47 (m, 2 H), 0.68 (m, 2 H), 1.43 (m, 2 H), 1.52 - 1.61 (m, 4 H), 1.77 (m, 2 H), 2.12 - 2.19 (m, 1 H), 2.40 (m, 1 H), 2.50 (m, 1 H), 2.68 (m, 1 H), 2.82 - 2.89 (m, 2 H), 3.03 (s, 3H), 3.37 - 3.46 (m, 3 H), 3.62 (s, 3 H), 3.75 (m, 2 H), 3.98 (m, 2 H), 7.12 (dd, J=8.0, 1.6 Hz, 1 H), 7.31 (d, J=8.0 Hz, 1 H), 7.45 (s, 1 H); MS (ESI) (M+H)+ 483.3.
Example 22:
N-(4-(Cyclopropylamino)-4-oxobutyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000075_0002
To a solution of 4-(cyclopropylamino)-N-ethyl-4-oxobutan-l-aminium chloride (206 mg, 995.56 μmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylic acid (156 mg, 497.78 μmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (118 mg, 49 %). IH NMR (400 MHz, METHAN0L-D4) δ 0.2 -0.75 (m, 4H), 1.11 (m, 2 H), 1.25 (m, 1 H), 1.46 (m, 2 H), 1.57 (m, 3 H), 1.77 (m, 3 H), 1.92 (m, 2H), 2.09 - 2.28 (m, 2 H), 2.31 - 2.42 (m, 1 H), 2.65 (m, 1 H), 2.77 - 2.86 (m, 2 H), 3.28 - 3.60 (m, 7 H), 3.62 (s, 3H), 3.98 (dd, J=11.3, 3.5 Hz, 2 H), 7.08 (d, J =8.0 Hz, 1 H), 7.31 (d, J=8.0 Hz, 1 H), 7.41 (s, 1 H); MS (ESI) (M+H)+ 466.2.
Example 23:
N-(4-(Cyclopropylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000076_0001
To a solution of 4-(cyclopropylamino)-N-methyl-4-oxobutan-l-aminium chloride (134 mg, 0.7 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylic acid (156 mg, 0.5 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (69 mg, 31 %). IH NMR (400 MHz, METHANOL-D4) δ 0.2 -0.70 (m, 4H), 1.43 (m, 2 H), 1.56 (m, 3 H), 1.76 (m, 3 H), 1.93 (m, 2H), 2.09 - 2.28 (m, 2 H), 2.31 - 2.42 (m, 1 H), 2.65 (m, 1 H), 2.77 - 2.86 (m, 2 H), 3.03 (m, 3H), 3.28 - 3.60 (m, 5 H), 3.62 (s, 3H), 3.97 (dd, J=I 1.3, 3.5 Hz, 2 H), 7.12 (s 1 H), 7.30 (d, J=8.0 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ 452.2913.
Example 24:
N-(4-(Methylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000077_0001
To a solution of 4-(methylamino)-N-methyl-4-oxobutan-l-aminium chloride (176 mg, 1.0 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (156 mg, 0.5 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (104 mg, 49 %). IH NMR (400 MHz, METHANOL-D4) δ 1.43 (m, 2 H), 1.56 (m, 3 H), 1.76 (m, 2 H), 1.93 (m, 3 H), 2.158 (m, 1 H), 2.26 (m, 1 H), 2.38 (m, 1 H), 2.52 (m, 1 H), 2.68 (m, 3 H), 2.77 - 2.86 (m, 2 H), 3.03 (m, 3H), 3.40 (m, 3 H), 3.56 (m, 1 H), 3.62 (s, 3H), 3.97 (dd, J=11.3, 3.5 Hz, 2 H), 7.12 (s 1 H), 7.30 (d, J=8.0 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ 426.2757.
Example 25:
N-(4-(Ethylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000077_0002
To a solution of 4-(ethylamino)-N-methyl-4-oxobutan-l-aminium chloride (185 mg, 1.5 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carboxylic acid (156 mg, 0.5 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (143 mg, 65 %). IH NMR (400 MHz, METHANOL-D4) δ 0.8 -1.12 (m, 3H), 1.43 (m, 2 H), 1.52 (m, 3 H), 1.76 (m, 2 H), 1.93 (m, 3H), 2.13 (m, 1 H), 2.25 (m, IH), 2.34 (m, 1 H), 2.65 (m, 1 H), 2.77 - 2.86 (m, 2 H), 2.9- 3.25 (m, 5 H), 3.3 - 3.60 (m, 4 H), 3.60 (s, 3H), 3.97 (m, 2 H), 7.12 (s 1 H), 7.29 (d, J=8.0 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ 440.2913.
Example 26:
N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000078_0001
To a solution of N-methyl-4-(2-fluoroethylamino)-4-oxobutan-l-aminium chloride (320 mg, 1.5 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylic acid (156 mg, 0.5 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 C . The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (89 mg, 39 %). IH NMR (400 MHz, METHANOL-D4) δ 1.43 (m, 2 H), 1.56 (m, 3 H), 1.76 (m, 2 H), 1.93 (m, 3 H), 2.13 (m, 1 H), 2.33 (m, 2 H), 2.65 (m, 1 H), 2.83 (m, 2 H), 3.03 (m, 3 H), 3.15 - 3.60 (m, 4 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.3, 3.5 Hz, 2 H), 4.1 - 4.5 (m, 2 H), 7.12 (s 1 H), 7.30 (d, J=8.0 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ 458.2819.
Example 27 3-cyclohexyl-9-methyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH- carbazole
Figure imgf000079_0001
Step A 3-cyclohexyl-9-methyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9- tetrahydro-lH-carbazole
Figure imgf000079_0002
Sodium hydride (60 mg, 1.5 mmol) was added to a solution of 3-cyclohexyl-6-[(4- methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH-carbazole (120 mg, 0.32 mmol) (see following steps B, and C for preparation) in TΗF (10 mL). Stirring for 1 h at room temperature, methyl iodide (135 mg, 0.95 mmol) was added. The reaction mixture was stirred overnight at room temperature, quenched with NaHCO3 (5 mL), diluted with EtOAc (100 mL), washed with water (10 mL) and NaCl (10 mL), and then dried over Na2SU4. The crude product was purified by MPLC on silica gel using Hex/EtOAc (1:1) to give 117 mg (94%) of a white solid as the title compound. 1H NMR (400 MHz, CHLOROFORM-D) δ 0.98 (d, J=6.25 Hz, 3 H), 1.03 - 1.43 (m, 10 H), 1.50 - 1.73 (m, 5 H), 1.75 - 1.90 (m, 5 H), 2.03 - 2.17 (m, 1 H), 2.34 - 2.48 (m, 1 H), 2.60 - 2.73 (m, 1 H), 2.75 - 3.01 (m, 4 H), 3.63 (s, 3 H), 7.19 - 7.23 (m, 2 H), 7.56 (s, 1 H); MS (APPI) (M+H)+= 393.2; Anal. Calcd for C26H36N2O3+O.25 MeOH: C, 78.71; H, 9.31; N, 6.99; Found: C, 78.73; H, 9.30; N, 7.02.
Step B: 3-cyclohexyl-2,3,4,9-tetrahydro-LH-carbazole-6-carboxylic acid
Figure imgf000079_0003
4-Hydrazinobenzoic acid (0.76 g, 5.0 mmol) and 4-cyclohexyl cyclohexanone (0.99 g, 5.5 mmol) in dioxane (15 ml) and concentrated hydrochloric acid (1.5 ml) were heated overnight at reflux. Upon evaporation, the residue was dissolved in EtOAc (200 mL), washed with water (2x20 mL), NaCl (2x20 mL) and dried over Na2SO4. After concentration, 1.67 g of a brown solid was obtained, which was used directly for next step without further purification. MS (APPI) (M+H)+= 298.23.
Step C: 3-cyclohexyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH- carbazole
Figure imgf000080_0001
DIPEA (0.65 g, 0.89 mL, 5.0 mmol) was added to a solution of 3-cyclohexyl-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid (0.83 g, 2.5 mmol) and 4-methylpiperidine (0.50 g, 0.60 mL, 5.0 mmol) in DMF (15 mL). Stirring for 20 min, ΗATU (1.43 g, 3.75 mmol) was added at 0 0C. The mixture was stirred overnight at room temperature, quenched with water (100 mL) and extracted with EtOAc (3x50 mL). The combined organic phase was washed with water (2x50 mL), NaCl (2x50 mL) and dried over Na2SO4. The crude product was purified by MPLC on silica gel using Ηex/EtOAc (1:1) to give 0.54g (57%) of a light yellow solid as the title compound. 1Η NMR (400 MHz, CHLOROFORM-D) δ 0.98 (d, J=6.25 Hz, 3 H), 1.05 - 1.43 (m, 11 H), 1.58 - 1.74 (m, 5 H), 1.79 (d, J=13.67 Hz, 5 H), 1.99 - 2.14 (m, 1 H), 2.40 (m, 1 H), 2.67 - 3.09 (m, 4 H), 7.13 - 7.19 (m, 1 H), 7.24 (s, 1 H), 7.54 (s, 1 H), 7.80 (s, 1 H).
Example 28
3-cyclohexyl-9-ethyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH- carbazole
Figure imgf000081_0001
Following the procedure for Step A in Example 27, using 3-cyclohexyl-6-[(4- methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH-carbazole (120 mg, 0.32 mmol), sodium hydride (60 mg, 1.5 mmol) and ethyl iodide (149 mg, 0.95 mmol) in TΗF (10 mL). The crude product was purified by MPLC on silica gel using Ηex/EtOAc (1:1) to give 104 mg (81%) of a white solid as the title compound. 1H NMR (400 MHz, CHLOROFORM-D) δ 0.98 (d, J=6.25 Hz, 3 H), 1.04 - 1.29 (m, 10 H), 1.32 (t, J=7.23 Hz, 3 H), 1.59 - 1.73 (m, 5 H), 1.74 - 1.89 (m, 5 H), 2.03 - 2.15 (m, 1 H), 2.42 (dd, J=13.87, 8.40 Hz, 1 H), 2.60 - 2.75 (m, 1 H), 2.75 - 3.00 (m, 4 H), 4.02 - 4.14 (m, 2 H), 7.16 - 7.25 (m, 2 H), 7.55 (s, 1 H); MS (APPI) (M+H)+= 407.3
Example 29
3-cyclohexyl-6-[(4-methylpiperidin-l-yl)carbonyl]-9-(methylsulfonyl)-2,3,4,9- tetrahydro-lH-carbazole
Figure imgf000081_0002
Following the procedure for Step A in Example 27, using 3-cyclohexyl-6-[(4- methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH-carbazole (120 mg, 0.32 mmol), sodium hydride (60 mg, 1.5 mmol) and methanesulfonyl chloride (73 mg, 0.64 mmol) in TΗF (10 mL). The crude product was purified by MPLC on silica gel using CΗ2Cl2/Et0Ac (5:1) to give 67 mg (46%) of a white solid as the title compound. 1H NMR (400 MHz, CHLOROFORM-D) δ 0.99 (d, J=6.64 Hz, 3 H), 1.02 - 1.39 (m, 10 H), 1.47 . 1.74 (m> 5 H), 1.74 - 1.89 (m, 5 H), 2.03 - 2.15 (m, 1 H), 2.28 - 2.40 (m, 1 H), 2.68 - 2.88 (m, 3 H), 2.98 (s, 3 H), 3.08 - 3.18 (m, 1 H), 3.62 - 3.88 (m, 0.5 H), 4.59 - 4.83 (m, 0.5 H), 7.29 (dd, J=8.59, 1.56 Hz, 1 H), 7.50 (s, 1 H), 7.97 (d, J=8.59 Hz, 1 H); MS (APPI) (M+H)+= 457.3; Anal. Calcd for C26H36N2O3 S+0.2 H2O: C, 67.85; H, 7.97; N, 6.09; Found: C, 67.85; H, 7.90; N, 6.14.
Example 30
3-cyclohexyl-9-(ethylsulfonyl)-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9- tetrahydro-lH-carbazole
Figure imgf000082_0001
Following the procedure for Step A in Example 27, using 3-cyclohexyl-6-[(4- methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH-carbazole (120 mg, 0.32 mmol), sodium hydride (60 mg, 1.5 mmol) and ethanesulfonyl chloride (82 mg, 0.64 mmol) in TΗF (10 mL). The crude product was purified by MPLC on silica gel using CΗ2Cl2/Et0Ac (10:1) to give 80 mg (53%) of a white solid as the title compound. 1H NMR (400 MHz, CHLOROFORM-D) δ 0.99 (d, J=6.25 Hz, 3 H), 1.02 - 1.15 (m, 3 H), 1.19 (t, J=7.42 Hz, 3 H), 1.22 - 1.37 (m, 5 H), 1.46 - 1.73 (m, 5 H), 1.74 - 1.92 (m, 5 H), 2.03 - 2.16 (m, 1 H), 2.27 - 2.42 (m, 1 H), 2.66 - 3.07 (m, 4 H), 3.09 - 3.17 (m, 1 H), 3.21 (q, J=7.42 Hz, 2 H), 3.66 - 3.92 (m, 1 H), 4.59 - 4.85 (m, 1 H), 7.24 - 7.31 (m, 1 H), 7.49 (d, J=0.78 Hz, 1 H), 7.95 (d, J=8.59 Hz, 1 H); MS (APPI) (M+H)+= 471.3; Anal. Calcd for C27H38N2O3S: C, 68.90; H, 8.14; N, 5.95; Found: C, 68.73; H, 7.80; N, 6.30.
Example 31
3-cyclohexyl-N-[2-(cyclopropylamino)-2-oxoethyl]-N-methyl-9-(methylsulfonyl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000083_0001
Step A: 3-cyclohexyl-N- [2-(cyclopropylamino)-2-oxoethyl] -N-methyl-9-
(methylsulfonyl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000083_0002
Following the procedure for Step A in Example 27, using 3-cyclohexyl-N-[2- (cyclopropylamino)-2-oxoethyl]-N-methyl-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamide (121 mg, 0.30 mmol) (see following step B for preparation), sodium hydride (119 mg, 3.0 mmol) and methanesulfonyl chloride (340 mg, 3.0 mmol) in DMF (6 mL). The crude product was purified by MPLC on silica gel using EtOAc and then reverse-phase ΗPLC using high pΗ column 50-70% MeCN/Η2O to give 50 mg (34%) of a white solid as the title compound. 1H NMR (400 MHz, METHANOL-D4) δ 0.36 - 0.44 (m, 1 H), 0.48 - 0.58 (m, 1 H), 0.70 (dd, J=10.55, 6.25 Hz, 2 H), 1.02 - 1.39 (m, 6 H), 1.44 - 1.72 (m, 3 H), 1.74 - 1.92 (m, 4 H), 2.03 - 2.19 (m, 1 H), 2.26 - 2.45 (m, 1 H), 2.58 - 2.88 (m, 2 H), 3.02 - 3.18 (m, 7 H), 3.89 (s, 1.5 H), 4.13 (s, 1.5 H), 7.30 (d, J=8.59 Hz, 0.5 H), 7.37 (d, J=8.59 Hz, 0.5 H), 7.50 (s, 0.5 H), 7.61 (s, 0.5 H), 7.95 (d, J=8.59 Hz, 0.5 H), 7.98 (d, J=8.98 Hz, 0.5 H); MS (APPI) (M+H)+= 486.2.
Step B: 3-cyclohexyl-iV-[2-(cyclopropylamino)-2-oxoethyl]-iV-methyl-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000084_0001
Following the procedure for Step C in Example 27, using 3-Cyclohexyl-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid (0.42 g, 1.25 mmol), N^cyclopropyl-N2- methylglycinamide (0.24 g, 1.88 mmol), DIPEA (0.33 g, 0.44 mL, 2.5 mmol) and ΗATU (0.72 g, 1.89 mmol) in DMF (10 mL). The crude product was purified by MPLC on silica gel using EtOAc to give 0.34g (67%) of colorless syrup as the title compound. 1Η NMR (400 MHz, CHLOROFORM-D) δ 0.51 - 0.60 (m, 2 H), 0.76 - 0.87 (m, 2 H), 1.01 - 1.44 (m, 6 H), 1.54 - 1.74 (m, 2 H), 1.74 - 1.90 (m, 4 H), 1.99 - 2.13 (m, 2 H), 2.40 (m, 1 H), 2.70 - 2.79 (m, 4 H), 3.15 (s, 3 H), 4.03 - 4.16 (m, 2 H), 7.17 - 7.25 (m, 1 H), 7.28 (s, 1 H), 7.60 (s, 1 H), 7.89 (s, 1 H), 8.02 (s, 1 H); MS (APPI) (M+H)+= 408.29.
Example 32
3-cyclohexyl-N-[2-(cyclopropylamino)-2-oxoethyl]-9-(isopropylsulfonyl)-N-methyl-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000084_0002
Following the procedure for Step A in Example 27, using 3-cyclohexyl-N-[2- (cyclopropylamino)-2-oxoethyl]-N-methyl-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamide (121 mg, 0.30 mmol), sodium hydride (119 mg, 3.0 mmol) and isopropylsulfonyl chloride (423 mg, 3.0 mmol) in DMF (6 mL). The crude product was purified by MPLC on silica gel using EtOAc and then reverse-phase ΗPLC using high pΗ column 50-70% MeCN/Η2O to give 53 mg (35%) of a white solid as the title compound. 1H NMR (400 MHz, CHLOROFORM-D) δ 0.49 - 0.61 (m, 2 H), 0.74 - 0.90 (m, 2 H), 0.99 - 1.38 (m, H H), 1.44 - 1.63 (m, 4 H), 1.64 - 1.90 (m, 3 H), 2.03 - 2.15 (m, 1 H), 2.25 - 2.45 (m, 1 H), 2.62 - 2.94 (m, 3 H), 3.05 - 3.23 (m, 4 H), 3.35 - 3.58 (m, 1 H), 3.94 - 4.21 (m, 2 H), 6.62 - 6.79 (m, 1 H), 7.32 (d, J=9.37 Hz, 1 H), 7.57 (s, 1 H), 7.97 (d, J=7.81 Hz, 1 H); MS (APPI) (M+H)+= 514.2.
Example 33
N-Ethyl-9-methyl-N-(2-oxo-2-(tetrahydro-2H-pyran-4-ylamino)ethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000085_0001
To a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylic acid (63 mg, 0.20 mmol) and DIPEA (1.0 mL) in DMF (2 mL) was added
HATU (114 mg, 0.3 mmol) at 0 0C. After 1 hr at r.t, 2-(ethylamino)acetic acid (22.80 mg,
0.22 mmol) was added. The reaction mixture was stirred for 2 hr at r.t, and followed by addition of tetrahydro-2H-pyran-4-amine, HCl (55.3 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water N-ethyl-9-methyl-N-(2-oxo-2-
(tetrahydro-2H-pyran-4-ylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide (8.0 mg, 8.3 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.19 (m, 3 H), 1.38 - 1.48 (m, 3 H), 1.56 (m, 4 H), 1.76 (m, 4 H), 2.11 - 2.20 (m, 1 H), 2.37 (m, 1 H), 2.67 (m, 1 H), 2.76 - 2.88 (m, 2 H), 3.37 - 3.49 (m, 6 H), 3.62 (s, 3 H),
3.89 (m, 3 H), 3.97 (m, 3 H), 4.09 (m, 1 H), 7.18 (s, 1 H), 7.30 (d, J=8.20 Hz, 1 H), 7.50
(s, 1 H). MS (ESI) (M+H)+ 482.2.
Example 34 N-Ethyl-9-methyl-N-(2-oxo-2-((S)-tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000086_0001
To a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylic acid (63 mg, 0.20 mmol) and DIPEA (1.0 mL) in DMF (2 mL) was added HATU (114 mg, 0.3 mmol) at 0 0C. After 1 hr at r.t, 2-(ethylamino)acetic acid (22.80 mg, 0.22 mmol) was added. The reaction mixture was stirred for 2 hr at r.t, and followed by addition of (S)-tetrahydrofuran-3 -amine (35.0 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water N-ethyl-9-methyl-N-(2-oxo-2-((S)- tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (8.0 mg, 8.5 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.14 (m, 3 H), 1.36 - 1.48 (m, 2 H), 1.56 (m, 4 H), 1.76 (m, 3 H), 1.84 (m, 1 H), 2.13 (m, 2 H), 2.37 (m, 1 H), 2.67 (m, 1 H), 2.76 - 2.88 (m, 2 H), 3.37 - 3.46 (m, 3 H), 3.52 (m, 2 H), 3.61 (s, 3 H), 3.79 (m, 2 H), 3.97 (dd, J=10.94, 3.52 Hz, 2 H), 4.11 (m, 1 H), 4.38 (m, 1 H), 7.17 (s, 1 H), 7.30 (d, J=7.81 Hz, 1 H), 7.51 (s, 1 H). MS (ESI) (M+H)+ 468.2.
Example 35
N-Ethyl-9-methyl-N-(2-oxo-2-((R)-tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000086_0002
To a 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (63 mg, 0.20 mmol) and DIPEA (1.0 mL) in DMF (2 mL) was added HATU (114 mg, 0.3 mmol) at 0 0C. After 1 hr at r.t, 2-(ethylamino)acetic acid (22.80 mg, 0.22 mmol) was added. The reaction mixture was stirred for 2 hr at r.t, and followed by addition of (R)-tetrahydrofuran-3 -amine (35.0 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water N-ethyl-9-methyl-N-(2-oxo-2-((R)- tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (9.0 mg, 9.6 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.14 (m, 3 H), 1.36 - 1.48 (m, 2 H), 1.56 (m, 4 H), 1.76 (m, 3 H), 1.84 (m, 1 H), 2.13 (m, 2 H), 2.37 (m, 1 H), 2.67 (m, 1 H), 2.76 - 2.88 (m, 2 H), 3.37 - 3.46 (m, 3 H), 3.52 (m, 2 H), 3.61 (s, 3 H), 3.79 (m, 2 H), 3.97 (dd, J=10.94, 3.52 Hz, 2 H), 4.11 (m, 1 H), 4.38 (m, 1 H), 7.17 (s, 1 H), 7.30 (d, J=7.81 Hz, 1 H), 7.51 (s, 1 H). MS (ESI) (M+H)+
468.2. HRMS calcd for (C H N2O3 + H)+, 468.2857; found, 468.2856.
Example 36
N-Ethyl-9-methyl-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000087_0001
To a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylic acid (63.0 mg, 0.20 mmol) and DIPEA (1.0 mL) in DMF (2 mL) was added HATU (114 mg, 0.3 mmol) at 0 0C. After 1 hr at r.t, 2-(ethylamino)acetic acid (22.80 mg, 0.22 mmol) was added. The reaction mixture was stirred for 2 hr at r.t, and followed by addition of oxetan-3-amine, HCl (44.0 mg, 0.40 mmol) and HATU (114 mg, 0.3 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water and purified by high pH HPLC (20 -40) again to provide the title compound N-ethyl-9-methyl-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (34.0 mg, 37.3 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.10 - 1.22 (m, 3 H), 1.34 - 1.45 (m, 2 H), 1.47 - 1.57 (m, 3 H), 1.73 (t, J=12.11 Hz, 2 H), 2.14 (m, 1 H), 2.35 (m, 1 H), 2.67 (m, 1 H), 2.79 (m, 2 H), 3.32 - 3.43 (m, 3 H), 3.43 -3.60 (m, 2 H), 3.59 (s, 3 H), 3.96 (dd, J=I 1.33, 3.12 Hz, 2 H), 3.90 -4.20 (m, 2 H), 4.35 -4.65 (m, 2 H), 4.78 - 5.0 (m, 2 H), 7.16 (m, 1 H), 7.30 (d, J=8.0 Hz, 1 H), 7.52 (m, 1 H); MS (ESI) (M+H)+ 454.2
Example 37
N-Ethyl-N-(4-hydroxybutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000088_0001
To a solution of 4-(ethylamino)butan-l-ol (47.1 mg, 0.40 mmol), 9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (63.0 mg, 0.20 mmol) and DIPEA (0.3 mL) in DMF (2 mL) was added HATU (114 mg, 0.3 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-ethyl-N-(4-hydroxybutyl)- 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (52.0 mg, 62.7 %) as a white solid. IH NMR (400 MHz, METHANOL-D4) δ ppm 1.12 (m, 2 H), 1.26 (m, 2 H), 1.34 - 1.45 (m, 2 H), 1.54 (m, 3 H), 1.68 (m, 2 H), 1.74 (m, 3 H), 2.14 (m, 1 H), 2.37 (m, 1 H), 2.67 (m, 1 H), 2.82 (m, 2 H), 3.34 - 3.6 (m, 8 H), 3.61 (s, 3 H), 3.98 (d, J=8.20 Hz, 2 H), 7.1 l(d, J = 8.0 Hz, I H), 7.31 (d, J = 8.0 Hz, 1 H), 7.43 (s, 1
H); HRMS calcd for (C 25 R 36N 2O 3, + H)+, 413.2799; found, 413.2791.
Example 38 N-(2-(Cyanomethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000089_0001
To a solution of N-(cyanomethyl)-2-(ethylamino)acetamide, trifluoroacetic acid (153 mg, 0.60 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (94 mg, 0.30 mmol) and DIPEA (0.5 mL) in DMF (3 mL) was added HATU (228 mg, 0.6 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide N-(2- (cyanomethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (14.0 mg, 10.7 %) as a white solid: IH NMR (400 MHz, METHANOL-D4) δ ppm 1.16 (m, 3 H), 1.40 (m, 2 H), 1.54 (m, 3 H), 1.75 (t, J=12.11 Hz, 2 H), 2.14 (m, 1 H), 2.37 (m, 1 H), 2.67 (m, 1 H), 2.80 (m, 2 H), 3.32 - 3.60 (m, 4 H), 3.61 (s, 3 H), 3.96 (d, J=8.59 Hz, 2 H), 4.17 (m, 4 H), 7.18 (s, 1 H), 7.30 (d, J=7.81 Hz, 1 H), 7.54 (s, 1 H); MS (ESI) (M+H)+ 437.3;
Example 39
N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000089_0002
To a solution of 2-(cyclopropylamino)-N-ethyl-2-oxoethanaminium, Chloride (107 mg, 0.60 mmol), 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (90 mg, 0.30 mmol) and DIPEA (0.5 mL) in DMF (3 mL) was added HATU (190 mg, 0.5 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-(2- (cyclopropylamino)-2-oxoethyl)-N-ethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (26.0 mg, 20.42 %) as white solid. IH NMR (400 MHz, METHAN0L-D4) δ ppm 0.4 - 0.6 (m, 2 H), 0.70 (m, 2 H), 1.14 (m, 3 H), 1.38 - 1.50 (m, 2 H), 1.50 - 1.61 (m, 3 H), 1.76 (m, 2 H), 2.09 (m, 1 H), 2.36 (m, 1 H), 2.65 (m, 1 H), 2.71 - 2.83 (m, 3 H), 3.37 - 3.48 (m, 4 H), 3.90 - 4.12 (m, 4 H), 7.10 (s, 1
H), 7.25 (d, J=8.0 Hz, 1 H), 7.48 (s, 1 H); HRMS calcd for (C25H33N3O3 + H)+, 424.2595; found, 424.2594.
Example 40 N-((S)-1 -(2-Fluoroethylamino)-1 -oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000090_0001
To a solution of (S)-I -(2-fluoroethylamino)-N- methyl- l-oxopropan-2-aminium, chloride (111 mg, 0.60 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (94 mg, 0.30 mmol) and DIPEA (0.5 mL) in DMF (3 mL) was added HATU (228 mg, 0.6 mmol) at 0 0C. The reaction mixture was stirred for 2 hrs.at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-((S)- 1 -(2-fluoroethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (18.0 mg, 13.5 %) as white solid. IH NMR (400 MHz, METHANOL-D4) δ ppm 1.42 (m, 5 H), 1.49 - 1.59 (m, 3 H), 1.75 (m, 2 H), 2.14 (m, 1 H), 2.37 (m, 1 H), 2.66 (m, 1 H), 2.77 - 2.87 (m, 2 H), 3.00 (s, 3 H), 3.35 - 3.45 (m, 2 H), 3.47 (t, J=4.88 Hz, 1 H), 3.54 (t, J=4.88 Hz, 1 H), 3.61 (s, 3 H), 3.96 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.40 (t, J=5.08 Hz, 1 H), 4.52 (t, J=5.08 Hz, 1 H), 4.8 (m, IH), 7.18 (d, J=8.0 Hz, 1 H), 7.31 (d, J=8.0 Hz, 1 H), 7.52 (s,
1 H); MS (ESI) (M+H)+ 444.2; HRMS calcd for (C25H34FN3O3 + H)+, 444.2657; found, 444.2662. Example 41
N-((S)-1-(Cyclopropylamino)-1-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000091_0001
To a solution of ((S)-I -(eye lopropylamino)-N- methyl- l-oxopropan-2-aminium, Chloride (107 mg, 0.60 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (94 mg, 0.30 mmol) and DIPEA (0.5 mL) in DMF (3 mL) was added HATU (228 mg, 0.6 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse- phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound N-((S)-l-(cyclopropylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (75 mg, 57 %) as white solid. IH NMR (400 MHz, METHANOL-D4) δ ppm 0.51 (m, 2 H), 0.68 - 0.75 (m, 2 H), 1.41 (m, 5 H), 1.54 (m, 3 H), 1.75 (m, 2 H), 2.14 (m, 1 H), 2.37 (m, 1 H), 2.62 - 2.71 (m, 2 H), 2.77 - 2.86 (m, 2 H), 3.01 (s, 3 H), 3.36 - 3.44 (m, 2 H), 3.61 (s, 3 H), 3.97 (dd, J=I 1.13, 3.32 Hz, 2 H), 4.56 (m, IH), 7.16 (s, 1 H), 7.30 (d, J=8.59 Hz, 1 H), 7.49 (d,
J=I.95 Hz, 1 H); MS (ESI) (M+H)+ 438.3. HRMS calcd for (C26H35N3O3 + H)+,
438.2751; found, 438.2746.
Example 42
N-(4-(Cyclopropylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000092_0001
Step A: N-(4-(Cyclopropylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000092_0002
To a solution of 4-(cyclopropylamino)-4-oxobutan-l-aminium chloride (179 mg, 1.00 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carboxylic acid (157 mg, 0.50 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The residue was dissolved in EtOAc, and was washed with NH4OH (2 N), brine and dried over anhydrous sodium sulfate. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound as white solid (68 mg, 31 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 0.45 (m, 2 H), 0.66 (m, 2 H), 1.37 -1.49 (m, 2 H), 1.51 -1.61 (m, 3 H), 1.77 (m, 2 H), 1.85 -1.92 (m, 2H), 2.13 - 2.24 (m, 3 H), 2.42 (m, IH), 2.70 (m, 1 H), 2.80 - 2.89 (m, 2 H), 3.35 - 3.50 (m, 5 H), 3.62 (s, 3H), 3.98 (dd, J=I 1.3, 3.5 Hz, 2 H), 7.29 (d, J =8.6 Hz, 1 H), 7.58 (d, J=8.6 Hz, 1 H), 7.93 (s, 1 H); MS (ESI) (M+H)+ 438.3.
Step B: 4-(cyclopropylamino)-4-oxobutan-l-aminium chloride
Figure imgf000092_0003
To a solution of cyclopropylamine (1.14 g, 20 mmol), 4-(tert- butoxycarbonylamino)butanoic acid (2.030 g, 9.99 mmol), and DIPEA (3 mL) in DMF (30 mL) was added HATU (4.56 g, 12 mmol) at O 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The residue was dissolved in EtOAc, and was washed with NH4OH (2 N), brine and dried over anhydrous sodium sulfate.
Removal of solvents provided a residue that was dissolved in 50 mL of IM HCl/AcOH and stirred at rt for 3h. The solvent was evaporated to give the desired product, which was used directly in the next step.
Example 43
N-(1-(Cyclopropylcarbamoyl)cyclopropyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000093_0001
To a solution of l-(cyclopropylcarbamoyl)-N-methylcyclopropanaminium chloride (191 mg, 1.00 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (157 mg, 0.50 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse- phase HPLC using an acetonitrile gradient 30 to 50 % in water to provide the title compound as white solid (7 mg, 3 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 0.71 (m, 2 H), 0.78 (m, 2 H), 1.13 (m, 1 H), 1.32 -1.36 (m, 2 H), 1.38 -1.49 (m, 4 H), 1.57 (m, 3 H), 1.73 -1.82 (m, 2H), 2.17 (m, 1 H), 2.37 (m, IH), 2.60 -2.75 (m, 2 H), 2.80 - 2.89 (m, 1 H), 3.38 - 3.46 (m, 2 H), 3.62 (s, 3H), 3.98 (dd, J=I 1.3, 3.7 Hz, 2 H), 7.21 (d, J =8.6 Hz, 1 H), 7.28 (d, J=8.6 Hz, 1 H), 7.53 (s, 1 H); MS (ESI) (M+H)+ 450.2.
Example 44 N-(2-Fluoroethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H- carbazole-6-carboxamide
Figure imgf000094_0001
To a solution of 2-fluoroethanaminium chloride (199 mg, 2.00 mmol), 9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (313 mg, 1.00 mmol) and DIPEA (0.8 mL) in DMF (8 mL) was added HATU (456 mg, 1.2 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC using an acetonitrile gradient 20 to 50 % in water to provide the title compound as white solid (268 mg, 75 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.34 - 1.45 (m, 2 H), 1.46 - 1.56 (m, 3 H), 1.73 (m, 2 H), 2.08 - 2.16 (m, 1 H), 2.31 - 2.39 (m, 1 H), 2.64 (m, 1 H), 2.79 (m, 2 H), 3.35 - 3.43 (m, 2 H), 3.59 (s, 3 H), 3.63 (t, J=5.27 Hz, 1 H), 3.69 (t, J=5.27 Hz, 1 H), 3.96 (dd, J=10.94, 3.91 Hz, 2 H), 4.48 (t, J=5.08 Hz, 1 H), 4.60 (t, J=5.27 Hz, 1 H), 7.27 (d, J=8.59 Hz, 1 H), 7.60 (dd, J=8.59, 1.95 Hz, 1 H), 7.95 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)+ 359.2135.
Example 45
N-Ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000094_0002
To a solution of N-ethyl-4-(2-fluoroethylamino)-4-oxobutan-l-aminium chloride (213 mg, 1.00 mmol), 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (157 mg, 0.50 mmol) and DIPEA (0.5 mL) in DMF (5 mL) was added HATU (228 mg, 0.6 mmol) at 0 0C. The reaction mixture was stirred for 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse- phase HPLC using an acetonitrile gradient 20 to 50 % in water after three times to provide the title compound N-ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (22.86 %) as white solid (54 mg). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.05 - 1.31 (m, 3 H), 1.35 - 1.46 (m, 2 H), 1.48 - 1.58 (m, 3 H), 1.74 (t, J=12.50 Hz, 2 H), 1.80 - 2.08 (m, 3 H), 2.14 (m, 1 H), 2.20 - 2.40 (m, 2 H), 2.60 - 2.71 (m, 1 H), 2.77 - 2.86 (m, 2 H), 3.15 - 3.60 (m, 8 H) 3.50 (s, 2 H), 3.60 (s, 3 H), 3.96 (dd, J=10.94, 3.52 Hz, 2 H), 4.10 - 4.50 (m, 2 H), 7.08 (d, J=8.20 Hz, 1 H), 7.30 (d, J=8.20 Hz, 1 H), 7.41 (s, 1 H); MS (ESI) (M+H)+ 472.2.
Example 46
N-((R)-l-(2-fluoroethylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000095_0001
HATU (55.8 mg, 0.15 mmol) and 2-Fluoroethylamine hydrochloride (11.24 mg, 0.11 mmol) were added slowly at 0 0C to a solution of (2R)-2-(N,9-dimethyl-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)propanoic acid (45 mg,
0.11 mmol) and N,N-diisopropylethylamine (0.059 mL, 0.34 mmol) in DMF (0.896 mL).
Reaction mixture was stirred at room temperature for 4 hours. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-((R)-l-(2- fluoroethylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (66.2 %) was purified by Prep-LCMS reverse-phase using a low pH 40-60% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.36 - 1.50 (m, 7 H), 1.50 - 1.64 (m, 5 H), 1.77 (t, J=13.28 Hz, 2 H), 2.10 - 2.23 (m, 1 H), 2.29 - 2.47 (m, 1 H), 2.59 - 2.75 (m, 1 H), 2.79 - 2.91 (m, 2 H), 3.02 (s, 3 H), 3.37 - 3.47 (m, 2 H), 3.49 (t, J=4.88 Hz, 1 H), 3.56 (t, J=4.88 Hz, 1 H), 3.63 (s, 3 H), 3.98 (dd, J=I 1.33, 3.91 Hz, 2 H), 4.42 (t, J=4.88 Hz, 1 H), 4.54 (t, J=5.08 Hz, 1 H), 7.11 - 7.25 (m, 1 H); [M+H]+ calc. = 444.2657, [M+H]+ obs. = 444.2670. Example 47
N-((R)-l-(ethylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000096_0001
HATU (71.8 mg, 0.19 mmol) and ethylamine hydrochloride (15.39 mg, 0.19 mmol) were added slowly at 0 0C to a solution of (2R)-2-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)propanoic acid (37.6 mg, 0.09 mmol) and N,N-diisopropylethylamine (0.049 mL, 0.28 mmol) in DMF (0.749 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-((R)-1- (ethylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (71.5 %) was purified by Prep-HPLC reverse- phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD-D4) δ ppm l.l4 (t, J=7.03 Hz, 3 H), 1.36 - 1.51 (m, 6 H), 1.51 - 1.66 (m, 4 H), 1.71 - 1.86 (m, 2 H), 2.13 - 2.23 (m, 1 H), 2.32 - 2.47 (m, 1 H), 2.63 - 2.78 (m, 1 H), 2.80 - 2.92 (m, 2 H), 3.02 (s, 3 H), 3.24 (m, 2 H), 3.38 - 3.51 (m, 2 H), 3.64 (s, 3 H), 3.99 (dd, J=I 1.33, 2.34 Hz, 2 H), 7.14 - 7.26 (m, 1 H), 7.30 - 7.38 (m, 1 H), 7.47 - 7.58 (m, 1 H); [M+H]+ calc. = 426.2751, [M+H]+ obs. = 426.2749.
Example 48
N-ethyl-N-(2-hydroxypropyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000097_0001
Step A. N-ethyl-N-(2-hydroxypropyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000097_0002
A solution of N-ethyl-9-methyl-N-(2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (103.7 mg, 0.27 mmol) in THF (25 mL) was cooled to -78 0C. Methylmagnesium chloride (0.136 mL, 0.41 mmol) 3M in THF was added slowly and the reaction mixture was stirred for 2 h; then the mixture was allowed to reach room temperature slowly. After 14h the reaction mixture was filtered, and the solvent was evaporated in vacuo. The N-ethyl-N-(2-hydroxypropyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (21.4 mg, 16 %) was purified by Prep-HPLC reverse-phase using a low pH 40-60% ACN/water system. IH NMR (400 MHz, CD3OD-D4) δ ppm 0.88 - 1.00 (m, 1 H), 1.02 - 1.16 (m, 2 H), 1.18 - 1.31 (m, 3 H), 1.35 - 1.50 (m, 3 H), 1.51 - 1.63 (m, 3 H), 1.78 (t, J=13.67 Hz, 2 H), 2.11 - 2.24 (m, 1 H), 2.33 - 2.46 (m, 1 H), 2.62 - 2.77 (m, 1 H), 2.78 - 2.91 (m, 2 H), 3.32 - 3.55 (m, 6 H), 3.59 - 3.68 (m, 3 H), 3.99 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.08 - 4.26 (m, 1 H), 7.08 - 7.22 (m, 1 H), 7.29 - 7.38 (m, 1 H), 7.42 - 7.53 (m, 1 H); MS (ESI) (M+H)+ 399.4.
Step B. N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000098_0001
HATU (485 mg, 1.28 mmol) and 2-(Ethylamino)ethanol (0.124 mL, 1.28 mmol) were added slowly at O 0C to a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid (200 mg, 0.64 mmol) and N ,N- diisopropylethylamine (0.334 mL, 1.92 mmol) in DMF (6.877 mL). Reaction mixture was stirred at room temperature for 2h. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-ethyl-N-(2-hydroxyethyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (179 mg, 56.2 %) was purified by Prep-HPLC reverse-phase using a low pH 50-70% ACN/water system. IH NMR (400 MHz, CD3OD-D4) δ ppm 1.04 - 1.32 (m, 3 H), 1.30 - 1.47 (m, 2 H), 1.46 - 1.59 (m, 3 H), 1.74 (t, J=13.67 Hz, 2 H), 2.07 - 2.17 (m, 1 H), 2.35 (dd, J=15.23, 7.81 Hz, 1 H), 2.59 - 2.71 (m, 1 H), 2.76 - 2.86 (m, 2 H), 3.35 - 3.45 (m, 3 H), 3.45 - 3.57 (m, 3 H), 3.60 (s, 3 H), 3.61 - 3.71 (m, 2 H), 3.75 - 3.88 (m, 1 H), 3.97 (dd, J=I l.13, 4.10 Hz, 2 H), 7.11 - 7.18 (m, 1 H), 7.26 - 7.33 (m, 1 H), 7.46 - 7.50 (m, 1 H); MS (ESI) (M+H)+ 385.4.
Step C. N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000098_0002
Stirred 500.0 mg of 4 A molecular sieves in dry DCM (2.048 mL), N-ethyl-N-(2- hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxamide (100.0 mg, 0.26 mmol) and 4-Methylmorpholine-4-oxide (76 mg, 0.65 mmol) (20.0 mL) for 30 minutes. Tetrapropylammonium perruthenate (4.57 mg, 0.01 mmol) was then added. After 4h of stirring at room temperature, the reaction mixture was filtered and the solvent evaporated in vacuo. The N-ethyl-9-methyl-N-(2-oxoethyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (56.3 mg, 56.6 %) was purified by flash column with a DCM/MeOH to provide the title compound as oil. MS (ESI) (M+H)+ 383.3.
Example 49
N-(2-(2-Cyanoethylamino)-2-oxoethyl)-N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide
Figure imgf000099_0001
To a solution of 9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (117 mg, 0.30 mmol) and DIPEA (1.0 mL) in DMF (2 mL) was added HATU (125 mg, 0.33 mmol) at 0 0C. After 1 hr at r.t, 2-(ethylamino)acetic acid (33.9 mg, 0.33 mmol) was added. The reaction mixture was stirred for 2 hr at r.t, and followed by addition of 3-aminopropanenitrile (41.9 mg, 0.60 mmol) and HATU (125 mg, 0.33 mmol). The reaction mixture was stirred for additional 2 hr at r.t and the solvent was concentrated. The product was purified by preparative reverse-phase HPLC (high pH) using an acetonitrile gradient 20 to 40 % in water to provide N-(2-(2- cyanoethylamino)-2-oxoethyl)-N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide (66.0 mg, 41.8 %). IH NMR (400 MHz, METHANOL-D4) δ ppm 1.12 (m, 5 H), 1.23 (m, 1 H), 1.41 (m, 2 H), 1.56 (m, 3 H), 1.71 - 1.81 (m, 2 H), 2.13 (m, 1 H), 2.35 (m, 1 H), 2.60 - 2.71 (m, 2 H), 2.83 (m, 2 H), 3.14 (m, 1 H), 3.26 - 3.36 (m, 3 H), 3.42 (m, 4 H), 3.62 (m, 1 H), 3.98 (m, 3 H), 4.17 (m, 1 H), 7.73 (m, 1 H), 7.63 (m, 0.5 H), 7.97 (m, 1 H), 8.43 (m, 1 H). HRMS calcd for (C27H36N4O5 S+ H)+, 529.24792; found, 529.24811. Example 50
Step A: (3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)piperidine-3-carboxamide
Figure imgf000100_0001
(3 S)-Ethyl 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidine-3-carboxylate (140 mg, 0.31 mmol) was dissolved in dioxane (8 mL) containing lithium hydroxide (0.619 mL, 0.62 mmol) (IM) and was stirred at 23 0C for 3h. The solvent was evaporated. The residue was dissolved in DMF (8.00 mL) containing N,N-diisopropylethylamine (0.135 mL, 0.77 mmol). HATU (141 mg, 0.37 mmol) and cyclopropylamine (0.026 mL, 0.37 mmol) were added and the solution was stirred at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 50-70%B and lyophilized. Yield: 85 mg (59%) (Purification: Gilson system equipped with Luna C-18 column, 250 X 50 mm, 15u Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 55mL/min, 30 min run, rt): 1H NMR (400 MHz, METHANOL-D4) δ 0.45 (s, 2 H), 0.67 (s, 2 H), 1.34 - 1.49 (m, 3 H), 1.50 - 1.62 (m, 4 H), 1.76 (m, 4 H), 1.87 - 1.95 (m, 1 H), 2.11 - 2.21 (m, 1 H), 2.29 - 2.44 (m, 2 H), 2.60 - 2.72 (m, 1 H), 2.76 - 2.91 (m, 2 H), 3.12 (s, 1 H), 3.35 - 3.47 (m, 2 H), 3.62 (s, 3 H), 3.79 (s, 1 H), 3.97 (dd, J=I 0.94, 3.52 Hz, 2 H), 4.45 (s, 1 H), 7.12 (dd, J=8.40, 1.76 Hz, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.46 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+ = 464.2.
Step B: (3S)-Ethyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidine-3-carboxylate
Figure imgf000101_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (100 mg, 0.32 mmol), HATU (146 mg, 0.38 mmol) and (S)-(+)-nipecotic acid ethyl ester (0.059 mL, 0.38 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.083 mL, 0.48 mmol) at rt for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by flash using 20-80%
EtOAc / heptane gradient. Yield: 140 mg (97%); 1H NMR (400 MHz, DMSO-D6) δ 1.05 - 1.15 (m, 2 H), 1.21 - 1.36 (m, 3 H), 1.40 - 1.53 (m, 4 H), 1.56 - 1.75 (m, 4 H), 1.90 - 1.98 (m, 1 H), 2.01 - 2.09 (m, 1 H), 2.24 - 2.34 (m, 1 H), 2.48 - 2.57 (m, 1 H), 2.58 - 2.67 (m, 1 H), 2.69 - 2.85 (m, 2 H), 3.01 (t, J=10.74 Hz, 1 H), 3.12 (s, 1 H), 3.22 - 3.31 (m, 2 H), 3.35 (s, 3 H), 3.58 (s, 3 H), 3.86 (dd, J=10.94, 3.52 Hz, 2 H), 3.96 - 4.05 (m, 1 H), 7.05 (d, J=8.59 Hz, 1 H), 7.34 (d, J=8.20 Hz, 1 H), 7.39 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+ = 453.30.
Example 51
(3S)-N-cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carbonyl)piperidine-3-carboxamide (Isomers 1 and 2).
Figure imgf000101_0002
(3 S)-N-Cyclopropyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-6-carbonyl)piperidine-3-carboxamide (80 mg, 0.17 mmol) was separated by chiral HPLC. Chiral Purification: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 20% iso-propanol/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min ran, rt. Chiral analytical HPLC: ChiraPak AD column, 20% iso- propanol/hexanes, lmL/min, 30 min ran, 25°C Yield: Isomer 1: 35mg (44%) Isomer 2: 40mg (50%)
Isomer 1: 1H NMR (400 MHz, METHANOL-D4) δ 0.45 (s, 2 H), 0.68 (s, 2 H), 1.35 - 1.49 (m, 3 H), 1.50 - 1.64 (m, 4 H), 1.76 (t, J=12.89 Hz, 4 H), 1.85 - 1.97 (m, 1 H), 2.10 - 2.22 (m, 1 H), 2.30 - 2.44 (m, 2 H), 2.57 - 2.74 (m, 1 H), 2.83 (t, J=14.45 Hz, 2 H), 3.06 - 3.20 (m, 1 H), 3.35 - 3.49 (m, 2 H), 3.62 (s, 3 H), 3.81 (s, 1 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.46 (s, 1 H), 7.12 (dd, J=8.59, 1.56 Hz, I H), 7.31 (d, J=7.81 Hz, 1 H), 7.46 (d, J=I.17 Hz, 1 H); Chiral HPLC k' = 4.88; MS (ESI) (M+H)+ = 464.2; accurate mass: (M+H) = 464.290.
Isomer 2: 1H NMR (400 MHz, METHANOL-D4) δ 0.44 (s, 2 H), 0.67 (s, 2 H), 1.35 - 1.49 (m, 3 H), 1.50 - 1.65 (m, 4 H), 1.76 (t, J=13.48 Hz, 4 H), 1.86 - 1.96 (m, 1 H), 2.11 - 2.20 (m, 1 H), 2.30 - 2.44 (m, 2 H), 2.61 - 2.74 (m, 1 H), 2.77 - 2.90 (m, 2 H), 3.13 (s, 1 H), 3.36 - 3.49 (m, 2 H), 3.62 (s, 3 H), 3.82 (s, 1 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.45 (s, 1 H), 7.12 (dd, J=8.59, 1.56 Hz, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.45 (d, J=I.17 Hz, 1 H); Chiral HPLC k' = 6.34; MS (ESI) (M+H)+ = 464.2; accurate mass: (M+H) = 464.292.
Example 52
(R)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide and (S)-N,9-dimethyl-N-(4- (methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide
Chiral separation of N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (80 mg, 0.19 mmol) was done as the following: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 45% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min ran, rt. Chiral analytical HPLC: ChiraPak AD column, 40% EtOH/hexanes, lmL/min, 30 min ran, 25°C. (R)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 1, 30 mg, 37.5 %):
Figure imgf000103_0001
1H NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.50 (m, 2 H), 1.52 - 1.61 (m, 3 H), 1.77 (t, J=12.70 Hz, 2 H), 1.86 (s, 1 H), 1.96 (s, 2 H), 2.13 - 2.20 (m, 1 H), 2.26 (s, 1 H), 2.34 - 2.44 (m, 1 H), 2.49 (s, 1 H), 2.64 - 2.73 (m, 2 H), 2.79 - 2.90 (m, 2 H), 3.04 (s, 3 H), 3.36 - 3.47 (m, 3 H), 3.55 (s, 1 H), 3.63 (s, 3 H), 3.98 (dd, J=10.94, 3.52 Hz, 2 H), 7.13 (s, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 426.2; Chiral HPLC k' = 3.20. Recrystallization:
(R)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (0.98 g, 2.30 mmol) was dissolved in MeCN (1 mL) at room temperature. After stirring for 5 min, white solids were formed and collected. The white solids were recrystallized from MeCN solution (5 mL) to provide long rod crystals (827 mg, 84%). m.p. 134-136 0C; [α]D = +55.1° (1.00, CDCl3); HRMS m/z calcd for C26H36N3O3 [M+ H]+ 426.2751 , found 426.2749.
X-Ray study of the crystal is carried under the following condition and using the following parameters:
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
The molecular structure is shown in the following diagram.
Figure imgf000107_0001
(S)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (isomer 2, 30 mg, 37.5 %):
Figure imgf000107_0002
1H NMR (400 MHz, METHANOL-D4) δ 1.38 - 1.50 (m, 2 H), 1.53 - 1.60 (m, 3 H), 1.78 (t, J=12.30 Hz, 2 H), 1.85 (s, 1 H), 1.96 (s, 2 H), 2.13 - 2.20 (m, 1 H), 2.26 (s, 1 H), 2.39 (dd, ./=16.21, 6.84 Hz, 1 H), 2.49 (s, 1 H), 2.65 - 2.74 (m, 2 H), 2.80 - 2.89 (m, 2 H), 3.04 (s, 3 H), 3.37 - 3.47 (m, 3 H), 3.55 (s, 1 H), 3.63 (s, 3 H), 3.98 (dd, J=I 1.33, 3.91 Hz, 2 H), 7.12 (s, 1 H) 7.31 (d, J=8.59 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 426.2; Chiral HPLC k' = 4.79.
Example 53
(R)-N-Ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide and (S)-N-Ethyl-N-(2- (2-fluoroethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide.
Chiral separation of N-ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (75 mg, 0.17 mmol) was done as the following: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 45% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, rt. Chiral analytical HPLC: ChiraPak AD column, 40% EtOH/hexanes, lmL/min, 30 min run, 25°C. (R)-N-Ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 1, 25 mg, 33 %):
Figure imgf000108_0001
1H NMR (400 MHz, METHANOL-D4) δ 1.10 - 1.26 (m, 3 H), 1.38 - 1.48 (m, 2 H), 1.53 - 1.62 (m, 3 H), 1.77 (t, J=13.28 Hz, 2 H), 2.12 - 2.20 (m, 1 H), 2.38 (s, 1 H), 2.64 - 2.74
(m, 1 H), 2.83 (t, J=14.84 Hz, 2 H), 3.38 - 3.44 (m, 3 H), 3.47 (s, 1 H), 3.53 (s, 2 H), 3.63 (s, 3 H), 3.98 (dd, J=I l.13, 3.32 Hz, 2 H), 4.03 (s, 1 H), 4.15 (s, 1 H), 4.39 (s, 1 H), 4.51 (s, 1 H), 7.18 (d, J=7.42 Hz, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.52 (s, 1 H); MS (ESI) (M+H)+ = 444.2; Chiral HPLC k' = 4.42.
(S)-N-Ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 2, 25 mg, 33 %):
Figure imgf000109_0001
1H NMR (400 MHz, METHANOL-D4) δ 1.12 - 1.25 (m, 3 H), 1.37 - 1.49 (m, 2 H), 1.52 - 1.61 (m, 3 H), 1.77 (t, J=13.28 Hz, 2 H), 2.13 - 2.20 (m, 1 H), 2.36 (dd, J=10.35, 4.49 Hz, 1 H), 2.63 - 2.73 (m, 1 H), 2.77 - 2.89 (m, 2 H), 3.36 - 3.46 (m, 3 H), 3.47 (s, 1 H), 3.53 (s, 2 H), 3.62 (s, 3 H), 3.98 (dd, J=I 1.33, 3.52 Hz, 2 H), 4.04 (s, 1 H), 4.15 (s, 1 H), 4.39 (s, 1 H), 4.51 (s, 1 H), 7.18 (d, J=6.64 Hz, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.53 (s, 1 H); MS (ESI) (M+H)+ = 444.2; Chiral HPLC k' = 5.83
Example 54 (R)-N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide and (S)-N-(2-
(Cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Chiral separation of N-(2-(cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (85 mg, 0.19 mmol) was done as the following: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 30% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, rt. Chiral analytical HPLC: ChiraPak AD column, 25% EtOH/hexanes, lmL/min, 30 min run, 25°C (R)-N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 1, 25 mg, 29 %):
Figure imgf000110_0001
1H NMR (400 MHz, METHANOL-D4) δ 0.39 - 0.55 (m, 2 H), 0.70 (d, J=5.47 Hz, 2 H), 1.11 - 1.22 (m, 3 H), 1.36 - 1.49 (m, 2 H), 1.56 (s, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 2.13 - 2.20 (m, 1 H), 2.37 (dd, J=15.23, 5.08 Hz, 1 H), 2.62 - 2.73 (m, 2 H), 2.77 - 2.89 (m, 2 H), 3.36 - 3.46 (m, 3 H), 3.53 (s, 1 H), 3.62 (s, 3 H), 3.93 (s, 1 H), 3.98 (dd, J=I 1.13, 3.32 Hz, 2 H), 4.06 (s, 1 H), 7.17 (s, 1 H), 7.30 (d, J=8.20 Hz, 1 H), 7.51 (s, 1 H); MS (ESI) (M+H)+ = 438.3; Chiral HPLC k' = 3.86. (S)-N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 2, 26 mg, 31 %):
Figure imgf000110_0002
1H NMR (400 MHz, METHANOL-D4) δ 0.37 - 0.56 (m, 2 H), 0.70 (d, J=5.86 Hz, 2 H), 1.09 - 1.24 (m, 3 H), 1.37 - 1.49 (m, 2 H), 1.56 (s, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 2.12 - 2.22 (m, 1 H), 2.32 - 2.43 (m, 1 H), 2.61 - 2.73 (m, 2 H), 2.77 - 2.90 (m, 2 H), 3.36 - 3.46 (m, 3 H), 3.53 (s, 1 H), 3.62 (s, 3 H), 3.93 (s, 1 H), 3.98 (dd, J=I 1.13, 3.32 Hz, 2 H), 4.07 (s, 1 H), 7.18 (s, 1 H), 7.30 (d, J=7.42 Hz, 1 H), 7.51 (s, 1 H); MS (ESI) (M+H)+ = 438.3; Chrial HPLC k' = 4.81.
Example 55
(R)-N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide and (S)-N-(4-(2- Fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide.
Chiral separation of N-(4-(2-fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (55 mg, 0.12 mmol) was done as the following: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 20% iPrOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min ran, rt. Chiral analytical HPLC: ChiraPak AD column, 20% iPrOH/hexanes, lmL/min, 30 min ran, 25°C (R)-N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 1, 27 mg, 49 %):
Figure imgf000111_0001
1H NMR (400 MHz, METHANOL-D4) δ 1.38 - 1.49 (m, 2 H), 1.52 - 1.62 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 1.87 (s, 1 H), 1.99 (s, 2 H), 2.12 - 2.21 (m, 1 H), 2.31 (s, 1 H), 2.34 - 2.44 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.79 - 2.91 (m, 2 H), 3.04 (s, 3 H), 3.15 - 3.25 (m, 1 H), 3.35 - 3.47 (m, 3 H), 3.50 (s, 1 H), 3.57 (s, 1 H), 3.63 (s, 3 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.17 (s, 0.5 H), 4.29 (s, 0.5 H), 4.37 (s, 0.5 H), 4.49 (s, 0.5 H), 7.12 (s, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 458.3; Chiral HPLC k' = 7.76. (S)-N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (isomer 2, 24 mg, 43 %):
Figure imgf000111_0002
1H NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.50 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.77 (t, J=12.11 Hz, 2 H), 1.87 (s, 1 H), 1.98 (s, 2 H), 2.12 - 2.20 (m, 1 H), 2.31 (s, 1 H), 2.38 (dd, J=15.62, 7.03 Hz, 1 H), 2.63 - 2.75 (m, 1 H), 2.84 (dd, J=12.11, 2.73 Hz, 2 H), 3.04 (s, 3 H), 3.21 (s, 1 H), 3.36 - 3.47 (m, 3 H), 3.50 (s, 1 H), 3.57 (s, 1 H), 3.63 (s, 3 H), 3.98 (dd, J=I 1.33, 3.91 Hz, 2 H), 4.18 (s, 0.5 H), 4.29 (s, 0.5 H), 4.37 (s, 0.5 H), 4.49 (s, 0.5 H), 7.12 (s, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 458.3; Chiral HPLC k' = 9.46.
Example 56 (R)-N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide and (S)-N-ethyl-N-(2-hydroxyethyl)-9- methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamide.
Chiral separation of N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (90 mg, 0.23 mmol) was done as the following: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 15% 1:1 MeOH:iPrOH / hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, rt. Chiral analytical HPLC: ChiraPak AD column, 15% MeOH:iPrOH / hexanes, lmL/min, 30 min run, 25°C. Products needed to be repurifϊed by reversed-phase HPLC as their NMR showed the presence of impurities. Reversed-phase purification: Gilson system equipped with Luna C-18 column, 250 X 21.2 mm, 15u. Mobile phase: 30- 50%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt.
(R)-N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (isomer 1, 25 mg, 28 %):
Figure imgf000113_0001
1H NMR (400 MHz, METHANOL-D4) δ 1.11 (s, 2 H), 1.23 (s, 1 H), 1.37 - 1.49 (m, 2 H), 1.51 - 1.62 (m, 3 H), 1.77 (t, J=13.28 Hz, 2 H), 2.13 - 2.20 (m, 1 H), 2.32 - 2.43 (m, 1 H), 2.62 - 2.74 (m, 1 H), 2.78 - 2.89 (m, 2 H), 3.36 - 3.50 (m, 4 H), 3.54 - 3.66 (m, 6 H), 3.80 (s, 1 H), 3.98 (dd, J=I 1.13, 4.10 Hz, 2 H), 7.12 (dd, J=8.20, 1.56 Hz, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (d, J=0.78 Hz, 1 H); chiral HPLC k' = 5.68; MS (ESI) (M+H)+ = 385.2; accurate mass: (M+H) = 385.248. (S)-N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (isomer 2, 25 mg, 28 %):
Figure imgf000113_0002
1H NMR (400 MHz, METHANOL-D4) δ 1.11 (s, 2 H), 1.19 - 1.28 (m, 1 H), 1.36 - 1.48 (m, 2 H), 1.51 - 1.60 (m, 3 H), 1.76 (t, J=13.28 Hz, 2 H), 2.11 - 2.20 (m, 1 H), 2.37 (dd, J=15.62, 7.03 Hz, 1 H), 2.61 - 2.73 (m, 1 H), 2.78 - 2.89 (m, 2 H), 3.35 - 3.51 (m, 4 H), 3.62 (s, 6 H), 3.80 (s, 1 H), 3.97 (dd, J=I 1.52, 3.71 Hz, 2 H), 7.12 (dd, J=8.20, 1.56 Hz, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (d, J=0.78 Hz, 1 H); chiral HPLC k' = 6.93; MS (ESI) (M+H)+ = 385.2; accurate mass: (M+H) = 385.248.
Example 57
N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)pyrrolidine-3-carboxamide
Figure imgf000114_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (100 mg, 0.32 mmol), HATU (146 mg, 0.38 mmol) and 3-
(cyclopropylcarbamoyl)pyrrolidinium chloride (73.0 mg, 0.38 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3 solution, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 30-50% and lyophilized.
Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt.
Yield: 40 mg (28%). IH NMR (400 MHz, METHANOL-D4) δ 0.04 (m, 2 H), 0.29 (m, 2 H), 0.96 - 1.09 (m, 2 H), 1.10 - 1.20 (m, 3 H), 1.36 (t, J=12.70 Hz, 2 H), 1.61 - 1.70 (m, 1 H), 1.72 - 1.80 (m, 2 H), 1.92 - 2.03 (m, 1 H), 2.19 - 2.33 (m, 2 H), 2.39 - 2.50 (m, 2.5 H), 2.56 - 2.65 (m, 0.5 H), 2.96 - 3.07 (m, 2 H), 3.16 - 3.24 (m, 4 H), 3.25 - 3.41 (m, 3 H), 3.57 (dd, J=I 1.13, 3.71 Hz, 2 H), 6.83 - 6.88 (m, 1 H), 6.89 - 6.93 (m, 1 H), 7.20 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)+ = 450.2; accurate mass: (M+H) = 450.275.
Example 58
Step A: (3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (Isomers 1 and 2).
Figure imgf000114_0002
Chiral separation of (3S)-N-cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (100 mg, 0.22 mmol). Chiral Purification: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 35% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min ran, rt. Chiral analytical HPLC: ChiraPak AD column, 40% EtOH/hexanes, lmL/min, 30 min ran, 25°C Yield: Isomer 1: 42 mg (42%) Isomer 2: 42 mg (42%)
Isomer 1: 1H NMR (400 MHz, METHANOL-D4) δ 0.40 (s, 1 H), 0.48 (s, 1 H), 0.69 (dd, J=23.44, 6.25 Hz, 2 H), 1.37 - 1.50 (m, 2 H), 1.52 - 1.63 (m, 3 H), 1.77 (t, J=12.70 Hz, 2 H), 2.01 - 2.10 (m, 1 H), 2.12 - 2.21 (m, 2 H), 2.33 - 2.43 (m, 1 H), 2.55 - 2.63 (m, 0.5 H), 2.63 - 2.74 (m, 1 H), 2.79 - 2.89 (m, 3 H), 2.96 - 3.06 (m, 0.5 H), 3.37 - 3.47 (m, 2 H), 3.54 - 3.66 (m, 4 H), 3.67 - 3.82 (m, 3 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.24 - 7.28 (m, 1 H), 7.28 - 7.33 (m, 1 H), 7.60 (s, 1 H); chiral HPLC k' = 2.33; MS (ESI) (M+H)+ = 450.2; accurate mass: (M+H) = 450.275.
Isomer 2: 1H NMR (400 MHz, METHANOL-D4) δ 0.40 (s, 1 H), 0.48 (s, 1 H), 0.68 (dd, J=23.63, 6.84 Hz, 2 H), 1.37 - 1.49 (m, 2 H), 1.52 - 1.62 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 2.01 - 2.09 (m, 1 H), 2.12 - 2.21 (m, 2 H), 2.39 (dd, J=15.62, 7.03 Hz, 1 H), 2.55 - 2.63 (m, 0.5 H), 2.64 - 2.74 (m, 1 H), 2.80 - 2.90 (m, 3 H), 2.97 - 3.06 (m, 0.5 H), 3.37 - 3.46 (m, 2 H), 3.55 - 3.65 (m, 4 H), 3.67 - 3.80 (m, 3 H), 3.98 (dd, J=I 1.33, 3.52 Hz, 2 H), 7.23 - 7.28 (m, 1 H), 7.29 - 7.33 (m, 1 H), 7.60 (d, J=I.17 Hz, 1 H); chiral HPLC k' = 3.60; MS (ESI) (M+H)+ = 450.2; accurate mass: (M+H) = 450.275.
Step B: (S)-N-Cyclopropylpyrrolidine-3-carboxamide hydrochloride
Figure imgf000115_0001
(S)-l-N-Boc-beta-proline (500 mg, 2.32 mmol), cyclopropylamine (0.193 mL, 2.79 mmol) and O-(7-azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1060 mg, 2.79 mmol) were stirred in DMF (10 mL) containing
N,N-diisopropylethylamine (0.607 mL, 3.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% aqueous KHSO4, aqueous saturated NaHCO3, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The residue was stirred in hydrogen chloride (1.16E+04 μL, 11.60 mmol) (IM in AcOH) at 23 0C for 2-3h. The solvent was evaporated. The residue was washed with ether and the ether layer was decanted. The product was dried under vacuum overnight. The product was used directly for the next step. MS (ESI) (M+H)+ = 255.21 (Boc product). Yield: 450mg (100%)
Step C: (3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-ό-carbony^pyrrolidine-S-carboxamide
Figure imgf000116_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (125 mg, 0.40 mmol), (S)-N-cyclopropylpyrrolidine-3-carboxamide hydrochloride (91 mg, 0.48 mmol) and HATU (182 mg, 0.48 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.174 mL, 1.00 mmol) at 23 0C for Ih. LC/MS showed presence of 1:1 product with HATU intermediate. Another 1.2 eq of (S)-N- cyclopropylpyrrolidine-3-carboxamide hydrochloride was added along with 1.5 eq of DIPEA and solution was stirred at rt for another 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN;
30mL/min, 25 min run, rt. Yield: 1 lOmg (61%); 1H NMR (400 MHz, METHANOL-D4) δ 0.40 (s, 1 H), 0.48 (s, 1 H), 0.68 (dd, J=24.22, 6.64 Hz, 2 H), 1.36 - 1.48 (m, 2 H), 1.55 (s, 3 H), 1.76 (t, J=12.50 Hz, 2 H), 2.00 - 2.07 (m, 1 H), 2.12 - 2.19 (m, 2 H), 2.33 - 2.42
(m, 1 H), 2.59 (s, 0.5 H), 2.63 - 2.74 (m, 1 H), 2.77 - 2.89 (m, 2 H), 2.96 - 3.04 (m, 0.5 H), 3.36 - 3.46 (m, 2 H), 3.55 - 3.66 (m, 5 H), 3.67 - 3.82 (m, 3 H), 3.97 (dd, J=I 1.33, 2.73 Hz, 2 H), 7.24 - 7.34 (m, 2 H), 7.60 (s, 1 H); MS (ESI) (M+H)+ = 450.45.
Example 59 Step A: (3R)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (Isomers 1 and 2).
Figure imgf000117_0001
Chiral separation of (3R)-N-cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (90 mg, 0.20 mmol). Chiral Purification: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 35% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, rt. Chiral analytical HPLC: ChiraPak AD column, 40% EtOH/hexanes, lmL/min, 30 min run, 25°C. Yield: Isomer 1: 35 mg (39%) Isomer 2: 35 mg (39%)
Isomer 1: 1H NMR (400 MHz, METHANOL-D4) δ 0.40 (s, 1 H), 0.48 (s, 1 H), 0.68 (dd, J=23.44, 7.03 Hz, 2 H), 1.36 - 1.48 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.76 (t, J=12.70 Hz, 2 H), 2.01 - 2.07 (m, 1 H), 2.12 - 2.21 (m, 2 H), 2.32 - 2.42 (m, 1 H), 2.55 - 2.62 (m, 0.5 H), 2.63 - 2.72 (m, 1 H), 2.79 - 2.91 (m, 3 H), 2.97 - 3.05 (m, 0.5 H), 3.36 - 3.46 (m, 2 H), 3.55 - 3.65 (m, 4 H), 3.66 - 3.79 (m, 3 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.24 - 7.28 (m, 1 H), 7.28 - 7.33 (m, 1 H), 7.60 (s, 1 H); chiral HPLC k' = 4.34; MS (ESI) (M+H)+ = 450.2; accurate mass: (M+H) = 450.275.
Isomer 2: 1H NMR (400 MHz, METHANOL-D4) δ 0.40 (s, 1 H), 0.48 (s, 1 H), 0.69 (dd, J=23.63, 6.45 Hz, 2 H), 1.36 - 1.49 (m, 2 H), 1.52 - 1.61 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 2.01 - 2.09 (m, 1 H), 2.12 - 2.21 (m, 2 H), 2.34 - 2.44 (m, 1 H), 2.59 (m, 0.5 H), 2.63 - 2.74 (m, 1 H), 2.80 - 2.91 (m, 3 H), 2.96 - 3.05 (m, 0.5 H), 3.36 - 3.47 (m, 2 H), 3.56 - 3.66 (m, 4 H), 3.68 - 3.82 (m, 3 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.24 - 7.28 (m, 1 H), 7.28 - 7.33 (m, 1 H), 7.60 (d, J=I.17 Hz, 1 H); chiral HPLC k' = 5.95; MS (ESI) (M+H)+ = 450.2; accurate mass: (M+H) = 450.275.
Step B: (RJ-N-Cyclopropylpyrrolidine-S-carboxamide hydrochloride
Figure imgf000118_0001
(R)-l-N-Boc-beta-proline (500 mg, 2.32 mmol), cyclopropylamine (0.193 mL, 2.79 mmol) and HATU (1060 mg, 2.79 mmol) were stirred in DMF (10 mL) containing N,N- diisopropylethylamine (0.607 mL, 3.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% aqueous KHSO4, aqueous saturated NaHCO3, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The residue was stirred in hydrogen chloride (1.16E+04 μL, 11.60 mmol) (IM in AcOH) at 23 0C for 2-3h. The solvent was evaporated. The residue was washed with ether and the ether layer was decanted. The product was dried under vacuum overnight and used directly for the next step. MS (ESI) (M+H)+ = 255.21 (Boc product). Yield: 460mg (104%)
Step C: (3R)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-ό-carbony^pyrrolidine-S-carboxamide
Figure imgf000118_0002
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (125 mg, 0.40 mmol), (R)-N-cyclopropylpyrrolidine-3-carboxamide hydrochloride (91 mg, 0.48 mmol) and HATU (182 mg, 0.48 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.174 mL, 1.00 mmol) at 23 0C for Ih. LC/MS showed presence of 1:1 product with HATU intermediate. Another 1.2 eq of (R)-N- cyclopropylpyrrolidine-3-carboxamide hydrochloride was added along with 1.5 eq of DIPEA and solution was stirred at rt for another 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN;
30mL/min, 25 min run, rt. Yield: 90mg (50%); 1H NMR (400 MHz, METHANOL-D4) δ 0.40 (s, 1 H), 0.48 (s, 1 H), 0.69 (dd, J=24.02, 6.84 Hz, 2 H), 1.36 - 1.49 (m, 2 H), 1.52 -
1.61 (m, 3 H), 1.77 (t, J=12.70 Hz, 2 H), 2.01 - 2.10 (m, 1 H), 2.12 - 2.20 (m, 2 H), 2.33 -
2.43 (m, 1 H), 2.56 - 2.62 (m, 0.5 H), 2.63 - 2.73 (m, 2 H), 2.80 - 2.89 (m, 2 H), 2.98 -
3.05 (m, 0.5 H), 3.36 - 3.46 (m, 2 H), 3.58 - 3.64 (m, 4 H), 3.66 - 3.82 (m, 3 H), 3.98 (dd,
J=I 1.13, 3.32 Hz, 2 H), 7.24 - 7.28 (m, 1 H), 7.29 - 7.34 (m, 1 H), 7.60 (s, 1 H); MS (ESI) (M+H)+ = 450.50.
Example 60
Step A: N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide
Figure imgf000119_0001
Methyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)pyrrolidine-3-carboxylate (100 mg, 0.24 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.471 mL, 0.47 mmol) (IM) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in DMF (5.00 mL) containing N ,N- diisopropylethylamine (0.103 mL, 0.59 mmol) and 2-fluoroethylamine hydrochloride (28.1 mg, 0.28 mmol) along with O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (107 mg, 0.28 mmol) were added. The solution was stirred at 23 0C for Ih. The solution was concentrated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 63 mg (59%); 1H NMR (400 MHz, METHANOL-D4) δ 1.35 - 1.45 (m, 2 H), 1.54 (s, 3 H), 1.74 (t, J=12.50 Hz, 2 H), 2.00 - 2.09 (m, 1 H), 2.10 - 2.22 (m, 2 H), 2.30 - 2.41 (m, 1 H), 2.60 - 2.71 (m, 1 H), 2.77 - 2.87 (m, 2 H), 2.92 - 3.02 (m, 0.5 H), 3.06 - 3.15 (m, 0.5 H), 3.35 - 3.47 (m, 3 H), 3.52 (s, 1 H), 3.60 (s, 4 H), 3.67 - 3.85 (m, 3 H), 3.96 (d, J=8.20 Hz, 2 H), 4.35 (m, 1 H), 4.42 - 4.54 (m, 1 H), 7.23 - 7.33 (m, 2 H), 7.60 (s, 1 H); MS (ESI) (M+H)+ = 456.2; accurate mass: (M+H) = 456.265.
Step B: Methyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)pyrrolidine-3-carboxylate
Figure imgf000120_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (100 mg, 0.32 mmol), methyl 3-pyrrolidinecarboxylate (49.5 mg, 0.38 mmol) and HATU (146 mg, 0.38 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.083 mL, 0.48 mmol) at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by flash using EtOAc as eluent. Yield: 110 mg (81%); 1H NMR (400 MHz, METHANOL-D4) δ
1.36 - 1.48 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.76 (t, J=12.50 Hz, 2 H), 2.07 - 2.18 (m, 2 H),
2.19 - 2.29 (m, 1 H), 2.32 - 2.43 (m, 1 H), 2.61 - 2.73 (m, 1 H), 2.79 - 2.88 (m, 2 H), 3.07 - 3.17 (m, 0.5 H), 3.20 - 3.28 (m, 0.5 H), 3.36 - 3.46 (m, 2 H), 3.62 (s, 3 H), 3.63 - 3.74 (m, 4 H), 3.73 - 3.84 (m, 2 H), 3.97 (dd, J=I 0.94, 3.52 Hz, 2 H), 7.23 - 7.28 (m, 1 H), 7.28 - 7.33 (m, 1 H), 7.59 (s, 1 H); MS (ESI) (M+H)+ = 425.43.
Example 61
N-Ethyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-
6-carbonyl)pyrrolidine-3-carboxamide
Figure imgf000121_0001
Methyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)pyrrolidine-3-carboxylate (85 mg, 0.20 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.400 mL, 0.40 mmol) (IM) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in DMF (5 mL) containing N,N- diisopropylethylamine (0.087 mL, 0.50 mmol) and ethylamine (0.120 mL, 0.24 mmol) (2M / THF) along with HATU (114 mg, 0.30 mmol) were added. The solution was stirred at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt.
Yield: 50 mg (57%); 1H NMR (400 MHz, DMSO-D6) δ 0.90 - 1.07 (m, 2 H), 1.25 - 1.38 (m, 2 H), 1.42 - 1.56 (m, 3 H), 1.70 (t, J=I 1.72 Hz, 2 H,) 1.92 - 2.07 (m, 3 H), 2.26 - 2.38 (m, 1 H), 2.58 - 2.70 (m, 1 H), 2.74 - 2.88 (m, 3 H), 3.01 (d, 2 H), 3.29 (t, J=I 1.72 Hz, 2 H), 3.45 - 3.58 (m, 5 H), 3.61 (s, 3 H), 3.89 (d, J=7.81 Hz, 2 H), 7.23 (d, J=8.20 Hz, 1 H), 7.35 (d, J=8.20 Hz, 1 H), 7.56 (s, 1 H), 7.84 - 8.05 (m, 1 H); MS (ESI) (M+H)+ = 438.3; accurate mass: (M+H) = 438.274.
Example 62 Step A: N-Cyclopropyl-2-((3R)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidin-3-yl)acetamide
Figure imgf000122_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (100 mg, 0.32 mmol), (R)-N-cyclopropyl-2-(pyrrolidin-3-yl)acetamide hydrochloride (65.3 mg, 0.32 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N- tetramethyluronium hexafluorophosphate (182 mg, 0.48 mmol) were stirred in DMF
(5mL) containing N,N-diisopropylethylamine (0.167 mL, 0.96 mmol) at 23 0C for 2h.
The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous saturated NaHCO3, brine and dried over anhydrous NaiSCv The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 50 mg (34%); 1H NMR (400 MHz, METHANOL-D4) δ 0.27 - 0.34 (m, 0.5 H), 0.36 - 0.43 (m, 0.5 H), 0.46 - 0.52 (m, 1 H), 0.59 - 0.66 (m, 1 H), 0.69 - 0.75 (m, 1 H), 1.37 - 1.49 (m, 2 H), 1.51 - 1.61 (m, 3.5 H), 1.63 - 1.71 (m, 0.5 H), 1.76 (t, J=12.89 Hz, 2 H), 1.98 - 2.08 (m, 0.5 H), 2.11 - 2.18 (m, 2 H), 2.20 - 2.26 (m, 0.5 H), 2.27 - 2.32 (m, 0.5 H), 2.34 - 2.43 (m, 1 H), 2.47 - 2.57 (m, 1 H), 2.62 - 2.73 (m, 2 H), 2.80 - 2.88 (m, 2 H), 3.21 - 3.29 (m, 1 H), 3.37 - 3.47 (m, 2 H), 3.55 - 3.61 (m, 1 H), 3.63 (s, 3 H), 3.65 - 3.73 (m, 1 H), 3.75 - 3.83 (m, 0.5 H), 3.99 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.24 - 7.29 (m, 1 H), 7.30 - 7.33 (m, 1 H), 7.61 (d, J=5.08 Hz, 1 H); MS (ESI) (M+H)+ = 464.2; Accurate mass: (M+H) = 464.290.
Step B: (R)-N-Cyclopropyl-2-(pyrrolidin-3-yl)acetamide hydrochloride
Figure imgf000123_0001
(R)-2-(l-(tert-Butoxycarbonyl)pyrrolidin-3-yl)acetic acid (500 mg, 2.18 mmol), HATU (995 mg, 2.62 mmol) and cyclopropylamine (0.181 mL, 2.62 mmol) were stirred in DMF (10 mL) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% aqueous KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The product was then dissolved in Hydrogen chloride (10.90 mL, 10.90 mmol) (IM / AcOH) and stirred at 23 0C for 3-4h. The solvent was evaporated and the product was dried under vacuum overnight. The product was used directly for the next step. Yield: 400 mg (90%).
Example 63
Step A: N-((3S)-l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide
Figure imgf000123_0002
tert-Butyl (3S)- l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- IH- carbazole-6-carbonyl)pyrrolidin-3-ylcarbamate (150 mg, 0.31 mmol) was stirred in hydrogen chloride (6.23 mL, 6.23 mmol) (IM in AcOH) at 23 0C for 2-3h. The solvent was evaporated. The product was rinsed twice with ether and the ether layer was decanted. The product was dried under vacuum. The residue was dissolved in CH2CI2 (5 mL) containing triethylamine (0.217 mL, 1.56 mmol) and cyclopropanecarbonyl chloride (0.034 mL, 0.37 mmol) was added. The solution was stirred at 23 0C for Ih. The solution was washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min ran, rt. Yield: 80 mg (57%); 1H NMR (400 MHz, METHANOL-D4) δ 0.65 - 0.82 (m, 3 H), 0.87 (s, 1 H), 1.37 - 1.51 (m, 2 H), 1.51 - 1.66 (m, 4 H), 1.78 (t, J=13.87 Hz, 2 H), 1.84 - 1.93 (m, 0.5 H), 1.95 - 2.05 (m, 0.5 H), 2.10 - 2.20 (m, 1.5 H), 2.21 - 2.31 (m, 0.5 H), 2.34 - 2.45 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.79 - 2.90 (m, 2 H), 3.38 - 3.47 (m, 2.5 H), 3.50 (m, 0.5 H), 3.64 (s, 3 H), 3.66 - 3.76 (m, 1.5 H), 3.78 - 3.91 (m, 1.5 H), 3.99 (dd, J=I 1.33, 3.52 Hz, 2 H), 4.22 - 4.30 (m, 0.5 H), 4.43 - 4.51 (m, 0.5 H), 7.24 - 7.37 (m, 2 H), 7.63 (d, J=17.97 Hz, 1 H); MS (ESI) (M+H)+ = 450.2; Accurate mass: (M+H) = 450.276.
Step B: tert-Butyl (3S)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-ό-carbony^pyrrolidin-S-ylcarbamate
Figure imgf000124_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (100 mg, 0.32 mmol), (S)-(-)-3-(Boc-amino)pyrrolidine (71.3 mg, 0.38 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (146 mg, 0.38 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.083 mL, 0.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by flash chromatography using EtOAc as eluent. Yield: 150 mg (98%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.36 - 1.51 (m, 11 H), 1.53 - 1.66 (m, 5 H), 1.75 (t, J=10.35 Hz, 2 H), 1.88 (s, 1 H), 2.12 - 2.28 (m, 2 H), 2.37 - 2.48 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.79 - 2.90 (m, 3 H), 3.51 (s, 1 H), 3.63 (s, 3 H), 3.70 - 3.96 (m, 2 H), 4.05 (dd, J=I 1.52, 3.71 Hz, 2 H), 4.16 - 4.38 (m, 1 H), 4.52 - 4.79 (m, 1 H), 7.23 (d, J=8.59 Hz, 1 H), 7.34 (s, 1 H), 7.69 (s, 1 H); MS (ESI) (M+H)+ = 492.33. Example 64
Step A: (3S)-N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (Isomers 1 and 2).
Figure imgf000125_0001
Chiral separation of (3S)-N-(2-fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-3-carboxamide (65 mg, 0.14 mmol). Products had to be repurifϊed by reversed-phase HPLC after chiral separation using 30-50%B. Chiral Purification: Gilson system equipped with a Chiracel AD column, 5 cm ID X 50 cm L, 2Ou using 60% EtOH/ 40% hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min run, rt. Chiral analytical HPLC: ChiraPak AD column, 60% EtOH/ 40% hexanes, lmL/min, 30 min run, 25°C. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: Isomer 1: 25 mg (39%) Isomer 2: 26 mg (40%)
Isomer 1: 1H NMR (400 MHz, METHANOL-D4) δ 1.26 - 1.36 (m, 1 H), 1.40 - 1.51 (m, 2 H), 1.54 - 1.64 (m, 3 H), 1.79 (t, J=12.70 Hz, 2 H), 2.05 - 2.15 (m, 1 H), 2.15 - 2.28 (m, 2 H), 2.35 - 2.45 (m, 1 H), 2.65 - 2.76 (m, 1 H), 2.82 - 2.92 (m, 2 H), 2.96 - 3.05 (m, 0.5 H), 3.09 - 3.20 (m, 0.5 H), 3.38 - 3.50 (m, 3 H), 3.55 (t, J=4.69 Hz, 0.5 H), 3.58 - 3.63 (m, 0.5 H), 3.65 (s, 3 H), 3.67 - 3.74 (m, 1 H), 3.74 - 3.88 (m, 2 H), 4.00 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.34 (t, J=4.88 Hz, 0.5 H), 4.42 (t, J=4.88 Hz, 0.5 H), 4.46 (t, J=4.88 Hz, 0.5 H), 4.53 (t, J=4.88 Hz, 0.5 H), 7.26 - 7.31 (m, 1 H), 7.31 - 7.36 (m, 1 H), 7.62 (d, J=0.78 Hz, 1 H); Chiral k' = 3.35; MS (ESI) (M+H)+ = 456.2; accurate mass: (M+H) = 456.265.
Isomer 2: 1H NMR (400 MHz, METHANOL-D4) δ 1.27 - 1.35 (m, 1 H), 1.38 - 1.52 (m, 2 H), 1.54 - 1.65 (m, 3 H), 1.80 (t, J=12.50 Hz, 2 H), 2.12 (s, 1 H), 2.15 - 2.27 (m, 2 H), 2.36 - 2.47 (m, 1 H), 2.66 - 2.76 (m, 1 H), 2.82 - 2.92 (m, 2 H), 2.97 - 3.06 (m, 0.5 H), 3.10 - 3.18 (m, 0.5 H), 3.39 - 3.50 (m, 3 H), 3.55 (t, J=4.88 Hz, 0.5 H), 3.59 - 3.64 (m, 0.5 H), 3.65 (s, 3 H), 3.68 - 3.76 (m, 1 H), 3.75 - 3.90 (m, 2 H), 4.00 (dd, J=I 1.13, 3.71 Hz, 2 H) 4.34 (t, J=4.30 Hz, 0.5 H), 4.42 (t, J=4.88 Hz, 0.5 H), 4.46 (t, J=4.88 Hz, 0.5 H), 4.53 (t, J=4.88 Hz, 0.5 H), 7.25 - 7.31 (m, 1 H), 7.31 - 7.37 (m, 1 H), 7.62 (d, J=I.17 Hz, 1 H); Chiral k' = 5.54; MS (ESI) (M+H)+ = 456.2; accurate mass: (M+H) = 456.265.
Step B: (S)-N-(2-Fluoroethyl)pyrrolidine-3-carboxamide hydrochloride
Figure imgf000126_0001
(S)-l-Boc-pyrrolidine-3-carboxylic acid (350 mg, 1.63 mmol), 2-fluoroethylamine hydrochloride (194 mg, 1.95 mmol) and HATU (742 mg, 1.95 mmol) were stirred in
DMF (10 mL) containing N,N-diisopropylethylamine (0.708 mL, 4.07 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4.
The product was quickly flashed through a silica plug using EtOAc as eluent. The solvent was evaporated. The product was then stirred in hydrogen chloride (16.26 mL,
16.26 mmol) (IM in AcOH) at 23 0C for 3-4h. The solvent was evaporated and the product was dried under vacuum overnight. Yield: 215 mg (67%); 1H NMR (400 MHz,
METHANOL-D4) δ 2.07 - 2.18 (m, 1 H), 2.26 - 2.37 (m, 1 H), 3.17 - 3.25 (m, 1 H), 3.32
- 3.37 (m, 1 H), 3.37 - 3.44 (m, 2 H), 3.44 - 3.50 (m, 2 H), 3.51 - 3.54 (m, 1 H), 4.38 - 4.42 (m, 1 H), 4.52 (t, J=5.08 Hz, 1 H).
Step C: (3S)-N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-ό-carbony^pyrrolidine-S-carboxamide
Figure imgf000127_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (120 mg, 0.38 mmol), (S)-N-(2-fluoroethyl)pyrrolidine-3-carboxamide hydrochloride (113 mg, 0.57 mmol) and HATU (218 mg, 0.57 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.167 mL, 0.96 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous NaiSCv The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 65 mg (37%); 1H NMR (400 MHz, METHANOL-D4) δ 1.39 - 1.49 (m, 2 H), 1.54 - 1.62 (m, 3 H), 1.79 (t, J=12.50 Hz, 2 H), 2.11 (m, 1 H), 2.14 - 2.21 (m, 1.5 H), 2.21 - 2.28 (m, 0.5 H), 2.36 - 2.45 (m, 1 H), 2.65 - 2.75 (m, 1 H), 2.82 - 2.86 (m, 1 H), 2.86 - 2.91 (m, 1 H), 2.97 - 3.06 (m, 0.5 H), 3.11 - 3.19 (m, 0.5 H, 3.38 - 3.42 (m, 1 H), 3.42 - 3.45 (m, 1 H), 3.45 - 3.50 (m, 1 H), 3.55 (t, J=4.30 Hz, 0.5 H), 3.58 - 3.62 (m, 0.5 H,) 3.64 (s, 3 H), 3.66 - 3.72 (m, 1 H), 3.73 - 3.80 (m, 1.5 H), 3.81 - 3.88 (m, 0.5 H), 4.00 (dd, J=10.94, 3.52 Hz, 2 H), 4.34 (t, J=4.88 Hz, 0.5 H), 4.41 (t, J=4.69 Hz, 0.5 H), 4.44 - 4.49 (m, 0.5 H), 4.53 (t, J=4.69 Hz, 0.5 H), 7.26 - 7.30 (m, 1 H), 7.31 - 7.35 (m, 1 H), 7.62 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)+ = 456.45.
Example 65
Step A: (3S)-N-(Cyclopropylmethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- l^^-tetrahydro-lH-carbazole-o-carbony^pyrrolidine-S-carboxamide
Figure imgf000128_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (100 mg, 0.32 mmol), (S)-N-(cyclopropylmethyl)pyrrolidine-3-carboxamide hydrochloride (78 mg, 0.38 mmol) and HATU (146 mg, 0.38 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih.
The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCθ3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt.
Yield: 95 mg (64%); 1H NMR (400 MHz, METHANOL-D4) δ 0.18 (m, 2 H) 0.47 (m, 2 H), 0.84 - 1.03 (m, 1 H), 1.34 - 1.48 (m, 2 H), 1.55 (s, 3 H), 1.76 (t, J=12.89 Hz, 2 H), 2.03 - 2.11 (m, 1 H), 2.11 - 2.24 (m, 2 H), 2.31 - 2.42 (m, 1 H), 2.61 - 2.72 (m, 1 H), 2.79 - 2.87 (m, 2 H), 2.92 - 3.02 (m, 1.5 H), 3.04 - 3.14 (m, 1.5 H), 3.37 - 3.47 (m, 2 H), 3.58 - 3.66 (m, 4 H), 3.68 - 3.79 (m, 2 H), 3.79 - 3.88 (m, 1 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.25 - 7.30 (m, 1 H), 7.30 - 7.34 (m, 1 H), 7.62 (s, 1 H); MS (ESI) (M+H)+ = 464.2; Accurate mass (M+H) = 464.290.
Step B: (S)-N-(Cyclopropylmethyl)pyrrolidine-3-carboxamide hydrochloride
Figure imgf000128_0002
(S)-l-(tert-Butoxycarbonyl)pyrrolidine-3-carboxylic acid (200 mg, 0.93 mmol), 0-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (424 mg, 1.12 mmol) and (aminomethyl)cyclopropane (0.097 mL, 1.12 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.243 mL, 1.39 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by a short flash column using 50% EtOAc / hexanes to 100% EtOAc. The fractions were concentrated. The product was then dissolved in hydrogen chloride (4.65 mL, 4.65 mmol) (IM in AcOH) and stirred at 23 0C for 2-3h. The solvent was evaporated. The residue was washed with ether. The product was dried under vacuum overnight. Yield: 180mg (95%); 1H NMR (400 MHz, METHANOL-D4) δ 0.17 - 0.23 (m, 2 H), 0.46 - 0.53 (m, 2 H), 0.90 - 1.01 (m, 1 H), 2.06 - 2.17 (m, 1 H), 2.25 - 2.36 (m, 1 H), 3.02 - 3.08 (m, 2 H), 3.14 - 3.24 (m, 1 H), 3.27 - 3.35 (m, 1 H), 3.36 - 3.43 (m, 2 H), 3.43 - 3.50 (m, I H).
Example 66
Step A: N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-4-yl)cyclopropanecarboxamide
Figure imgf000129_0001
tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-4-ylcarbamate (135 mg, 0.27 mmol) was stirred in hydrogen chloride (6.81 mL, 6.81 mmol) (lM/AcOH) at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in dichloromethane (5 mL) containing triethylamine (0.190 mL, 1.36 mmol). Cyclopropanecarbonyl chloride (0.030 mL, 0.33 mmol) was added dropwise and the solution was stirred at 23 0C for Ih. The solution was washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min ran, rt. Yield: 70 mg (55%); 1H NMR (400 MHz, METHANOL-D4) δ 0.69 - 0.77 (m, 2 H), 0.79 - 0.87 (m, 2 H), 1.37 - 1.51 (m, 4 H), 1.50 - 1.62 (m, 5 H), 1.77 (t, J=13.87 Hz, 2 H), 1.90 (s, 2 H), 2.14 - 2.21 (m, 1 H), 2.39 (dd, J=15.23, 7.03 Hz, 1 H), 2.62 - 2.75 (m, 1 H), 2.80 - 2.91 (m, 2 H), 3.13 (s, 2 H), 3.37 - 3.48 (m, 2 H), 3.64 (s, 3 H), 3.87 - 3.96 (m, 1 H), 3.99 (dd, J=I 1.52, 3.71 Hz, 2 H), 4.52 (s, 1 H), 7.15 (dd, J=8.59, 1.56 Hz, 1 H), 7.33 (d, J=8.20 Hz, 1 H), 7.49 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)+ = 464.2; accurate mass: (M+H) = 464.291.
Step B: tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-4-ylcarbamate
Figure imgf000130_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylic acid (100 mg, 0.32 mmol), 4-(N-Boc amino)-piperidine (77 mg, 0.38 mmol) and O-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (146 mg, 0.38 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.083 mL,
0.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in
EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by flash chromatography using a gradient
50% EtOAc / heptane to 100% EtOAc. Yield: 140mg (89%); 1H NMR (400 MHz, DMSO-D6) δ 1.24 - 1.33 (m, 4 H), 1.37 (s, 9 H), 1.45 - 1.54 (m, 3 H), 1.66 - 1.75 (m, 4 H), 2.05 - 2.11 (m, 1 H), 2.28 - 2.36 (m, 1 H), 2.62 - 2.69 (m, 1 H), 2.74 - 2.86 (m, 2 H), 2.97 (s, 2 H), 3.25 - 3.30 (m, 4 H), 3.50 (s, 1 H), 3.61 (s, 3 H), 3.89 (dd, J=10.74, 2.54 Hz, 2 H), 6.86 (d, J=8.20 Hz, 1 H), 7.05 (dd, J=8.40, 1.37 Hz, 1 H), 7.37 (d, J=8.59 Hz, 1 H), 7.39 (s, 1 H); MS (ESI) (M+H)+ = 496.41. Example 67
Step A: N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-yl)cyclopropanecarboxamide
Figure imgf000131_0001
tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-3-ylcarbamate (140 mg, 0.28 mmol) was stirred in hydrogen chloride (2.82 mL, 2.82 mmol) (lM/AcOH) at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The residue was dissolved in dichloromethane (5 mL) containing triethylamine (0.098 mL, 0.71 mmol) and cyclopropanecarbonyl chloride (0.031 mL, 0.34 mmol) was added dropwise. The solution was stirred at 23 0C for Ih. The solution was washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 60 mg (46%);
1H NMR (400 MHz, METHANOL-D4) δ 0.62 - 0.80 (m, 4 H), 1.37 - 1.48 (m, 2 H), 1.51 - 1.63 (m, 6 H), 1.77 (t, J=I 1.33 Hz, 2 H), 1.93 - 2.02 (m, 1 H), 2.11 - 2.20 (m, 1 H), 2.30 - 2.44 (m, 1 H), 2.63 - 2.73 (m, 1 H), 2.78 - 2.89 (m, 2 H), 3.15 (s, 2 H), 3.36 - 3.47 (m, 3 H), 3.62 (s, 3 H), 3.83 (s, 2 H), 3.97 (dd, J=I 1.13, 3.32 Hz, 2 H), 7.14 (ddd, J=8.40, 1.37, 1.17 Hz, 1 H), 7.29 (d, J=8.20 Hz, 1 H), 7.48 (s, 1 H); MS (ESI) (M+H)+ = 464.2; accurate mass: (M+H) = 464.290.
Step B: tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-ylcarbamate
Figure imgf000132_0001
9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-β-carboxylic acid (100 mg, 0.32 mmol), 3-N-Boc-amino piperidine (77 mg, 0.38 mmol) and HATU (146 mg, 0.38 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.083 mL, 0.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by flash chromatography using a gradient of 50%EtOAc / heptane to 100% EtOAc. Yield: 150 mg (95%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.38 - 1.44 (m, 9 H), 1.45 - 1.56 (m, 4 H), 1.56 - 1.65 (m, 5 H), 1.71 - 1.80 (m, 3 H), 1.95 (s, 1 H), 2.12 - 2.19 (m, 1 H), 2.38 - 2.49 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.78 - 2.87 (m, 2 H), 2.88 - 2.97 (m, 1 H), 3.37 - 3.47 (m, 3 H), 3.63 (s, 3 H), 3.75 (s, IH), 3.81 - 3.91 (m, 1 H), 4.04 (dd, J=I 1.33, 2.73 Hz, 2 H), 7.24 (s, 2 H), 7.61 (s, 1 H); MS (ESI) (M+H)+ = 496.59.
Example 68
Step A: (R)-(3S)-N-(2,2-Difluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)- l^^-tetrahydro-lH-carbazole-o-carbony^pyrrolidine-S-carboxamide.
Figure imgf000132_0002
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (100 mg, 0.32 mmol), (S)-N-(2,2-difluoroethyl)pyrrolidine-3- carboxamide hydrochloride (82 mg, 0.38 mmol) and HATU (146 mg, 0.38 mmol) were stirred in DMF (8 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: 40-60%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 48 mg (32%); 1H NMR (400 MHz, METHANOL-D4) δ 1.35 - 1.47 (m, 2 H), 1.49 - 1.60 (m, 3 H), 1.76 (t, J=12.70 Hz, 2 H), 2.03 - 2.11 (m, 1 H), 2.12 - 2.27 (m, 2 H), 2.32 - 2.42 (m, 1 H), 2.61 - 2.73 (m, 1 H), 2.78 - 2.88 (m, 2 H), 2.96 - 3.05 (m, 0.5 H), 3.09 - 3.19 (m, 0.5 H), 3.36 - 3.46 (m, 2 H), 3.46 - 3.59 (m, 3 H), 3.61 (s, 3 H), 3.64 - 3.73 (m, 1 H), 3.71 - 3.87 (m, 2 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 5.65 - 6.06 (m, 1 H), 7.23 - 7.28 (m, 1 H), 7.28 - 7.33 (m, 1 H), 7.60 (s, 1 H), 8.44 (d, J=53.91 Hz, 1 H); MS (ESI) (M+H)+ = 474.2; accurate mass: (M+H) = 474.56.
Step B: (S)-N-(2,2-Difluoroethyl)pyrrolidine-3-carboxamide hydrochloride
Figure imgf000133_0001
(S)-l-(tert-Butoxycarbonyl)pyrrolidine-3-carboxylic acid (500 mg, 2.32 mmol), 2,2- difluoroethanamine (226 mg, 2.79 mmol) and HATU (1060 mg, 2.79 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.607 mL, 3.48 mmol) at 23 0C for Ih. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by flash chromatography using EtOAc as eluent. The product was then stirred in hydrogen chloride (11.61 mL, 11.61 mmol) (IM/ AcOH) at 23 0C for 2h. The solvent was evaporated. The residue was precipitated in ether, filtered and dried. Yield: 375 mg (75%); 1H NMR (400 MHz, METHANOL-D4) δ 2.04 - 2.17 (m, 1 H), 2.23 - 2.37 (m, 1 H), 3.15 - 3.25 (m, 1 H), 3.30 - 3.41 (m, 3 H), 3.45 - 3.53 (m, 1 H), 3.52 - 3.61 (m, 2 H), 5.68 - 6.07 (m, 1 H). Step C: (R)-Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate and (S)-Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxylate
Figure imgf000134_0001
Chiral separation of methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxylate (16.28g, 49.7 mmol) was done by using a Chiralcel OD column with an eluent of 60/40 hexanes/EtOH at rt. Analytical chiral HPLC: OD-H column, 4.6 X 250 mm, 60/40 hexanes/EtOH. (R)-Methyl 9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carboxylate (isomer 1, 7.13 g, 88 %):
1U NMR (400 MHz, DMSO-D6) δ 1.21 - 1.36 (m, 2 H), 1.40 - 1.54 (m, 3 H), 1.63 - 1.73 (m, 2 H), 2.00 - 2.08 (m, 1 H), 2.25 - 2.36 (m, 1 H), 2.56 - 2.67 (m, 1 H), 2.73 - 2.84 (m, 2 H), 3.21 - 3.31 (m, 2 H), 3.60 (s, 3 H), 3.79 (s, 3 H), 3.83 - 3.91 (m, 2 H), 7.40 (d, J=8.59 Hz, 1 H), 7.66 (dd, J=8.59, 1.56 Hz, 1 H), 8.04 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)+ = 328.30; chiral HPLC k' = 2.43.
(S)-Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylate (isomer 2, 7.01 g, 86 %): 1U NMR (400 MHz, DMSO-D6) δ 1.23 - 1.35 (m, 2 H), 1.41 - 1.51 (m, 3 H), 1.68 (m, 2 H), 2.01 - 2.08 (m, 1 H), 2.27 - 2.36 (m, 1 H), 2.58 - 2.67 (m, 1 H), 2.75 - 2.84 (m, 2 H), 3.22 - 3.30 (m, 2 H), 3.60 (s, 3 H), 3.79 (s, 3 H), 3.84 - 3.90 (m, 2 H), 7.40 (d, J=8.59 Hz, 1 H), 7.66 (dd, J=8.59, 1.56 Hz, 1 H), 8.04 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)+ = 328.31; chiral HPLC k' = 3.70.
Step D: (R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid.
Figure imgf000135_0001
(R)-Methyl 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylate (1.00 g, 3.05 mmol) was stirred in dioxane (100 mL) containing lithium hydroxide (9.16 mL, 9.16 mmol) (IM) at 50 0C overnight. The solvent was concentrated. The aqueous layer was washed with ether. The aqueous layer was then acidified with 2M HCl. The product precipitated and was filtered and dried under vacuum. Yield: 875mg
(91%); 1H NMR (400 MHz, DMSO-D6) δ 1.23 - 1.36 (m, 2 H), 1.42 - 1.52 (m, 3 H), 1.65 - 1.72 (m, 2 H), 2.02 - 2.09 (m, 1 H), 2.28 - 2.36 (m, 1 H), 2.58 - 2.68 (m, 1 H), 2.74 - 2.85 (m, 2 H), 3.23 - 3.30 (m, 2 H), 3.60 (s, 3 H), 3.83 - 3.90 (m, 2 H), 7.37 (d, J=8.59 Hz, 1 H), 7.65 (dd, J=8.59, 1.56 Hz, 1 H), 8.02 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)+ = 314.21.
Example 69
Step A: (R)-(3S)-N-Ethyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-ό-carbony^pyrrolidine-S-carboxamide.
Figure imgf000135_0002
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (100 mg, 0.32 mmol), (S)-N-ethylpyrrolidine-3-carboxamide hydrochloride (68.4 mg, 0.38 mmol) and HATU (146 mg, 0.38 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C-18 column, 250 X 21.2 mm, 15u. Mobile phase: 30- 50%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min ran, rt. Yield: lOOmg (71%); 1H NMR (400 MHz, METHANOL-D4) δ 1.05 (t, J=7.23 Hz, 1 H), 1.12 (t,
J=7.23 Hz, 1 H), 1.35 - 1.48 (m, 2 H), 1.50 - 1.60 (m, 3 H), 1.76 (t, J=12.70 Hz, 2 H), 2.02 - 2.10 (m, 1 H), 2.11 - 2.21 (m, 2 H), 2.32 - 2.41 (m, 1 H), 2.62 - 2.73 (m, 1 H), 2.79
- 2.87 (m, 2 H), 2.88 - 2.96 (m, 0.5 H), 3.02 - 3.08 (m, 0.5 H), 3.10 - 3.18 (m, 1 H), 3.18 -
3.26 (m, 1 H), 3.37 - 3.45 (m, 2 H), 3.56 - 3.61 (m, 1 H), 3.62 (s, 3 H), 3.64 - 3.74 (m, 2
H), 3.72 - 3.84 (m, 1 H), 3.97 (dd, J=I 1.33, 3.52 Hz, 2 H), 7.24 - 7.28 (m, 1 H), 7.28 -
7.33 (m, 1 H), 7.60 (s, 1 H); MS (ESI) (M+H)+ = 438.3; accurate mass (M+H) = 438.275.
Step B: (S)-N-E thylpyrrolidine-3-carboxamide hydrochloride
Figure imgf000136_0001
S)-l-(tert-Butoxycarbonyl)pyrrolidine-3-carboxylic acid (500 mg, 2.32 mmol), ethylamine (1.742 mL, 3.48 mmol) and HATU (1060 mg, 2.79 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.607 mL, 3.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by flash using EtOAc as eluent. The product was then stirred in hydrogen chloride (11.61 mL, 11.61 mmol) (IM/ AcOH) at 23 0C for 2h. The solvent was evaporated. The product was rinsed several times with ether, filtered and dried.
Yield: 375mg (90%); 1H NMR (400 MHz, METHANOL-D4) δ 1.10 (t, J=7.42 Hz, 3 H), 2.08 (ddd, J=13.67, 6.64 Hz, 1 H), 2.28 (ddd, J=20.70, 7.81, 7.42 Hz, 1 H), 3.07 - 3.15 (m, 1 H), 3.19 (q, J=7.29 Hz, 2 H), 3.32 - 3.40 (m, 2 H), 3.40 - 3.48 (m, 2 H).
Example 70 Step 1 : N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-yl)propionamide
Figure imgf000137_0001
(3-Aminopiperidin-l-yl)(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazol-6-yl)methanone (75 mg, 0.19 mmol) and propionyl chloride (0.020 mL, 0.23 mmol) were stirred in dichloromethane (5 mL) containing triethylamine (0.040 mL, 0.28 mmol) at 23 0C for Ih. The solvent was evaporated and the product was directly purified by reversed-phase HPLC. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: 30-50%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 70mg (82%); IH NMR (400 MHz, METHANOL-D4) δ 1.03 (s, 2 H), 1.37 - 1.51 (m, 2 H), 1.52 - 1.65 (m, 5 H), 1.79 (t, J=10.94 Hz, 3 H), 1.95 - 2.03 (m, 1 H), 2.08 - 2.21 (m, 3 H), 2.32 - 2.46 (m, 1 H), 2.64 - 2.75 (m, 1 H), 2.79 - 2.91 (m, 2 H), 3.16 (s, 1 H), 3.38 - 3.49 (m, 2 H), 3.64 (s, 3 H), 3.84 (s, 2 H), 3.99 (dd, J=I l.13, 3.71 Hz, 2 H), 7.16 (dt, J=8.30, 1.51 Hz, 1 H), 7.32 (d, J=8.59 Hz, 1 H), 7.50 (s, 1 H); MS (ESI) (M+H)+ = 452.2; Accurate mass: (M+H) = 452.290.
Step B: (3-Aminopiperidin-1 -yl)(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-1 H-carbazol-6-yl)methanone
Figure imgf000137_0002
tert-Butyl l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-3-ylcarbamate (see Example 18, Step B) (750 mg, 1.51 mmol) was stirred in hydrogen chloride (7566 μL, 7.57 mmol) (IM / AcOH) at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and CH2CI2 and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The solvent was evaporated. Yield: 502mg (84%); 1H NMR (400 MHz, METHAN0L-D4) δ 1.35 - 1.49 (m, 4 H), 1.51 - 1.61 (m, 4 H), 1.77 (t, J=13.09 Hz, 3 H), 1.99 - 2.07 (m, 1 H), 2.13 - 2.19 (m, 1 H), 2.34 - 2.42 (m, 1 H), 2.63 - 2.74 (m, 1 H), 2.79 - 2.89 (m, 4 H), 3.36 - 3.46 (m, 2 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.13, 4.10 Hz, 2 H), 7.13 (dd, J=8.40, 1.76 Hz, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.47 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+ = 396.31.
Example 71 N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-3-yl)isobutyramide
Figure imgf000138_0001
(3-Aminopiperidin-l-yl)(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazol-6-yl)methanone (75 mg, 0.19 mmol) and isobutyryl chloride (0.024 mL, 0.23 mmol) were stirred in CH2CI2 (5 mL) containing triethylamine (0.040 mL, 0.28 mmol) at 23 0C for Ih. The solvent was evaporated and the product was directly purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C-18 column, 250 X 21.2 mm, 15u. Mobile phase: 30-50%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 75mg (85%); 1U NMR (400 MHz, METHANOL-D4) δ 1.03 (s, 6 H), 1.37 - 1.50 (m, 2 H), 1.52 - 1.64 (m, 6 H), 1.73 - 1.84 (m, 3 H), 1.92 - 2.02 (m, 1 H), 2.11 - 2.20 (m, 1 H), 2.30 - 2.45 (m, 2 H), 2.61 - 2.74 (m, 1 H), 2.77 - 2.91 (m, 2 H), 3.03 - 3.15 (m, 1 H), 3.22 (s, 1 H), 3.35 - 3.48 (m, 2 H), 3.62 (s, 3 H), 3.82 (s, 1 H), 3.98 (dd, J=I 1.52, 3.71 Hz, 2 H), 7.14 (dt, J=8.30, 1.51 Hz, 1 H), 7.30 (d, J=8.20 Hz, 1 H), 7.49 (s, 1 H); MS (ESI) (M+H)+ = 466.2; accurate mass (M+H) = 466.307.
Example 72 2-Cyclopropyl-N-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-yl)acetamide
Figure imgf000139_0001
(3-Aminopiperidin-l-yl)(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazol-6-yl)methanone (75 mg, 0.19 mmol), HATU (87 mg, 0.23 mmol) and cyclopropylacetic acid (22.78 mg, 0.23 mmol) were stirred in DMF (5 mL) containing
N,N-diisopropylethylamine (0.050 mL, 0.28 mmol) at 23 0C for Ih. The solvent was evaporated. The product was directly purified by reversed-phase HPLC and lyophilized.
Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: 30-50%B; A: H2O with 0.05% TFA v/v; B: CH3CN;
30mL/min, 25 min run, rt. Yield: 72 mg (79%); 1H NMR (400 MHz, METHANOL-D4) δ 0.11 (s, 2 H), 0.45 (s, 2 H), 0.92 (s, 1 H), 1.36 - 1.49 (m, 2 H), 1.52 - 1.64 (m, 5 H), 1.77 (t, J=10.94 Hz, 3 H), 1.92 - 2.05 (m, 3 H), 2.16 (t, J=7.62 Hz, 1 H), 2.32 - 2.46 (m, 1 H), 2.62 - 2.74 (m, 1 H), 2.77 - 2.89 (m, 2 H), 3.13 - 3.23 (m, 1 H), 3.37 - 3.47 (m, 2 H), 3.62 (s, 3 H), 3.85 (s, 2 H), 3.98 (dd, J=10.94, 3.52 Hz, 2 H), 7.14 (ddd, J=8.40, 1.56, 1.37 Hz, 1 H), 7.30 (d, J=8.59 Hz, 1 H), 7.48 (s, 1 H); MS (ESI) (M+H)+ = 478.3; accurate mass: (M+H) = 478.307.
Example 73 Step A: (R)-N-(4-(2-Hydroxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide.
Figure imgf000139_0002
(R)-Methyl 4-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-6-carboxamido)butanoate (100 mg, 0.23 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.469 mL, 0.47 mmol) (IM) at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The product was dissolved in DMF (5.00 mL) containing N,N-diisopropylethylamine (0.102 mL, 0.59 mmol) and ethanolamine (0.017 mL, 0.28 mmol) along with HATU (107 mg, 0.28 mmol) were added. The solution was stirred at 23 0C for Ih. The solvent was evaporated. The product was directly purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: 20-40%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 55 mg (52%); 1H NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.49 (m, 2 H), 1.51 - 1.62 (m, 3 H), 1.76 (t, J=12.50 Hz, 2 H), 1.86 (s, 1 H), 1.99 (d, J=I 1.72 Hz, 2 H), 2.11 - 2.20 (m, 1 H), 2.30 (s, 1 H), 2.34 - 2.43 (m, 1 H), 2.62 - 2.73 (m, 1 H), 2.79 - 2.90 (m, 2 H), 3.04 (s, 4 H), 3.36 - 3.46 (m, 4 H), 3.57 (s, 2 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.13 (s, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 456.2; accurate mass: (M+H) = 456.286.
Step B: Methyl 4-(tert-butoxycarbonyl(methyl)amino)butanoate
Figure imgf000140_0001
4-(Methylamino)butyric acid hydrochloride (1.0 g, 6.51 mmol) and di-tert-butyl dicarbonate (1.797 mL, 7.81 mmol) were stirred in dioxane (50 mL) and water (10 mL) containing triethylamine (1.361 mL, 9.77 mmol) at 23 0C for 3h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% ICHSO4, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The residue was then dissolved in methanol (50.0 mL) at 00C and (trimethylsilyl)diazomethane (9.77 mL, 19.53 mmol) was added dropwise to the stirring solution until a light yellow color persisted. The solution was then stirred at 23 0C for 15 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, aqueous saturated NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by flash chromatography using a gradient: 20% to 50% EtOAc / heptane. Yield: 1.17g
(78%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.45 (s, 9 H), 1.84 (ddd, J=14.26, 7.42, 7.23 Hz, 2 H), 2.32 (t, J=7.42 Hz, 2 H), 2.84 (s, 3 H), 3.25 (t, J=6.84 Hz, 2 H), 3.68 (s, 3 H); MS (ESI) (M+H)+ = 232.23.
Step C: Methyl 4-(methylamino)butanoate hydrochloride
Figure imgf000141_0001
Methyl 4-(tert-butoxycarbonyl(methyl)amino)butanoate (1.15 g, 4.97 mmol) was stirred in hydrogen chloride (14.92 ml, 14.92 mmol) (IM / AcOH) at 23 0C for 2h. The solvent was evaporated. The product was precipitated in ether, filtered and dried. Yield: 740mg (89%); 1H NMR (400 MHz, METHANOL-D4) δ 1.96 (ddd, J=15.04, 7.42, 7.23 Hz, 2 H), 2.49 (t, J=7.03 Hz, 2 H), 2.70 (s, 3 H), 3.01 - 3.08 (m, 2 H), 3.68 (s, 3 H).
Step D: (R)-Methyl 4-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamido)butanoate (Isomer 1).
Figure imgf000141_0002
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (185 mg, 0.59 mmol), methyl 4-(methylamino)butanoate hydrochloride (119 mg, 0.71 mmol) and HATU (269 mg, 0.71 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.257 mL, 1.48 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by flash chromatography using EtOAc as eluent. Yield: 240mg
(95%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.41 - 1.52 (m, 2 H), 1.52 - 1.63 (m, 5 H), 1.71 - 1.81 (m, 2 H), 1.91 - 2.02 (m, 2 H), 2.11 - 2.19 (m, 1 H), 2.36 - 2.47 (m, 2 H), 2.63 - 2.74 (m, 1 H), 2.78 - 2.90 (m, 2 H), 3.05 (s, 3 H), 3.37 - 3.47 (m, 3 H), 3.58 - 3.70 (m, 6 H), 4.04 (dd, J=I 1.52, 2.93 Hz, 2 H), 7.17 - 7.21 (m, 1 H), 7.21 - 7.25 (m, 1 H), 7.54 (s, 1 H); MS (ESI) (M+H)+ = 427.41.
Example 74 Step A: (R)-N-((3S)-l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carbonyl)piperidin-3-yl)cyclopropanecarboxamide.
Figure imgf000142_0001
(R)-tert-Butyl (3S)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidin-3-ylcarbamate (75 mg, 0.15 mmol) was stirred in hydrogen chloride (0.757 mL, 0.76 mmol) (IM / AcOH) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous
NaHCO3, brine and dried over anhydrous Na2SU4. The solvent was evaporated. The product was dissolved in DCM (5 mL) containing triethylamine (0.032 mL, 0.23 mmol) and cyclopropanecarbonyl chloride (0.016 mL, 0.18 mmol) was added dropwise. The solution was stirred at 23 0C for Ih. The solvent was evaporated and the product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C-18 column, 250 X 21.2 mm, 15u. Mobile phase: 30- 50%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min ran, rt. Yield: 48 mg (68%); 1H NMR (400 MHz, METHANOL-D4) δ 0.68 (s, 4 H), 1.36 - 1.49 (m, 2 H), 1.50 - 1.63 (m, 6 H), 1.72 - 1.82 (m, 2 H), 1.93 - 2.02 (m, 1 H), 2.11- 2.19 (m, 1 H), 2.35 - 2.44 (m, 1 H), 2.63 - 2.73 (m, 1 H), 2.78 - 2.89 (m, 2 H), 3.18 (s, 2 H), 3.37 - 3.46 (m, 3 H), 3.62 (s, 3 H), 3.82 (s, 2 H), 3.98 (dd, J=10.55, 3.52 Hz, 2 H), 7.14 (dd, J=8.59, 1.56 Hz, 1 H), 7.29 (d, J=8.20 Hz, 1 H), 7.48 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+ = 464.2; accurate mass: (M+H) = 464.291.
Step B: (R)- tert-Butyl (3S)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carbonyl)piperidin-3-ylcarbamate.
Figure imgf000143_0001
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (100 mg, 0.32 mmol), (S)-3-N-Boc-amino piperidine (77 mg, 0.38 mmol) and HATU (146 mg, 0.38 mmol) were stirred in DMF (5 mL) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by flash chromatography using a gradient: 30% EtOAc / heptane to
100% EtOAc. Yield: 148 mg (94%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.41 (s, 9 H), 1.44 - 1.55 (m, 4 H), 1.55 - 1.66 (m, 5 H), 1.71 - 1.80 (m, 3 H), 1.95 (s, 1 H), 2.10 - 2.19 (m, 1 H), 2.39 - 2.49 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.78 - 2.90 (m, 2 H), 3.42 (t, J=I 1.72 Hz, 3 H), 3.63 (s, 3 H), 3.70 - 3.77 (m, 1 H), 3.80 - 3.90 (m, 1 H), 4.04 (dd, J=10.94, 3.12 Hz, 2 H), 7.24 (s, 2 H), 7.61 (s, 1 H); MS (ESI) (M+H)+ = 496.51.
Example 75 Step A: (R)-N,9-Dimethyl-N-(4-oxo-4-((S)-tetrahydrofuran-3-ylamino)butyl)-3- (tetrahydro-lH-pyran^-y^-l^^P-tetrahydro-lH-carbazole-ό-carboxamide.
Figure imgf000144_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (75 mg, 0.18 mmol), (R)-tetrahydrofuran-3-amine hydrochloride (22.47 mg, 0.18 mmol) and HATU (83 mg, 0.22 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.079 mL, 0.45 mmol) at 23 0C for Ih. The solvent was evaporated. The product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: 30-50%B; A: H2O with 0.05% TFA v/v;
B: CH3CN; 30mL/min, 25 min run, rt. Yield: 72mg (82%); 1H NMR (400 MHz, METHANOL-D4) δ 1.35 - 1.49 (m, 2 H), 1.50 - 1.61 (m, 3 H), 1.77 (t, J=12.11 Hz, 2 H), 1.85 (s, 1 H), 1.98 (d, 2 H), 2.11 - 2.19 (m, 2 H), 2.27 (s, 1 H), 2.32 - 2.44 (m, 1 H), 2.60 - 2.75 (m, 1 H), 2.79 - 2.89 (m, 2 H), 3.04 (s, 3 H), 3.34 - 3.46 (m, 3 H), 3.56 (s, 2 H), 3.62 (s, 3 H), 3.70 - 3.89 (m, 2 H), 3.97 (dd, J=I 1.33, 3.52 Hz, 2 H), 4.07 (s, 0.5 H), 4.36 (s, 0.5 H), 7.12 (s, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 482.2; accurate mass: (M+H) = 482.301.
Step B: (R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)butanoic acid (Isomer 1)
Figure imgf000144_0002
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (250 mg, 0.80 mmol), methyl 4-(methylamino)butanoate hydrochloride (160 mg, 0.96 mmol) and HATU (364 mg, 0.96 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.347 mL, 1.99 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The product was purified by flash chromatography using EtOAc as eluent. The product was then dissolved in dioxane (5 mL) containing lithium hydroxide (1.595 mL, 1.60 mmol) (IM) and the solution was stirred at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, brine and dried over anhydrous Na2SO4. Yield: 300mg (91%); 1H NMR (400 MHz, DMSO-D6) δ 1.22 - 1.37 (m, 2 H), 1.41 - 1.53 (m, 3 H), 1.68 (t, J=12.30 Hz, 2 H), 1.72 - 1.80 (m, 2 H), 2.01 - 2.08 (m, 1 H), 2.10 - 2.23 (m, 1 H), 2.29 (dd, J=14.84, 8.20 Hz, 1 H), 2.57 - 2.68 (m, 1 H), 2.71 - 2.85 (m, 2 H), 2.90 (s, 3 H), 3.21 - 3.31 (m, 4 H), 3.59 (s, 3 H), 3.87 (dd, J=9.37, 1.95 Hz, 2 H), 7.05 (d, J=8.20 Hz, 1 H), 7.33 (d, J=8.59 Hz, 1 H), 7.38 (s, 1 H); MS (ESI) (M+H)+ = 413.42.
Example 76
(R)-N,9-Dimethyl-N-(4-(oxetan-3-ylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4- yl^jS^P-tetrahydro-lH-carbazole-ό-carboxamide.
Figure imgf000145_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (75 mg, 0.18 mmol), oxetan-3 -amine hydrochloride (23.90 mg, 0.22 mmol) and HATU (83 mg, 0.22 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.079 mL, 0.45 mmol) at 23 0C for Ih. The solvent was concentrated. The residue was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Synergi Polar-RP, 30 x 50 mm, 4 mm particle size. Mobile phase: 30-50%B; A: H2O with 15mM NH4CO3 and
0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. Yield: 45mg (53%); 1H
NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.51 (m, 2 H), 1.53 - 1.62 (m, 3 H), 1.78 (t, J=12.30 Hz, 2 H), 1.86 (s, 1 H), 1.99 (s, 2 H), 2.13 - 2.20 (m, 1 H), 2.31 (s, 1 H), 2.35 - 2.46 (m, 1 H), 2.64 - 2.75 (m, 1 H), 2.81 - 2.90 (m, 2 H), 3.04 (s, 3 H), 3.36 - 3.47 (m, 3 H), 3.57 (s, 1 H), 3.63 (s, 3 H), 3.98 (dd, J=10.94, 3.52 Hz, 2 H), 4.26 (s, 1 H), 4.51 (s, 1 H), 4.62 (s, 1 H), 4.79 (s, 1 H), 7.12 (s, 1 H), 7.31 (d, J=8.20 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 468.2; accurate mass : (M+H) = 468.286.
Example 77
(R)-N-(4-(3-Hydroxypropylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide.
Figure imgf000146_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (73 mg, 0.18 mmol), HATU (81 mg, 0.21 mmol) and 3- amino-1-propanol (0.016 mL, 0.21 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.046 mL, 0.27 mmol) at 23 0C for Ih. The solvent was evaporated. The product was purified directly by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with a Synergi Polar-RP, 30 x 50 mm, 4 mm particle size. Mobile phase: 30-50%B; A: H2O with 15mM NH4CO3 and
0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. Yield: 35 mg (42%); 1H
NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.50 (m, 3 H), 1.52 - 1.62 (m, 3 H), 1.69 (s, 1 H), 1.77 (t, J=12.30 Hz, 2 H), 1.86 (s, 1 H), 1.96 (s, 2 H), 2.12 - 2.20 (m, 1 H), 2.27 (s,
1 H), 2.34 - 2.44 (m, 1 H), 2.63 - 2.74 (m, 1 H), 2.79 - 2.90 (m, 2 H), 3.04 (s, 4 H), 3.24 (s, 1 H), 3.35 - 3.47 (m, 4 H), 3.56 (s, 2 H), 3.62 (s, 3 H), 3.98 (dd, J=I l.13, 3.71 Hz, 2 H), 7.12 (s, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.46 (s, 1 H); MS (ESI) (M+H)+ = 470.2; accurate mass: (M+H) = 470.301
Example 78
Step A: (R)-N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3- (tetrahydro-lH-pyran^-yl^jS^P-tetrahydro-lH-carbazole-o-carboxamide
Figure imgf000147_0001
(R)-Methyl 9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate (45 mg, 0.11 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.222 mL, 0.22 mmol) (IM) at 500C for 2-3h. The solvent was evaporated. The residue was dissolved in DMF (5.00 mL) containing N,N- diisopropylethylamine (0.048 mL, 0.28 mmol) and N-ethyl-2-(2-hydroxyethylamino)-2- oxoethanaminium 2,2,2-trifluoroacetate (34.7 mg, 0.13 mmol) along with HATU (63.3 mg, 0.17 mmol) were added. The solution was stirred at 23 0C for Ih. More N-ethyl-2- (2-hydroxyethylamino)-2-oxoethanaminium 2,2,2-trifluoroacetate (34.7 mg, 0.13 mmol) was added and the solution was stirred at 23 0C for another Ih. The solvent was concentrated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SU4. The product was purified by reversed-phase HPLC using 30-50%B and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C- 18 column, 250 X 21.2 mm, 15u. Mobile phase: A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. Yield: 15 mg (26%);
1H NMR (400 MHz, METHANOL-D4) δ 1.14 (t, J=7.42 Hz, 4 H), 1.20 - 1.27 (m, 2 H), 1.27 - 1.37 (m, 2 H), 1.40 - 1.50 (m, 2 H), 1.53 - 1.66 (m, 3 H), 1.74 - 1.85 (m, 2 H), 2.13
- 2.22 (m, 1 H), 2.32 - 2.44 (m, 1 H), 2.77 - 2.92 (m, 2 H), 3.11 - 3.21 (m, 1 H), 3.31 - 3.40 (m, 3 H), 3.39 - 3.49 (m, 3 H), 3.53 - 3.67 (m, 2 H), 4.00 (dd, J=I 1.13, 3.32 Hz, 3 H), 4.19 (s, 1 H), 7.31 - 7.40 (m, 1 H), 7.55 - 7.66 (m, 1 H), 7.93 - 8.04 (m, 1 H); MS (ESI) (M+H)+ = 520.2; Accurate mass: (M+H) = 520.247.
Step B: Methyl S-Ctetrahydro-ΣH-pyran^-yl^S^-tetrahydro-lH-carbazole-ό- carboxylate
Figure imgf000148_0001
3-(Tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (250 mg, 0.84 mmol) was dissolved in MeOH (20 mL). (Trimethylsilyl)diazomethane (2.088 mL, 4.18 mmol) was added dropwise at 00C until a light yellow color persisted. The solution was then stirred at 23 0C for 30 min. The solvent was evaporated. The product was purified by flash chromatography using a gradient of 20% - 80% EtOAc / heptane.
Yield: 170 mg (65%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.42 - 1.52 (m, 2 H), 1.52 - 1.60 (m, 1 H), 1.60 - 1.69 (m, 2 H), 1.76 (d, J=UA l Hz, 2 H), 2.07 - 2.10 - 2.15 (m, 1 H), 2.39 - 2.45 (m, 1 H), 2.77 (s, 2 H), 2.89 (dd, J=15.23, 4.30 Hz, 1 H), 3.43 (t, J=I 1.72 Hz, 2 H), 3.93 (s, 3 H), 4.05 (dd, J=I 1.13, 2.54 Hz, 2 H), 7.24 - 7.30 (m, 1 H), 7.84 (d, J=8.59 Hz, 1 H), 7.94 (s, 1 H), 8.22 (s, 1 H); MS (ESI) (M+H)+ = 314.28.
Step C: (R)-Methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole- 6-carboxylate and (S)-Methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate
Chiral separation of methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylate (150 mg, 0.48 mmol) was done as the following: Gilson system equipped with a Chiracel OD column, 5 cm ID X 50 cm L, 2Ou using 15% EtOH/hexanes with 0.1% diethylamine v/v; 100 mL/min, 60 min ran, rt. Chiral analytical HPLC: ChiraCel OD column, 20% EtOH/hexanes, 1 mL/min, 30 min ran, 25°C. (R)-Methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylate (isomer 1, 62 mg, 41 %).
Figure imgf000149_0001
1H NMR (400 MHz, CHLOROFORM-D) δ 1.43 - 1.52 (m, 2 H), 1.52 - 1.60 (m, 2 H), 1.59 - 1.70 (m, 1 H), 1.76 (d, J=12.50 Hz, 2 H), 2.07 - 2.15 (m, 1 H), 2.37 - 2.47 (m, 1 H), 2.75 - 2.81 (m, 2 H), 2.89 (dd, J=15.23, 3.91 Hz, 1 H), 3.38 - 3.47 (m, 2 H), 3.93 (s, 3 H), 4.05 (dd, J=I 1.52, 3.32 Hz, 2 H), 7.29 (s, 1 H), 7.84 (dd, J=8.59, 1.56 Hz, 1 H), 7.92 (s, 1 H), 8.22 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)+ = 314.21; chiral HPLC k' = 2.36.
(S)-Methyl 3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylate (isomer 2, 68 mg, 45 %).
Figure imgf000149_0002
1H NMR (400 MHz, CHLOROFORM-D) δ 1.42 - 1.52 (m, 2 H), 1.52 - 1.60 (m, 2 H), 1.60 - 1.69 (m, 1 H), 1.76 (d, ./=12.11 Hz, 2 H), 2.07 - 2.16 (m, 1 H), 2.37 - 2.47 (m, 1 H), 2.75 - 2.81 (m, 2 H), 2.90 (dd, 7=15.23, 4.30 Hz, 1 H), 3.38 - 3.47 (m, 2 H), 3.93 (s, 3 H), 4.05 (dd, J=I 1.52, 3.32 Hz, 2 H), 7.26 - 7.30 (m, 1 H), 7.84 (dd, J=8.59, 1.56 Hz, 1 H), 7.91 (s, 1 H), 8.22 (s, 1 H); MS (ESI) (M+H)+ = 314.20; chiral HPLC k' = 2.72.
Step D: (R)- Methyl 9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylate.
Figure imgf000150_0001
(R)-Methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylate (62 mg, 0.20 mmol) was dissolved in DMF (5 mL) at 0 0C under N2. Sodium hydride (39.6 mg, 0.99 mmol) was added slowly and the solution was stirred at 0 0C for 30 min. Ethanesulfonyl chloride (0.037 mL, 0.40 mmol) was added and the solution was stirred at rt for Ih. Another 1 eq. of ethanesulfonyl chloride (0.037 mL, 0.40 mmol) was added and the solution was stirred at rt for another 2h. LC/MS showed that the reaction was still not completed but reaction was quenched anyway at 0 0C with saturated aqueous NaHCO3 and the solvent was evaporated. The residue was dissolved in EtOAc and washed with water, brine and dried over anhydrous Na2SU4. The product was purified by flash chromatography using a gradient of 20% - 80% EtOAc / heptane. Yield: 45 mg
(56%); 1H NMR (400 MHz, CHLOROFORM-D) δ 1.22 (t, J=7.42 Hz, 3 H), 1.42 - 1.51 (m, 2 H), 1.50 - 1.58 (m, 2 H), 1.57 - 1.67 (m, 1 H), 1.71 - 1.79 (m, 2 H), 2.10 - 2.18 (m, 1 H), 2.32 - 2.43 (m, 1 H), 2.80 - 2.90 (m, 2 H), 3.12 - 3.21 (m, 1 H), 3.25 (q, J=7.42 Hz, 2 H), 3.42 (t, J=I 1.52 Hz, 2 H), 3.95 (s, 3 H), 4.05 (dd, J=I 1.13, 3.32 Hz, 2 H), 7.94 - 7.98 (m, 1 H), 7.98 - 8.02 (m, 1 H), 8.15 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)+ = 406.24.
Example 79 (9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((R)-3-hydroxypyrrolidin-l-yl)methanone
Figure imgf000151_0001
.9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (150 mg, 0.38 mmol), (i?)-pyrrolidin-3-ol (36.7 mg, 0.42 mmol) and N- ethyl-N-isopropylpropan-2-amine (0.147 mL, 0.84 mmol) are mixed in DMF (10.0 mL), and HATU (146 mg, 0.38 mmol) is added. The mixture is stirred at room temperature for 1 hour, and the solvent is evaporated. The mixture is diluted in IN NaOH (50 mL) and extracted 3 times with EtOAc (3X50 mL). The combined organic phases are dried over sodium sulfate, the mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Gemini (5μm particle size) 21.2 x 50 mm, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (110 mg, 62%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.36 - 1.62 (m, 8 H) 1.72 (t, J=13.87 Hz, 2 H) 1.89 - 2.02 (m, 2 H) 2.08 - 2.20 (m, 2 H) 2.25 - 2.39 (m, 1 H) 2.72 - 2.92 (m, J=16.41 Hz, 2 H) 3.06 - 3.18 (m, 1 H) 3.21 (q, J=7.42 Hz, 2 H) 3.40 (t, J=I 1.72 Hz, 2 H) 3.47 - 3.59 (m, 1 H) 3.59 - 3.72 (m, 1 H) 3.73 - 3.91 (m, 2 H) 4.03 (dd, J=I 1.52, 3.32 Hz, 2 H) 4.53 (d, J=61.33 Hz, 1 H) 7.42 (dd, J=19.92, 8.98 Hz, 1 H) 7.63 (d, J=8.98 Hz, 1 H) 7.95 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 461.2.
Example 80
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((S)-3-hydroxypyrrolidin-l-yl)methanone
Figure imgf000151_0002
9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (160 mg, 0.41 mmol), (.S)-pyrrolidin-3-ol (39.2 mg, 0.45 mmol), N-ethyl- N-isopropylpropan-2-amine (0.078 mL, 0.45 mmol) are mixed in DMF (10.0 mL) and HATU (171 mg, 0.45 mmol) is added. The mixture is stirred at room temperature for 2 hours, and the solvent is evaporated. EtOAc (75mL) is added, and the mixture is washed with IN NaOH (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Gemini (5μm particle size) 21.2 x 50 mm, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (118 mg, 63%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.18 (t, J=7.23 Hz, 3 H) 1.35 - 1.64 (m, 6 H) 1.72 (t, J=13.67 Hz, 2 H) 1.92 - 2.07 (m, 2 H) 2.07 - 2.18 (m, 1 H) 2.25 - 2.42 (m, 1 H) 2.68 - 2.95 (m, J=15.62 Hz, 2 H) 3.02 - 3.19 (m, 1 H) 3.21 (q, J=7.29 Hz, 2 H) 3.40 (t, J=I 1.72 Hz, 2 H) 3.45 - 3.60 (m, 1 H) 3.59 - 3.73 (m, 1 H) 3.72 - 3.92 (m, ./=12.50, 8.98 Hz, 2 H) 4.03 (dd, J=I 1.91, 2.93 Hz, 2 H) 4.53 (d, J=62.11 Hz, 1 H) 7.42 (dd, ./=20.12, 8.79 Hz, 1 H) 7.63 (d, J=8.98 Hz, 1 H) 7.95 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 461.2.
Example 81
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((R)-3-hydroxypiperidin-l-yl)methanone
Figure imgf000152_0001
9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (160 mg, 0.41 mmol), (i?)-piperidin-3-ol hydrochloride (56.2 mg, 0.41 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.149 mL, 0.86 mmol) are mixed in DMF (10.0 mL), and HATU (155 mg, 0.41 mmol) is added. After 2 hours, the solvent is evaporated, and the residue is diluted in EtOAc (75mL). The mixture is washed with IN NaOH (75mL), and the aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Gemini (5μm particle size) 21.2 x 50 mm, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (132 mg, 68%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.19 (t, J=7.42 Hz, 3 H) 1.36 - 1.66 (m, 10 H) 1.72 (t, J=12.89 Hz, 2 H) 2.08 - 2.19 (m, 1 H) 2.26 - 2.39 (m, 1 H) 2.78 (dd, J=16.02, 4.69 Hz, 1 H) 2.82 - 2.93 (m, 1 H) 3.06 - 3.18 (m, 1 H) 3.21 (q, J=7.42 Hz, 2 H) 3.40 (t, J=I 1.72 Hz, 2 H) 3.92 - 4.00 (m, 1 H) 4.03 (dd, J=I 1.52, 3.32 Hz, 2 H) 7.27 (dd, J=8.20, 1.56 Hz, 1 H) 7.50 (s, 1 H) 7.95 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 475.2.
Example 82
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)(4-hydroxypiperidin-l-yl)methanone
Figure imgf000153_0001
9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (160 mg, 0.41 mmol), piperidin-4-ol (55.0 mg, 0.54 mmol) and N-ethyl- N-isopropylpropan-2-amine (0.078 mL, 0.45 mmol) are mixed in DMF (10.0 mL), and HATU (155 mg, 0.41 mmol) is added. The mixture is stirred for 2 hours, and the solvent is evaporated. The residue is diluted in EtOAc (75mL) and washed with IN NaOH (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL), and organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Gemini (5μm particle size) 21.2 x 50 mm, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (109 mg, 56%). 1U NMR (400 MHz, CHLOROFORM-D) δ ppm 1.19 (t, J=7.42 Hz, 3 H) 1.35 - 1.66 (m, 10 H) 1.72 (t, J=13.28 Hz, 2 H) 1.94 (s, 1 H) 2.06 - 2.18 (m, 1 H) 2.27 - 2.39 (m, J=9.77 Hz, 1 H) 2.78 (dd, ./=16.02, 3.91 Hz, 1 H) 2.82 - 2.93 (m, 1 H) 3.07 - 3.18 (m, 1 H) 3.21 (q, J=7.42 Hz, 2 H) 3.40 (t, J=I 1.72 Hz, 3 H) 4.03 (dd, J=I 1.91, 2.93 Hz, 2 H) 7.30 (dd, J=8.40, 1.37 Hz, 1 H) 7.53 (s, 1 H) 7.95 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 475.2.
Example 83
N6-Ethyl-N6-(2-(ethylamino)-2-oxoethyl)-N9,N9-dimethyl-3-(tetrahydro-2H-pyran-
4-yl)-3,4-dihydro-lH-carbazole-6,9(2H)-dicarboxamide
Figure imgf000154_0001
Step A: 9-[(Dimethylamino)carbonyl]-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid
Figure imgf000154_0002
Solid KHMDS (800 mg, 4.00 mmol) is mixed in THF (10.0 mL) at -78°C, and 3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (200 mg,
0.67 mmol) is added in one portion. The mixture is warmed to 00C and stirred for 10 minutes. The mixture is cooled to -78°C and then stirred for 1 hour. Dimethylcarbamic chloride (0.55 mL, 6.00 mmol) is added, and the mixture is stirred for 3 hours at 00C.
Saturated ammonium chloride (10OmL) is added, and the aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated to yield a solid (205 mg), which is used without purification.
Step B: N6-Ethyl-N6-(2-(ethylamino)-2-oxoethyl)-N9,N9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-3,4-dihydro-lH-carbazole-6,9(2H)-dicarboxamide
Figure imgf000155_0001
9-(Dimethylcarbamoyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (205 mg, 0.55 mmol), N-ethyl-2-(ethylamino)acetamide (72.0 mg, 0.55 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.096 mL, 0.55 mmol) are mixed in DMF (10.0 mL) at 00C. HATU (210 mg, 0.55 mmol) is added, and the mixture is stirred for 1 hour. The solvent is evaporated, and the residue is diluted in EtOAc (75 mL). The mixture is washed with saturated ammonium chloride (75 mL), and the aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The solvent is evaporated, and the product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Synergi Polar (4μm particle size) 21.2 x 50 mm, mobile phase A = water (0.05% TFA), B = MeCN, (49 mg, 2 steps 18%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.09 - 1.26 (m, 6 H) 1.37 - 1.95 (m, 10 H) 2.02 - 2.16 (m, 1 H) 2.27 - 2.44 (m, 1 H) 2.72 - 2.94 (m, 3 H) 3.04 (d, J=2.73 Hz, 6 H) 3.26 - 3.37 (m, 2 H) 3.41 (t, J=I 1.72 Hz, 2 H) 3.48 (s, 1 H) 4.03 (dd, J=I 1.13, 3.32 Hz, 2 H) 4.10 (s, 1 H) 7.22 - 7.26 (m, 2 H) 7.53 (s, 1 H); MS (ESI) (M+H)+ 483.3.
Example 84
N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000156_0001
3-(Tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (1.51 g, 5.08 mmol) and N-ethyl-2-(ethylamino)acetamide (0.651 g, 5.08 mmol) are mixed in DMF (20.0 mL), and the resulting mixture is cooled to 0 0C. N-Ethyl-N-isopropylpropan- 2-amine (0.885 mL, 5.08 mmol) is added followed by HATU (1.931 g, 5.08 mmol). After 1 hour, the mixture is diluted with IN HCl (10OmL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep Cl 8 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (996 mg, 48%). 1H NMR (400 MHz, CHLOROFORM-D) δppm 1.17 (t, J=7.42 Hz, 3 H) 1.19 - 1.22 (m, 3 H) 1.39 - 1.68 (m, 7 H) 1.73 (t, J=12.11 Hz, 2 H) 2.09b (d, J=I 1.72 Hz, 1 H) 2.38 (dd, J=14.45, 9.77 Hz, 1 H) 2.73 - 2.87 (m, 3 H) 3.32 (dt, J=13.67, 7.03, 6.64 Hz, 2 H) 3.49 (d, J=6.64 Hz, 2 H) 4.03 (dd, J=I 1.33, 3.12 Hz, 2 H) 4.07 - 4.16 (m, 2 H) 7.17 (dd, J=8.20, 1.56 Hz, 1 H) 7.27 (d, J=8.20 Hz, 1 H) 7.55 (s, 1 H) 7.90 (s, 1 H); MS (ESI) (M+H)+ 412.3.
Example 85
Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4- yl)-3,4-dihydro-lH-carbazol-9(2H)-yl)acetate
Figure imgf000156_0002
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide (0.996 g, 2.42 mmol) is mixed in THF (40.0 mL) and cooled to 00C. Solid KHMDS (2.414 g, 12.10 mmol) is added, and the mixture is stirred at 00C for 30 minutes. Ethyl 2-iodoacetate (1.431 mL, 12.10 mmol) is added, and the mixture is stirred for 30 minutes. The mixture is diluted with a saturated solution of ammonium chloride (75mL), and then extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep C18 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (618 mg, 51%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.11 - 1.20 (m, 6 H) 1.24 (t, J=7.03 Hz, 2 H) 1.30 (t, J=7.23 Hz, 1 H) 1.37 - 1.65 (m, 5 H) 1.71 (t, J=10.35 Hz, 2 H) 2.07 - 2.21 (m, ./=10.16 Hz, 1 H) 2.39 (dd, ./=14.06, 8.59 Hz, 1 H) 2.57 - 2.77 (m, 2 H) 2.82 (dd, J=15.23, 2.73 Hz, 1 H) 3.30 (q, J=20.31, 14.06, 7.03 Hz, 2 H) 3.40 (t, J=I 1.72 Hz, 2 H) 3.48 (d, J=7.03 Hz, 2 H) 4.02 (dd, J=I 1.13, 3.32 Hz, 2 H) 4.08 (s, 1 H) 4.17 (d, J=7.03 Hz, 1 H) 4.21 (d, J=7.03 Hz, 1 H) 4.22 (d, J=7.42 Hz, 1 H) 4.25 (d, J=7.03 Hz, 1 H) 4.72 (s, 2 H) 7.15 (d, J=8.20 Hz, 1 H) 7.20 (dd, J=8.59, 1.56 Hz, IH) 7.56 (s, 1 H); MS (ESI) (M+H)+ 498.4.
Example 86
2-(6-(Ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)- 3,4-dihydro-lH-carbazol-9(2H)-yl)acetic acid
Figure imgf000157_0001
Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)- 3,4-dihydro-lH-carbazol-9(2H)-yl)acetate (50.0 mg, 0.10 mmol) is mixed in THF (5.00 mL), and 6N sodium hydroxide (5.00 mL, 30.00 mmol) is added. The mixture is stirred at room temperature for 12 hours. The solvents are evaporated, and the residue is dissolved in IN NaOH (5OmL). The mixture is washed with EtOAc (5OmL), and the organic phase is extracted 3 times with IN NaOH (3X50 mL). The aqueous phases are combined, and 6N HCl is added until the pH is acidic, as indicated by pH paper. The aqueous phase is extracted 3 times with EtOAc (3X50mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.13 (t, J=6.25 Hz, 6 H) 1.24 (s, 1 H) 1.38 - 1.61 (m, 5 H) 1.71 (t, J=10.55 Hz, 2 H) 2.06 (s, 2 H) 2.10 (d, J=8.59 Hz, 1 H) 2.36 (s, 1 H) 2.55 - 2.72 (m, 2 H) 2.78 (t, J=7.03 Hz, 1 H) 3.28 (t, J=6.25 Hz, 2 H) 3.40 (t, J=I 1.33 Hz, 3 H) 4.03 (d, J=10.16 Hz, 2 H) 4.11 (s, 1 H) 4.68 (s, 2 H) 7.00 - 7.18 (m, 3 H) 7.51 (s, 1 H); MS (ESI) (M+H)+ 470.4.
Example 87
9-(2-(diethylamino)-2-oxoethyl)-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000158_0001
2-(6-(Ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)-3,4- dihydro-lH-carbazol-9(2H)-yl)acetic acid (116 mg, 0.25 mmol) and diethylamine (0.038 mL, 0.37 mmol) are mixed in DMF (10.0 mL), and N-ethyl-N-isopropylpropan-2-amine (0.065 mL, 0.37 mmol) is added followed by HATU (141 mg, 0.37 mmol). The mixture is stirred at room temperature for 1 hour and then diluted with IN HCl (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Synergi Polar (4μm particle size) 21.2 x 50 mm, mobile phase A = water (0.05% TFA), B = MeCN, (23 mg, 17%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.09 - 1.20 (m, 9 H) 1.24 (t, J=7.03 Hz, 3 H) 1.38 - 1.67 (m, 5 H) 1.68 - 1.78 (m, 2 H) 2.10 (d, J=I 1.72 Hz, 1 H) 2.39 (dd, ./=14.65, 9.57 Hz, 1 H) 2.54 - 2.76 (m, 2 H) 2.82 (dd, J=16.02, 4.30 Hz, 1 H) 3.07 (s, 1 H) 3.31 (dt, ./=12.89, 7.42 Hz, 2 H) 3.35 - 3.45 (m, 6 H) 3.49 (d, J=7.03 Hz, 2 H) 4.02 (dd, J=I 1.13, 3.32 Hz, 2 H) 4.09 (s, 2 H) 4.77 (d, J=2.34 Hz, 2 H) 7.11 (d, J=8.59 Hz, 1 H) 7.18 (dd, J=8.59, 1.56 Hz, 1 H) 7.56 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)+ 525.3.
Example 88
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-(methylamino)-2-oxoethyl)-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000159_0001
2-(6-(Ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)-3,4- dihydro-lH-carbazol-9(2H)-yl)acetic acid (75.0 mg, 0.16 mmol) and methylamine hydrochloride (16.18 mg, 0.24 mmol) are mixed in DMF (10.0 mL), and N-ethyl-N- isopropylpropan-2-amine (0.042 mL, 0.24 mmol) is added followed by HATU (72.9 mg, 0.19 mmol). The mixture is stirred at room temperature for 30 minutes and then diluted with IN HCl (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 30 ml/min, Synergi Polar (4μm particle size) 21.2 x 50 mm, mobile phase A = water (0.05% TFA), B = MeCN, (17.0 mg, 22%). 1H NMR (400 MHz, CHLOROFORM- D) δppm 1.17 (t, J=7.23 Hz, 3 H) 1.19 - 1.26 (m, 2 H) 1.38 - 1.66 (m, 5 H) 1.73 (t, J=8.98 Hz, 2 H) 2.15 (d, J=10.94 Hz, 1 H) 2.38 (dd, J=14.84, 9.37 Hz, 1 H) 2.52 - 2.69 (m, 1 H) 2.68 - 2.70 (m, 2 H) 2.72 (d, J=4.69 Hz, 3 H) 2.84 (dd, J=16.41, 3.13 Hz, 1 H) 3.33 (q, J=14.06, 7.42, 7.42 Hz, 4 H) 3.41 (t, J=I 1.33 Hz, 2 H) 3.50 (d, J=5.47 Hz, 2 H) 4.04 (dd, J=I 1.33, 3.12 Hz, 2 H) 4.10 (s, 1 H) 4.67 (s, 2 H) 5.26 - 5.36 (m, 1 H) 7.19 (d, J=8.20 Hz, 1 H) 7.23 (dd, J=8.20, 0.78 Hz, 1 H) 7.59 (s, 1 H); MS (ESI) (M+H)+ 483.3.
Example 89 N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-hydroxy-2-methylpropyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000160_0001
Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)- 3,4-dihydro-lH-carbazol-9(2H)-yl)acetate (105 mg, 0.21 mmol) is mixed in THF (10.0 mL) and cooled to 0 0C. Methylmagnesium bromide (0.482 mL, 0.68 mmol) is added, and the mixture is stirred for 45 minutes. The mixture is diluted with a saturated solution of ammonium chloride (75mL) and then extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep C18 OBD, 30 x 150 mm, 5μm particle size, mobile phase
A =10mM ammonium bicarbonate, B = MeCN, (16.95 mg, 17%). 1H NMR (400 MHz,
CHLOROFORM-D) δ ppm 1.13 - 1.23 (m, 5 H) 1.28 (s, 6 H) 1.38 - 1.80 (m, 9 H) 2.13
(d, J=12.89 Hz, 1 H) 2.39 (dd, ./=14.84, 10.16 Hz, 1 H) 2.65 - 2.77 (m, 1 H) 2.85 (d, J=15.62 Hz, 2 H) 3.32 (q, J=7.03, 6.25 Hz, 2 H) 3.41 (dt, J=I 1.72, 1.95 Hz, 2 H) 3.50 (q,
J=6.51 Hz, 2 H) 3.93 - 4.07 (m, 4 H) 4.10 (s, 2 H) 6.94 (s, 1 H) 7.18 (dd, J=8.59, 1.56
Hz, 1 H) 7.39 (d, J=8.59 Hz, 1 H) 7.55 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+ 484.2.
Example 90 N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-hydroxyethyl)-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000161_0001
Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)- 3,4-dihydro-lH-carbazol-9(2H)-yl)acetate (105 mg, 0.21 mmol) is mixed in THF (10.0 mL) and cooled to 00C. LAH (0.264 mL, 0.53 mmol) is added, and the mixture is stirred at 00C for 20 minutes. The mixture is diluted with a saturated solution of ammonium chloride (75mL) and extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep Cl 8 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (40.0 mg, 42%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.16 (t, J=7.23 Hz, 3 H) 1.40 - 1.62 (m, 4 H) 1.65 (s, 2 H) 1.72 (t, J=I 1.33 Hz, 3 H) 2.13 (d, J=I 1.72 Hz, 1 H) 2.38 (dd, J=14.84, 9.37 Hz, 1 H) 2.65 - 2.78 (m, 1 H) 2.80 - 2.91 (m, J=5.86 Hz, 2 H) 3.31 (ddd, J=13.28, 7.42, 5.86 Hz, 2 H) 3.39 (t, J=I 1.72 Hz, 3 H) 3.48 (q, J=14.06, 7.42, 6.64 Hz, 3 H) 3.89 (t, J=5.08 Hz, 2 H) 4.02 (dd, J=10.94, 3.13 Hz, 2 H) 4.08 (s, 2 H) 4.19 (q, J=9.77, 5.47, 4.30 Hz, 2 H) 6.92 (s, 1 H) 7.18 (dd, J=8.59, 1.56 Hz, 1 H) 7.28 (d, J=8.59 Hz, 1 H) 7.56 (s, 1 H); MS (ESI) (M+H)+ 456.2.
Example 91 2-(N-Ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid.
Figure imgf000162_0001
9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (668mg, 1.71 mmol) is mixed in DMF (20.0 mL) and N-ethyl-N- isopropylpropan-2-amine (0.297 mL, 1.71 mmol) followed by HATU (649 mg, 1.71 mmol) are added. The mixture is stirred for 30 minutes and then diluted with IN HCl (75mL). The aqueous phase is extracted 3 times with DCM (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep C18 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (413 mg, 51%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.11 - 1.28 (m, 6 H) 1.37 - 1.65 (m, 5 H) 1.67 - 1.79 (m, 2 H) 1.98 - 2.01 (m, 1 H) 2.07 - 2.17 (m, 2 H) 2.23 - 2.47 (m, J=10.55 Hz, 1 H) 2.69 - 2.91 (m, 2 H) 3.06 - 3.29 (m, 3 H) 3.41 (t, J=10.55 Hz, 3 H) 3.98 - 4.11 (m, 2 H) 4.26 (s, 1 H) 7.31 (d, J=8.20 Hz, 1 H) 7.54 (s, 1 H) 7.74 (s, 1 H) 7.95 (d, J=8.20 Hz, 1 H); MS (ESI) (M+H)+ 477.4.
Example 92
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000162_0002
2-(N-Ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid (189 mg, 0.40 mmol) and l-aminopropan-2-ol (29. Σ mg, 0.40 mmol) are mixed in DMF (10.0 mL), and N-ethyl-N-isopropylpropan-2-amine (0.069 mL, 0.40 mmol) is added followed by HATU (151 mg, 0.40 mmol). The mixture is stirred for 30 minutes and then diluted with IN HCl (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified the product by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep C18 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (116.1 mg, 55%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.19 (d, J=6.25 Hz, 6 H) 1.20 - 1.25 (m, 2 H) 1.37 - 1.65 (m, 5 H) 1.72 (t, J=12.11 Hz, 2 H) 2.13 (d, J=10.94 Hz, 1 H) 2.32 (s, 1 H) 2.73 - 2.90 (m, 2 H) 3.08 - 3.28 (m, 5 H) 3.40 (t, J=I 1.72 Hz, 2 H) 3.44 - 3.57 (m, 2 H) 3.92 - 3.99 (m, 1 H) 4.03 (dd, J=I 1.52, 2.93 Hz, 2 H) 4.08 - 4.17 (m, J=7.03 Hz, 4 H) 7.05 (s, 1 H) 7.30 (d, J=8.59 Hz, 1 H) 7.47 - 7.56 (m, J=8.20 Hz, 1 H) 7.97 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 534.4.
Example 93
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-methoxyethylamino)-2-oxoethyl)-3-(tetrahydro-
IH-pyran-^yl^jS^P-tetrahydro-lH-carbazole-ό-carboxamide
Figure imgf000163_0001
2-(N-Ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid (80 mg, 0.17 mmol) and 2-methoxyethanamine
(0.015 mL, 0.17 mmol) are mixed in DMF (10.0 mL), and N-ethyl-N-isopropylpropan-2- amine (0.029 mL, 0.17 mmol) is added followed by HATU (63.8 mg, 0.17 mmol). The mixture is stirred for 30 minutes and then diluted with IN HCl (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep
C18 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (49.3 mg, 55%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.14 - 1.17 (m, 1 H) 1.20 (t, J=7.42 Hz, 6 H) 1.35 - 1.64 (m, 5 H) 1.66 (s, 2 H) 1.71 (t, J=14.06 Hz, 2 H) 2.12 (d, J=I 1.72 Hz, 1 H) 2.32 (dd, J=15.43, 9.96 Hz, 1 H) 2.71 - 2.90 (m, 2 H) 3.11 - 3.18 (m, 1 H) 3.22 (q, J=7.42 Hz, 2 H) 3.37 (s, 3 H) 3.41 (d, J=12.11 Hz, 2 H) 3.48 (s, 4 H) 4.03 (dd, J=I 1.33, 3.13 Hz, 2 H) 4.14 (s, 1 H) 6.84 (s, 1 H) 7.30 (dd, J=8.59, 1.56 Hz, 1 H) 7.52 (d, J=I.17 Hz, 1 H) 7.96 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 534.4.
Example 94 N-Ethyl-9-(ethylsulfonyl)-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000164_0001
2-(N-Ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid (100 mg, 0.21 mmol) and oxetan-3 -amine hydrochloride (22.99 mg, 0.21 mmol) are mixed in DMF (10.0 mL) and N-ethyl-N- isopropylpropan-2-amine (0.037 mL, 0.21 mmol) is added followed by HATU (80 mg, 0.21 mmol). The mixture is stirred for 30 minutes and then diluted with IN HCl (75mL). The aqueous phase is extracted 3 times with EtOAc (3X75mL). The organic phases are combined and dried over sodium sulfate. The mixture is filtered, and the solvent is evaporated. The product is purified by HPLC: Gilson prep pumps, flow rate: 45 ml/min, X-Bridge Prep Cl 8 OBD, 30 x 150 mm, 5μm particle size, mobile phase A =10mM ammonium bicarbonate, B = MeCN, (69 mg, 62%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.16 - 1.25 (m, 5 H) 1.37 - 1.58 (m, 5 H) 1.62 (s, 4 H) 1.72 (t, J=12.50 Hz, 2 H) 2.14 (d, J=12.50 Hz, 1 H) 2.27 - 2.40 (m, 1 H) 2.73 - 2.91 (m, 2 H) 3.09 - 3.20 (m, 1 H) 3.23 (q, J=7.42 Hz, 2 H) 3.40 (t, J=I 1.72 Hz, 2 H) 3.44 - 3.53 (m, 1
H) 4.03 (dd, J=I 1.13, 2.93 Hz, 2 H) 4.11 (s, 1 H) 4.55 (t, J=6.64 Hz, 2 H) 4.93 (t, J=7.03 Hz, 2 H) 5.05 (quint, J=7.03 Hz, 1 H) 7.30 (d, J=9.77 Hz, 1 H) 7.53 (s, 1 H) 7.98 (d, J=7.81 Hz, 1 H); MS (ESI) (M+H)+ 532.3.
Example 95 N- [2-(cyclopropylamino)-2-oxoethyl] -9-(cyclopropylmethyl)-iV-ethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-LH-carbazole-6-carboxamide
Figure imgf000165_0001
Step A: N- [2-(cyclopropylamino)-2-oxoethyl] -9-(cyclopropylmethyl)-iV-ethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000165_0002
N,N-Diisopropylethylamine (89 μL, 0.51 mmol) was added to a solution of 9-
(cyclopropylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (0.17 mmol) and N-cyclopropyl-2-(ethylamino)acetamide hydrochloride (61 mg, 0.34 mmol) in DMF (5 mL). Stirring for 20 min, HATU (97 mg, 0.26 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, diluted with water (50 mL), and extracted with EtOAc (3x25 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (20 mL) and dried with Na2SC>4. Upon evaporation of the solvent, the crude product was purified by reverse-phase HPLC using high pH column 30-50% MeCN/H2O to give 67.8 mg (83% ) of a white solid as the title compound. IH NMR (400 MHz, METHANOL-D4) δ 0.29 - 0.38 (m, 2 H), 0.40 - 0.60 (m, 4 H), 0.72 (m, 2 H), 1.08 - 1.30 (m, 4 H), 1.38 - 1.66 (m, 5 H), 1.74 - 1.88 (m, 2 H), 2.19 (m, 1 H), 2.32 - 2.49 (m, 1 H), 2.62 - 2.97 (m, 3 H), 3.38 - 3.66 (m, 4 H), 3.90 - 4.16 (m, 7 H), 7.13 - 7.25 (m, 1 H), 7.31 - 7.43 (m, 1 H), 7.45 - 7.60 (m, 1 H); HRMS m/z calcd for [M+H]+ 478.30642, found 478.30499.
Step B: methyl 3-chloro-4-(cyclopropylmethylamino)benzoate
Figure imgf000166_0001
Sodium triacetoxyborohydride (3.47 g, 16.39 mmol) was added to a solution of methyl 4- amino-3-chlorobenzoate (1.014 g, 5.46 mmol), cyclopropanecarboxaldehyde (0.816 mL, 10.93 mmol), and acetic acid (1.876 mL, 32.78 mmol) in CH2Cl2 (40 mL). The reaction mixture was stirred at room temperature under nitrogen for 24 h. After concentration, the product was taken up with EtOAc (100 mL), washed with saturated NaHCO3 (3x20 mL), NaCl (20 mL) and dried over Na2SO4. The crude product was purified by MPLC on silica gel using Hex/EtOAc(4:l) to give 1.154g (88%) of a colorless oil. IH NMR (400 MHz, CHLOROFORM-D) δ 0.27 - 0.32 (m, 2 H), 0.59 - 0.65 (m, 2 H), 1.09 - 1.21 (m, 1 H), 3.07 (dd, J=7.03, 5.08 Hz, 2 H), 3.86 (s, 3 H), 4.82 - 4.95 (m, 1 H), 6.59 (d, J=8.59 Hz, 1 H), 7.82 (dd, J=8.59, 1.95 Hz, 1 H), 7.95 (d, J=1.95 Hz, 1 H); MS (ESI) (M+H)+: 240.13.
Step C: methyl 9-(cyclopropylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylate
Figure imgf000166_0002
Methyl 3-chloro-4-(cyclopropylmethylamino)benzoate (0.360 g, 1.5 mmol), 4- (tetrahydro-2H-pyran-4-yl)cyclohexanone (0.547 g, 3.00 mmol), acetic acid (0.129 mL, 0.135 g, 2.25 mmol), and magnesium sulfate (0.090 g, 0.75 mmol) were suspended in DMA (5 mL). Nitrogen was bubbled through the solution for 10 min. Potassium phosphate (0.414 g, 1.95 mmol) and bis(tri-t-butylphosphine)palladium(0) (0.077 g, 0.15 mmol) were added, and nitrogen was bubbled through the mixture for an additional 5 min. The reaction mixture was heated for 3 h at 110 0C. After cooling to room temperature, the reaction mixture was filtered through Celite. The filtrate was diluted with EtOAc (100 mL), washed with water (3x15 mL) and NaCl (2x15 mL), and dried with Na2SC>4. The crude product was purified by MPLC on silica gel using Hex/EtOAc
(4:1) to give 0.125 g (23%) of a white solid. IH NMR (400 MHz, CHLOROFORM-D) δ 0.33 (m, 2 H), 0.51 - 0.58 (m, 2 H), 1.11 - 1.22 (m, I H), 1.40 - 1.69 (m, 5 H), 1.71 - 1.82 (m, 2 H), 2.10 - 2.21 (m, 1 H), 2.39 - 2.49 (m, 1 H), 2.65 - 2.87 (m, 2 H), 2.88 - 2.97 (m, 1 H), 3.37 - 3.49 (m, 2 H), 3.84 - 3.91 (m, 1 H), 3.93 (s, 3 H), 3.96 - 4.01 (m, 1 H), 4.02 - 4.08 (m, 2 H), 7.28 (d, J=8.59 Hz, 1 H), 7.82 - 7.89 (m, 1 H), 8.23 (s, 1 H); MS (ESI) (M+H)+: 368.24.
Step D : 9-(cyclopropylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid
Figure imgf000167_0001
Lithium hydroxide (16 mg, 0.68 mmol) was added to a solution of methyl 9-
(cyclopropylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylate (125 mg, 0.34 mmol) in ethanol (5 mL) and water (0.5 mL). The reaction mixture was heated for 4 h at 80 0C. After cooling to room temperature, 2 N HCl (2 mL) was added. Upon evaporation and dried in vacuo, the white solid was dissolved in DMF (10 mL) and used directly for next step. MS (ESI) (M+H)+: 354.23. Example 96
9-(Cyclopropylmethyl)-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000168_0001
N,N-Diisopropylethylamine (89 μL, 0.51 mmol) was added to a solution of 9- (cyclopropylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (0.17 mmol) and N-ethyl-2-(ethylamino)acetamide (44 mg, 0.34 mmol) in DMF (5 mL). Stirring for 20 min, HATU (97 mg, 0.26 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, diluted with water (50 mL), and extracted with EtOAc (3x25 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (20 mL) and dried with Na2SC>4. Upon evaporation of the solvent, the crude product was purified by reverse-phase HPLC using high pH column30- 50% MeCN/H2O to give 62.8 mg (79%) of a white solid as the title compound. IH NMR (400 MHz, METHANOL-D4): δ 0.28 - 0.38 (m, 2 H), 0.46 - 0.56 (m, 2 H), 1.05 - 1.31 (m, 6 H), 1.38 - 1.52 (m, 2 H), 1.53 - 1.67 (m, 3 H), 1.79 (t, J=13.28 Hz, 2 H), 2.13 - 2.25 (m, 1 H), 2.33 - 2.48 (m, 1 H), 2.67 - 2.81 (m, 1 H), 2.79 - 2.95 (m, 2 H), 3.19 - 3.27 (m, 3 H), 3.38 - 3.64 (m, 4 H), 3.89 - 4.19 (m, 6 H), 7.14 - 7.24 (m, 1 H), 7.33 - 7.42 (m, 1
H), 7.49 - 7.62 (m, 1 H); HRMS m/z calcd for [M+H]+ 466.30642, found 466.30549.
Example 97
9-Cyclobutyl-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000169_0001
Step A: 9-Cyclobutyl-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000169_0002
N,N-Diisopropylethylamine (89 μL, 0.51 mmol) was added to a solution of 9-cyclobutyl- 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (0.17 mmol) and N-ethyl-2-(ethylamino)acetamide (44 mg, 0.34 mmol) in DMF (5 mL). Stirring for 20 min, HATU (97 mg, 0.26 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, diluted with water (50 mL), and extracted with EtOAc (3x25 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (20 mL) and dried with Na2SC>4. Upon evaporation of the solvent, the crude product was purified by reverse-phase HPLC using high pH column 40-60% MeCN/H2O to give 59.3 mg (75%) of a white solid as the title compound. IH NMR (400 MHz, METHANOL-D4): δ 1.06 - 1.29 (m, 6 H), 1.36 - 1.50 (m, 2 H), 1.50 - 1.63 (m, 3 H), 1.78 (t, J=13.48 Hz, 2 H), 1.86 - 2.05 (m, 2 H), 2.11 - 2.21 (m, 1 H), 2.30 - 2.42 (m, 1 H), 2.42 - 2.60 (m, 2 H), 2.69 - 2.98 (m, 5 H), 3.19 - 3.29 (m, 2 H), 3.37 - 3.64 (m, 4 H), 3.99 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.05 - 4.21 (m, 2 H), 4.84 - 4.96 (m, 1 H), 7.18 (d, J=8.59 Hz, 1 H), 7.48 - 7.58 (m, 1 H), 7.61 (d, J=8.20 Hz, 1 H) ; MS (APPI) (M+H)+ :
466.2; HRMS m/z calcd for [M+H]+ 466.30642 , found 466.30464. Step B: methyl 3-chloro-4-(cyclobutylamino)benzoate
Figure imgf000170_0001
Sodium triacetoxyborohydride (1.75 g, 8.24 mmol) was added to a solution of methyl 4- amino-3-chlorobenzoate (0.51 g, 2.75 mmol), cyclobutanone (0.41 mL, 0.39 g, 5.50 mmol), and acetic acid (0.16 mL, 0.17 g, 2.75 mmol) were mixed in CH2CI2 (20 mL). The reaction mixture was stirred at room temperature under nitrogen for a weekend. After concentration, the product was taken up with EtOAc (100 mL), washed with saturated NaHCO3 (3x20 mL), NaCl (20 mL) and dried over Na2SO4. The crude product was purified by reverse-phase HPLC using high pH column 50-70% MeCN/H2θ to give 0.332 g (50%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D): δ 1.77 - 2.04 (m, 4 H), 2.34 - 2.56 (m, 2 H), 3.85 (s, 3 H), 3.92 - 4.07 (m, 1 H), 4.89 (d, J=5.47 Hz, 1 H), 6.52 (d, J=8.59 Hz, 1 H), 7.80 (dd, J=8.59, 1.56 Hz, 1 H), 7.93 (d, J=1.95 Hz, 1 H); MS (ESI) (M+H)+: 240.16.
Step C: methyl P-cyclobutyl-S-Ctetrahydro-lH-pyran-^yl^^A^tetrahydro-lH- carbazole-6-carboxylate
Figure imgf000170_0002
Methyl 3-chloro-4-(cyclobutylamino)benzoate (165 mg, 0.69 mmol), 4-(tetrahydro-2H- pyran-4-yl)cyclohexanone (376 mg, 2.07 mmol), acetic acid (59 μL, 62 mg 1.03 mmol), and magnesium sulfate (41 mg, 0.34 mmol) were suspended in DMA (3 mL). Nitrogen was bubbled throug the solution for 10 min. Potassium phosphate (190 mg, 0.89 mmol) and Bis(tri-t-butylphosphine)palladium(0) (35 mg, 0.07 mmol) were added, and nitrogen was bubbled through the mixture for an additional 5 min. The reaction mixture was heated for 14 h at 140 0C. After cooling to room temperature, the reaction mixture was diluted with water (15 mL), and extracted with EtOAc (4x20 mL). The combined organic phases were washed with water (2x15 mL) and NaCl (2x15 mL), and dried with Na2SC>4. The crude product was purified by MPLC on silica gel using Hex/EtOAc(4: 1) to give 195 mg (77%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM- D): δ 1.39 - 1.66 (m, 5 H), 1.76 (d, J=12.11 Hz, 2 H), 1.83 - 2.07 (m, 2 H), 2.09 - 2.19 (m, 1 H), 2.32 -2.62 (m, 3 H), 2.67 - 2.79 (m, 1 H), 2.81 - 2.97 (m, 4 H), 3.42 (t, J=I 1.52 Hz, 2 H), 3.93 (s, 3 H), 3.99 - 4.09 (m, 2 H), 4.71 - 4.90 (m, 1 H), 7.52 (d, J=8.59 Hz, 1 H), 7.82 (dd, J=8.59, 1.56 Hz, 1 H), 8.20 (s, 1 H); MS (ESI) (M+H)+: 368.21.
Step D : 9-(cyclopropylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid
Figure imgf000171_0001
Lithium hydroxide (50 mg, 2.09 mmol) was added to a solution of methyl 9-cyclobutyl- 3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxylate (195 mg, 0.53 mmol) in ethanol (5 mL) and water (0.5 mL). The reaction mixture was heated for 4 h at 80 0C. After cooling to room temperature, 2 N HCl (2 mL) was added. After evaporation and dried in vacuo, a white solid was obtained, which was dissolved in DMF (15 mL) and used directly for next step without further purification. MS (ESI) (M+H)+:
354.22.
Example 98
9-Cyclobutyl-N-ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000172_0001
N,N-Diisopropylethylamine (89 μL, 0.51 mmol) was added to a solution of 9-cyclobutyl- 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (0.17 mmol) and 2-(ethylamino)-N-(2-fluoroethyl)acetamide hydrochloride (63 mg, 0.34 mmol) in DMF (5 mL). Stirring for 20 min, HATU (97 mg, 0.26 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, diluted with water (50 mL), and extracted with EtOAc (3x25 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (20 mL) and dried with Na2SC>4. Upon evaporation of the solvent, the crude product was purified by reverse-phase HPLC using high pH column 40-60% MeCN/H2O to give 59.8 mg (73%) of a white solid as the title compound. IH NMR (400 MHz, METHANOL-D4) δ 1.10 - 1.31 (m, 3 H), 1.36 - 1.51 (m, 2 H), 1.51 - 1.65 (m, 3 H), 1.79 (t, J=12.89 Hz, 2 H), 1.87 - 2.08 (m, 2 H), 2.12 - 2.24 (m, 1 H), 2.30 - 2.43 (m, 1 H), 2.43 - 2.59 (m, 2 H), 2.67 - 3.00 (m, 5 H), 3.37 - 3.64 (m, 6 H), 4.00 (dd, J=I 1.33, 3.12 Hz, 2 H), 4.04 - 4.27 (m, 2 H), 4.34 - 4.62 (m, 2 H), 4.88 - 4.98 (m, 1 H), 7.17 (d, J=7.42 Hz, 1 H), 7.47 - 7.58 (m, 1 H), 7.61 (d, J=7.81 Hz, 1 H); MS (APPI)
(M+H)+: 484.2; HRMS m/z calcd for [M+H] 484.29700, found 484.29615.
Example 99
9-Cyclobutyl-N-ethyl-N-(2-(isopropylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000172_0002
N,N-Diisopropylethylamine (89 μL, 0.51 mmol) was added to a solution of 9-cyclobutyl- 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (0.17 mmol) and 2-(ethylamino)-N-isopropylacetamide (49 mg, 0.34 mmol) in DMF (5 mL). Stirring for 20 min, HATU (97 mg, 0.26 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, diluted with water (50 mL), and extracted with EtOAc (3x25 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (20 mL) and dried with Na2SC>4. Upon evaporation of the solvent, the crude product was purified by reverse-phase HPLC using high pH column 40-60% MeCN/H2O to give 61.0 mg (75%) of a white solid as the title compound. IH NMR (400 MHz, METHANOL-D4) δ 1.04 - 1.32 (m, 9 H), 1.37 - 1.50 (m, 2 H), 1.50 - 1.64 (m, 3 H), 1.72 - 1.85 (m, 2 H), 1.87 - 2.05 (m, 2 H), 2.12 - 2.22 (m, 1 H), 2.36 (dd, J=9.77, 3.91 Hz, 1 H), 2.43 - 2.59 (m, 2 H), 2.67 - 2.98 (m, 5 H), 3.37 - 3.63 (m, 4 H), 3.92 - 4.05 (m, 4 H), 4.07 - 4.18 (m, 1 H), 4.88 - 4.98 (m, 1 H), 7.17 (d, J=8.59 Hz, 1 H), 7.47 - 7.56 (m, 1 H), 7.60 (d, J=8.59 Hz, 1 H); MS (APPI) (M+H)+: 480.2 ; HRMS m/z calcd for [M+H]+ 480.32207 , found 480.32120.
Example 100 9-Ethyl-N-methyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000173_0001
Step A: 9-ethyl-N-methyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000174_0001
N,N-Diisopropylethylamine (105 μL, 0.60 mmol) was added to a solution of 4-(9-ethyl- N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (85 mg, 0.2 mmol) and methylamine (220 μL, 2.0 M in THF, 0.44 mmol) in DMF (5 mL). Stirring for 20 min, HATU (114 mg, 0.30 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the crude product was purified by reverse-phase HPLC using high pH column 30-50% MeCN/H2θ to give 56.3 mg (64%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.33 (t, J=7.03 Hz, 3 H), 1.39 - 1.68 (m, 6 H), 1.70 - 1.81 (m, 2 H), 1.92 - 2.07 (m, 2 H), 2.11 - 2.20 (m, 1 H), 2.25 - 2.36 (m, 1 H), 2.37 - 2.46 (m, 1 H), 2.64 - 2.76 (m, 1 H), 2.77 - 2.93 (m, 5 H), 3.06 (s, 3 H), 3.36 - 3.47 (m, 2 H), 3.55 - 3.71 (m, 2 H), 3.99 - 4.17 (m, 4 H), 7.08 - 7.16 (m, 1 H), 7.17 - 7.22 (m, 1 H), 7.24 - 7.29 (m, 1 H), 7.55 (d, J=I.17 Hz, 1 H); MS (APPI) (M+H)+:
440.2 ; HRMS m/z calcd for [M+H]+ 440.29077, found 440.29074.
Step B: 9-ethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6- carboxylic acid
Figure imgf000174_0002
Sodium hydride (3.30 g, 83 mmol) was added to a solution of 3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (4.49 g, 15 mmol) in DMF (100 mL) at 0 0C. Stirring for 45 min at 0 0C and 1 h at room temperature, iodoethane (4.85 mL, 60 mmol) was added. The mixture was stirred for 40 h at room temperature and quenched with water (20 mL). After concentration, the residue was dissolved in water (200 mL) and extracted with EtOAc (3x100 mL). The aqueous was acidified with 2N HCl to pH~5. The light yellow solid was collected by filtration and dried in vacuo to give 3.78 g (77%) of a white solid as the title compound IH NMR (400 MHz, CHLOROFORM-D) D 1.35 (t, J=7.23 Hz, 3 H), 1.43 - 1.69 (m, 5 H), 1.77 (d, J=I 1.72 Hz, 2 H), 2.12 - 2.24 (m, 1 H), 2.45 (dd, J=15.23, 8.59 Hz, 1 H), 2.63 - 3.02 (m, 3 H), 3.44 (t, J=I 1.33 Hz, 2 H), 3.95 - 4.20 (m, 4 H), 7.29 (d, J=8.59 Hz, 1 H), 7.93 (d, J=8.59 Hz, 1 H), 8.32 (s, 1 H); MS (ESI) (M+H)+: 328.21
Step C: methyl 4-(9-ethyl-N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-1 H-carbazole-6-carboxamido)butanoate
Figure imgf000175_0001
N,N-Diisopropylethylamine (2.09 mL, 12.0 mmol) was added to a solution of 9-ethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (1.31 g, 4.0 mmol) and methyl 4-(methylamino)butanoate hydrochloride (1.34 g, 8.0 mmol) in DMF (30 mL). Stirring for 20 min, HATU (2.28 g, 6.0 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (10 mL). After concentration, added 50 mL of water and extracted with EtOAc (3x25 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (20 mL) and dried with Na2SU4. Upon evaporation of the solvent, the crude product was purified by MPLC on silica gel using EtOAC to give 1.32 g (75%) of a white solid as the title compound. IH NMR (400 MHz, METHANOL-D4) δ 1.32 (t, J=7.23 Hz, 3 H), 1.39 - 1.67 (m, 5 H), 1.70 - 1.82 (m, 2 H), 1.86 - 2.06 (m, 2 H), 2.10 - 2.20 (m, 1 H), 2.27 - 2.57 (m, 2 H), 2.64 - 2.76 (m, 1 H), 2.76 - 2.91 (m, 2 H), 3.06 (s, 3 H), 3.33 - 3.79 (m, 7 H), 3.99 - 4.11 (m, 5 H), 7.14- 7.21 (m, 1 H), 7.20 - 7.26 (m, 1 H), 7.52 (s, 1 H); MS (ESI) (M+H)+: 441.33. Step D: 4-(9-ethyl-N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H- carbazole-6-carboxamido)butanoic acid
Figure imgf000176_0001
Lithium hydroxide (0.14 g, 5.98 mmol) was added to a solution of methyl 4-(9-ethyl-N- methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoate (1.32 g, 2.99 mmol) in methanol (20 mL) and water (10 mL). The reaction mixture was stirred for 4 h at room temperature, acidified with 2 N HCl (4 mL) to pH~5-6. After concentration, the residue was dissolved in EtOAc (200 mL) washed with water (2x25 mL), saturated NaCl (2x25 mL) and dried with Na2SU4. After evaporation the solvent and dried in vacuo, 1.21 g (94%) of a light yellow solid was obtained. MS (ESI) (M+H)+: 427.35; IH NMR (400 MHz, CHLOROFORM-D) δ 1.33 (t, J=7.23 Hz, 3 H), 1.40 - 1.68 (m, 6 H), 1.70 - 1.83 (m, 2 H), 1.91 - 2.06 (m, 2 H), 2.12 - 2.21 (m, 1 H), 2.30 - 2.57 (m, 2 H), 2.64 - 2.76 (m, 1 H), 2.77 - 2.93 (m, 2 H), 3.08 (s, 3 H), 3.43 (t, J=I 1.72 Hz, 2 H), 3.53 - 3.77 (m, 2 H), 3.97 - 4.13 (m, 4 H), 7.16 - 7.26 (m, 2 H), 7.54 (s, 1 H).
Example 101
9-Ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000176_0002
N,N-Diisopropylethylamine (105 μL, 0.60 mmol) was added to a solution of 4-(9-ethyl- N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (85 mg, 0.20 mmol) and 2-fluoroethylamine hydrochloride (40 mg, 0.40 mmol) in DMF (5 mL). Stirring for 20 min, HATU (114 mg, 0.30 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the crude product was purified by reverse- phase HPLC using high pH column 30-50% MeCN/H2O to give 65.8 mg (70%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.33 (t, J=7.23 Hz, 3 H), 1.40 - 1.67 (m, 6 H), 1.71 - 1.81 (m, 2 H), 1.92 - 2.08 (m, 2 H), 2.12 - 2.21(m, 1 H), 2.27 - 2.46 (m, 2 H), 2.65 - 2.77 (m, 1 H), 2.77 - 2.92 (m, 2 H), 3.06 (s, 3 H), 3.37 - 3.48 (m, 2 H), 3.49 - 3.74 (m, 4 H), 4.00 - 4.14 (m, 4 H), 4.39 - 4.64 (m, 2 H,) 7.17 - 7.22 (m, 1 H), 7.24 - 7.29 (m, 1 H,) 7.30 - 7.44 (m, 1 H), 7.55 (d, J=I.17 Hz, 1 H);
MS (APPI) (M+H)+: 472.2; HRMS m/z calcd for [M+H]+ 472.29700, found 472.29699.
Example 102
N-(4-(2,2-difluoroethylamino)-4-oxobutyl)-9-ethyl-N-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000177_0001
N,N-Diisopropylethylamine (105 μL, 0.60 mmol) was added to a solution of 4-(9-ethyl- N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (85 mg, 0.20 mmol) and 2,2-difluoroethylamine (32 mg, 0.40 mmol) in DMF (5 mL). Stirring for 20 min, HATU (114 mg, 0.30 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the crude product was purified by reverse-phase HPLC using high pH column 30-50% MeCN/H2O to give 63.9 mg (65% ) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.29 - 1.37 (m, 3 H), 1.40 - 1.67 (m, 6 H), 1.71 - 1.82 (m, 2 H), 1.92 - 2.07 (m, 2 H), 2.11 - 2.21 (m, 1 H), 2.30 - 2.51 (m, 2 H), 2.64 - 2.77 (m, 1 H), 2.78 - 2.93 (m, 2 H), 3.06 (s, 3 H), 3.36 - 3.48 (m, 2 H), 3.63 (dd, J=2.93, 1.76 Hz, 4 H), 3.99 - 4.14 (m, 4 H), 5.68 - 6.11 (m, 1 H), 7.16 - 7.22 (m, 1 H), 7.23 - 7.31 (m, 1 H), 7.55 (d, J=I.17 Hz, 1 H), 7.66 - 7.83 (m, J=5.27, 2.54 Hz,
1 H); MS (APPI) (M+H)+: 490.2; HRMS m/z calcd for [M+H]+ 490.28757, found 490.28740.
Example 103
9-Ethyl-N-methyl-N-(4-oxo-4-(2,2,2-trifluoroethylamino)butyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000178_0001
N,N-Diisopropylethylamine (105 μL, 0.60 mmol) was added to a solution of 4-(9-ethyl- N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (85 mg, 0.20 mmol) and 2,2,2-trifluoroethylamine (40 mg, 0.40 mmol) in DMF (5 mL). Stirring for 20 min, HATU (114 mg, 0.30 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the crude product was purified by reverse-phase HPLC using high pH column 30-50% MeCN/H2O to give 72.4 mg (71% ) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.33 (t, J=7.23 Hz, 3 H), 1.40 - 1.68 (m, 6 H), 1.71 - 1.82 (m, 2 H), 1.95 - 2.06 (m, 2 H), 2.12 - 2.21 (m, 1 H), 2.31 - 2.47 (m, 2 H), 2.65 - 2.77 (m, 1 H), 2.78 - 2.92 (m, 2 H), 3.06 (s, 3 H), 3.38 - 3.47 (m, 2 H), 3.58 - 3.71 (m, 2 H), 3.88 - 4.01 (m, 2 H), 4.02 - 4.13 (m, 4 H), 7.18 - 7.22 (m, 1 H), 7.25 - 7.29 (m, 1 H), 7.55 (d, J=I.17 Hz, 1 H), 8.06 - 8.19 (m, 1 H); MS (APPI) (M+H)+:
508.3; HRMS m/z calcd for [M+H]+ 508.27815, found 508.27792.
Example 104
9-Ethyl-N-(4-(2-hydroxyethylamino)-4-oxobutyl)-N-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000179_0001
N,N-Diisopropylethylamine (105 μL, 0.60 mmol) was added to a solution of 4-(9-ethyl- N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (85 mg, 0.20 mmol) and ethanolamine (24 mg, 0.40 mmol) in DMF (5 mL). Stirring for 20 min, HATU (114 mg, 0.30 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the crude product was purified by reverse-phase HPLC using high pH column 30-50% MeCN/H2O to give 65.4 mg (70%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.33 (t, J=7.23 Hz, 3 H), 1.41 - 1.68 (m, 6 H), 1.72 - 1.80 (m, 2 H), 1.97 - 2.08 (m, 2 H), 2.12 - 2.20 (m, 1 H), 2.28 - 2.37 (m, 2 H), 2.37 - 2.46 (m, 1 H), 2.65 - 2.77 (m, 1 H), 2.78 - 2.92 (m, 2 H), 3.08 (s, 3 H), 3.37 - 3.49 (m, 4 H), 3.58 - 3.68 (m, 2 H), 3.69 - 3.79 (m, 2 H), 4.01 - 4.13 (m, 4 H), 7.19 - 7.23 (m, 1 H), 7.24 - 7.30 (m, 1 H), 7.39 - 7.49 (m, 1 H), 7.55 (d, J=I.17 Hz, 1 H); MS
(APPI) (M+H)+: 470.2 ; HRMS m/z calcd for [M+H]+ 470.30133, found 470.30102.
Example 105
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000179_0002
Step A: N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-fluoroethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000180_0001
N,N-Diisopropylethylamine (115 μL, 0.66 mmol) was added to a solution of 9-(2- fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (0.22 mmol) and N-ethyl-2-(ethylamino)acetamide (57 mg, 0.44 mmol) in DMF (5 mL). Stirring for 20 min, HATU (125 mg, 0.33 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the residue was dissolved in EtOAc (100 mL), washed with water (2x10 mL), NaCl (2x10 mL) and dried with Na2SO4. The crude product was purified by MPLC on silica gel using Hex/EtOAc (1:1) and then EtOAc/MeOH (20:1) to give three fractions.
Fraction- 1: the ethyl ester from the Step D, yield: 54.3 mg (66%).
Fraction-2: the starting material from the Step D, 9.6 mg (13%).
Fraction-3 : the desired product, which was purified again by reverse-phase HPLC using high pH column 30-50% MeCN/H2O to give 15.5 mg (15%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.14 - 1.24 (m, 6 H), 1.38 - 1.68 (m, 5 H), 1.74 (t, J=10.94 Hz, 2 H), 2.09 - 2.20 (m, 1 H) ,2.36 - 2.46 (m, 1 H), 2.64 - 2.78 (m, 1 H), 2.78 - 2.91 (m, 2 H), 3.28 - 3.38 (m, 2 H), 3.42 (t, J=I 1.72 Hz, 2 H), 3.47 - 3.57 (m, 2 H), 4.04 (dd, J=I 1.33, 3.13 Hz, 2 H), 4.11 (s, 2 H), 4.27 - 4.41 (m, 2 H), 4.54 - 4.77 (m, 2 H), 6.85 - 7.07 (m, 1 H), 7.17 - 7.26 (m, 2 H), 7.59 (s, 1 H); MS (APPI) (M+H)+:
458.3; HRMS m/z calcd for [M+H]+ 458.28135, found 458.28116.
Step B: 3-chloro-4-(2-fluoroethylamino)benzonitrile
Figure imgf000181_0001
N,N-Diisopropylethylamine (4.37 mL, 25.1 mmol) was added to a solution of 2- fluoroethylamine hydrochloride (1.20 g, 12.0 mmol) and 3-chloro-4-fluorobenzonitrile (1.56 g, 10.0 mmol) in DMSO (15 mL) at room temperature. The reaction mixture was stirred over weekend at room temperature and 8 h at 45 0C, diluted with water (150 mL), and extracted with EtOAc (3x50 mL). The combined organic phases were washed with water (2x20 mL), saturated NaCl (2x20 mL) and dried with Na2SU4. The crude product was purified by MPLC on silica gel using Hex/EtOAc (4:1) to give 0.82 g (41%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 3.50 - 3.64 (m, 2 H), 4.57 - 4.77 (m, 2 H), 5.13 (s broad, 1 H), 6.67 (d, J=8.59 Hz, 1 H), 7.44 (dd, J=8.59, 1.95 Hz, 1 H), 7.55 (d, J=1.95 Hz, 1 H); MS (ESI) (M+H)+: 199.15.
Step C: 9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H- carbazole-6-carbonitrile
Figure imgf000181_0002
3-Chloro-4-(2-fluoroethylamino)benzonitrile (157 mg, 0.79 mmol), 4-(tetrahydro-2H- pyran-4-yl)cyclohexanone (433 mg, 2.38 mmol), acetic acid (68 μL, 71 mg, 1.19 mmol), and magnesium sulfate (48 mg, 0.40 mmol) were suspended in DMA (4 mL). Nitrogen was bubbled through the solution for 10 min. Potassium phosphate (218 mg, 1.03 mmol) and bis(tri-t-butylphosphine)palladium(0) (40 mg, 0.08 mmol) were added, and nitrogen was bubbled through the mixture for an additional 5 min. The reaction mixture was heated for 14 h at 140 0C. After cooling to room temperature, the reaction mixture was diluted with water (15 mL), and extracted with EtOAc (4x20 mL). The combined organic phases were washed with water (2x15 mL) and NaCl (2x15 mL), and dried with Na2SC>4.
The crude product was purified by MPLC on silica gel using Hex/EtOAC (1:1) to give 80.2 mg (31%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.40 - 1.70 (m, 5 H), 1.70 - 1.80 (m, 2 H), 2.13 - 2.22 (m, 1 H), 2.35 - 2.46 (m, 1 H), 2.66 - 2.77 (m, 1 H), 2.79 - 2.90 (m, 2 H), 3.38 - 3.48 (m, 2 H), 4.00 - 4.10 (m, 2 H), 4.29 - 4.40 (m, 2 H), 4.57 - 4.76 (m, 2 H), 7.29 (s, 1 H), 7.37 - 7.41 (m, 1 H), 7.80 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)+: 327.21.
Step D: 9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H- carbazole-6-carboxylic acid and ethyl 9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxylate
Figure imgf000182_0001
9-(2-Fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonitrile (71.4 mg, 0.22 mmol) was heated in 6 N hydrochloric acid (2 ml) and ethanol (3 mL) in a sealed tube at 1400C for 3 intervals 2 h using a Biotage (1-60) microwave instrument. Three major peaks were observed by LCMS: MS (ESI) (M+H)+ at 346.14 (30%), 374.27 (44%) and 327.21 (26%). The reaction mixture was diluted with water (20 mL) and extratced with EtOAC (3x20 mL). The combined organic phases was washed with saturated NaCl (2x10 mL) and dried with Na2SU4. After filtration and concentration, the crude product was used directly for next step without further purification.
Example 106
N-(4-(Ethylamino)-4-oxobutyl)-9-(2-fluoroethyl)-N-methyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000183_0001
Step A: N-(4-(ethylamino)-4-oxobutyl)-9-(2-fluoroethyl)-N-methyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H-carbazole-6-carboxamide
Figure imgf000183_0002
N,N-Diisopropylethylamine (105 μL, 0.60 mmol) was added to a solution of 9-(2- fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (0.15 mmol) and N-ethyl-4-(methylamino)butanamide hydrochloride (54 mg, 0.30 mmol) in DMF (5 mL). Stirring for 20 min, HATU (86 mg, 0.23 mmol) was added at 0 0C. The mixture was stirred for 3 h at room temperature, and quenched with water (0.5 mL). After concentration, the residue was dissolved in EtOAc (100 mL), washed with water (2x10 mL), NaCl (2x10 mL) and dried with Na2SO4. The crude product was purified by MPLC on silica gel using EtOAc/MeOH (20:1), and then by reverse-phase HPLC using high pH column 30-50% MeCN/H2O to give 11.7 mg (17%) of a white solid as the title compound. IH NMR (400 MHz, CHLOROFORM-D) δ 1.05 - 1.24 (m, 2 H), 1.37 - 1.68 (m, 7 H), 1.69 - 1.83 (m, 2 H), 1.87 - 2.08 (m, 2 H), 2.11 - 2.21 (m, 1 H), 2.22 - 2.35 (m, 1 H), 2.36 - 2.46 (m, 1 H), 2.63 - 2.77 (m, 1 H), 2.78 - 2.94 (m, 2 H), 3.04 (s, 3 H) 3.22 - 3.37 (m, 2 H) 3.42 (t, J=I 1.52 Hz, 2 H), 3.53 - 3.73 (m, 2 H), 4.04 (dd, J=I 0.74, 2.93 Hz, 2 H), 4.24 - 4.43 (m, 2 H), 4.55 - 4.77 (m, 2 H), 6.85 - 7.02 (m, 1 H), 7.15 - 7.25
(m, 2 H), 7.55 (s, 1 H); MS (APPI) (M+H)+: 472.2; HRMS m/z calcd for [M+H]+ 472.29700, found 472.29667. Step B: 9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H- carbazole-6-carboxylic acid
Figure imgf000184_0001
Lithium hydroxide (13.9 mg, 0.58 mmol) was added to a solution of ethyl 9-(2- fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylate (from Example 11) (54.3 mg, 0.15 mmol) in THF (5 mL) and water (0.5 ml). The reaction mixture was stirred for 5 h at 60 0C. After cooling to room temperature, 2 NHCl (1 mL) was added. Upon concentration, the crude product was used directly for next step without purification. MS (ESI) (M+H)+: 346.20.
Example 107
N-ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000184_0002
HATU (227 mg, 0.60 mmol) and 2-(ethylamino)-N-(2-hydroxyethyl)acetamide (202 mg, 1.38 mmol) were added slowly at 0 0C to a solution of 9-(ethylsulfonyl)-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (180 mg, 0.46 mmol) and N,N-diisopropylethylamine (0.240 mL, 1.38 mmol) in DMF (3.83 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as oil. The residue was dissolved in AcOEt and washed with NH4OH aq. in order to remove HATU. N-ethyl-9-(ethylsulfonyl)-N-(2-(2- hydroxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (75 mg, 25.9 %) was purified by Prep-HPLC reverse-phase with low pH 50-70% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.14 (t, J=7.23 Hz, 3 H), 1.19 - 1.29 (m, 1 H), 1.35 - 1.52 (m, 2 H), 1.49 - 1.67 (m, 2 H), 1.79 (t, J=10.35 Hz, 3 H), 2.10 - 2.24 (m, 1 H), 2.28 - 2.53 (m, 1 H), 2.74 - 2.95 (m, 2 H), 3.08 - 3.23 (m, 1 H), 3.33 - 3.49 (m, 9 H), 3.50 - 3.74 (m, 4 H), 4.00 (dd, J=I 1.52, 2.93 Hz, 4 H), 4.19 (s, 1 H), 7.28 - 7.45 (m, 1 H), 7.55 - 7.68 (m, 1 H), 7.89 - 8.12 (m, 1 H); MS (ESI) (M+H)+ 520.2.
Example 108
N-ethyl-9-(ethylsulfonyl)-N-(2-(3-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000185_0001
HATU (227 mg, 0.60 mmol) and 2-(ethylamino)-N-(3-hydroxypropyl)acetamide (147 mg, 0.92 mmol) were added slowly at 0 0C to a solution of 9-(ethylsulfonyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (180 mg, 0.46 mmol) and N,N-diisopropylethylamine (0.240 mL, 1.38 mmol) in DMF (3.83 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as oil. The residue was dissolved in AcOEt and washed with NH4OH aq. in order to remove HATU. N-ethyl-9-
(ethylsulfonyl)-N-(2-(3-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (7.40 mg, 3.02 %) was purified by Prep- HPLC reverse-phase using a low pH 50-70% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.11 - 1.18 (m, 5 H), 1.20 - 1.28 (m, 2 H), 1.33 - 1.39 (m, 1 H), 1.39 - 1.51 (m, 2 H), 1.52 - 1.67 (m, 4 H), 1.79 (t, J=10.74 Hz, 3 H), 2.13 - 2.22 (m, I H), 2.31 - 2.42 (m, 1 H), 2.79 - 2.90 (m, 1 H), 3.11 - 3.20 (m, 1 H), 3.32 - 3.39 (m, 4 H), 3.40 - 3.48 (m, 4 H), 3.53 - 3.75 (m, 3 H), 3.93 - 3.97 (m, 1 H), 4.00 (dd, J=I 1.13, 3.32 Hz, 2 H), 4.16 (s, 1 H), 7.29 -7.41 (m, 1 H), 7.53 - 7.66 (m, 1 H), 7.93 - 8.04 (m, 1 H); MS (ESI)
(M+H)+ 534.3.
Example 109
N-ethyl-9-(ethylsulfonyl)-N-(2-(3-fluoropropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000186_0001
HATU (227 mg, 0.60 mmol) and 2-(ethylamino)-N-(3-fluoropropyl)acetamide (224 mg, 1.38 mmol) were added slowly at O 0C to a solution of 9-(ethylsulfonyl)-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (180 mg, 0.46 mmol) and N,N-diisopropylethylamine (0.240 mL, 1.38 mmol) in DMF (3.83 mL). Reaction mixture was stirred at room temperature for an 5 hours. The solvent was then removed in vacuo to provide the crude compound as an oil. The residue was dissolved in AcOEt and washed with NH4OH aq. in order to remove HATU. N-ethyl-9-(ethylsulfonyl)-N-(2-(3- fluoropropylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (117 mg, 39.1 %) was purified by Prep-LCMS reverse-phase using a low pH 40-60% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.13 (t, J=7.23 Hz, 5 H), 1.19 - 1.31 (m, 1 H), 1.34 - 1.50 (m, 3 H), 1.50 - 1.65 (m, 3 H), 1.77 (U=I 1.33 Hz, 3 H), 1.81 - 1.99 (m, 2 H), 2.10 - 2.21 (m, 1 H), 2.26 - 2.44 (m, 1 H), 2.71 - 2.93 (m, 2 H), 3.00 - 3.19 (m, 1 H), 3.32 -3.48 (m, 6 H), 3.52 - 3.64 (m, 1 H), 3.98 (dd, J=I 1.52, 3.32 Hz, 3 H), 4.15 (s, 1 H), 4.26 - 4.62 (m, 2 H), 7.28 - 7.42 (m, 1 H), 7.52 - 7.67 (m, 1 H), 7.91 - 8.04 (m, 1 H); MS (ESI) (M+H)+ 536.4. Example 110
N-ethyl-9-(ethylsulfonyl)-N-(2-(2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000187_0001
HATU (164 mg, 0.43 mmol) and 2-(ethylamino)-N-(2-fluoroethyl)acetamide (59.0 mg, 0.40 mmol) were added slowly at O 0C to a solution of 9-(ethylsulfonyl)-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (130 mg, 0.33 mmol) and N,N-diisopropylethylamine (0.217 mL, 1.25 mmol) in DMF (2.64 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-ethyl-9-(ethylsulfonyl)-N-(2- (2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (40.6 %) was purified by Prep-HPLC reverse-phase using a low pH 50-70% ACN/water system. IH NMR (400 MHz, CDCl3) δ ppm 1.17 - 1.26 (m, 7 H), 1.36 - 1.65 (m, 6 H), 1.72 (t, J=12.70 Hz, 2 H), 2.07 - 2.18 (m, 1 H), 2.31 (dd, J=17.38, 9.57 Hz, 1 H), 2.69 - 2.97 (m, 2 H), 3.09 - 3.19 (m, 1 H), 3.22 (q, J=7.42 Hz, 2 H), 3.34 - 3.46 (m, 3 H), 3.44 - 3.50 (m, 1 H), 3.57 (q, J=5.08 Hz, 1 H), 3.64 (q, J=5.34 Hz, 1 H), 4.03 (dd, J=I 1.33, 3.13 Hz, 2 H), 4.16 (s, 1 H), 4.45 (t, J=4.88 Hz, 1 H), 4.57 (t, J=4.88 Hz, 1 H), 7.27 - 7.33 (m, 1 H), 7.49 - 7.56 (m, 1 H), 7.92 - 8.03 (m, 1 H); [M+H]+ calc. = 522.2432, [M+H]+ obs. = 522.2434
Example 111
2-(N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid
Figure imgf000188_0001
Step A. N-ethyl-9-(ethylsulfonyl)-N-(2-oxo-2-(2,2,2-trifluoroethylamino)ethyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000188_0002
HATU (89 mg, 0.24 mmol) and 2,2,2-Trifluoroethylamine (0.018 mL, 0.24 mmol) were added slowly at O 0C to a solution of 2-(N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)acetic acid (56 mg, 0.12 mmol) and N,N-diisopropylethylamine (0.125 mL, 0.72 mmol) in DMF (1.5 mL). Reaction mixture was stirred at room temperature for 2h30. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-ethyl-9- (ethylsulfonyl)-N-(2-oxo-2-(2,2,2-trifluoroethylamino)ethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide (58.9 mg, 74.6 %) was purified by Prep-HPLC reverse-phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.06 - 1.20 (m, 6 H), 1.19 - 1.32 (m, 1 H), 1.36 - 1.50 (m, 2 H), 1.50 - 1.68 (m, 3 H), 1.79 (t, J=12.11 Hz, 2 H), 2.11 - 2.23 (m, 1 H), 2.28 - 2.48 (m, I H), 2.72 - 2.96 (m, 2 H), 3.09 - 3.23 (m, 1 H), 3.32 - 3.39 (m, 2 H), 3.38 - 3.50 (m, 4 H), 3.53 - 3.67 (m, 1 H), 3.84 - 4.11 (m, 4 H), 4.23 (s, 1 H), 7.25 - 7.45 (m, 1 H), 7.49 - 7.69 (m, 1 H), 7.92 - 8.08 (m, 1 H); [M+H]+ calc. = 558.2244, [M+H]+ obs. = 558.2233. Step B. N-(2-(cyclopropylamino)-2-oxoethyl)-9-(ethylsulfonyl)-N-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000189_0001
HATU (291 mg, 0.77 mmol) and N-Ethylglycine (119 mg, 1.15 mmol) were added slowly at 0 0C to a solution of 9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxylic acid (150 mg, 0.38 mmol) and N,N- diisopropylethylamine (0.200 mL, 1.15 mmol) in DMF (3.04 mL). Reaction mixture was stirred at room temperature for 3h. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The 2-(N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)acetic acid (61.1 mg, 27.0 %) was purified by Prep-HPLC reverse-phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.06 - 1.22 (m, 6 H), 1.25 (t, J=7.03 Hz, 1 H), 1.32 - 1.50 (m, 2 H), 1.50 - 1.64 (m, 3 H), 1.78 (t, J=I 1.13 Hz, 2 H), 2.09 - 2.24 (m, 1 H), 2.27 - 2.53 (m, 1 H), 2.74 - 2.95 (m, 2 H), 3.04 - 3.24 (m, 1 H), 3.31 - 3.52 (m, 4 H), 3.60 (q, J=7.03 Hz, 1 H), 3.99 (dd, J=I 1.13, 3.32 Hz, 2 H), 4.04 (s, 1 H), 4.23 (s, 2 H), 7.18 - 7.44 (m, 1 H), 7.44 - 7.67 (m, 1 H), 7.86 - 8.09 (m, 1 H); MS (ESI) (M+H)+ 477.4.
Example 112
N-(2-(cyclopropylamino)-2-oxoethyl)-9-(ethylsulfonyl)-N-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000190_0001
HATU (189 mg, 0.50 mmol) and N-cyclopropyl-2-(methylamino)acetamide (73.7 mg, 0.57 mmol) were added slowly at O 0C to a solution of 9-(ethylsulfonyl)-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (150 mg, 0.38 mmol) and N,N-diisopropylethylamine (0.199 mL, 1.14 mmol) in DMF (3.19 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as oil. The residue was dissolved in AcOEt and washed with NH4OH aq. in order to remove HATU. N-(2-(cyclopropylamino)-2- oxoethyl)-9-(ethylsulfonyl)-N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide (109 mg, 38.9 %) was purified by Prep-LCMS reverse- phase using a low pH 40-60% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 0.38 - 0.57 (m, 2 H), 0.72 (dd, J=I 1.72, 6.64 Hz, 2 H), 1.13 (t, J=7.42 Hz, 3 H), 1.33 - 1.48 (m, 2 H), 1.48 - 1.62 (m, 3 H), 1.76 (t, J=10.16 Hz, 3 H), 2.08 - 2.18 (m, 1 H), 2.25 - 2.40 (m, 1 H), 2.59 - 2.88 (m, 3 H), 3.04 - 3.19 (m, 4 H), 3.31- 3.37 (m, 2 H), 3.41 (t, J=I 1.91 Hz, 2 H), 3.92 (s, 1 H), 3.98 (dd, J=I 1.13, 2.93 Hz, 2 H), 4.15 (s, 1 H), 7.28 - 7.43 (m, 1 H), 7.50 -7.67 (m, 1 H), 7.92 - 8.02 (m, 1 H); MS (ESI) (M+H)+ 502.3.
Example 113
(2R)-l-(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)-N-(2-fluoroethyl)pyrrolidine-2-carboxamide
Figure imgf000191_0001
Step A. (2R)-l-(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carbonyl)-N-(2-fluoroethyl)pyrrolidine-2-carboxamide
Figure imgf000191_0002
HATU (78 mg, 0.20 mmol) and 2-Fluoroethylamine hydrochloride (20.37 mg, 0.20 mmol) were added slowly at 0 0C to a solution of (2R)-l-(9-(ethylsulfonyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-2- carboxylic acid (50 mg, 0.10 mmol) and N,N-diisopropylethylamine (0.0523 mL, 0.30 mmol) in DMF (0.812 mL). Reaction mixture was stirred at room temperature for 3h. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The (2R)-l-(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)-N-(2-fluoroethyl)pyrrolidine-2-carboxamide (69.8 %) was purified by Prep-HPLC reverse-phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.14 (t, J=7.42 Hz, 3 H), 1.35 - 1.67 (m, 6 H), 1.78 (t, J=10.74 Hz, 2 H), 1.83 - 2.08 (m, 3 H), 2.11 - 2.20 (m, 1 H), 2.28 - 2.42 (m, 2 H), 2.76 - 2.91 (m, 2 H), 3.09 - 3.28 (m, 2 H), 3.34 (q, J=7.68 Hz, 2 H), 3.39 - 3.47 (m, 2 H), 3.47 - 3.65 (m, 2 H), 3.67 -3.82 (m, 2 H), 3.99 (dd, J=I 1.13, 3.32 Hz, 2 H), 4.42 (t, J=5.08 Hz, 1 H), 4.52 - 4.61 (m, 1 H), 7.47 - 7.54 (m, 1 H), 7.74 - 7.81 (m, 1 H), 7.91 - 8.02 (m, 1 H); [M+H]+ calc. = 534.2433, [M+H]+ obs. = 534.2433. Step B. N-(2-(cyclopropylamino)-2-oxoethyl)-9-(ethylsulfonyl)-N-methyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000192_0001
HATU (583 mg, 1.53 mmol) and (R)-tert-butyl pyrrolidine-2-carboxylate (262 mg, 1.53 mmol) were added slowly at 0 0C to a solution of 9-(ethylsulfonyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (300 mg, 0.77 mmol) and N,N-diisopropylethylamine (0.400 mL, 2.30 mmol) in DMF (6.08 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The (2R)-tert-butyl l-(9-(ethylsulfonyl)-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-2- carboxylate (53.0 %) was purified by Prep-LCMS reverse-phase using a low pH 60-80% ACN/water system. MS (ESI) (M+H)+ 545.5.
Step C. (2R)-l-(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carbonyl)pyrrolidine-2-carboxylic acid
Figure imgf000192_0002
The (2R)-tert-butyl l-(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carbonyl)pyrrolidine-2-carboxylate (253.6 mg, 0.47 mmol) was diluted in MeOH (3.152 mL) and lithium hydroxide (111 mg, 4.66 mmol) in water (0.315 mL) was added. The reaction mixture was stirred at 50 0C until total completion of the reaction. Acetic acid was slowly added to obtain a pH of 5-6 and the mixture was concentrated in vacuo. The (2R)-l-(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl)pyrrolidine-2-carboxylic acid (24.81 %) and the (2R)-l-(3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carbonyl) pyrrolidine-2-carboxylic acid (69.6 mg, 34.6 %) were purified by Prep-HPLC reverse- phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD-D4) δ ppm 1.14 (t, J=7.42 Hz, 3 H), 1.32 - 1.66 (m, 6 H), 1.78 (t, J=10.16 Hz, 2 H), 1.85 - 1.97 (m, 1 H), 1.98 - 2.11 (m, 2 H), 2.12 - 2.22 (m, 1 H), 2.28 - 2.47 (m, 2 H), 2.79 - 2.92 (m, 2 H), 3.08 - 3.23 (m, 1 H), 3.35 (q, J=7.68 Hz, 2 H), 3.43 (t, J=I 1.91 Hz, 2 H), 3.54 - 3.80 (m, 2 H), 3.99 (dd, J=I 1.33, 3.13 Hz, 2 H), 4.60 (dd, J=8.20, 5.47 Hz, 1 H), 7.43 - 7.56 (m, 1 H), 7.67 - 7.74 (m, 1 H), 7.92 - 8.06 (m, 1 H); MS (ESI) (M+H)+ 489.4.
Example 114
N-(2-(2,2-difluoroethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000193_0001
Step A. N-(2-(2,2-difluoroethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000193_0002
HATU (134 mg, 0.35 mmol) and 2,2-difluoroethanamine (0.024 mL, 0.35 mmol) were added slowly at 0 0C to a solution of 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)acetic acid (70 mg, 0.18 mmol) and N,N-diisopropylethylamine (0.118 mL, 0.68 mmol) in DMF (2 mL). Reaction mixture was stirred at room temperature for 3h. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-(2-(2,2-difluoroethylamino)-2- oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (78 mg, 77 %) was purified by Prep-HPLC reverse-phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD) δ ppm 1.08 - 1.28 (m, 4 H), 1.31 - 1.48 (m, 2 H), 1.47 - 1.61 (m, 3 H), 1.74 (t, J=13.28 Hz, 2 H), 2.08 - 2.20 (m, 1 H), 2.29 - 2.46 (m, 1 H), 2.57 - 2.72 (m, 1 H), 2.74 - 2.90 (m, 2 H), 3.35 - 3.46 (m, 2 H), 3.45 - 3.58 (m, 4 H), 3.60 (s, 3 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 4.02 - 4.29 (m, 2 H), 5.60 - 6.13 (m, 1 H), 7.13 - 7.23 (m, 1 H), 7.25 - 7.36 (m, 1 H), 7.45 - 7.61 (m, 1 H); [M+H]+ calc. = 462.2563, [M+H]+ obs. = 462.2559.
Step B. 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1 H- carbazole-6-carboxamido)acetic acid
Figure imgf000194_0001
HATU (243 mg, 0.64 mmol) and N-Ethylglycine (99 mg, 0.96 mmol) were added slowly at 0 0C to a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxylic acid (100 mg, 0.32 mmol) and N,N-diisopropylethylamine (0.167 mL, 0.96 mmol) in DMF (2.53 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamido)acetic acid (115 mg, 70.3 %) was purified by Prep-HPLC reverse-phase using a low pH 60-80% ACN/water system. MS (ESI) (M+H)+ 399.4.
Example 115 N-ethyl-N-(2-((R)-2-hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000195_0001
HATU (72.5 mg, 0.19 mmol) and (R)-(-)-l-amino-2-propanol (0.015 mL, 0.19 mmol) were added slowly at O 0C to a solution of 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)acetic acid (38 mg, 0.10 mmol) and N,N-diisopropylethylamine (0.0523 mL, 0.30 mmol) in DMF (0.757 mL). Reaction mixture was stirred at room temperature for 5h. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-ethyl-N-(2-((R)-2- hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (10.97 mg, 20.20 %) was purified by Prep- HPLC reverse-phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, CD3OD-D4) δ ppm 1.05 - 1.30 (m, 7 H), 1.37 - 1.53 (m, 3 H), 1.53 - 1.67 (m, 4 H), 1.78 (t, J=13.09 Hz, 2 H), 2.11 - 2.25 (m, 1 H), 2.33 - 2.45 (m, 1 H), 2.63 - 2.77 (m, 1 H), 2.79 - 2.93 (m, 2 H), 3.08 - 3.23 (m, 1 H), 3.37 - 3.60 (m, 5 H), 3.64 (s, 3 H), 3.76 - 3.92 (m, 1 H), 3.99 (dd, J=I 1.33, 3.52 Hz, 2 H), 4.09 - 4.22 (m, 1 H), 7.16 - 7.25 (m, 1 H), 7.27 - 7.38 (m, 1 H), 7.49 - 7.60 (m, 1 H); [M+H]+ calc. = 456.2857, [M+H]+ obs. = 456.2853.
Example 116 N-ethyl-N-(2-((S)-2-hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000195_0002
HATU (303 mg, 0.80 mmol) and (S)-(+)-l-amino-2-propanol (0.063 mL, 0.80 mmol) were added slowly at 0 0C to a solution of 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)acetic acid (159 mg, 0.40 mmol) and N,N-diisopropylethylamine (0.208 mL, 1.19 mmol) in DMF (3.17 mL). Reaction mixture was stirred at room temperature for 3h. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-ethyl-N-(2-((S)-2- hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (99 mg, 43.5 %) was purified by Prep-HPLC reverse-phase using a low pH 50-70% ACN/water system. IH NMR (400 MHz, CD3OD- D4) δ ppm 1.07 - 1.28 (m, 7 H), 1.34 - 1.50 (m, 3 H), 1.50 - 1.62 (m, 4 H), 1.76 (t, J=13.09 Hz, 2 H), 2.04 - 2.19 (m, 1 H), 2.36 (dd, J=12.11, 5.47 Hz, 1 H), 2.60 - 2.74 (m, 1 H), 2.76 - 2.90 (m, 2 H), 3.10 - 3.20 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.36 - 3.57 (m, 5 H), 3.62 (s, 3 H), 3.75 - 3.90 (m, 1 H), 3.98 (dd, J=I l.13, 3.32 Hz, 2 H), 4.05 - 4.20 (m, 1 H), 7.17 - 7.24 (m, 1 H), 7.52 - 7.58 (m, 1 H); [M+H]+ calc. = 456.2857, [M+H]+ obs. = 456.2853.
Example 117
N-ethyl-N-(2-(2-methoxyethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000196_0001
HATU (169 mg, 0.44 mmol) and 2-Methoxyethylamine (0.039 mL, 0.44 mmol) were added slowly at 0 0C to a solution of 2-(N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)acetic acid (88.4 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.115 mL, 0.66 mmol) in DMF (1.761 mL). Reaction mixture was stirred at room temperature for 2h30. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The N-ethyl-N-(2-(2- methoxyethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide (59.8 mg, 47.3 %) was purified by Prep-HPLC reverse-phase using a low pH 60-80% ACN/water system. IH NMR (400 MHz, DMSO- D6) δ ppm 0.99 - 1.15 (m, 3 H), 1.23 - 1.38 (m, 2 H), 1.42 - 1.55 (m, 3 H), 1.69 (t, J=13.48 Hz, 2 H), 2.00 - 2.11 (m, 1 H), 2.25 - 2.37 (m, 1 H), 2.57 - 2.89 (m, 3 H), 3.19 - 3.40 (m, 11 H), 3.60 (s, 3 H), 3.89 (d, J=9.37 Hz, 2 H), 3.92 - 4.02 (m, 1 H), 4.10 - 4.28 (m, 2 H), 7.06 - 7.16 (m, 1 H), 7.29 - 7.40 (m, 1 H), 7.93 - 8.04 (m, 1 H); [M+H]+ calc. = 456.2857, [M+H]+ obs. = 456.2857.
Example 118 N-((R)-l-(cyclopropylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000197_0001
Step A. (2R)-2-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)propanoic acid
Figure imgf000197_0002
HATU (84 mg, 0.22 mmol) and cyclopropanamine (9,99 DL, 0.14 mmol) were added slowly at 0 0C to a solution of (2R)-2-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)propanoic acid (67.9 mg, 0.17 mmol) and N,N-diisopropylethylamine (0.089 mL, 0.51 mmol) in DMF (1.352 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound yellow oil. The N-((R)-l-(cyclopropylamino)-l- oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide (74.6 mg, 47 %) was purified by Prep-LCMS reverse-phase using a low pH 40-60% ACN/water system. IH NMR (400 MHz, CD3OD) D ppm 0.52 (s, 2 H), 0.73 (dd, J=7.03, 1.17 Hz, 2 H), 1.35 - 1.49 (m, 6 H), 1.50 - 1.63 (m, 4 H), 1.76 (t, J=12.30 Hz, 2 H), 2.11 - 2.19 (m, 1 H), 2.30 - 2.43 (m, 1 H), 2.62 - 2.73 (m, 2 H), 2.78 - 2.89 (m, 2 H), 3.03 (s, 3 H), 3.36 - 3.47 (m, 2 H), 3.62 (s, 3 H), 3.98 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.13 - 7.21 (m, 1 H), 7.24 - 7.37 (m, 1 H), 7.41 - 7.58 (m, 1 H); MS (ESI) (M+H)+ 438.3.
Step B. (2R)-2-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)propanoic acid
Figure imgf000198_0001
HATU (631 mg, 1.66 mmol) and N-methyl-D-alanine (395 mg, 3.83 mmol) were added slowly at O 0C to a solution of 9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxylic acid (400 mg, 1.28 mmol) and N,N-diisopropylethylamine (0.667 mL, 3.83 mmol) in DMF (10.0 mL). Reaction mixture was stirred at room temperature for an O/N. The solvent was then removed in vacuo to provide the crude compound as yellow oil. The (2R)-2-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3,4,9-tetrahydro-lH-carbazole-6-carboxamido)propanoic acid (210 mg, 41 %) was purified by Prep-LCMS reverse-phase using a low pH 40-60% ACN/water system. IH NMR (400 MHz, CD3OD) D ppm 1.28 - 1.47 (m, 5 H), 1.47 - 1.64 (m, 5 H), 1.65 - 1.81 (m, 2 H), 2.02 - 2.23 (m, 1 H), 2.26 - 2.49 (m, 1 H), 2.67 (s, 1 H), 2.74 - 2.92 (m, 2 H), 2.97 - 3.08 (m, 3 H), 3.33 - 3.51 (m, 2 H), 3.62 (s, 3 H), 3.97 (d, J=10.55 Hz, 2 H), 7.05 - 7.26 (m, 1 H), 7.29 - 7.40 (m, 1 H), 7.44 - 7.65 (m, 1 H); MS (ESI) (M+H)+ 399.4.
Example 119: Step A:
(R)-N-((S)-l-Hydroxy-5-(oxetan-3-ylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000199_0001
(S)-5-Acetoxy-4-((R)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)pentanoic acid (53 mg, 0.11 mmol), oxetan-3 -amine hydrochloride (13.18 mg, 0.12 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (45.7 mg, 0.12 mmol) were stirred in DMF (5 mL) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. The solvent was evaporated. The residue was dissolved in MeOH (2 mL) and sodium methoxide (0.025 mL, 0.11 mmol) (25% w/v in MeOH) was added. The solution was stirred at 23 0C for 5 min. The product was purified by reversed-phase HPLC and lyophilized (37 mg, 68 %). Reversed-phase purification: Gilson system equipped with X-Bridge Prep C18 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 20-40%B; A: H2O with 15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. 1H NMR (400 MHz, METHANOL-D4) δ 1.29 - 1.43 (m, 2 H), 1.45 - 1.55 (m, 3 H), 1.57 - 1.66 (m, I H), 1.70 (t, J=I 1.91 Hz, 2 H), 1.76 - 1.85 (m, 1 H), 1.88 - 1.98 (m, 0.5 H), 2.01 - 2.07 (m, 0.5 H), 2.07 - 2.13 (m, 1 H), 2.22 - 2.29 (m, 1 H), 2.29 - 2.37 (m, 1 H), 2.57 - 2.68 (m, 1 H), 2.78 (d, J=16.02 Hz, 2 H), 2.85 (d, J=27.73 Hz, 3 H), 3.30 - 3.39 (m, 2 H), 3.47 (dd, J=I .91, 4.88 Hz, 0.5 H), 3.55 (s, 3 H), 3.58 - 3.67 (m, 1.5 H), 3.91 (dd, J=I 1.13, 4.10 Hz, 2 H), 3.96 - 4.04 (m, 0.5 H), 4.19 - 4.28 (m, 1 H), 4.41 - 4.50 (m, 1 H), 4.52 - 4.60 (m, 1.5 H), 4.60 - 4.67 (m, 0.5 H), 4.69 - 4.78 (m, 1 H), 4.81 - 4.89 (m, 0.5 H), 7.09 - 7.18 (m, 1 H), 7.19 - 7.27 (m, 1 H), 7.47 (d, J=15.62 Hz, 1 H); (M+H) = 498.2; Accurate mass: calculated (M+H)+ for C28H39N3O5: 498.29625; Found: 498.29580.
Step B: (S)-Benzyl 5-acetoxy-4-(tert-butoxycarbonyl(methyl)amino)pentanoate
Figure imgf000200_0001
BoC-N-Me-GIu(OBzI)-OH (2.0 g, 5.69 mmol) was dissolved in DME (25 mL) at 0 0C. 4- Methylmorpholine (0.626 mL, 5.69 mmol) was added dropwise followed by isobutyl chloroformate (0.738 mL, 5.69 mmol). The solution was stirred at 0 0C for 5 min. The white precipitate was filtered and rinsed with DME. The filtrate was placed back at 0 0C and a solution of sodium borohydride (0.301 mL, 8.54 mmol) in water (10 mL) was added slowly. The solution was then stirred at 0 0C for 30 min. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. The solvent was concentrated. The residue was dissolved in DCM (10 mL) containing triethylamine (1.190 mL, 8.54 mmol) at 0 0C and acetyl chloride (0.445 mL, 6.26 mmol) was added dropwise. The solution was stirred at 0 0C for 30 min. The solution was washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. The product was purified by flash chromatography (1.73g, 80 %). Flash chromatography is done using a 8Og RediSep column on an Isco Companion system with a gradient of 20-
50% EtOAc in heptane. 1H NMR (400 MHz, CHLOROFORM-D) δ 1.44 (d, J=6.64 Hz, 9 H), 1.76 - 1.87 (m, 2 H), 2.01 - 2.06 (m, 3 H), 2.33 - 2.41 (m, 2 H), 2.70 (d, J=15.23 Hz, 3 H), 4.01 - 4.14 (m, 2 H), 4.21 - 4.31 (m, 0.5 H), 4.36 - 4.46 (m, 0.5 H), 5.12 (s, 2 H), 7.31 - 7.40 (m, 5 H); (M+H) = 380.22. Step C:
(S)-Benzyl 5-acetoxy-4-(methylamino)pentanoate hydrochloride
Figure imgf000201_0001
(S)-Benzyl 5-acetoxy-4-(tert-butoxycarbonyl(methyl)amino)pentanoate (1.70 g, 4.48 mmol) was stirred in hydrogen chloride (13.44 mL, 13.44 mmol) (IM in AcOH) at 23 0C for Ih. The solvent was concentrated. The residue was washed a few times with ether and dried under vacuum. The product was used directly for the next step (1.45g, 102 %) (high yield is probably due to the presence of AcOH in the product). (M+H) = 280.22
Step D:
(S)-Benzyl 5-acetoxy-4-((R)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamido)pentanoate
Figure imgf000201_0002
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (300 mg, 0.96 mmol), (S)-benzyl 5-acetoxy-4-(methylamino)pentanoate hydrochloride (333 mg, 1.05 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (400 mg, 1.05 mmol) were stirred in DMF (10 mL) containing N,N-diisopropylethylamine (0.417 mL, 2.39 mmol) at 23 0C for Ih. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO4, aqueous saturated NaHCO3, brine and dried over MgSO4. The product was purified by flash chromatography (395 mg, 72 %). Flash chromatography is done using a 4Og RediSep column using an Isco Companion system using a gradient of 50-90%
EtOAc in heptane. 1H NMR (400 MHz, CHLOROFORM-D) δ 1.45 (m, 2 H), 1.51 - 1.63 (m, 3 H), 1.67 - 1.79 (m, 3 H), 1.82 - 1.94 (m, 1 H), 1.99 (s, 1 H), 2.10 (s, 3 H), 2.14 (s, 1 H), 2.33 - 2.44 (m, 2 H), 2.53 (s, 1 H), 2.63 - 2.74 (m, 1 H), 2.76 - 2.84 (m, 2 H), 2.91 (m, 3 H), 3.36 - 3.47 (m, 2 H), 3.62 (s, 3 H), 4.03 (d, J=I 1.33 Hz, 2 H), 4.27 (d, 2 H), 5.01 (s, 1 H), 5.10 - 5.18 (m, 1 H), 7.12 - 7.18 (m, 1 H), 7.19 - 7.23 (m, 1 H), 7.28 - 7.40 (m, 5 H), 7.52 (s, 1 H); (M+H) = 575.39.
Step E:
(S)-5-Acetoxy-4-((R)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamido)pentanoic acid
Figure imgf000202_0001
(S)-Benzyl 5-acetoxy-4-((R)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamido)pentanoate (315 mg, 0.55 mmol) was shaken in ethyl acetate (25 mL) containing palladium (29.2 mg, 0.03 mmol) (10% Pd/C) under hydrogen atmosphere 45 psi at 23 0C for 4h. The solution was filtered through celite and the solvent was concentrated. The product was purified by flash chromatography (260 mg, 98 %). Flash chromatography is done using a 12g RediSep column using an Isco
Companion system with a gradient of 5% MeOH in DCM. 1H NMR (400 MHz, CHLOROFORM-D) δ 1.41 - 1.51 (m, 2 H), 1.50 - 1.56 (m, 1 H), 1.56 - 1.64 (m, 2 H), 1.69 - 1.79 (m, 2 H), 1.88 - 2.00 (m, 2 H), 2.12 (s, 3 H), 2.14 - 2.19 (m, 1 H), 2.35 - 2.44 (m, 1 H), 2.49 (s, 1 H), 2.64 - 2.75 (m, 1 H), 2.77 - 2.87 (m, 2 H), 2.88 - 2.98 (m, 3 H), 3.36 - 3.48 (m, 2 H), 3.64 (s, 3 H), 4.04 (dd, J=I 1.52, 2.93 Hz, 2 H), 4.21 (s, 1 H), 4.34 (s, 0.5 H), 4.99 (s, 0.5 H), 7.16 - 7.21 (m, 1 H), 7.22 - 7.26 (m, 1 H), 7.52 - 7.57 (m, 1 H); (M+H) = 485.35.
Example 120:
(R)-N-((S)-5-(2,2-Difluoroethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000203_0001
(S)-5-Acetoxy-4-((R)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)pentanoic acid (100 mg, 0.21 mmol), 2,2-difluoroethylamine
(18.40 mg, 0.23 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (86 mg, 0.23 mmol) were stirred in DMF (8 mL) containing N,N- diisopropylethylamine (0.072 mL, 0.41 mmol) at 23 0C for Ih. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. The solvent was evaporated. The residue was dissolved in methanol (5 mL) and sodium methoxide (0.047 mL, 0.21 mmol) (25% solution in MeOH) was added. The solution was stirred at 23 0C for 5 min. The solvent was concentrated. The product was purified by reversed-phase
HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X- Bridge Prep Cl 8 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A:
H2O with 15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (45 mg, 43 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.35 - 1.50 (m, 2 H), 1.57 (s, 3 H), 1.65 - 1.74 (m, 1 H), 1.77 (t, J=I 1.72 Hz, 2 H), 1.84 - 1.93 (m, 1 H), 1.96 - 2.08 (m, 0.5 H), 2.10 - 2.20 (m, 1.5 H), 2.30 - 2.44 (m, 2 H), 2.61 - 2.73 (m, 1 H), 2.84 (d, J=15.62 Hz, 2 H), 2.92 (d, J=26.95 Hz, 3 H), 3.13 - 3.24 (m, 1 H), 3.36 - 3.47 (m, 2 H), 3.48 - 3.58 (m, 1.5 H), 3.62 (s, 3 H), 3.64 - 3.74 (m, 1.5 H), 3.97 (dd, J=10.35, 2.93 Hz, 2 H), 4.05 (s, 1 H), 4.69 (s, 1 H), 5.44 - 5.50 (m, 0.2 H), 5.61 (s, 0.2 H) 5.70 - 5.79 (m, 0.2 H), 5.86 (s, 0.2 H), 6.00 (s, 0.2 H), 7.14 - 7.24 (m, 1 H), 7.25 - 7.34 (m, 1 H), 7.52 (d, J=6.25 Hz, 1 H); (M+H) = 506.2; Accurate mass: calculated (M+H)+ for C27H37F2N3O4: 506.28249; Found: 506.28214.
Example 121:
(R)-N-((S)-5-(2-Fluoroethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000204_0001
(R)-((4S)-5-Acetoxy-4-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamido)pentanoic acid (200 mg, 0.41 mmol), 2-fluoroethylamine hydrochloride (49.3 mg, 0.50 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (173 mg, 0.45 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine (0.180 mL, 1.03 mmol) at 23 0C for Ih. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. The solvent was evaporated. The residue was dissolved in methanol (2 mL) and sodium methoxide (0.094 mL, 0.41 mmol) (25% NaOMe/MeOH) was added. The solution was stirred at 23 0C for 5 min. The product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep Cl 8 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A: H2O with
15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (145mg, 72 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.35 - 1.48 (m, 2 H), 1.55 (s, 3 H), 1.63 - 1.71 (m, 1 H), 1.76 (t, J=I 1.91 Hz, 2 H), 1.95 - 2.04 (m, 0.5 H), 2.08 - 2.18 (m, 1.5 H), 2.29 - 2.33 (m, 1 H), 2.34 - 2.41 (m, 1 H), 2.62 - 2.72 (m, 1 H), 2.83 (d, J=15.23 Hz, 2 H), 2.92 (d, J=27.34 Hz, 3 H), 3.20 - 3.26 (m, 1 H), 3.29 - 3.35 (m, 0.5 H), 3.36 - 3.45 (m, 2.5 H), 3.47 - 3.51 (m, 0.5 H), 3.53 (d, J=4.69 Hz, 0.5 H), 3.61 (s, 3 H), 3.64 - 3.73 (m, 1.5 H), 3.97 (dd, J=10.94, 3.91 Hz, 2 H), 4.01 - 4.10 (m, 0.5 H), 4.21 (t, J=4.88 Hz, 0.5 H), 4.32 (t, J=4.88 Hz, 0.5 H), 4.37 (t, J=4.88 Hz, 0.5 H), 4.49 (t, J=4.88 Hz, 0.5 H), 4.65 - 4.74 (m, 0.5 H), 7.16 - 7.23 (m, 1 H), 7.25 - 7.33 (m, 1 H), 7.53 (d, J=7.42 Hz, 1 H); (M+H) = 488.3; Accurate mass: calculated (M+H)+ for C27H38FN3O4: 488.28191; Found:488.29164.
Example 122:
(R)-N-(4-(Cyanomethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide
Figure imgf000205_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (100 mg, 0.24 mmol), aminoacetonitrile hydrochloride (33.6 mg, 0.36 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (138 mg, 0.36 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.127 mL, 0.73 mmol) at 23 0C for Ih. The solvent was concentrated. The product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep Cl 8 OD, 30 x 50 mm, 5 mm particle size. Mobile phase: 20-40%B; A: H2O with 15mM NH4CO3 and
0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (55mg, 50 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.36 - 1.49 (m, 2 H), 1.51 - 1.60 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 1.86 (s, 1 H), 1.99 (s, 2 H), 2.12 - 2.19 (m, 1 H), 2.30 - 2.42 (m, 2 H), 2.62 - 2.73 (m, 1 H), 2.78 - 2.89 (m, 2 H), 3.04 (s, 3 H), 3.36 - 3.46 (m, 3 H), 3.56 (s, 1 H), 3.62 (s, 3 H), 3.87 (s, 1 H), 3.97 (dd, J=10.94, 3.52 Hz, 2 H), 4.12 (s, 1 H), 7.12 (s, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.46 (s, 1 H); (M+H) = 451.2; Accurate mass: calculated (M+H)+ for C26H34N4O3: 451.27037; Found: 451.26987.
Example 123:
(R)-N-((S)-l-Hydroxy-5-(methylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide Step A:
(R)-N-((S)-l-Hydroxy-5-(methylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-lH-pyran^-yl^jS^P-tetrahydro-lH-carbazole-o-carboxamide
Figure imgf000206_0001
(S)-N-Methyl-4-(methylamino)-5-(trityloxy)pentanamide (184 mg, 0.46 mmol) (R)-9- methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (130 mg, 0.41 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (173 mg, 0.46 mmol) were stirred in DMF (8 mL) containing N,N- diisopropylethylamine (0.145 mL, 0.83 mmol) at 23 0C for 24h. The solvent was concentrated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, 5% KHSO4, brine and dried over anhydrous MgSO4. The product was purified by flash chromatography. The product was then stirred in dioxane (8.00 mL) containing hydrogen chloride (0.519 mL, 2.07 mmol) (4M in dioxane) at 23 0C for Ih. The solvent was concentrated. The residue was purified by reversed-phase HPLC and lyophilized. Flash chromatography was done using a 4Og RediSep column using an Isco Companion system using a gradient of 5% MeOH / EtOAc. Reversed-phase purification: Gilson system equipped with X-Bridge Prep C18 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 20-40%B; A: H2O with 15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN;
45mL/min, 15 min ran, rt. (107mg, 57 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.35 - 1.49 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.64 - 1.72 (m, 1 H), 1.76 (t, J=I 1.91 Hz, 2 H), 1.81 - 1.89 (m, 1 H), 1.90 - 1.99 (m, 0.5 H), 2.04 - 2.11 (m, 0.5 H), 2.12 - 2.18 (m, 1 H), 2.24 - 2.31 (m, 1 H), 2.38 (dd, J=15.23, 7.03 Hz, 1 H), 2.48 (s, 2 H), 2.63 - 2.74 (m, 2 H), 2.80 - 2.86 (m, 2 H), 2.87 - 2.96 (m, 3 H), 3.35 - 3.46 (m, 2 H), 3.51 (dd, 0.5 H), 3.61 (s, 3 H), 3.64 - 3.72 (m, 1.5 H), 3.97 (dd, J=I 1.13, 4.10 Hz, 2 H), 4.01 - 4.08 (m, 0.5 H), 4.69 (s, 0.5 H), 7.15 - 7.22 (m, 1 H), 7.25 - 7.33 (m, 1 H) 7.52 (d, J=9.37 Hz, 1 H); (M+H) = 456.2; Accurate mass: calculated (M+H)+ for C26H37N3O4: 456.28568; Found: 456.28608.
Step B: (S)-5-(trityloxymethyl)pyrrolidin-2-one
Figure imgf000207_0001
A mixture of (S)-5-(hydroxymethyl)pyrrolidin-2-one (2.07 g, 17.98 mmol), triethylamine (2.506 mL, 17.98 mmol) and N,N-dimethylpyridin-4-amine (0.220 g, 1.80 mmol) in DCM (55.0 mL) was stirred at room temperature for 5 minutes. Chloromethanetriyltribenzene (5.01 g, 17.98 mmol) was added in portions, and the mixture was stirred at room temperature for 60 hours. Water (100 mL) was added, and the phases were separated. The organic extract was washed with water (2 X 100 mL) and brine (3 X 100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The product, (S)-5-(trityloxymethyl)pyrrolidin-2-one, was sufficiently pure to be used in the next step. 1H NMR (400 MHz, CHLOROFORM-D) D ppm 1.54 - 1.75 (m, 1 H) 2.03 - 2.21 (m, 1 H) 2.28 (t, J=8.20 Hz, 2 H) 2.93 - 3.04 (m, 1 H) 3.18 (dd, J=8.98, 3.91 Hz, 1 H) 3.76 - 3.91 (m, J=5.66, 4.10 Hz, 1 H) 5.87 (s, 1 H) 7.20 - 7.25 (m, 3 H) 7.26 - 7.31 (m, 6 H) 7.35 - 7.41 (m, 6 H). Step C: (S)-l-methyl-5-(trityloxymethyl)pyrrolidin-2-one
Figure imgf000208_0001
A mixture of (S)-5-(trityloxymethyl)pyrrolidin-2-one (6.43 g, 17.98 mmol) and iodomethane (2.244 mL, 35.96 mmol) in DMF (75.0 mL) under a nitrogen atmosphere was stirred at -15°C for 5 minutes. NaHMDS (21.58 mL, 21.58 mmol) was added, and the resulting mixture was stirred at -15°C for 20 minutes and at room temperature for 3 hours. A saturated solution of ammonium chloride (75 mL) and water (100 mL) were added to the reaction mixture, and the phases were separated. The aqueous phase was extracted with DCM (3 X 10OmL). The combined organic extracts were washed with water (3 x 100 mL) and brine (2 X 100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was diluted in Et2θ, and the resulting slurry was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel, eluting with mixtures of EtOAc in heptane (0 to 100%) to afford (S)-l-methyl-5-(trityloxymethyl)pyrrolidin-2-one (3.76 g,
56% for 2 steps). 1H NMR (400 MHz, CHLOROFORM-D) D ppm 1.73 - 1.90 (m, 1 H) 2.03 - 2.17 (m, 1 H) 2.22 - 2.38 (m, 1 H) 2.42 - 2.61 (m, 1 H) 2.74 (s, 3 H) 3.12 (dd, J=9.96, 4.49 Hz, 1 H) 3.27 (dd, J=9.96, 3.71 Hz, 1 H) 3.53 - 3.61 (m, 1 H) 7.19 - 7.25 (m, 3 H) 7.26 - 7.32 (m, 6 H) 7.36 - 7.41 (m, 6 H).
Step D: (S)-N-Methyl-4-(methylamino)-5-(trityloxy)pentanamide
Figure imgf000209_0001
A mixture of methanamine hydrochloride (0.852 g, 12.63 mmol) in THF (20.0 mL) under a nitrogen atmosphere was stirred at room temperature for 5 minutes. Butyllithium (12.63 mL, 25.25 mmol) was added, and the resulting mixture was stirred for 30 minutes. A solution of (S)-l-methyl-5-(trityloxymethyl)pyrrolidin-2-one (0.938 g, 2.53 mmol) in THF (20.00 mL) was added, and the resulting mixture was stirred at room temperature for 2 hours. A saturated solution of ammonium chloride (100 mL) was added to the reaction mixture, and the phases were separated. The aqueous phase was extracted with EtOAc (4 X 75 mL), and the combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with mixtures of EtOAc, Et3N and
MeOH (8:1:1) to afford (S)-N-Methyl-4-(methylamino)-5-(trityloxy)pentanamide
(421mg, 41%). 1H NMR (400 MHz, CHLOROFORM-D) D ppm 1.74 (qd, J=6.64, 2.73 Hz, 2 H) 2.06 - 2.19 (m, 2 H) 2.20 - 2.23 (m, 3 H) 2.52 - 2.61 (m, 1 H) 2.70 (d, J=4.69 Hz, 3 H) 3.03 (dd, J=9.37, 5.86 Hz, 1 H) 3.15 (dd, J=9.37, 4.30 Hz, 1 H) 6.22 (s, 1 H) 7.17 - 7.24 (m, 3 H) 7.25 - 7.31 (m, J=7.23, 7.23 Hz, 6 H) 7.36 - 7.42 (m, J=6.84, 6.84 Hz, 6 H); (M+H) = 403.3.
Example 124: (R)-N-((S)-l-Hydroxy-5-(isopropylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide Step A:
(R)-N-((S)-l-Hydroxy-5-(isopropylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000210_0001
(S)-N-isopropyl-4-(methylamino)-5-(trityloxy)pentanamide (227 mg, 0.53 mmol), (R)-9- methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (150 mg, 0.48 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (200 mg, 0.53 mmol) were stirred in DMF (8 mL) containing N,N- diisopropylethylamine (0.167 mL, 0.96 mmol) at 23 0C for 24h. The solvent was concentrated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3, 5% KHSO4, brine and dried over anhydrous MgSO4. The product was purified by flash chromatography. The product was then dissolved in dioxane (10 mL) and hydrogen chloride (0.598 mL, 2.39 mmol) (4M / dioxane) was added. The solution was stirred at 23 0C for 4-5h. The solvent was concentrated. The product was purified by reversed-phase HPLC and lyophilized. Flash chromatography is done using a 4Og RediSep column using an Isco Companion system using a gradient of EtOAc. Reversed- phase purification: Gilson system equipped with X-Bridge Prep C18 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A: H2O with 15mM NH4CO3 and 0.375%
NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (110 mg, 48 %). 1H NMR (400
MHz, METHANOL-D4) δ 0.96 (d, J=5.86 Hz, 3 H), 1.11 (t, J=7.23 Hz, 3 H), 1.35 - 1.47 (m, 2 H), 1.55 (s, 3 H), 1.60 - 1.69 (m, 0.5 H), 1.75 (t, J=12.30 Hz, 3 H), 1.82 - 1.95 (m, 1 H), 2.00 - 2.10 (m, 0.5 H), 2.11 - 2.18 (m, 1 H), 2.21 - 2.29 (m, 1 H), 2.32 - 2.41 (m, 1 H), 2.61 - 2.71 (m, 1 H), 2.79 - 2.87 (m, 2 H), 2.87 - 2.97 (m, 3 H), 3.35 - 3.45 (m, 2 H), 3.51 (m, 0.5 H), 3.60 (s, 3 H), 3.63 - 3.71 (m, 1 H), 3.72 - 3.80 (m, 0.5 H), 3.96 (d, J=10.94 Hz, 2 H), 4.00 - 4.07 (m, 0.5 H), 4.63 - 4.72 (m, 0.5 H), 7.16 - 7.22 (m, 1 H), 7.25 - 7.33 (m, 1 H), 7.50 - 7.55 (m, 1 H); (M+H) = 484.2; Accurate mass: calculated (M+H)+ for C28H41N3O4: 484.31698; Found: 484.31682.
Step B: (S)-N-isopropyl-4-(methylamino)-5-(trityloxy)pentanamide
Figure imgf000211_0001
A mixture of propan-2-amine hydrochloride (643 mg, 6.73 mmol) in THF (20.0 mL) under a nitrogen atmosphere was stirred at room temperature for 5 minutes. Butylithium (6.73 mL, 13.46 mmol) was added, and the resulting mixture was stirred for 30 minutes. A solution of (S)-l-methyl-5-(trityloxymethyl)pyrrolidin-2-one (500 mg, 1.35 mmol, see example 5 for synthesis) in THF (20.00 mL) was added, and the mixture was stirred at room temperature for 12 hours. A saturated solution of ammonium chloride (10OmL) and a 5% solution of KHSO4 (1OmL) were added to the reaction mixture, and the phases were separated. The aqueous phase was extracted with EtOAc (4 X 75 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with mixtures of EtOAc, Et3N and MeOH (8:1:1) to afford (S)-N-isopropyl-4-(methylamino)-5-(trityloxy)pentanamide (284 mg, 49%). 1H NMR (400 MHz, METHANOL-D4) D ppm 1.00 (d, J=5.86 Hz, 5 H) 1.55 - 1.75 (m, 2 H) 1.98 (t, J=7.42 Hz, 2 H) 2.15 (s, 3 H) 2.42 - 2.53 (m, 1 H) 3.00 (dd, J=9.57, 6.05 Hz, 1 H) 3.11 (dd, J=9.77, 4.69 Hz, 1 H) 3.17 - 3.24 (m, 1 H) 3.75 - 3.87 (m, 1 H) 7.12 (tt, 3 H) 7.16 - 7.22 (m, J=7.42, 7.42 Hz, 6 H) 7.30 - 7.37 (m, 6 H); (M+H) =431.4.
Example 125:
(R)-N-((S)-5-(Ethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro- 2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide Step A:
(R)-N-((S)-5-(Ethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-lH-pyran^-y^-l^^P-tetrahydro-lH-carbazole-o-carboxamide
Figure imgf000212_0001
(S)-N-Ethyl-4-(methylamino)-5-(trityloxy)pentanamide (439 mg, 1.05 mmol), (R)-9- methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxylic acid (300 mg, 0.96 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (400 mg, 1.05 mmol) were stirred in DMF (10 mL) containing N,N- diisopropylethylamine (0.333 mL, 1.91 mmol) at 23 0C for 24h. The solution was then diluted with saturated aqueous NH4Cl and extracted (3X) with DCM. The organic layer was dried over anhydrous MgSO4 and purified by flash chromatography. The product was then stirred in IM HCl/AcOH at rt for Ih. Some acetylated product was observed. The solvent was concentrated. The residue was dissolved in MeOH (1OmL) and NaOMe (28% w/v) was added. The solution was stirred at rt for 10 min. The product was purified by reversed-phase HPLC and lyophilized. Flash chromatography is done using a 4Og RediSep column using an Isco Companion system with a gradient of EtOAc. Reversed-phase purification: Gilson system equipped with X-Bridge Prep C18 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 20-40%B; A: H2O with 15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (215 mg, 48 %). 1H
NMR (400 MHz, METHANOL-D4) δ 0.96 (t, J=7.23 Hz, 1 H), 1.10 (t, J=7.23 Hz, 1 H), 1.35 - 1.48 (m, 2 H), 1.55 (s, 3 H), 1.62 - 1.71 (m, 1 H), 1.76 (t, J=12.30 Hz, 2 H), 1.81 - 1.89 (m, 1 H), 1.90 - 1.97 (m, 0.5 H), 2.02 - 2.11 (m, 0.5 H), 2.11 - 2.18 (m, 1 H), 2.23 - 2.31 (m, 1 H), 2.33 - 2.42 (m, 1 H), 2.61 - 2.72 (m, 1 H), 2.78 - 2.90 (m, 3.5 H), 2.95 (s, 2 H), 2.97 - 3.06 (m, 0.5 H), 3.14 - 3.22 (m, 1 H), 3.36 - 3.45 (m, 2 H), 3.51 (dd, J=I 1.72, 4.69 Hz, 0.5 H), 3.61 (s, 3 H), 3.63 - 3.72 (m, 1.5 H), 3.93 - 4.00 (m, 2 H), 4.00 - 4.09 (m, 0.5 H) ,4.64 - 4.73 (m, 0.5 H), 7.15 - 7.23 (m, 1 H), 7.25 - 7.32 (m, 1 H), 7.53 (d, J=9.37 Hz, 1 H); (M+H) = 470.2; Accurate mass: calculated (M+H)+ for C27H39N3O4: 470.30133; Found: 470.30112. Step B: (S)-N-Ethyl-4-(methylamino)-5-(trityloxy)pentanamide
Figure imgf000213_0001
A mixture of ethanamine hydrochloride (659 mg, 8.08 mmol) in THF (20.0 mL) under a nitrogen atmosphere was stirred at room temperature for 5 minutes. Butyllithium (8.08 mL, 16.15 mmol) was added, and the resulting mixture was stirred for 20 minutes. A solution of (S)-l-methyl-5-(trityloxymethyl)pyrrolidin-2-one (600 mg, 1.62 mmol, see example 5 for synthesis) in THF (20.00 mL) was added, and the mixture was stirred at room temperature for 12 hours. A saturated solution of ammonium chloride (100 mL) and a 5% solution of KHSO4 (10 mL) were added to the reaction mixture, and the phases were separated. The aqueous phase was extracted with EtOAc (4 X 75 mL), and the combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with mixtures of EtOAc, MeOH and Et3N (8:1:1) to afford (S)-N-Ethyl-4-(methylamino)-5-(trityloxy)pentanamide (531 mg, 79%). 1H NMR (400 MHz, METHANOL-D4) D ppm 0.98 (t, J=7.42 Hz, 2 H) 1.54 - 1.76 (m, 2 H) 1.99 (t, J=7.81 Hz, 2 H) 2.04 (s, 3 H) 2.15 (s, 3 H) 2.85 - 3.16 (m, 4 H) 7.13 (tt, J=7.03, 1.56 Hz, 2 H) 7.17 - 7.23 (m, 6 H) 7.32 - 7.37 (m, 6 H); (M+H) = 417.4.
Example 126:
(R)-N-(4-(Methoxyamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide
Figure imgf000214_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (80 mg, 0.19 mmol), methoxylamine hydrochloride (17.82 mg, 0.21 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (81 mg, 0.21 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.084 mL, 0.48 mmol) at 23 0C for Ih. The solvent was concentrated. The product was directly purified by reversed phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep
Cl 8 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A: H2O with
15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (55 mg, 64 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.49 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 1.86 (s, 2 H), 1.97 (s, 1 H), 2.12 - 2.20 (m, 2 H), 2.34 - 2.43 (m, 1 H), 2.63 - 2.73 (m, 1 H), 2.80 - 2.89 (m, 2 H), 3.03 (s, 3 H), 3.36 - 3.46 (m, 4 H), 3.57 (s, 2 H), 3.62 (s, 3 H), 3.67 (s, 1 H), 3.97 (dd, J=I 1.52, 4.10 Hz, 2 H), 7.13 (s, 1 H), 7.31 (d, J=8.98 Hz, 1 H), 7.46 (s, 1 H); (M+H) = 442.3; Accurate mass: calculated (M+H)+ for C25H35N3O4: 442.27003; Found: 442.27043.
Example 127:
(R)-N-(4-(2,2-Dimethylhydrazinyl)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000215_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (80 mg, 0.19 mmol), 1,1-dimethylhydrazine (0.018 mL, 0.23 mmol) and O-(7-azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (88 mg, 0.23 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.084 mL, 0.48 mmol) at 23 0C for Ih. The solvent was concentrated. The product was purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep C18 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A: H2O with 15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (57 mg, 65 %). 1H
NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.49 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.77 (t, J=12.70 Hz, 2 H), 1.87 (s, 2 H), 1.95 (s, 1 H), 2.12 - 2.21 (m, 2 H), 2.32 (s, 2 H), 2.34 - 2.43 (m, 2 H), 2.46 - 2.55 (m, 3 H), 2.64 - 2.73 (m, 1 H), 2.79 - 2.89 (m, 2 H), 3.04 (s, 3 H), 3.36 - 3.46 (m, 3 H), 3.56 (s, 1 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.33, 3.91 Hz, 2 H), 7.13 (s, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.45 (s, 1 H); (M+H) = 455.3; Accurate mass: calculated (M+H)+ for C26H38N4O3: 455.30167; Found: 455.30119.
Example 128:
(R)-N-(4-(2-Methoxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000216_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (80mg, 0.19 mmol), 2-methoxyethylamine (0.020 mL, 0.23 mmol) and O-(7-azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (88 mg, 0.23 mmol) were stirred in DMF (5 mL) containing N,N- diisopropylethylamine (0.084 mL, 0.48 mmol) at 23 0C for Ih. The solvent was concentrated. The product was directly purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep Cl 8 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A: H2O with
15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (60 mg, 66 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.36 - 1.50 (m, 2 H), 1.51 - 1.61 (m, 3 H), 1.77 (t, J=12.11 Hz, 2 H), 1.87 (s, 1 H), 1.97 (s, 2 H), 2.11 - 2.19 (m, 1 H), 2.28 (s, 1 H), 2.34 - 2.43 (m, 1 H), 2.62 - 2.73 (m, 1 H), 2.80 - 2.89 (m, 2 H), 3.04 (s, 3 H), 3.12 (s, 1 H), 3.23 (s, 2 H), 3.30 - 3.36 (m, 3 H), 3.36 - 3.46 (m, 4 H), 3.56 (s, 1 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.33, 3.91 Hz, 2 H), 7.12 (s, 1 H), 7.30 (d, J=8.98 Hz, 1 H), 7.46 (s, 1 H); (M+H) = 470.2; Accurate mass: calculated (M+H)+ for C27H39N3O4: 470.30133; Found: 470.30124.
Example 129:
(R)-N-(4-(lH-Pyrrol-l-ylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000217_0001
(R)-4-(N,9-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxamido)butanoic acid (80mg, 0.19 mmol), 1-aminopyrrole (0.018 mL, 0.23 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (88 mg, 0.23 mmol) were stirred in DMF (5 mL) containing N,N-diisopropylethylamine
(0.084 mL, 0.48 mmol) at 23 0C for Ih. The solvent was concentrated. The product was directly purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep C18 OBD, 30 x 50 mm, 5 mm particle size.
Mobile phase: 30-50%B; A: H2O with 15mM NH4CO3 and 0.375% NH4OH v/v, B:
CH3CN; 45mL/min, 15 min run, rt. (47 mg, 50 %). 1H NMR (400 MHz, METHANOL-
D4) δ 1.36 - 1.49 (m, 2 H), 1.50 - 1.62 (m, 3 H), 1.76 (t, J=13.09 Hz, 2 H), 1.96 (s, 1 H), 2.07 (s, 1 H), 2.11 - 2.21 (m, 2 H), 2.34 - 2.49 (m, 2 H), 2.63 - 2.76 (m, 1 H), 2.84 (t, J=14.65 Hz, 2 H), 3.07 (s, 3 H), 3.36 - 3.51 (m, 3 H), 3.64 (s, 4 H), 3.93 - 4.03 (m, 2 H), 5.94 (s, 1 H), 6.04 (s, 1 H), 6.20 (s, 1 H), 6.64 (s, 1 H), 7.16 (d, J=7.03 Hz, 1 H), 7.33 (d, J=8.59 Hz, 1 H), 7.51 (s, 1 H); (M+H) = 477.2; Accurate mass: calculated (M+H)+ for C28H36N4O3: 477.28602; Found: 477.28622.
Example 130: Step A:
(R)-N-Ethyl-N-(4-(2-hydroxyethylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000218_0001
(R)-9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carboxylic acid (100 mg, 0.32 mmol), 4-(ethylamino)-N-(2-hydroxyethyl)butanamide hydrochloride (81 mg, 0.38 mmol) and O-(7-azabenzotriazol-l-yl)-N,N,N',N- tetramethyluronium hexafluorophosphate (146 mg, 0.38 mmol) were stirred in DMF (8 mL) containing N,N-diisopropylethylamine (0.139 mL, 0.80 mmol) at 23 0C for Ih. Another 1.2 eq of 4-(ethylamino)-N-(2-hydroxyethyl)butanamide hydrochloride (81 mg, 0.38 mmol) was added and the solution was stirred for another Ih. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. LC/MS showed presence of product at 512, probably acylated product from residual AcOH. The residue was then stirred in 5 mL of MeOH containing some NaOMe at rt for 15min. LC/MS showed only the presence of the desired product. Purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with X-Bridge Prep Cl 8 OBD, 30 x 50 mm, 5 mm particle size. Mobile phase: 30-50%B; A: H2O with
15mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN; 45mL/min, 15 min run, rt. (75 mg, 50 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.10 (s, 2 H), 1.23 (s, 1 H), 1.37 - 1.48 (m, 2 H), 1.52 - 1.60 (m, 3 H), 1.77 (t, J=12.50 Hz, 2 H), 1.82 - 1.90 (m, 1 H), 1.92 -
2.02 (m, 2 H), 2.12 - 2.19 (m, 1 H), 2.29 (s, 1 H), 2.33 - 2.42 (m, 1 H), 2.63 - 2.73 (m, 1
H), 2.79 - 2.89 (m, 2 H), 3.03 - 3.16 (m, 1 H), 3.30 - 3.37 (m, 2 H), 3.36 - 3.46 (m, 4 H),
3.49 - 3.60 (m, 3 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.08 (d, J=8.20 Hz, 1
H), 7.31 (d, J=8.20 Hz, 1 H), 7.41 (s, 1 H); (M+H) = 470.2; Accurate mass: calculated (M+H)+ for C27H39N3O4: 470.30133; Found: 470.30192.
Step B: 4-(Ethylamino)butanoic acid
Figure imgf000219_0001
l-Ethyl-2-pyrrolidinone (2.016 mL, 17.67 mmol) and barium hydroxide hydrate (3.35 g, 17.67 mmol) were refluxed in water (20 mL) at 110 0C for 12h. The solution was cooled to 00C and CO2 gas was bubbled through the solution for 15 min to precipitate the barium hydroxide. The solution was filtered and the filtrate was concentrated to dryness. The solid obtained was triturated with MeCN, filtered and washed with ether. The product was dried under vacuum. (1.20 g , 52 %). 1H NMR (400 MHz, DEUTERIUM OXIDE) δ 1.21 (t, J=7.42 Hz, 3 H), 1.77 - 1.90 (m, 2 H), 2.23 (t, J=7.23 Hz, 2 H), 2.91 - 3.07 (m, 4 H).
Step C: 4-(tert-Butoxycarbonyl(ethyl)amino)butanoic acid
Figure imgf000219_0002
4-(Ethylamino)butanoic acid (1.15 g, 8.77 mmol) was dissolved in a mixture of dioxane (50 mL) and water (50.0 mL) containing potassium carbonate (0.997 mL, 17.53 mmol) at 00C. Di-tert-butyl dicarbonate (2.218 mL, 9.64 mmol) was added and the solution was stirred at 23 0C overnight. The solvent was concentrated. The aqueous residue was washed with ether. The aqueous layer was then acidified with 5% KHSO4 and extracted (2X) with EtOAc. The organic phase was dried over anhydrous MgSO4 and evaporated. (1.55 g, 76 %). 1H NMR (400 MHz, CHLOROFORM-D) D 1.11 (t, J=7.03 Hz, 3 H), 1.46 (s, 9 H), 1.85 (dt, J=14.06, 7.03 Hz, 2 H), 2.37 (t, J=7.03 Hz, 2 H), 3.16 - 3.32 (m, 4 H); (M+H) = 232.27.
Step D:
4-(Ethylamino)-N-(2-hydroxyethyl)butanamide hydrochloride
Figure imgf000220_0001
4-(tert-Butoxycarbonyl(ethyl)amino)butanoic acid (300 mg, 1.30 mmol), O-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (592 mg, 1.56 mmol) and ethanolamine (0.094 mL, 1.56 mmol) were stirred in DMF (8 mL) containing N,N-diisopropylethylamine (0.339 mL, 1.95 mmol) at 23 0C for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, saturated aqueous NaHCO3, brine and dried over anhydrous MgSO4. The product was purified by flash chromatography. The product was then stirred in hydrogen chloride (12.97 mL, 12.97 mmol) (IM in AcOH) at 23 0C for Ih. The solvent was concentrated. The product was washed a few times with ether and dried under vacuum. Still some AcOH left in the product. Used directly for the next step. Yield: 275 mg (122%); (M+H) = 289.29 (Boc product; de-Boc product could not be observed by LC/MS).
Example 131:
(R)-N-(4-(2-Hydroxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide
Figure imgf000221_0001
(R)-Methyl 4-(N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-6-carboxamido)butanoate (100 mg, 0.23 mmol) was stirred in dioxane (5 mL) containing lithium hydroxide (0.469 mL, 0.47 mmol) (IM) at 23 0C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO4, brine and dried over anhydrous Na2SO4. The solvent was evaporated. The product was dissolved in DMF (5.00 mL) containing N,N-diisopropylethylamine (0.102 mL, 0.59 mmol) and ethanolamine (0.017 mL, 0.28 mmol) along with O-(7-azabenzotriazol-l-yl)- N,N,N',N'-tetramethyluronium hexafluorophosphate (107 mg, 0.28 mmol) were added. The solution was stirred at 23 0C for Ih. The solvent was evaporated. The product was directly purified by reversed-phase HPLC and lyophilized. Reversed-phase purification: Gilson system equipped with Luna C-18 column, 250 X 21.2 mm, 15u. Mobile phase: 20-40%B; A: H2O with 0.05% TFA v/v; B: CH3CN; 30mL/min, 25 min run, rt. (55 mg, 52 %). 1H NMR (400 MHz, METHANOL-D4) δ 1.37 - 1.49 (m, 2 H), 1.51 - 1.62 (m, 3 H), 1.76 (t, J=12.50 Hz, 2 H), 1.86 (s, 1 H), 1.99 (d, J=I 1.72 Hz, 2 H), 2.11 - 2.20 (m, 1 H), 2.30 (s, 1 H), 2.34 - 2.43 (m, 1 H), 2.62 - 2.73 (m, 1 H), 2.79 - 2.90 (m, 2 H), 3.04 (s, 4 H), 3.36 - 3.46 (m, 4 H), 3.57 (s, 2 H), 3.62 (s, 3 H), 3.97 (dd, J=I 1.13, 3.71 Hz, 2 H), 7.13 (s, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.46 (s, 1 H); (M+H) = 456.2; Accurate mass: calculated (M+H)+ for C26H37N3O4: 456.28568; Found: 456.286.

Claims

What is claimed is:
1. A compound of formula I, a pharmaceutically acceptable salt thereof, a diastereomer, an enantiomer, or a mixture thereof:
Figure imgf000222_0001
wherein
Y is selected from
Figure imgf000222_0002
Figure imgf000222_0003
is selected from -H, Ci-6alkyl, C2-6alkenyl, C3_6cycloalkyl, C3_6cycloalkyl-Ci_
4alkyl, -C(O)-NR14R15, -SC=O)2-NR14R15, -S(=O)2-Ci_6alkyl, -S(=0)2-C6-ioaryl, - S(=O)2-C2_5heteroaryl, -C(=O)-Ci_6alkyl, -C(=O)-O-Ci_6alkyl, C6-ioaryl-Ci_4alkyl and C2_ 5heteroaryl-Ci_4alkyl, wherein said Ci-βalkyl, C2_6alkenyl, -S(=O)2-Ci_6alkyl, -S(=O)2-C5- loaryl, -S(=O)2-C2_5heteroaryl, -C(=0)-Ci_6alkyl, C6-ioaryl-Ci_4alkyl and C2_5heteroaryl- Ci_4alkyl used in defining R are optionally substituted with one or more groups selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(=0> NH2, -C(=0)-NR2 and -C(=0)-NHR;
R2 is selected from Cs-όheterocycloalkyl, C3_6heterocycloalkyl-Ci_4alkyl, C3_6cycloalkyl, C3_6cycloalkyl-Ci_4alkyl, Ci_6alkyl, C2_6alkenyl, Cβ-ioaryl, Co-ioaryl-Ci- 4alkyl, C2_6heteroaryl, C2_6heteroaryl-Ci_4alkyl, -C(=O)-Ci_6alkyl, -C(=O)-C3-6cycloalkyl and -C(=NH)-Ci_6alkyl, wherein said Cs-όheterocycloalkyl, C3_6heterocycloalkyl-Ci_ 4alkyl, C3-6cycloalkyl, C3-6cycloalkyl-Ci_4alkyl, Ci-βalkyl, C2_6alkenyl, Cs-ioaryl, Cδ-ioaryl- Ci_4alkyl, C2_6heteroaryl, C2_6heteroaryl-Ci_4alkyl, -C(=O)-Ci_6alkyl, -C(=O)-C3- όCycloalkyl and -C(=NH)-Ci_6alkyl used in defining R are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -CN, -C(=O)-NH2 and -C(=O)-NHR;
R3 and R4 are independently selected from -H, C3-6cycloalkyl, C3_6heterocycloalkyl, C2_sheteroaryl, Cό-ioaryl, Ci-6alkyl, Ci-6alkoxy, amino, Q- ealkylamino, diCi_6alkylamino, -C(=O)-C1-6alkyl, -C(=O)-O-C1-6alkyl, -C(O)-C3- ecycloalkyl, -C(=O)-NR14R15 and -S(=O)2-NR14R15, wherein said C3-6cycloalkyl, Q-βheterocycloalkyl, C2-5heteroaryl, Cβ-ioaryl, Q_6alkyl, Ci_6alkoxy, Ci_6alkylamino, diCi_6alkylamino, -C(O)-Q_6alkyl, -C(O)-0-Q_6alkyl, and -C(=O)-C3-6cycloalkyl used in defining R3 and R4 are optionally substituted with one or more groups selected from - OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -Q=O)-NH2, -CN, -C(O)-NR2 and -C(O)-NHR;
R5 is selected from -H, Q-6alkyl, and C3_6Cycloalkyl;
R6 is independently selected from -H, -CN, -NO2, Q_6alkoxy, halogen, Q-6alkyl, -OH, -NH2, -NHC(O)R12 and -C(O)NR12R13;
R12 and R13 are independently selected from -H, Q_6alkyl, Ci_6alkoxy, C3. 6heterocycloalkyl, C3_6cycloalkyl-Ci_4alkyl, and C3_6cycloalkyl wherein said Q^alkyl, Q- βalkoxy, Q-βheterocycloalkyl, C3_6cycloalkyl-Ci_4alkyl and C3_6Cycloalkyl used in defining R12 and R13 are optionally substituted with one or more halogens or -OH; R14 and R15 are independently selected from -H, Q-βalkyl, Cβ-ioaryl, Ce-ioaryl-Q.
4alkyl, C2-5heterocyclyl, C2-5heterocyclyl-Ci-4alkyl, C2_6alkenyl, C3_6cycloalkyl, and C3_ 6Cycloalkyl-Q-4alkyl, N,N-di(Q-4alkyl)amido-Q-6alkyl, hydroxy-Q_6alkyl and Q- 6alkoxy-Ci_6alkyl that are optionally substituted with one or groups selected from halogen, -OH, -CN, -NH2 and methoxy; Q is independently selected from Q^alkylene, Q-βalkylidene and
Figure imgf000223_0001
, wherein said Ci_6alkylene and Q_6alkylidene are optionally substituted with on or more groups selected from -OR, -R, hydroxy-Q_6alkyl, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)- NR2 and -C(O)-NHR; X is selected from -OH, halogen or -OR; n is independently selected from 1, 2 and 3; p, q and m are independently selected from O, 1, 2 and 3; and
R is independently Ci_6alkyl.
2. A compound as claimed in claim 1, wherein
R1 is selected from Ci-βalkyl, C3-6cycloalkyl, C3-6cycloalkyl-Ci-4alkyl, and - S(=O)2-C1-6alkyl;
R2 is selected from Ci-6alkyl, C2-sheterocycloalkyl and C3_6cycloalkyl wherein said Ci-6alkyl, C2-sheterocycloalkyl and C3_6cycloalkyl used in defining R2 is optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2- R, halogen, -OH, -NH2, -NHR, -CN, -Q=O)-NH2, and -C(O)-NHR;
R3 and R4 are independently selected from -H, C3-6cycloalkyl, C3_ 6heterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and
Figure imgf000224_0001
wherein said C3-6cycloalkyl, Q-δheterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and Ci_6alkyl used in defining R is optionally substituted with one or more groups selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(O)-NH2, -C(O)-NR2, and -C(O)-NHR;
R5 is selected from -H, Ci_6alkyl, and C3_6cycloalkyl;
R6 is selected from C1-6alkyl, -OH, -NH2, -NHC(O)R12 and -C(O)NR12R13; R12 and R13 are independently selected from -H, Ci-βalkyl, Ci_6alkoxy, C3.
6heterocycloalkyl, C3_6cycloalkyl-Ci_4alkyl, and C3_6cycloalkyl wherein said Ci_6alkyl, C1- 6alkoxy, Q-δheterocycloalkyl, C3-6cycloalkyl-Ci-4alkyl, and C3-6cycloalkyl used in defining R12 and R13 is optionally substituted with one or more haolgens; and
R is independently Ci_6alkyl.
3. A compound as claimed in any one of claims 1-2, wherein
R1 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, allyl, -S(O)2-CH3, -S(O)2-CH2CH3, 2-methoxyethyl, tetrahydropyran-4-yl-methyl, 1- propylsulfonyl, 2-propylsulfonyl, cyclopropylsulfonyl, phenyl, phenylsulfonyl, 2- (methoxycarbonyl)-phenylsulfonyl; 2-(hydroxycarbonyl)-phenylsulfonyl, 1 -methyl- IH- imidazol-4-yl-sulfonyl, lH-imidazol-1-yl-sulfonyl, (5-methylisoxazol-4-yl)sulfonyl, morpholin-4-ylcarbonyl, 4-amino-phenyl, -CH2-C(=O)-N(CH3)2, -C(=O)-N(CH3)2, - S(=O)2-N(CH3)2, -SC=O)2-NHCH2CH3, -C(O)-CH2CH2CH3, -CH2-C(O)-OCH3, - CH2-C(O)-OCH2CH3, -CH2-CO2H, benzyl, 4-aminobenzyl, 4-nitrobenzyl, 4- methylsulfonyl-benzyl, 4-methylthio-benzyl, 4-acetylamino-benzyl, 4-methoxy-benzyl, 4-ethoxy-benzyl, 2,6-difluorobenzyl, (6-chloro-l,3-benzodioxol-5-yl)methyl, (5- ethoxycarbonyl)-fur-2-yl-methyl, (2-methyl- 1 ,3-thiazol-4-yl)-methyl, (5-methyl- isoxazol-4-yl)-methyl, pyridin-2-ylmethyl, cyclobutylmethyl, and cyclopropylmethyl; and
R2 is selected from methyl, ethyl, isopropyl, propyl, 2-methy-propyl, 1 -butyl, tert- butyl, 1-pentyl, l-acetyl-piperidin-4-yl, tetrahydrothien-3-yl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-tetrahydro- 2H-pyranyl, tetrahydro-thiopyran-4-yl, 2-pyrimidinyl, 1-iminoethyl, 2-pyridinyl, 3,4,5,6- tetrahydropyrdin-2-yl, 3,4-dihydro-2H-pyrrol-5-yl, 2-pyridinyl-methyl, 3- pyridinylmethyl, 4-pyridinylmethyl, l-methyl-4-piperidinyl, 4-piperidinyl, (6-methyl- pyridin-2-yl)methyl, (2-ethyl-4-methyl-lH-imidazol-5-yl)methyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-3-ylmethyl, 1 -ethyl- lH-pyrazol-4-yl, 1,3-dimethyl- lH-pyrazol-5-yl, (3-methylpyridin-4-yl)methyl, l,3-oxazol-2-ylmethyl, l,3-oxazol-5- ylmethyl, 2-(tetrahydro-2H-pyran-4-yl)ethyl, tetrahydro-2H-pyran-4-ylmethyl, 2- phenylethyl, 2-methoxybenzyl, 3,3,3-trifluoropropyl, 2,2-difluoroethyl, 2- hydroxycyclopentyl, (l-ethyl-3-methyl-lH-pyrazol-5-yl)methyl, 2,l,3-benzoxadiazol-5- ylmethyl, 3-thienylmethyl, 2-trifluoromethyl-benzyl, 3-methylbutyl, cyclohex-3-en-l- ylmethyl, 2-fluoro-6-methoxybenzyl, 2-phenyl-propyl, 2-ethyl-butyl, cyclobutylcarbonyl, 2,2-difluoropropanoyl, cyclopentylcarbonyl, tetrahydro-2H-pyran-4-ylcarbonyl, cyclopropylcarbonyl, propylcarbonyl, N-ethylaminocarbonyl, N- isopropylaminocarbonyl, cyclopropylsulfonyl, and ethylsulfonyl.
4. A compound as claimed in any one of claims 1-3, wherein
Figure imgf000225_0001
;
R5 is selected from -H, Ci_6alkyl, and C3_6Cycloalkyl; R3 and R4 are independently selected from -H, C3-6cycloalkyl, C3- 6heterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and Ci^alkyl, wherein said Ci-βalkyl, Cs-δheterocycloalkyl, C2_5heteroaryl, diCi_6alkylamino, Ci-βalkoxy, and C3- όCycloalkyl used in defining R and R are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, - C(O)-NH2, -CN, and -Q=O)-NHR;
Q is Ci-6alkylene or Ci_6alkylidene, optionally substituted with one or more -CH2OH; and
R is C1-6alkyl.
5. A compound as claimed in any one of claims 1-4, wherein
Y is
Figure imgf000226_0001
R5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl; R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl used in defining R3 and R4 are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen; -OH, -NH2, -NHR, -C(O)-NH2, -CN and -C(O)-NHR;
Q is Ci_6alkylene or Ci_6alkylidene, optionally substituted with one or more -CH2OH; and R is Ci_6alkyl.
6. A compound as claimed in any one of claims 1-5, wherein
Figure imgf000227_0001
R5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl; R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, oxetanyl, pyrrolyl, methoxy, dimethylamino, and cyclohexyl used in defining R3 and R4 are optionally substituted with one or more groups selected from fluoro, -CN, -OH, and methoxy;
R1 is selected from methyl, ethyl, -S(=O)2-CH3, -S(=O)2-CH2CH3, and 2- propylsulfonyl;
Q is selected from Ci-6alkylene, hydroxymethyl-Ci_6alkylene, and Ci_6alkylidene; and R2 is tetrahydropyranyl.
A compound as claimed in claim 1 , wherein
Figure imgf000227_0002
R5 is selected from methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, and t-butyl; R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl,
1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, and cyclohexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, and cyclohexyl used in defining R and R are optionally substituted with one or more fluoro; R1 is selected from methyl, ethyl, -S(=O)2-CH3, -S(=O)2-CH2CH3, and 2- propylsulfonyl;
Q |s
Figure imgf000228_0003
R2 is tetrahydropyranyl; n is selected from 1,2 and 3; and p, q are independently selected from O, 1, 2 and 3.
8. A compound as claimed in claim 1, wherein
Figure imgf000228_0001
R6 is selected from Ci_6alkyl, -OH, -NH2, -NHC(=O)R12 and -C(=O)NR12R13 wherein R12 and R13 are independently selected from -H, Ci-βalkyl, and C3_6Cycloalkyl wherein said Ci_6alkyl and C3_6cycloalkyl used in defining R12 and R13 is optionally substituted with one or more halogens; and n is 1, 2, or 3; and m is 1.
9. A compound as claimed in any one of claims 1 and 8, wherein
Figure imgf000228_0002
R6 is selected from methyl, -OH, -NH2, -NHC(=O)R12 and -C(=O)NR12R13 wherein R12 and R13 are independently selected from -H, Ci_6alkyl, and C3_6Cycloalkyl wherein said Ci_6alkyl and C3_6cycloalkyl used in defining R12 and R13 is optionally substituted with one or more halogens;
R1 is selected from methyl, ethyl, -S(=O)2-CH3, -S(=O)2-CH2CH3j and 2- propylsulfonyl;
R2 is selected from C3_6cycloalkyl, tetrahydropyranyl and Ci_6alkyl; and n is 1,2 or 3; and m is 1.
10. A compound as claimed in claim I, wherein
Y is
Figure imgf000229_0001
R5 is selected from -H, Ci-βalkyl, and C3-6cycloalkyl;
R3 and R4 are independently selected from -H, Chalky 1, -C(=0)-Ci_6alkyl, -C(=O)-C3-6cycloalkyl, -C(O)-NR14R15 and -S(O)-NR14R15; wherein said C1-6alkyl, -C(O)-Ci_6alkyl and -C(O)-C3 -6cycloalkyl used in defining R3 and R4 is optionally substituted with one or more group selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(O)-NH2, -C(O)-NR2 and -C(O)-NHR; Q is Ci_6alkylene or Ci_6alkylidene; R is Ci_6alkyl; and
R14 and R15 are independently selected from -H, Ci-βalkyl, Cβ-ioaryl, Cδ-ioaryl-Ci. 4alkyl, Cs-δheterocyclyl, C3-6heterocyclyl-Ci_4alkyl, C2_6alkenyl, C3-6cycloalkyl, C3- δCycloalkyl-Ci^alkyl, N,N-di(Ci-4alkyl)amido-Ci.6alkyl, hydroxy-Ci_6alkyl and Ci-
6alkoxy-Ci_6alkyl that are optionally substituted with one or more groups selected from halogen, -OH, -CN, -NH2 and methoxy.
11. A compound as claimed in any one of claims 1 and 10, wherein
Y is
Figure imgf000229_0002
R5 is methyl; and
R3 and R4 are independently selected from -H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclobutyl, cyclopentyl, cyclopropanecarbonitryl, cyclohexyl, - C(0)-cyclopropyl, -CO2CH3, and -S(0)2-NH-cyclopropyl.
12. A compound as claimed in claim 1, wherein Y is
Figure imgf000230_0002
R3 and R4 are independently selected from -H, Ci-6alkyl, Ci_6cycloalkyl, C3- 6heterocycloalkyl, wherein said Ci_6alkyl, Ci-3cycloalkyl, and Cs-όheterocycloalkyl are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2- R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)-NR2 and -C(O)- NHR; and
R is C1-6alkyl.
13. A compound as claimed in claim 1, wherein
Figure imgf000230_0001
R3 and R4 are independently selected from -H, methyl, and ethyl wherein said methyl and ethyl are optionally substituted with -OH or halogen.
14. A compound as claimed in any one of claims 1-13, wherein R is tetrahydropyranyl.
15. A compound as claimed in any one of claims 1-14, wherein R2 is 4- tetrahydropyranyl.
16. A compound selected from
N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(+)-N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; (-)-N-[2-(Cyclopropylamino)-2-oxoethyl]-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-N-[2-(ethylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide; N-Ethyl-N-[2-(isopropylamino)-2-oxoethyl]-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carbonyl)piperidine-4-carboxamide; N-Ethyl-N-{2-[(2-fluoroethyl)amino]-2-oxoethyl}-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-[2-(Cyclopropylamino)-2-oxoethyl]-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Cyclopropyl-2-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbonyrjazetidin-S-yFjacetamide;
N,9-Dimethyl-N-(2-(methylamino)ethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-(2-(3-Cyclopropyl-l-methylureido)ethyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(2-(3 -Cyclopropyl- 1 -methylthioureido)ethyl)-N,9-dimethyl-3 -(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-{2-[(2-Fluoroethyl)amino]-2-oxoethyl}-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-[2-(methylamino)-2-oxoethyl]-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
Methyl, methyl[2-(methyl{[9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazol-6-yl]carbonyl}amino)ethyl]carbamate;
N-{2-[(Cyclopropylcarbonyl)(methyl)amino]ethyl}-N,9-dimethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Cyclopropyl- 1 - { [9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazol-β-yljcarbonyljpiperidine-S-carboxamide;
N-Cyclopropyl- 1 - { [9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazol-β-yljcarbonyljazetidine-S-carboxamide;
N-Ethyl-N-{2-[(l-isocyanocyclopropyl)amino]-2-oxoethyl}-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(3-(cyclopropylamino)-3-oxopropyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(4-(Cyclopropylamino)-4-oxobutyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Cyclopropylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Methylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Ethylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N-methyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; 3-cyclohexyl-9-methyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro-lH- carbazole;
3-cyclohexyl-9-ethyl-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3 ,4,9-tetrahydro- IH- carbazole;
3-cyclohexyl-6-[(4-methylpiperidin-l-yl)carbonyl]-9-(methylsulfonyl)-2,3,4,9- tetrahydro-lH-carbazole;
3-cyclohexyl-9-(ethylsulfonyl)-6-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,9-tetrahydro- lH-carbazole;
3-cyclohexyl-N-[2-(cyclopropylamino)-2-oxoethyl]-N-methyl-9-(methylsulfonyl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; 3-cyclohexyl-N-[2-(cyclopropylamino)-2-oxoethyl]-9-(isopropylsulfonyl)-N-methyl-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-(2-oxo-2-(tetrahydro-2H-pyran-4-ylamino)ethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-(2-oxo-2-((S)-tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-9-methyl-N-(2-oxo-2-((R)-tetrahydrofuran-3-ylamino)ethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-methyl-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Ethyl-N-(4-hydroxybutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(Cyanomethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-((S)- 1 -(2-Fluoroethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3 -(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-((S)-l-(Cyclopropylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; N-(4-(Cyclopropylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-(l-(Cyclopropylcarbamoyl)cyclopropyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-Fluoroethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamide;
N-Ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-((R)- 1 -(2-fluoroethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3 -(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; N-((R)- 1 -(ethylamino)- 1 -oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-N-(2-hydroxypropyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(2-Cyanoethylamino)-2-oxoethyl)-N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; (3 S)-N-Cyclopropyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-6-carbonyl)piperidine-3-carboxamide;
(3 S)-N-cyclopropyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^piperidine-S-carboxamide; N,9-Dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(2-(Cyclopropylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(2-Fluoroethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-N-(2-hydroxyethyl)-9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-Cyclopropyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3S)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3R)-N-Cyclopropyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
N-(2-Fluoroethyl)- 1 -(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
N-Ethyl-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)pyrrolidine-3-carboxamide; N-Cyclopropyl-2-((3R)- l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- IH- carbazole-β-carbony^pyrrolidin-S-y^acetamide;
N-((3 S)- 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide;
(3S)-N-(2-Fluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^pyrrolidine-S-carboxamide; (3S)-N-(Cyclopropylmethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9- tetrahydro-lH-carbazole-β-carbony^pyrrolidine-S-carboxamide;
N-( 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-4-yl)cyclopropanecarboxamide; N-(l-(9-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6- carbonyl)piperidin-3-yl)cyclopropanecarboxamide;
(3S)-N-(2,2-Difluoroethyl)-l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-β-carbony^pyrrolidine-S-carboxamide;
(3 S)-N-Ethyl- 1 -(9-methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- IH- carbazole-β-carbony^pyrrolidine-S-carboxamide;
N-( 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-3-yl)propionamide;
N-( 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-3-yl)isobutyramide; 2-Cyclopropyl-N-(l-(9-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-β-carbony^piperidin-S-y^acetamide;
N-(4-(2-Hydroxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-((3 S)- 1 -(9-Methyl-3 -(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6- carbonyl)piperidin-3-yl)cyclopropanecarboxamide;
N,9-Dimethyl-N-(4-oxo-4-((S)-tetrahydrofuran-3-ylamino)butyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N,9-Dimethyl-N-(4-(oxetan-3-ylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(4-(3-Hydroxypropylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((R)-3-hydroxypyrrolidin- l-yl)methanone; (9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((S)-3-hydroxypyrrolidin- 1 -yl)methanone;
(9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazol-6- yl)((R)-3 -hydroxypiperidin- 1 -yl)methanone; (9-(Ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazol-6-yl)(4- hydroxypiperidin- 1 -yl)methanone;
N6-Ethyl-N6-(2-(ethylamino)-2-oxoethyl)-N9,N9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-3,4-dihydro-lH-carbazole-6,9(2H)-dicarboxamide;
N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide;
Ethyl 2-(6-(ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)-
3,4-dihydro-lH-carbazol-9(2H)-yl)acetate;
2-(6-(Ethyl(2-(ethylamino)-2-oxoethyl)carbamoyl)-3-(tetrahydro-2H-pyran-4-yl)-3,4- dihydro- lH-carbazol-9(2H)-yl)acetic acid; 9-(2-(diethylamino)-2-oxoethyl)-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-(methylamino)-2-oxoethyl)-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-hydroxy-2-methylpropyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-hydroxyethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
2-(N-Ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid; N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-(ethylsulfonyl)-N-(2-(2-methoxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-Ethyl-9-(ethylsulfonyl)-N-(2-(oxetan-3-ylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran- 4-yl)-2,3,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-[2-(cyclopropylamino)-2-oxoethyl]-9-(cyclopropylmethyl)-N-ethyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-(Cyclopropylmethyl)-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; 9-Cyclobutyl-N-ethyl-N-(2-(ethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-Cyclobutyl-N-ethyl-N-(2-(2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
9-Cyclobutyl-N-ethyl-N-(2-(isopropylamino)-2-oxoethyl)-3-(tetrahydro-2H-pyran-4-yl)- 2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-Ethyl-N-methyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
9-Ethyl-N-(4-(2-fluoroethylamino)-4-oxobutyl)-N-methyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-(4-(2,2-difluoroethylamino)-4-oxobutyl)-9-ethyl-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
9-Ethyl-N-methyl-N-(4-oxo-4-(2,2,2-trifluoroethylamino)butyl)-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
9-Ethyl-N-(4-(2-hydroxyethylamino)-4-oxobutyl)-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-Ethyl-N-(2-(ethylamino)-2-oxoethyl)-9-(2-fluoroethyl)-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-(4-(Ethylamino)-4-oxobutyl)-9-(2-fluoroethyl)-N-methyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; N-ethyl-9-(ethylsulfonyl)-N-(2-(2-hydroxyethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-9-(ethylsulfonyl)-N-(2-(3-hydroxypropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-9-(ethylsulfonyl)-N-(2-(3-fluoropropylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-ethyl-9-(ethylsulfonyl)-N-(2-(2-fluoroethylamino)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
2-(N-ethyl-9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH- carbazole-6-carboxamido)acetic acid; N-(2-(cyclopropylamino)-2-oxoethyl)-9-(ethylsulfonyl)-N-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(2R)- 1 -(9-(ethylsulfonyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3 ,4,9-tetrahydro- 1 H-carbazole-
6-carbonyl)-N-(2-fluoroethyl)pyrrolidine-2-carboxamide;
N-(2-(2,2-difluoroethylamino)-2-oxoethyl)-N-ethyl-9-methyl-3-(tetrahydro-2H-pyran-4- yl)-2 ,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxamide;
N-ethyl-N-(2-((R)-2-hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
N-ethyl-N-(2-((S)-2-hydroxypropylamino)-2-oxoethyl)-9-methyl-3-(tetrahydro-2H- pyran-4-yl)-2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; N-ethyl-N-(2-(2-methoxyethylamino)-2-oxoethyl)-9-methyl-3 -(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
N-((R)-l-(cyclopropylamino)-l-oxopropan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; and pharmaceutically acceptable salts thereof.
17. A compound selected from:
(R)-N-((S)-l-Hydroxy-5-(oxetan-3-ylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-((S)-5-(2,2-Difluoroethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3- (tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-((S)-5-(2-Fluoroethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-(4-(Cyanomethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide; (R)-N-((S)-l-Hydroxy-5-(methylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro-
2H-pyran-4-yl)-2, 3, 4,9-tetrahydro-l H-carbazole-6-carboxamide; (R)-N-((S)-l-Hydroxy-5-(isopropylamino)-5-oxopentan-2-yl)-N,9-dimethyl-3-
(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-((S)-5-(Ethylamino)-l-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro-
2H-pyran-4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; (R)-N-(4-(Methoxyamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-
2,3 ,4,9-tetrahydro- lH-carbazole-6-carboxamide;
(R)-N-(4-(2,2-Dimethylhydrazinyl)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-(4-(2-Methoxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2 ,3 ,4,9-tetrahydro- 1 H-carbazole-6-carboxamide;
(R)-N-(4-(lH-Pyrrol-l-ylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide;
(R)-N-Ethyl-N-(4-(2-hydroxyethylamino)-4-oxobutyl)-9-methyl-3-(tetrahydro-2H-pyran-
4-yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; (R)-N-(4-(2-Hydroxyethylamino)-4-oxobutyl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4- yl)-2,3,4,9-tetrahydro-lH-carbazole-6-carboxamide; and pharmaceutically acceptable salts thereof.
18. A compound according to any one of claims 1-17 for use as a medicament.
19. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the therapy of pain.
20. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the treatment of anxiety disorders.
21. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders or cardiovascular disorders.
22. A pharmaceutical composition comprising a compound according to any one of claims 1-17 and a pharmaceutically acceptable carrier.
23. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-17.
24. A process for preparing a compound of Formula I comprising reacting a compound of Formula II with Y-H,
Figure imgf000240_0001
comprising reacting a compound of Formula II with Y-H,
Figure imgf000240_0002
wherein
Y is selected fro
Figure imgf000240_0004
Figure imgf000240_0003
R1 is selected from -H, Ci-6alkyl, C2-6alkenyl, C3_6cycloalkyl, C3-6Cycloalkyl-Ci- 4alkyl, -C(=O)-NR14R15, -SC=O)2-NR14R15, -S(=O)2-Ci_6alkyl, -S(=0)2-C6-ioaryl, - S(=O)2-C2_5heteroaryl, -C(=O)-C1-6alkyl, -C(=O)-O-C1-6alkyl, C6-ioaryl-Ci_4alkyl and C2_ 5heteroaryl-Ci_4alkyl, wherein said Ci^alkyl, C2_6alkenyl, -S(=O)2-Ci_6alkyl, -S(O)2-C6- loaryl, -S(=O)2-C2_5lieteroaryl, -C(=0)-Ci_6alkyl, C6-ioaryl-Ci-4alkyl and C2_5heteroaryl- Ci_4alkyl used in defining R are optionally substituted with one or more groups selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(O)- NH2, -C(O)-NR2 and -C(=O)-NHR;
R2 is selected from Cs-όheterocycloalkyl, C3_6heterocycloalkyl-Ci_4alkyl, C3_6cycloalkyl, C3_6Cycloalkyl-Ci_4alkyl, Ci_6alkyl, C2_6alkenyl, Cβ-ioaryl, Cό-ioaryl-Ci- 4alkyl, C2-6heteroaryl, C2-6heteroaryl-Ci-4alkyl, -C(=O)-Ci_6alkyl, -C(=O)-C3-6cycloalkyl and -C(=NH)-Ci_6alkyl, wherein said C3_6heterocycloalkyl, C3_6heterocycloalkyl-Ci_ 4alkyl, C3-6cycloalkyl, C3-6cycloalkyl-Ci_4alkyl, Ci-βalkyl, C2_6alkenyl, Cβ-ioaryl, Cδ-ioaryl- Ci_4alkyl, C2-6heteroaryl, C2-6heteroaryl-Ci-4alkyl, -C(=O)-Ci_6alkyl, -C(O)-C3- όCycloalkyl and -C(=NH)-Ci_6alkyl used in defining R2 are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -CN, -C(O)-NH2 and -C(O)-NHR;
R3 and R4 are independently selected from -H, C3-6cycloalkyl, Cs-όheterocycloalkyl, C2_sheteroaryl, Cβ-ioaryl, Ci-6alkyl, Ci-6alkoxy, amino, Ci- galkylamino, diCi_6alkylamino, -C(O)-C1-6alkyl, -C(O)-0-C1-6alkyl, -C(O)-C3- ecycloalkyl, -C(O)-NR14R15 and -S(=O)2-NR14R15, wherein said C3-6cycloalkyl, Cs-όheterocycloalkyl, C2_sheteroaryl, Cβ-ioaryl, Ci-6alkyl, Ci-6alkoxy, Ci_6alkylamino, diCi_6alkylamino, -C(O)-C1-6alkyl, -C(O)-0-C1-6alkyl, and -C(=O)-C3-6cycloalkyl used in defining R3 and R4 are optionally substituted with one or more groups selected from - OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)-NR2 and -C(O)-NHR;
R5 is selected from -H, Ci-βalkyl, and C3_6cycloalkyl;
R6 is independently selected from -H, -CN, -NO2, Ci_6alkoxy, halogen, Ci-βalkyl, -OH, -NH2, -NHC(O)R12 and -C(=O)NR12R13; R12 and R13 are independently selected from -H, Ci-βalkyl, Ci_6alkoxy, C3. δheterocycloalkyl, C3-6Cycloalkyl-Ci-4alkyl, and C3_6Cycloalkyl wherein said Ci-βalkyl, Ci- βalkoxy, Cs-όheterocycloalkyl, C3_6Cycloalkyl-Ci_4alkyl and C3_6cycloalkyl used in defining R , 12 and R 1 13 are optionally substituted with one or more halogens or -OH;
R14 and R15 are independently selected from -H, Ci^alkyl, Cβ-ioaryl, Cδ-ioaryl-Ci. 4alkyl, C2_5heterocyclyl, C2-5heterocyclyl-Ci-4alkyl, C2-6alkenyl, C3-6cycloalkyl, and C3- 6Cycloalkyl-Ci-4alkyl, N,N-di(Ci-4alkyl)amido-Ci.6alkyl, hydroxy-Ci_6alkyl and Ci- 6alkoxy-Ci_6alkyl that are optionally substituted with one or groups selected from halogen, -OH, -CN, -NH2 and methoxy;
Q is independently selected from Ci_6alkylene, Ci_6alkylidene and
Figure imgf000242_0001
, wherein said Ci_6alkylene and Ci_6alkylidene are optionally substituted with on or more groups selected from -OR, -R, hydroxy-Ci_6alkyl, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)- NR2 and -C(O)-NHR;
X is selected from -OH, halogen or -OR; n is independently selected from 1, 2 and 3; p, q and m are independently selected from O, 1, 2 and 3;
R is independently Ci-βalkyl; and Z is a halogen or -OH.
25. A process for preparing a compound of Formula I
Figure imgf000242_0002
comprising reacting a compound of formula III with R -X ,
Figure imgf000243_0001
wherein,
X1 is selected from halogen and OH;
Y is selected from
Figure imgf000243_0002
Figure imgf000243_0003
R is selected from -H, Ci-6alkyl, C2-6alkenyl, C3_6cycloalkyl, C3_6cycloalkyl-Ci_ 4alkyl, -C(=O)-NR14R15, -SC=O)2-NR14R15, -S(=O)2-Ci_6alkyl, -S(=0)2-C6-ioaryl, - S(=O)2-C2_5heteroaryl, -C(=O)-Ci_6alkyl, -C(=O)-O-Ci_6alkyl, C6-ioaryl-Ci_4alkyl and C2_ 5heteroaryl-Ci_4alkyl, wherein said Ci-βalkyl, C2_6alkenyl, -S(=O)2-Ci_6alkyl, -S(=O)2-C6- loaryl, -S(=O)2-C2_5heteroaryl, -C(=0)-Ci_6alkyl, C6-ioaryl-Ci_4alkyl and C2_5heteroaryl- Ci_4alkyl used in defining R are optionally substituted with one or more groups selected from -OR, R, -CO2H, -CO2-R, -SO2-R, halogen, -NO2, -OH, -NH2, -NHR, -CN, -C(=0> NH2, -C(=O)-NR2 and -C(=O)-NHR; R2 is selected from Cs-όheterocycloalkyl, C3_6heterocycloalkyl-Ci_4alkyl,
C3_6cycloalkyl, C3_6cycloalkyl-Ci_4alkyl, Ci_6alkyl, C2_6alkenyl, Cβ-ioaryl, Co-ioaryl-Ci- 4alkyl, C2_6heteroaryl, C2_6heteroaryl-Ci_4alkyl, -C(=O)-Ci_6alkyl, -C(=O)-C3-6cycloalkyl and -C(=NH)-Ci_6alkyl, wherein said Cs-όheterocycloalkyl, C3_6heterocycloalkyl-Ci_ 4alkyl, C3_6cycloalkyl, C3_6cycloalkyl-Ci_4alkyl, d_6alkyl, C2_6alkenyl, C6-ioaryl, C6-ioaryl- Ci_4alkyl, C2_6heteroaryl, C2_6heteroaryl-Ci_4alkyl, -C(=O)-Ci_6alkyl, -C(=O)-C3- όCycloalkyl and -C(=NH)-Ci_6alkyl used in defining R2 are optionally substituted with one or more groups selected from -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -CN, -C(=O)-NH2 and -C(=O)-NHR;
R3 and R4 are independently selected from -H, C3-6cycloalkyl, C3-6heterocycloalkyl, C2_sheteroaryl, Cό-ioaryl, Ci-6alkyl, Ci-6alkoxy, amino, Ci- ealkylamino, diCi_6alkylamino, -C(=O)-C1-6alkyl, -C(=O)-O-C1-6alkyl, -C(O)-C3- ecycloalkyl, -C(=O)-NR14R15 and -S(=O)2-NR14R15, wherein said C3-6cycloalkyl, Cs-όheterocycloalkyl, C2-5heteroaryl, Cβ-ioaryl, Ci-βalkyl, Ci_6alkoxy, Ci_6alkylamino, diCi_6alkylamino, -C(=O)-C1-6alkyl, -C(=O)-O-C1-6alkyl, and -C(=O)-C3-6cycloalkyl used in defining R3 and R4 are optionally substituted with one or more groups selected from - OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -Q=O)-NH2, -CN, -C(O)-NR2 and -C(O)-NHR;
R5 is selected from -H, d_6alkyl, and C3_6cycloalkyl;
R6 is independently selected from -H, -CN, -NO2, Ci-βalkoxy, halogen, Ci^alkyl, -OH, -NH2, -NHC(O)R12 and -C(O)NR12R13; R12 and R13 are independently selected from -H, Ci-βalkyl, Ci_6alkoxy, C3. δheterocycloalkyl, C3-6cycloalkyl-Ci-4alkyl, and C3-6cycloalkyl wherein said Ci-βalkyl, Ci- 6alkoxy, C3_6heterocycloalkyl, C3_6cycloalkyl-Ci_4alkyl and C3_6cycloalkyl used in defining R12 and R13 are optionally substituted with one or more halogens or -OH;
R14 and R15 are independently selected from -H, Ci-βalkyl, Cβ-ioaryl, Cό-ioaryl-Ci- 4alkyl, C2_sheterocyclyl, C2-5heterocyclyl-Ci-4alkyl, C2_6alkenyl, C3_6Cycloalkyl, and C3. 6cycloalkyl-Ci_4alkyl, N,N-di(Ci_4alkyl)amido-Ci_6alkyl, hydroxy-Ci_6alkyl and Ci- 6alkoxy-Ci_6alkyl that are optionally substituted with one or groups selected from halogen, -OH, -CN, -NH2 and methoxy;
Q is independently selected from Ci^alkylene, Ci_6alkylidene and
Figure imgf000244_0001
, wherein said Ci_6alkylene and Ci_6alkylidene are optionally substituted with on or more groups selected from -OR, -R, hydroxy-Ci_6alkyl, NO2, -CO2H, -CO2-R, -SO2-R, halogen, -OH, -NH2, -NHR, -C(O)-NH2, -CN, -C(O)- NR2 and -C(O)-NHR;
X is selected from -OH, halogen or -OR; n is independently selected from 1, 2 and 3; p, q and m are independently selected from O, 1, 2 and 3; and R is independently Ci_6alkyl.
PCT/GB2008/050713 2007-08-17 2008-08-15 Cannabinoid receptor ligands WO2009024819A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0815493-7A2A BRPI0815493A2 (en) 2007-08-17 2008-08-15 COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND.
EP08788684A EP2190838A1 (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands
CA2696697A CA2696697A1 (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands
MX2010001574A MX2010001574A (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands.
AU2008290325A AU2008290325A1 (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands
US12/673,617 US20110160180A1 (en) 2007-08-17 2008-08-15 Cannabinoid Receptor Ligands
JP2010520636A JP2010536737A (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands
CN200880112253A CN101827838A (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligand

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95647807P 2007-08-17 2007-08-17
US60/956,478 2007-08-17

Publications (1)

Publication Number Publication Date
WO2009024819A1 true WO2009024819A1 (en) 2009-02-26

Family

ID=39930420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050713 WO2009024819A1 (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands

Country Status (16)

Country Link
US (2) US20090062251A1 (en)
EP (1) EP2190838A1 (en)
JP (1) JP2010536737A (en)
KR (1) KR20100061491A (en)
CN (1) CN101827838A (en)
AR (1) AR067954A1 (en)
AU (1) AU2008290325A1 (en)
BR (1) BRPI0815493A2 (en)
CA (1) CA2696697A1 (en)
CL (1) CL2008002431A1 (en)
MX (1) MX2010001574A (en)
PE (1) PE20090598A1 (en)
RU (1) RU2010102992A (en)
TW (1) TW200908963A (en)
UY (1) UY31294A1 (en)
WO (1) WO2009024819A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530137A (en) * 2009-06-16 2012-11-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azetidine 2-carboxamide derivative that modulates CB2 receptor
TWI482749B (en) * 2009-12-11 2015-05-01 Bayer Cropscience Ag Process for preparing 2,2-difluoroethylamine and salts thereof proceeding from difluoroacetonitrile
US9334290B2 (en) 2013-06-25 2016-05-10 Bristol-Myers Squibb Company Substituted tetrahydrocarbazole and carbazole carboxamide compounds
US9688629B2 (en) 2014-10-24 2017-06-27 Bristol-Myers Squibb Company Indole carboxamide compounds
US9714234B2 (en) 2013-06-25 2017-07-25 Bristol-Myers Squibb Company Carbazole carboxamide compounds
US10023534B2 (en) 2014-10-24 2018-07-17 Bristol-Myers Squibb Company Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
US10266491B2 (en) 2014-10-24 2019-04-23 Bristol-Myers Squibb Company Carbazole derivatives
WO2021173593A1 (en) * 2020-02-24 2021-09-02 Galyan Bio, Inc. Indole compounds for the treatment of neurodegenerative diseases
EP4140481A1 (en) * 2021-08-26 2023-03-01 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof
WO2023025915A1 (en) * 2021-08-25 2023-03-02 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
JP5841361B2 (en) * 2011-06-29 2016-01-13 壽製薬株式会社 Tricyclic compound and pharmaceutical composition containing the same
JP6106452B2 (en) * 2012-12-05 2017-03-29 公益財団法人微生物化学研究会 Compound, method for producing the same, and method for producing oseltamivir phosphate
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US20100113502A1 (en) * 2005-03-22 2010-05-06 Astrazeneca Ab Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530137A (en) * 2009-06-16 2012-11-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azetidine 2-carboxamide derivative that modulates CB2 receptor
TWI482749B (en) * 2009-12-11 2015-05-01 Bayer Cropscience Ag Process for preparing 2,2-difluoroethylamine and salts thereof proceeding from difluoroacetonitrile
US10106559B2 (en) 2013-06-25 2018-10-23 Bristol-Myers Squibb Company Substituted tetrahydrocarbazole and carbazole carboxamide compounds
US9334290B2 (en) 2013-06-25 2016-05-10 Bristol-Myers Squibb Company Substituted tetrahydrocarbazole and carbazole carboxamide compounds
US9714234B2 (en) 2013-06-25 2017-07-25 Bristol-Myers Squibb Company Carbazole carboxamide compounds
US10435415B2 (en) 2013-06-25 2019-10-08 Bristol-Myers Squibb Company Substituted tetrahydrocarbazole and carbazole carboxamide compounds
US9850258B2 (en) 2013-06-25 2017-12-26 Bristol-Myers Squibb Company Substituted tetrahydrocarbazole and carbazole carboxamide compounds
US10266491B2 (en) 2014-10-24 2019-04-23 Bristol-Myers Squibb Company Carbazole derivatives
US10023534B2 (en) 2014-10-24 2018-07-17 Bristol-Myers Squibb Company Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
US9688629B2 (en) 2014-10-24 2017-06-27 Bristol-Myers Squibb Company Indole carboxamide compounds
US9802915B2 (en) 2014-10-24 2017-10-31 Bristol-Myers Squibb Company Indole carboxamide compounds
US10676434B2 (en) 2014-10-24 2020-06-09 Bristol-Myers Squibb Company Carbazole derivatives
US11053197B2 (en) 2014-10-24 2021-07-06 Bristol-Myers Squibb Company Carbazole derivatives
WO2021173593A1 (en) * 2020-02-24 2021-09-02 Galyan Bio, Inc. Indole compounds for the treatment of neurodegenerative diseases
WO2023025915A1 (en) * 2021-08-25 2023-03-02 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof
EP4140481A1 (en) * 2021-08-26 2023-03-01 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof

Also Published As

Publication number Publication date
EP2190838A1 (en) 2010-06-02
TW200908963A (en) 2009-03-01
PE20090598A1 (en) 2009-06-10
AR067954A1 (en) 2009-10-28
US20090062251A1 (en) 2009-03-05
CN101827838A (en) 2010-09-08
US20110160180A1 (en) 2011-06-30
UY31294A1 (en) 2009-03-31
AU2008290325A1 (en) 2009-02-26
CA2696697A1 (en) 2009-02-26
MX2010001574A (en) 2010-03-15
JP2010536737A (en) 2010-12-02
CL2008002431A1 (en) 2009-06-05
KR20100061491A (en) 2010-06-07
BRPI0815493A2 (en) 2015-02-10
RU2010102992A (en) 2011-09-27

Similar Documents

Publication Publication Date Title
EP2190838A1 (en) Cannabinoid receptor ligands
WO2006101434A1 (en) NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
EP1910340B1 (en) Indazolecarboxamide derivatives as 5ht4 receptor agonists
CA2650914A1 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
JP7488267B2 (en) Novel substituted sulfonylurea derivatives
JP2009534379A (en) Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (CB1) receptor ligands
EP1660443A2 (en) Cyclic amine bace-1 inhibitors having a benzamide substituent
DE69511086T2 (en) PYRIMIDINE DERIVATIVES
CZ253798A3 (en) Novel benzo-1,3-dioxolyl- and benzofuranyl-substituted pyrrolidine derivatives as endothelin antagonists
KR20080059297A (en) Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels
EP1797070A1 (en) Compounds, compositions containing them, preparations thereof and uses thereof ii
WO2005030761A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW202233620A (en) Cftr modulator compounds, compositions, and uses thereof
ES2310751T3 (en) DERIVATIVES OF BENCIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, THEIR PREPARATION AND THEIR USES.
WO2008036021A1 (en) Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands
WO2022217118A1 (en) Pyrimidine based ras modulators and uses thereof
TWI449700B (en) Azetidines as histamine h3 receptor antagonists
WO2008036022A1 (en) Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands
JP2023545065A (en) autotaxin inhibitor compounds
AU2005201160B2 (en) Endothelin antagonists
MX2007003121A (en) Compounds, compositions containing them, preparations thereof and uses thereof ii.
CZ2000348A3 (en) Pyrrolidine-3-karboxylic acid derivatives and their use as endothelin antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880112253.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788684

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008290325

Country of ref document: AU

Ref document number: MX/A/2010/001574

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 976/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010520636

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2696697

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008788684

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008290325

Country of ref document: AU

Date of ref document: 20080815

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107005774

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010102992

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0815493

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100212